A	O
novel	O
compound	O
heterozygous	O
mutation	O
in	O
the	O
CYP17	O
(	O
P450	O
17alpha-hydroxylase	O
)	O
gene	O
leading	O
to	O
17alpha-hydroxylase/17,20-lyase	O
deficiency	O
.	O

Mutations	O
in	O
the	O
CYP17	O
gene	O
impair	O
steroid	O
biosynthesis	O
in	O
the	O
adrenals	O
and	O
gonads	O
and	O
often	O
cause	O
17alpha-hydroxylase/17,20-lyase	O
deficiency	O
,	O
leading	O
to	O
amenorrhea	O
,	O
sexual	O
infantilism	O
,	O
and	O
hypokalemic	O
low	O
aldosterone	O
hypertension	O
.	O

Several	O
CYP17	O
mutations	O
resulting	O
in	O
17alpha-hydroxylase/17,20-lyase	O
deficiency	O
have	O
been	O
reported	O
previously	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
found	O
a	O
novel	O
CYP17	O
mutation	O
from	O
the	O
molecular	O
analysis	O
of	O
a	O
Korean	O
patient	O
with	O
primary	O
amenorrhea	O
with	O
a	O
46,XX	O
karyotype	O
,	O
and	O
hypokalemic	O
hypertension	O
.	O

We	O
sequenced	O
all	O
8	O
exons	O
of	O
the	O
CYP17	O
gene	O
that	O
were	O
amplified	O
from	O
patient's	O
genomic	O
DNA	O
using	O
polymerase	O
chain	O
reaction	O
(PCR)	O
and	O
found	O
a	O
compound	O
heterozygous	O
mutation	O
in	O
the	O
CYP17	O
structural	O
gene	O
;	O
a	O
1-base	O
deletion	O
and	O
a	O
1-base	O
transversion	O
G>A	B-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
+1	I-DNAMutation
of	I-DNAMutation
intron	I-DNAMutation
2	I-DNAMutation
,	O
leading	O
to	O
the	O
production	O
of	O
a	O
truncated	O
protein	O
(	O
1-417	O
amino	O
acids	O
)	O
,	O
and	O
a	O
3-base	O
deletion	O
(	O
TCC	O
,	O
either	O
350-351	O
or	O
351-352	O
codon	O
)	O
in	O
the	O
other	O
allele	O
.	O

Restriction	O
enzyme	O
digestion	O
analysis	O
of	O
patient's	O
and	O
parental	O
DNA	O
showed	O
that	O
the	O
1-base	O
deletion	O
and	O
the	O
3-base	O
deletion	O
are	O
inherited	O
from	O
mother	O
and	O
father	O
,	O
respectively	O
.	O

Here	O
we	O
conclude	O
that	O
these	O
novel	O
compound	O
heterozygous	O
mutations	O
might	O
account	O
for	O
the	O
patient's	O
clinical	O
manifestations	O
of	O
17alpha-hydroxylase/17,20-lyase	O
deficiency	O
.	O

Aryl	O
hydrocarbon	O
receptor	O
interacting	O
protein	O
(AIP)	O
gene	O
mutation	O
analysis	O
in	O
children	O
and	O
adolescents	O
with	O
sporadic	O
pituitary	O
adenomas	O
.	O

OBJECTIVE	O
:	O
Pituitary	O
adenomas	O
occur	O
rarely	O
in	O
childhood	O
and	O
adolescence	O
.	O

Pituitary	O
adenoma	O
predisposition	O
(PAP)	O
has	O
been	O
recently	O
associated	O
with	O
germline	O
mutations	O
in	O
the	O
aryl	O
hydrocarbon	O
receptor	O
interacting	O
protein	O
(AIP)	O
gene	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
examine	O
the	O
proportion	O
of	O
germline	O
AIP	O
mutations	O
in	O
apparently	O
sporadic	O
paediatric	O
pituitary	O
adenomas	O
.	O

DESIGN	O
:	O
Genomic	O
DNA	O
was	O
analysed	O
for	O
mutations	O
in	O
the	O
AIP	O
gene	O
,	O
by	O
PCR	O
amplification	O
and	O
direct	O
sequencing	O
.	O

PATIENTS	O
:	O
A	O
population-based	O
cohort	O
consisting	O
of	O
36	O
apparently	O
sporadic	O
paediatric	O
pituitary	O
adenoma	O
patients	O
,	O
referred	O
to	O
two	O
medical	O
centres	O
in	O
Italy	O
,	O
was	O
included	O
in	O
the	O
study	O
.	O

Patients	O
were	O
either	O
less	O
than	O
18	O
years	O
at	O
diagnosis	O
,	O
or	O
showed	O
clinical	O
evidence	O
of	O
adenoma	O
development	O
before	O
the	O
age	O
of	O
18	O
years	O
.	O

RESULTS	O
:	O
A	O
heterozygous	O
in-frame	O
deletion	O
arginine	B-ProteinMutation
555-to-tryptophan	I-ProteinMutation
(	O
(	B-DNAMutation
G	I-DNAMutation
-->	I-DNAMutation
C	I-DNAMutation
)	I-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
1201	I-DNAMutation
)	O
was	O
identified	O
in	O
one	O
GH-secreting	O
adenoma	O
patient	O
.	O

Loss	O
of	O
heterozygosity	O
(LOH)	O
analysis	O
of	O
tumour	O
DNA	O
revealed	O
the	O
loss	O
of	O
the	O
wild-type	O
allele	O
.	O

First	O
degree	O
relatives	O
carrying	O
the	O
mutation	O
were	O
clinically	O
unaffected	O
.	O

CONCLUSIONS	O
:	O
While	O
mutations	O
were	O
absent	O
in	O
non-GH-secreting	O
adenoma	O
patients	O
,	O
germline	O
AIP	O
mutations	O
can	O
be	O
found	O
in	O
children	O
and	O
adolescents	O
with	O
GH-secreting	O
tumours	O
,	O
even	O
in	O
the	O
absence	O
of	O
family	O
history	O
.	O

The	O
present	O
study	O
reports	O
the	O
AIP	O
mutation	O
analysis	O
results	O
on	O
patients	O
of	O
a	O
single	O
ethnic	O
origin	O
.	O

Clearly	O
,	O
further	O
studies	O
are	O
needed	O
to	O
improve	O
our	O
knowledge	O
on	O
the	O
role	O
of	O
AIP	O
in	O
paediatric	O
pituitary	O
adenomas	O
.	O

Strong	O
association	O
of	O
(	B-DNAMutation
T	I-DNAMutation
-->	I-DNAMutation
C	I-DNAMutation
)	I-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
2209	I-DNAMutation
substitution	O
in	O
the	O
MTHFR	O
gene	O
with	O
male	O
infertility--a	O
study	O
on	O
an	O
indian	O
population	O
and	O
a	O
meta-analysis	O
.	O

BACKGROUND	O
:	O
Methylenetetrahydrofolate	O
reductase	O
(MTHFR)	O
is	O
an	O
important	O
enzyme	O
of	O
folate	O
and	O
methionine	O
metabolism	O
,	O
making	O
it	O
crucial	O
for	O
DNA	O
synthesis	O
and	O
methylation	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
analyze	O
MTHFR	O
gene	O
G>T	B-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
c.898	I-DNAMutation
polymorphism	O
in	O
infertile	O
male	O
individuals	O
from	O
North	O
India	O
,	O
followed	O
by	O
a	O
meta-analysis	O
on	O
our	O
data	O
and	O
published	O
studies	O
.	O

METHODOLOGY/PRINCIPAL	O
FINDINGS	O
:	O
We	O
undertook	O
genotyping	O
on	O
a	O
total	O
of	O
837	O
individuals	O
including	O
well	O
characterized	O
infertile	O
(N=522)	O
and	O
confirmed	O
fertile	O
(N=315)	O
individuals	O
.	O

The	O
SNP	O
was	O
typed	O
by	O
direct	O
DNA	O
sequencing	O
.	O

Chi	O
square	O
test	O
was	O
done	O
for	O
statistical	O
analysis	O
.	O

Published	O
studies	O
were	O
searched	O
using	O
appropriate	O
keywords	O
.	O

Source	O
of	O
data	O
collection	O
for	O
meta-analysis	O
included	O
'Pubmed'	O
,	O
'Ovid'	O
and	O
'Google	O
Scholar'	O
.	O

Those	O
studies	O
analyzing	O
C-->T	B-DNAMutation
transversion	I-DNAMutation
at	I-DNAMutation
cDNA	I-DNAMutation
base	I-DNAMutation
463	I-DNAMutation
polymorphism	O
in	O
male	O
infertility	O
and	O
presenting	O
all	O
relevant	O
data	O
were	O
included	O
in	O
meta-analysis	O
.	O

The	O
genotype	O
data	O
for	O
infertile	O
subjects	O
and	O
fertile	O
controls	O
was	O
extracted	O
from	O
each	O
study	O
.	O

Chi	O
square	O
test	O
was	O
done	O
to	O
obtain	O
odds	O
ratio	O
(OR)	O
and	O
p-value	O
.	O

Meta-analysis	O
was	O
performed	O
using	O
Comprehensive	O
Meta-analysis	O
software	O
(	O
Version	O
2	O
)	O
.	O

The	O
frequency	O
of	O
mutant	O
(T)	O
allele	O
(p=0.0025)	O
and	O
genotypes	O
(CT+TT)	O
(p=0.0187)	O
was	O
significantly	O
higher	O
in	O
infertile	O
individuals	O
in	O
comparison	O
to	O
fertile	O
controls	O
in	O
our	O
case-control	O
study	O
.	O

The	O
overall	O
summary	O
estimate	O
(OR)	O
for	O
allele	O
and	O
genotype	O
meta-analysis	O
were	O
1.304	O
(p=0.000)	O
,	O
1.310	O
(p=0.000)	O
,	O
respectively	O
,	O
establishing	O
significant	O
association	O
of	O
G-->C	B-DNAMutation
transversion	I-DNAMutation
at	I-DNAMutation
1245	I-DNAMutation
position	I-DNAMutation
polymorphism	O
with	O
male	O
infertility	O
.	O

CONCLUSIONS/SIGNIFICANCE	O
:	O
C-->T	B-DNAMutation
transition	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
677	I-DNAMutation
substitution	O
associated	O
strongly	O
with	O
male	O
infertility	O
in	O
Indian	O
population	O
.	O

Allele	O
and	O
genotype	O
meta-analysis	O
also	O
supported	O
its	O
strong	O
correlation	O
with	O
male	O
infertility	O
,	O
thus	O
establishing	O
it	O
as	O
a	O
risk	O
factor	O
.	O

Variation	O
in	O
genotype	O
and	O
higher	O
virulence	O
of	O
a	O
strain	O
of	O
Sporothrix	O
schenckii	O
causing	O
disseminated	O
cutaneous	O
sporotrichosis	O
.	O

Sporotrichosis	O
is	O
usually	O
a	O
localized	O
,	O
lymphocutaneous	O
disease	O
,	O
but	O
its	O
disseminated	O
type	O
was	O
rarely	O
reported	O
.	O

The	O
main	O
objective	O
of	O
this	O
study	O
was	O
to	O
identify	O
specific	O
DNA	O
sequence	O
variation	O
and	O
virulence	O
of	O
a	O
strain	O
of	O
Sporothrix	O
schenckii	O
isolated	O
from	O
the	O
lesion	O
of	O
disseminated	O
cutaneous	O
sporotrichosis	O
.	O

We	O
confirmed	O
this	O
strain	O
to	O
be	O
S	O
.	O

schenckii	O
by(	O
	O
)	O
tubulin	O
and	O
chitin	O
synthase	O
gene	O
sequence	O
analysis	O
in	O
addition	O
to	O
the	O
routine	O
mycological	O
and	O
partial	O
ITS	O
and	O
NTS	O
sequencing	O
.	O

We	O
found	O
a	O
10-bp	O
deletion	O
in	O
the	O
ribosomal	O
NTS	O
region	O
of	O
this	O
strain	O
,	O
in	O
reference	O
to	O
the	O
sequence	O
of	O
control	O
strains	O
isolated	O
from	O
fixed	O
cutaneous	O
sporotrichosis	O
.	O

After	O
inoculated	O
into	O
immunosuppressed	O
mice	O
,	O
this	O
strain	O
caused	O
more	O
extensive	O
system	O
involvement	O
and	O
showed	O
stronger	O
virulence	O
than	O
the	O
control	O
strain	O
isolated	O
from	O
a	O
fixed	O
cutaneous	O
sporotrichosis	O
.	O

Our	O
study	O
thus	O
suggests	O
that	O
different	O
clinical	O
manifestation	O
of	O
sporotrichosis	O
may	O
be	O
associated	O
with	O
variation	O
in	O
genotype	O
and	O
virulence	O
of	O
the	O
strain	O
,	O
independent	O
of	O
effects	O
due	O
to	O
the	O
immune	O
status	O
of	O
the	O
host	O
.	O

Allele-specific	O
amplification	O
in	O
cancer	O
revealed	O
by	O
SNP	O
array	O
analysis	O
.	O

Amplification	O
,	O
deletion	O
,	O
and	O
loss	O
of	O
heterozygosity	O
of	O
genomic	O
DNA	O
are	O
hallmarks	O
of	O
cancer	O
.	O

In	O
recent	O
years	O
a	O
variety	O
of	O
studies	O
have	O
emerged	O
measuring	O
total	O
chromosomal	O
copy	O
number	O
at	O
increasingly	O
high	O
resolution	O
.	O

Similarly	O
,	O
loss-of-heterozygosity	O
events	O
have	O
been	O
finely	O
mapped	O
using	O
high-throughput	O
genotyping	O
technologies	O
.	O

We	O
have	O
developed	O
a	O
probe-level	O
allele-specific	O
quantitation	O
procedure	O
that	O
extracts	O
both	O
copy	O
number	O
and	O
allelotype	O
information	O
from	O
single	O
nucleotide	O
polymorphism	O
(SNP)	O
array	O
data	O
to	O
arrive	O
at	O
allele-specific	O
copy	O
number	O
across	O
the	O
genome	O
.	O

Our	O
approach	O
applies	O
an	O
expectation-maximization	O
algorithm	O
to	O
a	O
model	O
derived	O
from	O
a	O
novel	O
classification	O
of	O
SNP	O
array	O
probes	O
.	O

This	O
method	O
is	O
the	O
first	O
to	O
our	O
knowledge	O
that	O
is	O
able	O
to	O
(a)	O
determine	O
the	O
generalized	O
genotype	O
of	O
aberrant	O
samples	O
at	O
each	O
SNP	O
site	O
(	O
e.g.	O
,	O
CCCCT	O
at	O
an	O
amplified	O
site	O
)	O
,	O
and	O
(b)	O
infer	O
the	O
copy	O
number	O
of	O
each	O
parental	O
chromosome	O
across	O
the	O
genome	O
.	O

With	O
this	O
method	O
,	O
we	O
are	O
able	O
to	O
determine	O
not	O
just	O
where	O
amplifications	O
and	O
deletions	O
occur	O
,	O
but	O
also	O
the	O
haplotype	O
of	O
the	O
region	O
being	O
amplified	O
or	O
deleted	O
.	O

The	O
merit	O
of	O
our	O
model	O
and	O
general	O
approach	O
is	O
demonstrated	O
by	O
very	O
precise	O
genotyping	O
of	O
normal	O
samples	O
,	O
and	O
our	O
allele-specific	O
copy	O
number	O
inferences	O
are	O
validated	O
using	O
PCR	O
experiments	O
.	O

Applying	O
our	O
method	O
to	O
a	O
collection	O
of	O
lung	O
cancer	O
samples	O
,	O
we	O
are	O
able	O
to	O
conclude	O
that	O
amplification	O
is	O
essentially	O
monoallelic	O
,	O
as	O
would	O
be	O
expected	O
under	O
the	O
mechanisms	O
currently	O
believed	O
responsible	O
for	O
gene	O
amplification	O
.	O

This	O
suggests	O
that	O
a	O
specific	O
parental	O
chromosome	O
may	O
be	O
targeted	O
for	O
amplification	O
,	O
whether	O
because	O
of	O
germ	O
line	O
or	O
somatic	O
variation	O
.	O

An	O
R	O
software	O
package	O
containing	O
the	O
methods	O
described	O
in	O
this	O
paper	O
is	O
freely	O
available	O
at	O
http://genome.dfci.harvard.edu/~tlaframb/PLASQ	O
.	O

Genetic	O
and	O
epigenetic	O
alterations	O
of	O
the	O
NF2	O
gene	O
in	O
sporadic	O
vestibular	O
schwannomas	O
.	O

BACKGROUND	O
:	O
Mutations	O
in	O
the	O
neurofibromatosis	O
type	O
2	O
(NF2)	O
tumor-suppressor	O
gene	O
have	O
been	O
identified	O
in	O
not	O
only	O
NF2-related	O
tumors	O
but	O
also	O
sporadic	O
vestibular	O
schwannomas	O
(VS)	O
.	O

This	O
study	O
investigated	O
the	O
genetic	O
and	O
epigenetic	O
alterations	O
in	O
tumors	O
and	O
blood	O
from	O
30	O
Korean	O
patients	O
with	O
sporadic	O
VS	O
and	O
correlated	O
these	O
alterations	O
with	O
tumor	O
behavior	O
.	O

METHODOLOGY/PRINCIPAL	O
FINDINGS	O
:	O
NF2	O
gene	O
mutations	O
were	O
detected	O
using	O
PCR	O
and	O
direct	O
DNA	O
sequencing	O
and	O
three	O
highly	O
polymorphic	O
microsatellite	O
DNA	O
markers	O
were	O
used	O
to	O
assess	O
the	O
loss	O
of	O
heterozygosity	O
(LOH)	O
from	O
chromosome	O
22	O
.	O

Aberrant	O
hypermethylation	O
of	O
the	O
CpG	O
island	O
of	O
the	O
NF2	O
gene	O
was	O
also	O
analyzed	O
.	O

The	O
tumor	O
size	O
,	O
the	O
clinical	O
growth	O
index	O
,	O
and	O
the	O
proliferative	O
activity	O
assessed	O
using	O
the	O
Ki-67	O
labeling	O
index	O
were	O
evaluated	O
.	O

We	O
found	O
18	O
mutations	O
in	O
16	O
cases	O
of	O
30	O
schwannomas	O
(53%)	O
.	O

The	O
mutations	O
included	O
eight	O
frameshift	O
mutations	O
,	O
seven	O
nonsense	O
mutations	O
,	O
one	O
in-frame	O
deletion	O
,	O
one	O
splicing	O
donor	O
site	O
,	O
and	O
one	O
missense	O
mutation	O
.	O

Nine	O
patients	O
(30%)	O
showed	O
allelic	O
loss	O
.	O

No	O
patient	O
had	O
aberrant	O
hypermethylation	O
of	O
the	O
NF2	O
gene	O
and	O
correlation	O
between	O
NF2	O
genetic	O
alterations	O
and	O
tumor	O
behavior	O
was	O
not	O
observed	O
in	O
this	O
study	O
.	O

CONCLUSIONS/SIGNIFICANCE	O
:	O
The	O
molecular	O
genetic	O
changes	O
in	O
sporadic	O
VS	O
identified	O
here	O
included	O
mutations	O
and	O
allelic	O
loss	O
,	O
but	O
no	O
aberrant	O
hypermethylation	O
of	O
the	O
NF2	O
gene	O
was	O
detected	O
.	O

In	O
addition	O
,	O
no	O
clear	O
genotype/phenotype	O
correlation	O
was	O
identified	O
.	O

Therefore	O
,	O
it	O
is	O
likely	O
that	O
other	O
factors	O
contribute	O
to	O
tumor	O
formation	O
and	O
growth	O
.	O

Clinical	O
and	O
genetic	O
characterization	O
of	O
manifesting	O
carriers	O
of	O
DMD	O
mutations	O
.	O

Manifesting	O
carriers	O
of	O
DMD	O
gene	O
mutations	O
may	O
present	O
diagnostic	O
challenges	O
,	O
particularly	O
in	O
the	O
absence	O
of	O
a	O
family	O
history	O
of	O
dystrophinopathy	O
.	O

We	O
review	O
the	O
clinical	O
and	O
genetic	O
features	O
in	O
15	O
manifesting	O
carriers	O
identified	O
among	O
860	O
subjects	O
within	O
the	O
United	O
Dystrophinopathy	O
Project	O
,	O
a	O
large	O
clinical	O
dystrophinopathy	O
cohort	O
whose	O
members	O
undergo	O
comprehensive	O
DMD	O
mutation	O
analysis	O
.	O

We	O
defined	O
manifesting	O
carriers	O
as	O
females	O
with	O
significant	O
weakness	O
,	O
excluding	O
those	O
with	O
only	O
myalgias/cramps	O
.	O

DNA	O
extracted	O
from	O
peripheral	O
blood	O
was	O
used	O
to	O
study	O
X-chromosome	O
inactivation	O
patterns	O
.	O

Among	O
these	O
manifesting	O
carriers	O
,	O
age	O
at	O
symptom	O
onset	O
ranged	O
from	O
2	O
to	O
47	O
years	O
.	O

Seven	O
had	O
no	O
family	O
history	O
and	O
eight	O
had	O
male	O
relatives	O
with	O
Duchenne	O
muscular	O
dystrophy	O
(DMD)	O
.	O

Clinical	O
severity	O
among	O
the	O
manifesting	O
carriers	O
varied	O
from	O
a	O
DMD-like	O
progression	O
to	O
a	O
very	O
mild	O
Becker	O
muscular	O
dystrophy-like	O
phenotype	O
.	O

Eight	O
had	O
exonic	O
deletions	O
or	O
duplications	O
and	O
six	O
had	O
point	O
mutations	O
.	O

One	O
patient	O
had	O
two	O
mutations	O
(	O
an	O
exonic	O
deletion	O
and	O
a	O
splice	O
site	O
mutation	O
)	O
,	O
consistent	O
with	O
a	O
heterozygous	O
compound	O
state	O
.	O

The	O
X-chromosome	O
inactivation	O
pattern	O
was	O
skewed	O
toward	O
non-random	O
in	O
four	O
out	O
of	O
seven	O
informative	O
deletions	O
or	O
duplications	O
but	O
was	O
random	O
in	O
all	O
cases	O
with	O
nonsense	O
mutations	O
.	O

We	O
present	O
the	O
results	O
of	O
DMD	O
mutation	O
analysis	O
in	O
this	O
manifesting	O
carrier	O
cohort	O
,	O
including	O
the	O
first	O
example	O
of	O
a	O
presumably	O
compound	O
heterozygous	O
DMD	O
mutation	O
.	O

Our	O
results	O
demonstrate	O
that	O
improved	O
molecular	O
diagnostic	O
methods	O
facilitate	O
the	O
identification	O
of	O
DMD	O
mutations	O
in	O
manifesting	O
carriers	O
,	O
and	O
confirm	O
the	O
heterogeneity	O
of	O
mutational	O
mechanisms	O
as	O
well	O
as	O
the	O
wide	O
spectrum	O
of	O
phenotypes	O
.	O

A	O
histidine	B-ProteinMutation
626-to-arginine	I-ProteinMutation
substitution	O
in	O
the	O
5-HT(2C)	O
receptor	O
gene	O
influences	O
body	O
weight	O
regulation	O
in	O
females	O
with	O
seasonal	O
affective	O
disorder	O
:	O
an	O
Austrian-Canadian	O
collaborative	O
study	O
.	O

Most	O
females	O
with	O
seasonal	O
affective	O
disorder	O
(SAD)	O
exhibit	O
atypical	O
vegetative	O
symptoms	O
such	O
as	O
overeating	O
,	O
and	O
weight	O
gain	O
when	O
depressed	O
.	O

The	O
serotonin	O
2C	O
receptor	O
(5-HT(2C))	O
plays	O
a	O
key	O
role	O
in	O
control	O
of	O
appetite	O
and	O
satiety	O
.	O

A	O
5-HT(2C)	O
arginine	B-ProteinMutation
124-to-cysteine	I-ProteinMutation
substitution	O
,	O
coded	O
for	O
by	O
a	O
single	O
nucleotide	O
polymorphism	O
(	O
arginine	B-ProteinMutation
555-to-tryptophan	I-ProteinMutation
)	O
within	O
the	O
5-HT(2C)	O
gene	O
,	O
has	O
been	O
shown	O
to	O
influence	O
5-HT(2C)	O
function	O
.	O

We	O
hypothesized	O
that	O
histidine	B-ProteinMutation
626-to-arginine	I-ProteinMutation
influences	O
weight	O
regulation	O
in	O
females	O
with	O
SAD	O
.	O

Two	O
independent	O
samples	O
from	O
Austria	O
(	O
162	O
females	O
with	O
SAD	O
,	O
119	O
controls	O
)	O
,	O
and	O
Canada	O
(	O
90	O
females	O
with	O
SAD	O
,	O
42	O
controls	O
)	O
were	O
genotyped	O
for	O
arginine	B-ProteinMutation
124-to-cysteine	I-ProteinMutation
.	O

Influence	O
on	O
weight	O
regulation	O
was	O
analyzed	O
within	O
patients	O
with	O
atypical	O
features	O
.	O

In	O
Austrians	O
,	O
genotype	O
distribution	O
differed	O
between	O
patients	O
and	O
controls	O
(p=0.044)	O
and	O
methionine-->valine	B-ProteinMutation
substitution	I-ProteinMutation
at	I-ProteinMutation
codon	I-ProteinMutation
404	I-ProteinMutation
was	O
associated	O
with	O
weight	O
(p=0.039)	O
,	O
body	O
mass	O
index	O
(	O
BMI	O
;	O
p=0.038	O
)	O
,	O
and	O
seasonal	O
appetite	O
change	O
(p=0.031)	O
.	O

All	O
values	O
were	O
highest	O
in	O
Cys/Cys	O
,	O
intermediate	O
in	O
Cys/Ser	O
,	O
and	O
lowest	O
in	O
Ser/Ser	O
carriers	O
.	O

In	O
Canadian	O
patients	O
,	O
Ser-->Cys	B-ProteinMutation
substitution	I-ProteinMutation
at	I-ProteinMutation
the	I-ProteinMutation
codon	I-ProteinMutation
326	I-ProteinMutation
was	O
associated	O
with	O
minimum	O
lifetime	O
BMI	O
(p=0.046)	O
,	O
with	O
lowest	O
values	O
in	O
Ser/Ser	O
carriers	O
.	O

Our	O
data	O
provide	O
evidence	O
that	O
leucine	B-ProteinMutation
269	I-ProteinMutation
to	I-ProteinMutation
phenylalanine	I-ProteinMutation
mediates	O
severity	O
of	O
weight	O
regulation	O
disturbances	O
in	O
females	O
with	O
SAD	O
,	O
and	O
the	O
gene-dose	O
effect-like	O
differences	O
suggest	O
a	O
direct	O
functional	O
role	O
of	O
arginine	B-ProteinMutation
555-to-tryptophan	I-ProteinMutation
in	O
the	O
behavioral	O
regulation	O
of	O
body	O
weight	O
.	O

Genetic	O
homogeneity	O
for	O
inherited	O
congenital	O
microcoria	O
loci	O
in	O
an	O
Asian	O
Indian	O
pedigree	O
.	O

PURPOSE	O
:	O
Congenital	O
microcoria	O
is	O
a	O
rare	O
autosomal	O
dominant	O
developmental	O
disorder	O
of	O
the	O
iris	O
associated	O
with	O
myopia	O
and	O
juvenile	O
open	O
angle	O
glaucoma	O
.	O

Linkage	O
to	O
the	O
chromosomal	O
locus	O
13q31-q32	O
has	O
previously	O
been	O
reported	O
in	O
a	O
large	O
French	O
family	O
.	O

In	O
the	O
current	O
study	O
,	O
a	O
three	O
generation	O
Asian	O
Indian	O
family	O
with	O
15	O
congenital	O
microcoria	O
(	O
pupils	O
with	O
a	O
diameter	O
<2	O
mm	O
)	O
affected	O
members	O
was	O
studied	O
for	O
linkage	O
to	O
candidate	O
microsatellite	O
markers	O
at	O
the	O
13q31-q32	O
locus	O
.	O

METHODS	O
:	O
Twenty-four	O
members	O
of	O
the	O
family	O
were	O
clinically	O
examined	O
and	O
genomic	O
DNA	O
was	O
extracted	O
.	O

Microsatellite	O
markers	O
at	O
13q31-q32	O
were	O
PCR	O
amplified	O
and	O
run	O
on	O
an	O
ABI	O
Prism	O
310	O
genetic	O
analyzer	O
and	O
genotyped	O
with	O
the	O
GeneScan	O
analysis	O
.	O

Two	O
point	O
and	O
multipoint	O
linkage	O
analyses	O
were	O
performed	O
using	O
the	O
MLINK	O
and	O
SUPERLINK	O
programs	O
.	O

RESULTS	O
:	O
Peak	O
two	O
point	O
LOD	O
scores	O
of	O
3.5	O
,	O
4.7	O
,	O
and	O
5.3	O
were	O
found	O
co-incident	O
with	O
consecutive	O
markers	O
D13S154	O
,	O
DCT	O
,	O
and	O
D13S1280	O
.	O

Multipoint	O
analysis	O
revealed	O
a	O
4	O
cM	O
region	O
encompassing	O
D13S1300	O
to	O
D13S1280	O
where	O
the	O
LOD	O
remains	O
just	O
over	O
6.0	O
Thus	O
we	O
confirm	O
localization	O
of	O
the	O
congenital	O
microcoria	O
locus	O
to	O
chromosomal	O
locus	O
13q31-q32	O
.	O

In	O
addition	O
,	O
eight	O
individuals	O
who	O
had	O
both	O
microcoria	O
and	O
glaucoma	O
were	O
screened	O
for	O
glaucoma	O
genes	O
:	O
myocilin	O
(MYOC)	O
,	O
optineurin	O
(OPTN)	O
and	O
CYP1B1	O
.	O

Using	O
direct	O
sequencing	O
a	O
point	O
mutation	O
(	O
G-->C	B-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
135	I-DNAMutation
)	O
resulting	O
in	O
a	O
histidine	B-ProteinMutation
626-to-arginine	I-ProteinMutation
substitution	O
in	O
exon	O
1	O
of	O
the	O
MYOC	O
gene	O
was	O
observed	O
in	O
five	O
of	O
the	O
eight	O
glaucoma	O
patients	O
,	O
but	O
not	O
in	O
unaffected	O
family	O
members	O
and	O
100	O
unrelated	O
controls	O
.	O

CONCLUSIONS	O
:	O
We	O
have	O
confirmed	O
the	O
localization	O
of	O
the	O
congenital	O
microcoria	O
locus	O
(MCOR)	O
to	O
13q31-q32	O
in	O
a	O
large	O
Asian	O
Indian	O
family	O
and	O
conclude	O
that	O
current	O
information	O
suggests	O
this	O
is	O
a	O
single	O
locus	O
disorder	O
and	O
genetically	O
homogeneous	O
.	O

When	O
combined	O
with	O
the	O
initial	O
linkage	O
paper	O
our	O
haplotype	O
and	O
linkage	O
data	O
map	O
the	O
MCOR	O
locus	O
to	O
a	O
6-7	O
cM	O
region	O
between	O
D13S265	O
and	O
D13S1280	O
.	O

The	O
DCT	O
locus	O
,	O
a	O
member	O
of	O
the	O
tyrosinase	O
family	O
involved	O
in	O
pigmentation	O
,	O
maps	O
within	O
this	O
region	O
.	O

Data	O
presented	O
here	O
supports	O
the	O
hypothesis	O
that	O
congenital	O
microcoria	O
is	O
a	O
potential	O
risk	O
factor	O
for	O
glaucoma	O
,	O
although	O
this	O
observation	O
is	O
complicated	O
by	O
the	O
partial	O
segregation	O
of	O
MYOC	O
arginine	B-ProteinMutation
124-to-cysteine	I-ProteinMutation
(1q24.3-q25.2)	O
,	O
a	O
mutation	O
known	O
to	O
be	O
associated	O
with	O
glaucoma	O
in	O
India	O
.	O

Fine	O
mapping	O
and	O
candidate	O
gene	O
analysis	O
continues	O
with	O
the	O
hope	O
that	O
characterizing	O
the	O
micocoria	O
gene	O
will	O
lead	O
to	O
a	O
better	O
understanding	O
of	O
microcoria	O
and	O
glaucoma	O
causation	O
.	O

The	O
relationship	O
between	O
microcoria	O
,	O
glaucoma	O
,	O
and	O
the	O
MYOC	O
Phe-->Ser	B-ProteinMutation
at	I-ProteinMutation
codon	I-ProteinMutation
15	I-ProteinMutation
mutation	O
in	O
this	O
family	O
is	O
discussed	O
.	O

A	O
novel	O
two	O
nucleotide	O
deletion	O
in	O
the	O
apolipoprotein	O
A-I	O
gene	O
,	O
apoA-I	O
Shinbashi	O
,	O
associated	O
with	O
high	O
density	O
lipoprotein	O
deficiency	O
,	O
corneal	O
opacities	O
,	O
planar	O
xanthomas	O
,	O
and	O
premature	O
coronary	O
artery	O
disease	O
.	O

Familial	O
HDL	O
deficiency	O
(FHD)	O
is	O
a	O
rare	O
autosomal	O
dominant	O
lipoprotein	O
disorder	O
.	O

We	O
describe	O
a	O
novel	O
genetic	O
variant	O
of	O
the	O
apolipoprotein	O
A-I	O
(apoA-I)	O
gene	O
resulting	O
in	O
FHD	O
.	O

The	O
proband	O
is	O
a	O
51-year-old	O
woman	O
who	O
was	O
hospitalized	O
due	O
to	O
severe	O
heart	O
failure	O
.	O

Her	O
plasma	O
HDL-cholesterol	O
(C)	O
and	O
apoA-I	O
concentrations	O
were	O
0.08mmol/l	O
and	O
1mg/dl	O
,	O
respectively	O
.	O

She	O
exhibited	O
corneal	O
opacities	O
and	O
planar	O
xanthomas	O
on	O
eyelids	O
and	O
elbows	O
.	O

Coronary	O
angiography	O
demonstrated	O
extensive	O
obstructions	O
in	O
two	O
major	O
vessels	O
.	O

Genomic	O
DNA	O
sequencing	O
of	O
the	O
patient's	O
apoA-I	O
gene	O
revealed	O
a	O
homozygosity	O
for	O
a	O
GC	O
deletion	O
between	O
5	O
GC	O
repeats	O
in	O
exon	O
4	O
,	O
creating	O
a	O
frameshift	O
and	O
a	O
stop	O
codon	O
at	O
residue	O
178	O
.	O

We	O
designated	O
this	O
mutation	O
as	O
apoA-I	O
Shinbashi	O
.	O

The	O
proband's	O
father	O
,	O
son	O
,	O
and	O
daughter	O
were	O
found	O
to	O
be	O
heterozygous	O
for	O
this	O
mutation	O
and	O
their	O
HDL-C	O
and	O
apoA-I	O
levels	O
were	O
about	O
half	O
of	O
normal	O
levels	O
,	O
demonstrating	O
a	O
gene	O
dosage	O
effect	O
.	O

The	O
father	O
underwent	O
coronary	O
bypass	O
surgery	O
at	O
age	O
of	O
70	O
years	O
.	O

Lecithin-cholesterol	O
acyltransferase	O
(LCAT)	O
activity	O
was	O
decreased	O
by	O
63%	O
in	O
the	O
homozygote	O
and	O
31%	O
in	O
heterozygotes	O
,	O
respectively	O
.	O

This	O
new	O
case	O
of	O
apoA-I	O
deficiency	O
,	O
apoA-I	O
Shinbashi	O
,	O
is	O
the	O
first	O
case	O
involving	O
a	O
single	O
gene	O
defect	O
of	O
the	O
apoA-I	O
gene	O
to	O
develop	O
all	O
the	O
characteristics	O
for	O
apoA-I	O
deficiency	O
,	O
including	O
premature	O
coronary	O
heart	O
disease	O
.	O

Identification	O
of	O
novel	O
type	O
VII	O
collagen	O
gene	O
mutations	O
resulting	O
in	O
severe	O
recessive	O
dystrophic	O
epidermolysis	O
bullosa	O
.	O

In	O
this	O
work	O
,	O
we	O
studied	O
the	O
proband	O
in	O
a	O
small	O
nuclear	O
family	O
of	O
Chinese	O
and	O
Dutch/German	O
descent	O
and	O
identified	O
two	O
novel	O
mutations	O
in	O
the	O
type	O
VII	O
collagen	O
gene	O
leading	O
to	O
recessive	O
dystrophic	O
epidermolysis	O
bullosa	O
,	O
Hallopeau-Siemens	O
variant	O
(HS-RDEB)	O
.	O

The	O
maternal	O
mutation	O
is	O
a	O
single	O
base	O
pair	O
deletion	O
of	O
a	O
cytosine	O
nucleotide	O
in	O
exon	O
26	O
,	O
designated	O
GTT-->GCT	B-DNAMutation
transition	I-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
23	I-DNAMutation
,	O
resulting	O
in	O
a	O
frameshift	O
and	O
a	O
premature	O
termination	O
codon	O
(PTC)	O
within	O
the	O
same	O
exon	O
,	O
7	O
bp	O
downstream	O
of	O
the	O
site	O
of	O
the	O
mutation	O
.	O

The	O
paternal	O
mutation	O
is	O
a	O
A	B-DNAMutation
>	I-DNAMutation
G	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
313	I-DNAMutation
transition	O
located	O
at	O
the	O
5'	O
donor	O
splice	O
site	O
within	O
intron	O
51	O
,	O
designated	O
-AAGC	B-DNAMutation
at	I-DNAMutation
-222	I-DNAMutation
to	I-DNAMutation
-225	I-DNAMutation
.	O

This	O
mutation	O
leads	O
to	O
the	O
activation	O
of	O
a	O
cryptic	O
splice	O
site	O
,	O
32	O
bp	O
downstream	O
of	O
the	O
mutation	O
site	O
and	O
to	O
subsequent	O
aberrant	O
out-of-frame	O
splicing	O
,	O
resulting	O
in	O
two	O
alternative	O
mRNA	O
transcripts	O
and	O
a	O
downstream	O
PTC	O
.	O

To	O
our	O
knowledge	O
,	O
these	O
two	O
mutations	O
have	O
not	O
been	O
previously	O
reported	O
.	O

These	O
findings	O
extend	O
the	O
body	O
of	O
evidence	O
for	O
compound	O
heterozygous	O
mutations	O
leading	O
to	O
HS-RDEB	O
and	O
provide	O
the	O
basis	O
for	O
prenatal	O
diagnosis	O
in	O
this	O
family	O
.	O

Congenital	O
disorder	O
of	O
glycosylation	O
Ic	O
due	O
to	O
a	O
de	O
novo	O
deletion	O
and	O
an	O
hALG-6	O
mutation	O
.	O

We	O
describe	O
a	O
new	O
cause	O
of	O
congenital	O
disorder	O
of	O
glycosylation-Ic	O
(CDG-Ic)	O
in	O
a	O
young	O
girl	O
with	O
a	O
rather	O
mild	O
CDG	O
phenotype	O
.	O

Her	O
cells	O
accumulated	O
lipid-linked	O
oligosaccharides	O
lacking	O
three	O
glucose	O
residues	O
,	O
and	O
sequencing	O
of	O
the	O
ALG6	O
gene	O
showed	O
what	O
initially	O
appeared	O
to	O
be	O
a	O
homozygous	O
novel	O
point	O
mutation	O
(	O
-491	B-DNAMutation
A	I-DNAMutation
to	I-DNAMutation
T	I-DNAMutation
)	O
.	O

However	O
,	O
haplotype	O
analysis	O
showed	O
that	O
the	O
patient	O
does	O
not	O
carry	O
any	O
paternal	O
DNA	O
markers	O
extending	O
33kb	O
in	O
the	O
telomeric	O
direction	O
from	O
the	O
ALG6	O
region	O
,	O
and	O
microsatellite	O
analysis	O
extended	O
the	O
abnormal	O
region	O
to	O
at	O
least	O
2.5Mb	O
.	O

We	O
used	O
high-resolution	O
karyotyping	O
to	O
confirm	O
a	O
deletion	O
(10-12Mb)	O
[del(1)(p31.2p32.3)]	O
and	O
found	O
no	O
structural	O
abnormalities	O
in	O
the	O
father	O
,	O
suggesting	O
a	O
de	O
novo	O
event	O
.	O

Our	O
findings	O
extend	O
the	O
causes	O
of	O
CDG	O
to	O
larger	O
DNA	O
deletions	O
and	O
identify	O
the	O
first	O
Japanese	O
CDG-Ic	O
mutation	O
.	O

Detection	O
of	O
possible	O
restriction	O
sites	O
for	O
type	O
II	O
restriction	O
enzymes	O
in	O
DNA	O
sequences	O
.	O

In	O
order	O
to	O
make	O
a	O
step	O
forward	O
in	O
the	O
knowledge	O
of	O
the	O
mechanism	O
operating	O
in	O
complex	O
polygenic	O
disorders	O
such	O
as	O
diabetes	O
and	O
obesity	O
,	O
this	O
paper	O
proposes	O
a	O
new	O
algorithm	O
(	O
PRSD	O
-possible	O
restriction	O
site	O
detection	O
)	O
and	O
its	O
implementation	O
in	O
Applied	O
Genetics	O
software	O
.	O

This	O
software	O
can	O
be	O
used	O
for	O
in	O
silico	O
detection	O
of	O
potential	O
(hidden)	O
recognition	O
sites	O
for	O
endonucleases	O
and	O
for	O
nucleotide	O
repeats	O
identification	O
.	O

The	O
recognition	O
sites	O
for	O
endonucleases	O
may	O
result	O
from	O
hidden	O
sequences	O
through	O
deletion	O
or	O
insertion	O
of	O
a	O
specific	O
number	O
of	O
nucleotides	O
.	O

Tests	O
were	O
conducted	O
on	O
DNA	O
sequences	O
downloaded	O
from	O
NCBI	O
servers	O
using	O
specific	O
recognition	O
sites	O
for	O
common	O
type	O
II	O
restriction	O
enzymes	O
introduced	O
in	O
the	O
software	O
database	O
(	O
n	O
=	O
126	O
)	O
.	O

Each	O
possible	O
recognition	O
site	O
indicated	O
by	O
the	O
PRSD	O
algorithm	O
implemented	O
in	O
Applied	O
Genetics	O
was	O
checked	O
and	O
confirmed	O
by	O
NEBcutter	O
V2.0	O
and	O
Webcutter	O
2.0	O
software	O
.	O

In	O
the	O
sequence	O
NG_008724.1	O
(	O
which	O
includes	O
63632	O
nucleotides	O
)	O
we	O
found	O
a	O
high	O
number	O
of	O
potential	O
restriction	O
sites	O
for	O
ECO	O
R1	O
that	O
may	O
be	O
produced	O
by	O
deletion	O
(	O
n	O
=	O
43	O
sites	O
)	O
or	O
insertion	O
(	O
n	O
=	O
591	O
sites	O
)	O
of	O
one	O
nucleotide	O
.	O

The	O
second	O
module	O
of	O
Applied	O
Genetics	O
has	O
been	O
designed	O
to	O
find	O
simple	O
repeats	O
sizes	O
with	O
a	O
real	O
future	O
in	O
understanding	O
the	O
role	O
of	O
SNPs	O
(	O
Single	O
Nucleotide	O
Polymorphisms	O
)	O
in	O
the	O
pathogenesis	O
of	O
the	O
complex	O
metabolic	O
disorders	O
.	O

We	O
have	O
tested	O
the	O
presence	O
of	O
simple	O
repetitive	O
sequences	O
in	O
five	O
DNA	O
sequence	O
.	O

The	O
software	O
indicated	O
exact	O
position	O
of	O
each	O
repeats	O
detected	O
in	O
the	O
tested	O
sequences	O
.	O

Future	O
development	O
of	O
Applied	O
Genetics	O
can	O
provide	O
an	O
alternative	O
for	O
powerful	O
tools	O
used	O
to	O
search	O
for	O
restriction	O
sites	O
or	O
repetitive	O
sequences	O
or	O
to	O
improve	O
genotyping	O
methods	O
.	O

Interleukin-17F	O
gene	O
polymorphism	O
in	O
patients	O
with	O
chronic	O
immune	O
thrombocytopenia	O
.	O

INTRODUCTION	O
:	O
IL-17F	O
is	O
a	O
novel	O
inflammatory	O
cytokine	O
and	O
plays	O
an	O
important	O
role	O
in	O
some	O
autoimmune	O
diseases	O
.	O

We	O
investigated	O
the	O
association	O
between	O
chronic	O
ITP	O
and	O
the	O
frequency	O
of	O
the	O
single-nucleotide	O
polymorphism	O
rs763780	O
(	O
G>A	B-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
+1	I-DNAMutation
of	I-DNAMutation
intron	I-DNAMutation
2	I-DNAMutation
)	O
,	O
which	O
causes	O
a	O
His-to-Arg	O
substitution	O
at	O
amino	O
acid	O
161	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
We	O
examined	O
102	O
patients	O
(	O
men/women	O
,	O
40/62	O
;	O
median	O
age	O
,	O
42	O
)	O
diagnosed	O
with	O
chronic	O
ITP	O
and	O
188	O
healthy	O
controls	O
(	O
men/women	O
,	O
78/110	O
;	O
median	O
age	O
,	O
38	O
)	O
.	O

Genotyping	O
was	O
determined	O
by	O
the	O
polymerase	O
chain	O
reaction-restriction	O
fragment	O
length	O
polymorphism	O
(PCR-RFLP)	O
technique	O
.	O

RESULTS	O
:	O
Compared	O
with	O
the	O
control	O
group	O
,	O
patients	O
with	O
chronic	O
ITP	O
had	O
a	O
significantly	O
lower	O
frequency	O
of	O
the	O
IL-17F	O
7488CC	O
genotype	O
(	O
0%	O
vs	O
.	O

4.8%	O
,	O
P<0.05	O
)	O
.	O

The	O
number	O
of	O
IL-17F	O
7488C	O
alleles	O
among	O
the	O
patients	O
with	O
chronic	O
ITP	O
was	O
also	O
significantly	O
lower	O
than	O
in	O
the	O
control	O
group	O
(	O
8.7%	O
vs	O
.	O

15.2%	O
OR=0.48	O
,	O
95%CI=0.27-0.84	O
,	O
P=0.016	O
)	O
.	O

Furthermore	O
,	O
patients	O
with	O
the	O
IL-17F	O
7488TT	O
genotype	O
showed	O
a	O
severe	O
thrombocytopenic	O
state	O
(	O
platelet	O
count<10	O
10(9)	O
/L	O
)	O
at	O
diagnosis	O
than	O
those	O
with	O
the	O
IL-17F	O
7488TC	O
genotype	O
(	O
20.9%	O
vs	O
.	O

0%	O
,	O
P=0.04	O
)	O
.	O

CONCLUSION	O
:	O
These	O
findings	O
suggest	O
that	O
the	O
IL-17F	O
7488	O
T	O
allele	O
is	O
significantly	O
associated	O
with	O
the	O
development	O
of	O
chronic	O
ITP	O
,	O
suggesting	O
a	O
role	O
for	O
IL-17F	O
in	O
the	O
pathogenesis	O
of	O
chronic	O
ITP	O
.	O

Large	O
deletion	O
involving	O
exon	O
5	O
of	O
the	O
arylsulfatase	O
B	O
gene	O
caused	O
apparent	O
homozygosity	O
in	O
a	O
mucopolysaccharidosis	O
type	O
VI	O
patient	O
.	O

Apparent	O
homozygosity	O
for	O
the	O
mutation	O
Glu	B-ProteinMutation
272	I-ProteinMutation
to	I-ProteinMutation
stop	I-ProteinMutation
present	O
on	O
exon	O
5	O
of	O
the	O
arylsulfatase	O
B	O
(ARSB)	O
gene	O
in	O
a	O
mucopolysaccharidosis	O
type	O
VI	O
patient	O
was	O
solved	O
in	O
this	O
study	O
by	O
further	O
testing	O
for	O
a	O
second	O
mutation	O
.	O

Patient	O
cDNA	O
analysis	O
revealed	O
that	O
the	O
entire	O
exon	O
5	O
of	O
the	O
ARSB	O
gene	O
was	O
lacking	O
;	O
this	O
new	O
mutation	O
was	O
identified	O
as	O
(	B-DNAMutation
T	I-DNAMutation
-->	I-DNAMutation
C	I-DNAMutation
)	I-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
2209	I-DNAMutation
.	O

As	O
the	O
genomic	O
DNA	O
sequencing	O
excluded	O
the	O
presence	O
of	O
splicing	O
mutations	O
,	O
polymerase	O
chain	O
reaction	O
analysis	O
was	O
performed	O
for	O
polymorphisms	O
listed	O
in	O
the	O
NCBI	O
SNP	O
database	O
for	O
the	O
ARSB	O
gene	O
.	O

This	O
allowed	O
the	O
mutation	O
at	O
the	O
genomic	O
DNA	O
level	O
to	O
be	O
identified	O
as	O
(	B-DNAMutation
G	I-DNAMutation
-->	I-DNAMutation
C	I-DNAMutation
)	I-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
1201	I-DNAMutation
;	O
this	O
gross	O
deletion	O
,	O
involving	O
the	O
entire	O
exon	O
5	O
of	O
the	O
gene	O
and	O
parts	O
of	O
introns	O
4	O
and	O
5	O
led	O
to	O
a	O
frameshift	O
starting	O
at	O
amino	O
acid	O
300	O
and	O
resulting	O
in	O
a	O
protein	O
with	O
39%	O
amino	O
acids	O
different	O
from	O
the	O
normal	O
enzyme	O
.	O

We	O
stress	O
that	O
extensive	O
DNA	O
analysis	O
needs	O
to	O
be	O
performed	O
in	O
case	O
of	O
apparent	O
homozygosity	O
to	O
avoid	O
potential	O
errors	O
in	O
genetic	O
counseling	O
.	O

Genetic	O
polymorphisms	O
of	O
renin-angiotensin	O
system	O
and	O
progression	O
of	O
interstitial	O
nephritis	O
.	O

Genes	O
of	O
the	O
renin-angiotensin	O
system	O
(RAS)	O
are	O
involved	O
in	O
the	O
progression	O
of	O
renal	O
failure	O
.	O

Among	O
them	O
,	O
the	O
angiotensin-converting	O
enzyme	O
(ACE)	O
,	O
angiotensinogen	O
(AGT)	O
and	O
angiotensin	O
II	O
type	O
1	O
receptor	O
(AT1R)	O
genes	O
are	O
of	O
particular	O
interest	O
.	O

We	O
examined	O
polymorphisms	O
of	O
these	O
three	O
genes	O
for	O
association	O
with	O
the	O
development	O
of	O
interstitial	O
nephritis	O
and	O
progression	O
to	O
end-stage	O
renal	O
failure	O
.	O

The	O
allele	O
frequency	O
and	O
genotype	O
distribution	O
were	O
compared	O
in	O
90	O
patients	O
with	O
interstitial	O
nephritis	O
and	O
200	O
healthy	O
controls	O
.	O

DNA	O
samples	O
were	O
genotyped	O
by	O
polymerase	O
chain	O
reaction	O
(PCR)	O
.	O

We	O
did	O
not	O
find	O
statistically	O
significant	O
differences	O
between	O
groups	O
in	O
the	O
insertion/deletion	O
polymorphism	O
of	O
the	O
ACE	O
gene	O
.	O

An	O
involvement	O
of	O
methionine-->valine	B-ProteinMutation
substitution	I-ProteinMutation
at	I-ProteinMutation
codon	I-ProteinMutation
404	I-ProteinMutation
polymorphism	O
of	O
the	O
AGT	O
gene	O
in	O
renal	O
disease	O
was	O
observed	O
in	O
our	O
study	O
.	O

The	O
frequency	O
of	O
the	O
T	O
allele	O
was	O
higher	O
in	O
patients	O
than	O
in	O
controls	O
(	O
32%	O
vs	O
.	O

24%	O
)	O
.	O

In	O
the	O
G>T	B-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
c.898	I-DNAMutation
AT1R	O
polymorphism	O
the	O
homozygous	O
CC	O
genotype	O
was	O
also	O
more	O
frequent	O
in	O
interstitial	O
nephritis	O
patients	O
(	O
7%	O
vs	O
.	O

3.5%	O
)	O
.	O

In	O
patients	O
carrying	O
the	O
C	O
allele	O
,	O
an	O
average	O
time	O
to	O
ESRD	O
was	O
significantly	O
shorter	O
than	O
in	O
subjects	O
with	O
the	O
AA	O
genotype	O
.	O

Our	O
study	O
shows	O
the	O
association	O
of	O
the	O
AGT	O
and	O
AT1R	O
gene	O
polymorphisms	O
with	O
the	O
development	O
and	O
progression	O
of	O
interstitial	O
nephritis	O
.	O

The	O
C	O
allele	O
of	O
the	O
G-->C	B-DNAMutation
transversion	I-DNAMutation
at	I-DNAMutation
1245	I-DNAMutation
position	I-DNAMutation
polymorphism	O
appears	O
to	O
be	O
a	O
risk	O
factor	O
for	O
faster	O
disease	O
progression	O
.	O

Association	O
between	O
promoter	O
-1607	O
polymorphism	O
of	O
MMP1	O
and	O
lumbar	O
disc	O
disease	O
in	O
Southern	O
Chinese	O
.	O

BACKGROUND	O
:	O
Matrix	O
metalloproteinases	O
(MMPs)	O
are	O
involved	O
in	O
the	O
degradation	O
of	O
the	O
extracellular	O
matrix	O
of	O
the	O
intervertebral	O
disc	O
.	O

A	O
SNP	O
for	O
guanine	O
insertion/deletion	O
(	O
C-->T	B-DNAMutation
transversion	I-DNAMutation
at	I-DNAMutation
cDNA	I-DNAMutation
base	I-DNAMutation
463	I-DNAMutation
)	O
,	O
the	O
-1607	O
promoter	O
polymorphism	O
,	O
of	O
the	O
MMP1	O
gene	O
was	O
found	O
significantly	O
affecting	O
promoter	O
activity	O
and	O
corresponding	O
transcription	O
level	O
.	O

Hence	O
it	O
is	O
a	O
good	O
candidate	O
for	O
genetic	O
studies	O
in	O
DDD	O
.	O

METHODS	O
:	O
Southern	O
Chinese	O
volunteers	O
between	O
18	O
and	O
55	O
years	O
were	O
recruited	O
from	O
the	O
population	O
.	O

DDD	O
in	O
the	O
lumbar	O
spine	O
was	O
defined	O
by	O
MRI	O
using	O
Schneiderman's	O
classification	O
.	O

Genomic	O
DNA	O
was	O
isolated	O
from	O
the	O
leukocytes	O
and	O
genotyping	O
was	O
performed	O
using	O
the	O
Sequenom	O
platform	O
.	O

Association	O
and	O
Hardy-Weinberg	O
equilibrium	O
checking	O
were	O
assessed	O
by	O
Chi-square	O
test	O
and	O
Mann-Whitney	O
U	O
test	O
.	O

RESULTS	O
:	O
Our	O
results	O
showed	O
substantial	O
evidence	O
of	O
association	O
between	O
-1607	O
promoter	O
polymorphism	O
of	O
MMP1	O
and	O
DDD	O
in	O
the	O
Southern	O
Chinese	O
subjects	O
.	O

D	O
allelic	O
was	O
significantly	O
associated	O
with	O
DDD	O
(	O
p	O
value	O
=	O
0.027	O
,	O
odds	O
ratio	O
=	O
1.41	O
with	O
95%	O
CI	O
=	O
1.04-1.90	O
)	O
while	O
Genotypic	O
association	O
on	O
the	O
presence	O
of	O
D	O
allele	O
was	O
also	O
significantly	O
associated	O
with	O
DDD	O
(	O
p	O
value	O
=	O
0.046	O
,	O
odds	O
ratio	O
=	O
1.50	O
with	O
95%	O
CI	O
=	O
1.01-2.24	O
)	O
.	O

Further	O
age	O
stratification	O
showed	O
significant	O
genotypic	O
as	O
well	O
as	O
allelic	O
association	O
in	O
the	O
group	O
of	O
over	O
40	O
years	O
(	O
genotypic	O
:	O
p	O
value	O
=	O
0.035	O
,	O
odds	O
ratio	O
=	O
1.617	O
with	O
95%	O
CI	O
=	O
1.033-2.529	O
;	O
allelic	O
:	O
p	O
value	O
=	O
0.033	O
,	O
odds	O
ratio	O
=	O
1.445	O
with	O
95%	O
CI	O
=	O
1.029-2.029	O
)	O
.	O

Disc	O
bulge	O
,	O
annular	O
tears	O
and	O
the	O
Schmorl's	O
nodes	O
were	O
not	O
associated	O
with	O
the	O
D	O
allele	O
.	O

CONCLUSION	O
:	O
We	O
demonstrated	O
that	O
individuals	O
with	O
the	O
presence	O
of	O
D	O
allele	O
for	O
the	O
-1607	O
promoter	O
polymorphism	O
of	O
MMP1	O
are	O
about	O
1.5	O
times	O
more	O
susceptible	O
to	O
develop	O
DDD	O
when	O
compared	O
with	O
those	O
having	O
G	O
allele	O
only	O
.	O

Further	O
association	O
was	O
identified	O
in	O
individuals	O
over	O
40	O
years	O
of	O
age	O
.	O

Disc	O
bulge	O
,	O
annular	O
tear	O
as	O
well	O
as	O
Schmorl's	O
nodes	O
were	O
not	O
associated	O
with	O
this	O
polymorphism	O
.	O

Large	O
contiguous	O
gene	O
deletions	O
in	O
Sj	O
	O
gren-Larsson	O
syndrome	O
.	O

Sj	O
	O
gren-Larsson	O
syndrome	O
(SLS)	O
is	O
an	O
autosomal	O
recessive	O
disorder	O
characterized	O
by	O
ichthyosis	O
,	O
mental	O
retardation	O
,	O
spasticity	O
and	O
mutations	O
in	O
the	O
ALDH3A2	O
gene	O
for	O
fatty	O
aldehyde	O
dehydrogenase	O
,	O
an	O
enzyme	O
that	O
catalyzes	O
the	O
oxidation	O
of	O
fatty	O
aldehyde	O
to	O
fatty	O
acid	O
.	O

More	O
than	O
70	O
mutations	O
have	O
been	O
identified	O
in	O
SLS	O
patients	O
,	O
including	O
small	O
deletions	O
or	O
insertions	O
,	O
missense	O
mutations	O
,	O
splicing	O
defects	O
and	O
complex	O
nucleotide	O
changes	O
.	O

We	O
now	O
describe	O
2	O
SLS	O
patients	O
whose	O
disease	O
is	O
caused	O
by	O
large	O
contiguous	O
gene	O
deletions	O
of	O
the	O
ALDH3A2	O
locus	O
on	O
17p11.2	O
.	O

The	O
deletions	O
were	O
defined	O
using	O
long	O
distance	O
inverse	O
PCR	O
and	O
microarray-based	O
comparative	O
genomic	O
hybridization	O
.	O

A	O
24-year-old	O
SLS	O
female	O
was	O
homozygous	O
for	O
a	O
352-kb	O
deletion	O
involving	O
ALDH3A2	O
and	O
4	O
contiguous	O
genes	O
including	O
ALDH3A1	O
,	O
which	O
codes	O
for	O
the	O
major	O
soluble	O
protein	O
in	O
cornea	O
.	O

Although	O
lacking	O
corneal	O
disease	O
,	O
she	O
showed	O
severe	O
symptoms	O
of	O
SLS	O
with	O
uncommon	O
deterioration	O
in	O
oral	O
motor	O
function	O
and	O
loss	O
of	O
ambulation	O
.	O

The	O
other	O
19-month-old	O
female	O
patient	O
was	O
a	O
compound	O
heterozygote	O
for	O
a	O
1.44-Mb	O
contiguous	O
gene	O
deletion	O
and	O
a	O
missense	O
mutation	O
(	O
G-->C	B-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
135	I-DNAMutation
,	O
Ser-->Cys	B-ProteinMutation
substitution	I-ProteinMutation
at	I-ProteinMutation
the	I-ProteinMutation
codon	I-ProteinMutation
326	I-ProteinMutation
)	O
in	O
ALDH3A2	O
.	O

These	O
studies	O
suggest	O
that	O
large	O
gene	O
deletions	O
may	O
account	O
for	O
up	O
to	O
5%	O
of	O
the	O
mutant	O
alleles	O
in	O
SLS	O
.	O

Geneticists	O
should	O
consider	O
the	O
possibility	O
of	O
compound	O
heterozygosity	O
for	O
large	O
deletions	O
in	O
patients	O
with	O
SLS	O
and	O
other	O
inborn	O
errors	O
of	O
metabolism	O
,	O
which	O
has	O
implications	O
for	O
carrier	O
testing	O
and	O
prenatal	O
diagnosis	O
.	O

Exploratory	O
investigation	O
on	O
functional	O
significance	O
of	O
ETS2	O
and	O
SIM2	O
genes	O
in	O
Down	O
syndrome	O
.	O

Trisomy	O
of	O
the	O
21{st}	O
chromosome	O
leads	O
to	O
an	O
over	O
dosage	O
of	O
several	O
regulatory	O
genes	O
in	O
Down	O
syndrome	O
(DS)	O
.	O

Though	O
allelic	O
and	O
genotypic	O
combinations	O
formed	O
between	O
genes	O
are	O
interesting	O
,	O
till	O
date	O
,	O
this	O
particular	O
area	O
has	O
never	O
been	O
explored	O
in	O
DS	O
.	O

In	O
the	O
present	O
investigation	O
four	O
SNPs	O
in	O
two	O
transcription	O
factors	O
,	O
Single	O
minded	O
2	O
(SIM2)	O
and	O
V-ets	O
erythroblastosis	O
virus	O
E26	O
oncogene	O
homolog2	O
(ETS2)	O
,	O
located	O
in	O
the	O
21{st}	O
chromosome	O
were	O
genotyped	O
to	O
understand	O
their	O
role	O
in	O
DS	O
.	O

Genomic	O
DNA	O
of	O
eastern	O
Indian	O
probands	O
with	O
DS	O
(N=132)	O
,	O
their	O
parents	O
(N=209)	O
and	O
ethnically	O
matched	O
controls	O
(N=149)	O
was	O
subjected	O
to	O
PCR-based	O
analyses	O
of	O
functionally	O
important	O
SNPs	O
followed	O
by	O
statistical	O
analyses	O
.	O

ETS2	O
rs461155	O
showed	O
high	O
heterozygosity	O
in	O
DS	O
.	O

Significantly	O
lower	O
frequency	O
of	O
SIM2	O
C-G	O
haplotype	O
(rs2073601-rs2073416)	O
was	O
noticed	O
in	O
individuals	O
with	O
DS	O
(	O
P	O
value	O
=0.01669	O
)	O
and	O
their	O
fathers	O
(	O
P	O
value=0.01185	O
)	O
.	O

Significantly	O
lower	O
frequency	O
of	O
the	O
A-C-C-G	O
with	O
higher	O
frequency	O
of	O
A-C-A-G	O
haplotypes	O
was	O
also	O
noticed	O
in	O
subjects	O
with	O
DS	O
(	O
P	O
value	O
=0.02089	O
and	O
0.00588	O
respectively	O
)	O
.	O

Data	O
obtained	O
indicate	O
that	O
the	O
rs2073601	O
'A'	O
allele	O
,	O
responsible	O
for	O
nonsynonymous	O
substitution	O
of	O
leucine	O
to	O
methionine	O
,	O
may	O
have	O
some	O
role	O
in	O
DS	O
in	O
this	O
population	O
.	O

Genomic	O
characterization	O
of	O
five	O
deletions	O
in	O
the	O
LDL	O
receptor	O
gene	O
in	O
Danish	O
Familial	O
Hypercholesterolemic	O
subjects	O
.	O

BACKGROUND	O
:	O
Familial	O
Hypercholesterolemia	O
is	O
a	O
common	O
autosomal	O
dominantly	O
inherited	O
disease	O
that	O
is	O
most	O
frequently	O
caused	O
by	O
mutations	O
in	O
the	O
gene	O
encoding	O
the	O
receptor	O
for	O
low	O
density	O
lipoproteins	O
(LDLR)	O
.	O

Deletions	O
and	O
other	O
major	O
structural	O
rearrangements	O
of	O
the	O
LDLR	O
gene	O
account	O
for	O
approximately	O
5%	O
of	O
the	O
mutations	O
in	O
many	O
populations	O
.	O

METHODS	O
:	O
Five	O
genomic	O
deletions	O
in	O
the	O
LDLR	O
gene	O
were	O
characterized	O
by	O
amplification	O
of	O
mutated	O
alleles	O
and	O
sequencing	O
to	O
identify	O
genomic	O
breakpoints	O
.	O

A	O
diagnostic	O
assay	O
based	O
on	O
duplex	O
PCR	O
for	O
the	O
exon	O
7-8	O
deletion	O
was	O
developed	O
to	O
discriminate	O
between	O
heterozygotes	O
and	O
normals	O
,	O
and	O
bioinformatic	O
analyses	O
were	O
used	O
to	O
identify	O
interspersed	O
repeats	O
flanking	O
the	O
deletions	O
.	O

RESULTS	O
:	O
In	O
one	O
case	O
15	O
bp	O
had	O
been	O
inserted	O
at	O
the	O
site	O
of	O
the	O
deleted	O
DNA	O
,	O
and	O
,	O
in	O
all	O
five	O
cases	O
,	O
Alu	O
elements	O
flanked	O
the	O
sites	O
where	O
deletions	O
had	O
occurred	O
.	O

An	O
assay	O
developed	O
to	O
discriminate	O
the	O
wildtype	O
and	O
the	O
deletion	O
allele	O
in	O
a	O
simple	O
duplex	O
PCR	O
detected	O
three	O
FH	O
patients	O
as	O
heterozygotes	O
,	O
and	O
two	O
individuals	O
with	O
normal	O
lipid	O
values	O
were	O
detected	O
as	O
normal	O
homozygotes	O
.	O

CONCLUSION	O
:	O
The	O
identification	O
of	O
the	O
breakpoints	O
should	O
make	O
it	O
possible	O
to	O
develop	O
specific	O
tests	O
for	O
these	O
mutations	O
,	O
and	O
the	O
data	O
provide	O
further	O
evidence	O
for	O
the	O
role	O
of	O
Alu	O
repeats	O
in	O
intragenic	O
deletions	O
.	O

Two	O
novel	O
mutations	O
of	O
the	O
PAX6	O
gene	O
causing	O
different	O
phenotype	O
in	O
a	O
cohort	O
of	O
Chinese	O
patients	O
.	O

PURPOSE	O
:	O
Aniridia	O
(AN)	O
is	O
a	O
rare	O
congenital	O
panocular	O
disorder	O
caused	O
by	O
the	O
mutations	O
of	O
the	O
paired	O
box	O
homeotic	O
gene	O
6(PAX6)	O
gene	O
.	O

The	O
PAX6gene	O
is	O
also	O
involved	O
in	O
other	O
anterior	O
segment	O
malformations	O
including	O
Peters	O
anomaly	O
.	O

We	O
studied	O
the	O
PAX6gene	O
mutations	O
in	O
a	O
cohort	O
of	O
affected	O
individuals	O
with	O
different	O
clinical	O
phenotype	O
including	O
AN	O
,	O
coloboma	O
of	O
iris	O
and	O
choroid	O
,	O
or	O
anterior	O
segment	O
malformations	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Six	O
unrelated	O
families	O
and	O
10	O
sporadic	O
patients	O
were	O
examined	O
clinically	O
.	O

After	O
informed	O
consent	O
was	O
obtained	O
,	O
genomic	O
DNA	O
was	O
extracted	O
from	O
the	O
venous	O
blood	O
of	O
all	O
participants	O
.	O

Mutation	O
screening	O
of	O
all	O
exons	O
of	O
the	O
PAX6gene	O
was	O
performed	O
by	O
direct	O
sequencing	O
of	O
PCR-amplified	O
DNA	O
fragments	O
.	O

Multiplex	O
ligation-dependent	O
probe	O
amplification	O
(MLPA)	O
was	O
performed	O
to	O
detect	O
large	O
deletions	O
.	O

RESULTS	O
:	O
By	O
clinical	O
examination	O
,	O
the	O
patients	O
and	O
the	O
pedigrees	O
were	O
divided	O
into	O
the	O
following	O
three	O
groups	O
:	O
AN	O
,	O
coloboma	O
of	O
iris	O
and	O
choroids	O
,	O
and	O
the	O
anterior	O
segment	O
malformations	O
including	O
peters	O
anomaly	O
.	O

Sequencing	O
of	O
the	O
PAX6gene	O
,	O
three	O
intragenic	O
mutations	O
including	O
a	O
novel	O
heterozygous	O
splicing-site	O
mutations	O
C-->T	B-DNAMutation
transition	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
677	I-DNAMutation
(	O
leucine	B-ProteinMutation
269	I-ProteinMutation
to	I-ProteinMutation
phenylalanine	I-ProteinMutation
)	O
were	O
identified	O
in	O
the	O
patients	O
of	O
the	O
AN	O
group	O
.	O

A	O
novel	O
missense	O
mutation	O
GTT-->GCT	B-DNAMutation
transition	I-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
23	I-DNAMutation
(	O
arginine	B-ProteinMutation
555-to-tryptophan	I-ProteinMutation
)	O
was	O
detected	O
in	O
the	O
anterior	O
segment	O
malformation	O
group	O
.	O

The	O
mutation	O
histidine	B-ProteinMutation
626-to-arginine	I-ProteinMutation
located	O
in	O
the	O
homeodomain	O
region	O
of	O
the	O
PAX6	O
caused	O
the	O
phenotype	O
of	O
Peters	O
anomaly	O
in	O
family	O
A6	O
with	O
different	O
expressing	O
.	O

Through	O
MLPA	O
analysis	O
,	O
a	O
large	O
deletion	O
including	O
the	O
whole	O
PAX6gene	O
and	O
DKFZ	O
p686k1684gene	O
was	O
detected	O
in	O
one	O
sporadic	O
patient	O
from	O
the	O
AN	O
group	O
.	O

Neither	O
intragenic	O
mutation	O
nor	O
large	O
deletion	O
was	O
identified	O
in	O
the	O
group	O
with	O
coloboma	O
of	O
iris	O
and	O
choroid	O
.	O

CONCLUSION	O
:	O
Our	O
findings	O
further	O
confirmed	O
that	O
different	O
kind	O
of	O
mutations	O
might	O
cause	O
different	O
ocular	O
phenotype	O
,	O
and	O
clearly	O
clinical	O
phenotype	O
classification	O
might	O
increase	O
the	O
mutation	O
detection	O
rate	O
of	O
the	O
PAX6gene	O
.	O

A	O
novel	O
arginine	O
substitution	O
mutation	O
in	O
1A	O
domain	O
and	O
a	O
novel	O
27	O
bp	O
insertion	O
mutation	O
in	O
2B	O
domain	O
of	O
keratin	O
12	O
gene	O
associated	O
with	O
Meesmann's	O
corneal	O
dystrophy	O
.	O

AIM	O
:	O
To	O
determine	O
the	O
disease	O
causing	O
gene	O
defects	O
in	O
two	O
patients	O
with	O
Meesmann's	O
corneal	O
dystrophy	O
.	O

METHODS	O
:	O
Mutational	O
analysis	O
of	O
domains	O
1A	O
and	O
2B	O
of	O
the	O
keratin	O
3	O
(K3)	O
and	O
keratin	O
12	O
(K12)	O
genes	O
from	O
two	O
patients	O
with	O
Meesmann's	O
corneal	O
dystrophy	O
was	O
performed	O
by	O
polymerase	O
chain	O
reaction	O
amplification	O
and	O
direct	O
sequencing	O
.	O

RESULTS	O
:	O
Novel	O
mutations	O
of	O
the	O
K12	O
gene	O
were	O
identified	O
in	O
both	O
patients	O
.	O

In	O
one	O
patient	O
a	O
heterozygous	O
point	O
mutation	O
(	O
A	B-DNAMutation
>	I-DNAMutation
G	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
313	I-DNAMutation
=	O
arginine	B-ProteinMutation
124-to-cysteine	I-ProteinMutation
)	O
was	O
found	O
in	O
the	O
1A	O
domain	O
of	O
the	O
K12	O
gene	O
.	O

This	O
mutation	O
was	O
confirmed	O
by	O
restriction	O
digestion	O
.	O

In	O
the	O
second	O
patient	O
a	O
heterozygous	O
27	O
bp	O
duplication	O
was	O
found	O
inserted	O
in	O
the	O
2B	O
domain	O
at	O
nucleotide	O
position	O
1222	O
(	O
-AAGC	B-DNAMutation
at	I-DNAMutation
-222	I-DNAMutation
to	I-DNAMutation
-225	I-DNAMutation
)	O
of	O
the	O
K12	O
gene	O
.	O

This	O
mutation	O
was	O
confirmed	O
by	O
gel	O
electrophoresis	O
.	O

The	O
mutations	O
were	O
not	O
present	O
in	O
unaffected	O
controls	O
.	O

CONCLUSION	O
:	O
Novel	O
K12	O
mutations	O
were	O
linked	O
to	O
Meesmann's	O
corneal	O
dystrophy	O
in	O
two	O
different	O
patients	O
.	O

A	O
missense	O
mutation	O
replacing	O
a	O
highly	O
conserved	O
arginine	O
residue	O
in	O
the	O
beginning	O
of	O
the	O
helix	O
initiation	O
motif	O
was	O
found	O
in	O
one	O
patient	O
,	O
and	O
an	O
insertion	O
mutation	O
,	O
consisting	O
of	O
a	O
duplication	O
of	O
27	O
nucleotides	O
,	O
was	O
found	O
before	O
the	O
helix	O
termination	O
motif	O
in	O
the	O
other	O
.	O

Indirect	O
CFTR	O
mutation	O
identification	O
by	O
PCR/OLA	O
anomalous	O
electropherograms	O
.	O

Mutations	O
of	O
CFTR	O
gene	O
are	O
responsible	O
for	O
cystic	O
fibrosis	O
(CF)	O
and	O
other	O
clinical	O
conditions	O
such	O
as	O
congenital	O
absence	O
of	O
the	O
vas	O
deferens	O
(CAVD)	O
,	O
chronic	O
pancreatitis	O
(IP)	O
,	O
and	O
idiopathic	O
disseminated	O
bronchiectasis	O
(DBE)	O
classified	O
as	O
CFTR-related	O
disorders	O
.	O

The	O
PCR/OLA	O
assay	O
is	O
designed	O
to	O
detect	O
31	O
known	O
mutations	O
including	O
the	O
24	O
most	O
common	O
CF	O
mutations	O
worldwide	O
,	O
as	O
identified	O
by	O
the	O
CF	O
Consortium	O
.	O

In	O
order	O
to	O
define	O
the	O
CFTR	O
genotype	O
a	O
series	O
of	O
1812	O
individuals	O
from	O
central-southern	O
Italy	O
with	O
and	O
without	O
CF	O
manifestations	O
were	O
screened	O
by	O
using	O
the	O
PCR/OLA	O
assay	O
.	O

Here	O
we	O
report	O
the	O
description	O
of	O
five	O
cases	O
of	O
anomalous	O
electropherograms	O
obtained	O
after	O
PCR/OLA	O
analysis	O
,	O
that	O
led	O
to	O
the	O
identification	O
,	O
in	O
the	O
homozygous	O
state	O
,	O
of	O
two	O
point	O
mutations	O
(	O
Phe-->Ser	B-ProteinMutation
at	I-ProteinMutation
codon	I-ProteinMutation
15	I-ProteinMutation
and	O
Glu	B-ProteinMutation
272	I-ProteinMutation
to	I-ProteinMutation
stop	I-ProteinMutation
)	O
not	O
included	O
in	O
the	O
assay	O
test	O
panel	O
,	O
a	O
large	O
gene	O
deletion	O
(	O
CFTR-491	B-DNAMutation
A	I-DNAMutation
to	I-DNAMutation
T	I-DNAMutation
)	O
,	O
and	O
an	O
exonic	O
polymorphism	O
(	O
G>A	B-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
+1	I-DNAMutation
of	I-DNAMutation
intron	I-DNAMutation
2	I-DNAMutation
)	O
.	O

Haplotype	O
and	O
real	O
time	O
PCR	O
analysis	O
were	O
also	O
performed	O
in	O
the	O
subject	O
carrying	O
the	O
large	O
CFTR	O
deletion	O
.	O

The	O
study	O
demonstrates	O
that	O
the	O
PCR/OLA	O
assay	O
,	O
besides	O
being	O
an	O
efficient	O
and	O
user-friendly	O
method	O
to	O
screen	O
known	O
mutations	O
in	O
the	O
CFTR	O
gene	O
,	O
may	O
also	O
function	O
as	O
a	O
mutation/polymorphism-scanning	O
assay	O
,	O
at	O
least	O
for	O
certain	O
nucleotide	O
changes	O
located	O
in	O
some	O
critical	O
regions	O
of	O
the	O
gene	O
.	O

Leydig	O
cell	O
hypoplasia	O
due	O
to	O
inactivation	O
of	O
luteinizing	O
hormone	O
receptor	O
by	O
a	O
novel	O
homozygous	O
nonsense	O
truncation	O
mutation	O
in	O
the	O
seventh	O
transmembrane	O
domain	O
.	O

Inactivating	O
mutations	O
in	O
the	O
LH	O
receptor	O
are	O
the	O
predominant	O
cause	O
for	O
male	O
pseudohermaphroditism	O
in	O
subjects	O
with	O
Leydig	O
cell	O
hypoplasia	O
(LCH)	O
.	O

The	O
severity	O
of	O
the	O
mutations	O
,	O
correlates	O
with	O
residual	O
receptor	O
activities	O
.	O

Here	O
,	O
we	O
detail	O
the	O
clinical	O
presentation	O
of	O
one	O
subject	O
with	O
complete	O
male	O
pseudohermaphroditism	O
and	O
LCH	O
.	O

We	O
identify	O
within	O
the	O
proband	O
and	O
her	O
similarly	O
afflicted	O
sibling	O
a	O
homozygous	O
T	O
to	O
G	O
transversion	O
at	O
nucleotide	O
1836	O
in	O
exon	O
11	O
of	O
the	O
LH/CGR	O
gene	O
.	O

This	O
causes	O
conversion	O
of	O
a	O
tyrosine	O
codon	O
into	O
a	O
stop	O
codon	O
at	O
codon	O
612	O
in	O
the	O
seventh	O
transmembrane	O
domain	O
,	O
resulting	O
in	O
a	O
truncated	O
receptor	O
that	O
lacks	O
a	O
cytoplasmic	O
tail	O
.	O

In	O
vitro	O
,	O
in	O
contrast	O
to	O
cells	O
expressing	O
a	O
normal	O
LHR	O
,	O
cells	O
transfected	O
with	O
the	O
mutant	O
cDNA	O
exhibit	O
neither	O
surface	O
binding	O
of	O
radiolabeled	O
hCG	O
nor	O
cAMP	O
generation	O
.	O

In	O
vitro	O
expression	O
under	O
the	O
control	O
of	O
the	O
LHR	O
signal	O
peptide	O
of	O
either	O
a	O
wild	O
type	O
or	O
mutant	O
LHR-GFP	O
fusion	O
protein	O
shows	O
no	O
differences	O
in	O
receptor	O
cellular	O
localization	O
.	O

In	O
conclusion	O
,	O
the	O
in	O
vitro	O
studies	O
suggest	O
that	O
residues	O
in	O
the	O
seventh	O
transmembrane	O
domain	O
and	O
cytoplasmic	O
tail	O
are	O
important	O
for	O
receptor	O
binding	O
and	O
activation	O
without	O
playing	O
a	O
major	O
role	O
in	O
receptor	O
cellular	O
trafficking	O
.	O

Nucleotide	O
change	O
of	O
codon	O
38	O
in	O
the	O
X	O
gene	O
of	O
hepatitis	O
B	O
virus	O
genotype	O
C	O
is	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
hepatocellular	O
carcinoma	O
.	O

BACKGROUND/AIMS	O
:	O
The	O
hepatitis	O
B	O
virus	O
(HBV)	O
genotype	O
C	O
is	O
associated	O
with	O
the	O
development	O
of	O
hepatocellular	O
carcinoma	O
(HCC)	O
.	O

In	O
addition	O
,	O
the	O
HBV	O
X	O
gene	O
,	O
which	O
encodes	O
the	O
pleiotropic	O
transactivator	O
HBx	O
,	O
has	O
also	O
been	O
associated	O
with	O
the	O
development	O
of	O
HCC	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
whether	O
nucleotide	O
changes	O
in	O
the	O
X	O
gene	O
of	O
genotype	O
C	O
are	O
associated	O
with	O
the	O
development	O
of	O
HCC	O
.	O

METHODS/RESULTS	O
:	O
We	O
sequenced	O
the	O
X	O
gene	O
in	O
age-	O
and	O
sex-matched	O
39	O
HBV-infected	O
patients	O
with	O
HCC	O
and	O
36	O
HBV-infected	O
patients	O
without	O
HCC	O
.	O

A	O
novel	O
nucleotide	O
change	O
that	O
resulted	O
in	O
a	O
proline	O
to	O
serine	O
substitution	O
at	O
codon	O
38	O
in	O
HBx	O
(	O
codon-38	O
change	O
)	O
was	O
preferentially	O
found	O
in	O
patients	O
with	O
HCC	O
.	O

Then	O
,	O
sera	O
were	O
collected	O
from	O
a	O
new	O
group	O
of	O
age-	O
and	O
sex-matched	O
52	O
patients	O
with	O
HCC	O
and	O
51	O
patients	O
without	O
HCC	O
.	O

In	O
this	O
cohort	O
also	O
,	O
the	O
codon-38	O
change	O
was	O
associated	O
with	O
HCC	O
.	O

Multiple	O
logistic	O
regression	O
analysis	O
showed	O
the	O
prevalence	O
of	O
the	O
codon-38	O
change	O
was	O
significantly	O
associated	O
with	O
HCC	O
in	O
all	O
patients	O
(	O
P=0.001	O
,	O
odds	O
ratio	O
:	O
4.89	O
)	O
.	O

CONCLUSION	O
:	O
The	O
codon-38	O
change	O
in	O
genotype	O
C	O
is	O
an	O
independent	O
risk	O
factor	O
for	O
the	O
development	O
of	O
HCC	O
and	O
may	O
serve	O
as	O
a	O
useful	O
molecular	O
marker	O
for	O
predicting	O
the	O
clinical	O
outcomes	O
in	O
patients	O
infected	O
with	O
HBV	O
.	O

Insertion/deletion	O
polymorphism	O
of	O
angiotensin	O
converting	O
enzyme	O
gene	O
in	O
Kawasaki	O
disease	O
.	O

Polymorphism	O
of	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
gene	O
is	O
reported	O
to	O
be	O
associated	O
with	O
ischemic	O
heart	O
disease	O
,	O
hypertrophic	O
cardiomyopathy	O
,	O
and	O
idiopathic	O
dilated	O
cardiomyopathy	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
relationship	O
between	O
Kawasaki	O
disease	O
and	O
insertion/deletion	O
polymorphism	O
of	O
ACE	O
gene	O
.	O

Fifty	O
five	O
Kawasaki	O
disease	O
patients	O
and	O
43	O
healthy	O
children	O
were	O
enrolled	O
.	O

ACE	O
genotype	O
was	O
evaluated	O
from	O
each	O
of	O
the	O
subjects'	O
DNA	O
fragments	O
through	O
polymerase	O
chain	O
reaction	O
(PCR)	O
.	O

Frequencies	O
of	O
ACE	O
genotypes	O
(	O
DD	O
,	O
ID	O
,	O
II	O
)	O
were	O
12.7%	O
,	O
60.0%	O
,	O
27.3%	O
in	O
Kawasaki	O
group	O
,	O
and	O
41.9%	O
,	O
30.2%	O
,	O
27.9%	O
in	O
control	O
group	O
respectively	O
,	O
indicating	O
low	O
rate	O
of	O
DD	O
and	O
high	O
rate	O
of	O
ID	O
genotype	O
among	O
Kawasaki	O
patients	O
(p<0.01)	O
.	O

Comparing	O
allelic	O
(	O
I	O
,	O
D	O
)	O
frequencies	O
,	O
I	O
allele	O
was	O
more	O
prevalent	O
in	O
Kawasaki	O
group	O
than	O
in	O
control	O
group	O
(	O
57.3%	O
vs	O
.	O

43.0%	O
,	O
p<0.05	O
)	O
.	O

In	O
Kawasaki	O
group	O
,	O
both	O
genotype	O
and	O
allelic	O
frequencies	O
were	O
not	O
statistically	O
different	O
between	O
those	O
with	O
coronary	O
dilatations	O
and	O
those	O
without	O
.	O

ACE	O
gene	O
I/D	O
polymorphism	O
is	O
thought	O
to	O
be	O
associated	O
with	O
Kawasaki	O
disease	O
but	O
not	O
with	O
the	O
development	O
of	O
coronary	O
dilatations	O
.	O

Identification	O
of	O
a	O
novel	O
WFS1	O
mutation	O
(	O
methionine-->valine	B-ProteinMutation
substitution	I-ProteinMutation
at	I-ProteinMutation
codon	I-ProteinMutation
404	I-ProteinMutation
)	O
in	O
Japanese	O
patients	O
with	O
Wolfram	O
syndrome	O
.	O

Wolfram	O
syndrome	O
(WFS)	O
is	O
an	O
autosomal	O
recessive	O
disorder	O
characterized	O
by	O
early	O
onset	O
diabetes	O
mellitus	O
,	O
progressive	O
optic	O
atrophy	O
,	O
sensorineural	O
deafness	O
and	O
diabetes	O
insipidus	O
.	O

Affected	O
individuals	O
may	O
also	O
have	O
renal	O
tract	O
abnormalities	O
as	O
well	O
as	O
neurogical	O
and	O
psychiatric	O
syndromes	O
.	O

WFS1	O
encoding	O
a	O
transmembrane	O
protein	O
was	O
identified	O
as	O
the	O
gene	O
responsible	O
for	O
WFS	O
.	O

We	O
report	O
herein	O
a	O
Japanese	O
family	O
,	O
of	O
which	O
two	O
members	O
had	O
this	O
syndrome	O
.	O

In	O
the	O
WFS1	O
gene	O
of	O
these	O
patients	O
,	O
we	O
identified	O
a	O
novel	O
mutation	O
,	O
a	O
nine	O
nucleotide	O
insertion	O
(	O
Ser-->Cys	B-ProteinMutation
substitution	I-ProteinMutation
at	I-ProteinMutation
the	I-ProteinMutation
codon	I-ProteinMutation
326	I-ProteinMutation
)	O
.	O

In	O
addition	O
,	O
one	O
of	O
these	O
patients	O
had	O
preclinical	O
hypopituitarism	O
,	O
which	O
is	O
an	O
unusual	O
feature	O
of	O
WFS	O
.	O

As	O
only	O
the	O
two	O
family	O
members	O
homozygous	O
for	O
the	O
mutation	O
showed	O
WFS	O
,	O
these	O
data	O
support	O
the	O
notion	O
that	O
this	O
mutation	O
is	O
the	O
cause	O
of	O
WFS	O
.	O

Three	O
novel	O
IGFALS	O
gene	O
mutations	O
resulting	O
in	O
total	O
ALS	O
and	O
severe	O
circulating	O
IGF-I/IGFBP-3	O
deficiency	O
in	O
children	O
of	O
different	O
ethnic	O
origins	O
.	O

BACKGROUND/AIMS	O
:	O
To	O
date	O
,	O
four	O
mutations	O
in	O
the	O
IGFALS	O
gene	O
have	O
been	O
reported	O
.	O

We	O
now	O
describe	O
two	O
children	O
of	O
different	O
ethnic	O
background	O
with	O
total	O
acid-labile	O
subunit	O
(ALS)	O
and	O
severe	O
circulating	O
IGF-I/IGFBP-3	O
deficiencies	O
resulting	O
from	O
three	O
novel	O
mutations	O
in	O
the	O
IGFALS	O
gene	O
.	O

PATIENTS/METHODS	O
:	O
Serum	O
and	O
DNA	O
of	O
patients	O
were	O
analyzed	O
.	O

RESULTS	O
:	O
Case	O
1	O
is	O
a	O
12-year-old	O
boy	O
of	O
Mayan	O
origin	O
.	O

Case	O
2	O
is	O
a	O
5-year-old	O
girl	O
of	O
Jewish/Eastern	O
European	O
(	O
Polish	O
,	O
Russian	O
,	O
Austrian-Hungarian)/Icelandic/European	O
(	O
French	O
,	O
English	O
)	O
ancestry	O
.	O

The	O
reported	O
cases	O
had	O
moderate	O
short	O
stature	O
(	O
-2.91	O
and	O
-2.14	O
SDS	O
,	O
respectively	O
)	O
,	O
nondetectable	O
serum	O
ALS	O
and	O
extremely	O
low	O
serum	O
concentrations	O
of	O
IGF-I	O
and	O
IGFBP-3	O
.	O

Case	O
1	O
harbored	O
a	O
novel	O
homozygous	O
(	B-DNAMutation
G	I-DNAMutation
-->	I-DNAMutation
C	I-DNAMutation
)	I-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
1201	I-DNAMutation
mutation	O
in	O
a	O
highly	O
conserved	O
leucine-rich	O
repeat	O
(LRR)	O
17	O
motif	O
of	O
exon	O
2	O
,	O
representing	O
an	O
in-frame	O
insertion	O
of	O
3	O
amino	O
acids	O
,	O
LEL	O
.	O

Case	O
2	O
harbored	O
a	O
novel	O
heterozygous	O
leucine	B-ProteinMutation
269	I-ProteinMutation
to	I-ProteinMutation
phenylalanine/arginine	I-ProteinMutation
555-to-tryptophan	I-ProteinMutation
mutation	O
in	O
exon	O
2	O
,	O
located	O
within	O
a	O
highly	O
conserved	O
LRR	O
1	O
and	O
LRR	O
9	O
,	O
respectively	O
.	O

CONCLUSIONS	O
:	O
The	O
identification	O
of	O
additional	O
novel	O
IGFALS	O
mutations	O
,	O
resulting	O
in	O
severe	O
IGF-I/IGFBP-3	O
and	O
ALS	O
deficiencies	O
,	O
supports	O
IGFALS	O
as	O
a	O
candidate	O
gene	O
of	O
the	O
GH/IGF	O
system	O
,	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
primary	O
IGF	O
deficiency	O
,	O
and	O
represents	O
an	O
important	O
part	O
of	O
its	O
differential	O
diagnosis	O
.	O

Coincidence	O
of	O
mutations	O
in	O
different	O
connexin	O
genes	O
in	O
Hungarian	O
patients	O
.	O

Mutations	O
in	O
the	O
GJB2	O
gene	O
are	O
the	O
most	O
common	O
cause	O
of	O
hereditary	O
prelingual	O
sensorineural	O
hearing	O
impairment	O
in	O
Europe	O
.	O

Several	O
studies	O
indicate	O
that	O
different	O
members	O
of	O
the	O
connexin	O
protein	O
family	O
interact	O
to	O
form	O
gap	O
junctions	O
in	O
the	O
inner	O
ear	O
.	O

Mutations	O
in	O
different	O
connexin	O
genes	O
may	O
accumulate	O
and	O
,	O
consequently	O
lead	O
to	O
hearing	O
impairment	O
.	O

Therefore	O
,	O
we	O
screened	O
47	O
Hungarian	O
GJB2-	O
heterozygous	O
(	O
one	O
mutation	O
in	O
coding	O
exon	O
of	O
the	O
GJB2	O
gene	O
)	O
patients	O
with	O
hearing	O
impairment	O
for	O
DNA	O
changes	O
in	O
two	O
further	O
connexin	O
genes	O
(	O
GJB6	O
and	O
GJB3	O
)	O
and	O
in	O
the	O
5'	O
non-coding	O
region	O
of	O
GJB2	O
including	O
the	O
splice	O
sites	O
.	O

Eleven	O
out	O
of	O
47	O
GJB2-heterozygous	O
patients	O
analyzed	O
carried	O
the	O
splice	O
site	O
mutation	O
(	B-DNAMutation
T	I-DNAMutation
-->	I-DNAMutation
C	I-DNAMutation
)	I-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
2209	I-DNAMutation
in	O
the	O
5'UTR	O
region	O
of	O
GJB2	O
.	O

One	O
out	O
of	O
these	O
11	O
patients	O
showed	O
homozygous	O
G>T	B-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
c.898	I-DNAMutation
genotype	O
in	O
combination	O
with	O
histidine	B-ProteinMutation
626-to-arginine	I-ProteinMutation
.	O

Next	O
to	O
the	O
GJB2	O
mutations	O
we	O
noted	O
2	O
cases	O
of	O
deletion	O
in	O
GJB6	O
[Delta(GJB6-D13S1830)]	O
and	O
3	O
(	O
2	O
new	O
and	O
1	O
described	O
)	O
base	O
substitutions	O
in	O
GJB3	O
[	O
C-->T	B-DNAMutation
transversion	I-DNAMutation
at	I-DNAMutation
cDNA	I-DNAMutation
base	I-DNAMutation
463	I-DNAMutation
,	O
G-->C	B-DNAMutation
transversion	I-DNAMutation
at	I-DNAMutation
1245	I-DNAMutation
position	I-DNAMutation
and	O
C-->T	B-DNAMutation
transition	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
677	I-DNAMutation
(	O
arginine	B-ProteinMutation
124-to-cysteine)	I-ProteinMutation
]	O
which	O
are	O
unlikely	O
disease-causing	O
.	O

Our	O
results	O
suggest	O
the	O
importance	O
of	O
routine	O
screening	O
for	O
the	O
rather	O
frequent	O
G-->C	B-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
135	I-DNAMutation
mutation	O
(	O
in	O
addition	O
to	O
GTT-->GCT	B-DNAMutation
transition	I-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
23	I-DNAMutation
)	O
in	O
patients	O
with	O
hearing	O
impairment	O
.	O

Association	O
of	O
DNA	O
polymorphisms	O
within	O
the	O
CYP11B2/CYP11B1	O
locus	O
and	O
postoperative	O
hypertension	O
risk	O
in	O
the	O
patients	O
with	O
aldosterone-producing	O
adenomas	O
.	O

OBJECTIVES	O
:	O
Hypertension	O
often	O
persists	O
after	O
adrenalectomy	O
for	O
primary	O
aldosteronism	O
.	O

Traditional	O
factors	O
associated	O
with	O
postoperative	O
hypertension	O
were	O
evaluated	O
,	O
but	O
whether	O
genetic	O
determinants	O
were	O
involved	O
remains	O
poorly	O
understood	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
association	O
of	O
DNA	O
polymorphisms	O
within	O
steroid	O
synthesis	O
genes	O
(	O
CYP11B2	O
,	O
CYP11B1	O
)	O
and	O
the	O
postoperative	O
resolution	O
of	O
hypertension	O
in	O
Chinese	O
patients	O
undergoing	O
adrenalectomy	O
for	O
aldosterone-producing	O
adenomas	O
(APA)	O
.	O

METHODS	O
:	O
Ninety-three	O
patients	O
with	O
APA	O
were	O
assessed	O
for	O
postoperative	O
resolution	O
of	O
hypertension	O
.	O

All	O
patients	O
were	O
genotyped	O
for	O
rs1799998	O
(	O
A	B-DNAMutation
>	I-DNAMutation
G	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
313	I-DNAMutation
)	O
,	O
intron	O
2	O
conversion	O
,	O
rs4539	O
(	O
-AAGC	B-DNAMutation
at	I-DNAMutation
-222	I-DNAMutation
to	I-DNAMutation
-225	I-DNAMutation
)	O
within	O
CYP11B2	O
and	O
rs6410	O
(	O
-491	B-DNAMutation
A	I-DNAMutation
to	I-DNAMutation
T	I-DNAMutation
)	O
,	O
rs6387	O
(	O
G>A	B-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
+1	I-DNAMutation
of	I-DNAMutation
intron	I-DNAMutation
2	I-DNAMutation
)	O
within	O
CYP11B1	O
.	O

The	O
associations	O
between	O
CYPB11B2/CYP11B1	O
polymorphisms	O
and	O
persistent	O
postoperative	O
hypertension	O
were	O
assessed	O
by	O
multivariate	O
analysis	O
.	O

RESULTS	O
:	O
CYP11B2-CYP11B1	O
haplotype	O
was	O
associated	O
with	O
persistent	O
postoperative	O
hypertension	O
in	O
Chinese	O
patients	O
undergoing	O
adrenalectomy	O
with	O
APA	O
(	O
P	O
=	O
.006	O
)	O
.	O

Specifically	O
,	O
the	O
rs4539	O
(AA)	O
polymorphism	O
was	O
associated	O
with	O
persistent	O
postoperative	O
hypertension	O
(	O
P	O
=	O
.002	O
)	O
.	O

Multivariate	O
logistic	O
regression	O
revealed	O
the	O
common	O
haplotypes	O
H1	O
(AGACT)	O
,	O
H2	O
(AGAWT)	O
,	O
and	O
H3	O
(AGAWC)	O
were	O
associated	O
with	O
the	O
persistent	O
postoperative	O
hypertension	O
(	O
P	O
=	O
.01	O
,	O
0.03	O
,	O
0.005	O
after	O
Bonferroni	O
correction	O
)	O
.	O

Additional	O
predictors	O
of	O
persistent	O
postoperative	O
hypertension	O
included	O
duration	O
of	O
hypertension	O
(	O
P	O
<.0005	O
)	O
,	O
family	O
history	O
of	O
hypertension	O
(	O
P	O
=	O
.001	O
)	O
,	O
and	O
elevated	O
systolic	O
blood	O
pressure	O
(	O
P	O
=	O
.015	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
rs4539	O
(AA)	O
,	O
H1	O
,	O
H2	O
,	O
and	O
H3	O
are	O
genetic	O
predictors	O
for	O
postoperative	O
persistence	O
of	O
hypertension	O
for	O
Chinese	O
patients	O
treated	O
by	O
adrenalectomy	O
with	O
APA	O
.	O

DNA	O
polymorphisms	O
at	O
CYP11B2/B1	O
locus	O
may	O
confer	O
susceptibility	O
to	O
postoperative	O
hypertension	O
of	O
patients	O
with	O
APA	O
.	O

Hb	O
zoeterwoude	O
[	O
beta23(B5)Phe-->Ser	B-ProteinMutation
at	I-ProteinMutation
codon	I-ProteinMutation
15)	I-ProteinMutation
]	O
:	O
a	O
new	O
beta-globin	O
variant	O
found	O
in	O
association	O
with	O
erythrocytosis	O
.	O

We	O
describe	O
the	O
characterization	O
of	O
a	O
new	O
hemoglobin	O
(Hb)	O
variant	O
found	O
in	O
a	O
77-year-old	O
Dutch	O
woman	O
,	O
suspected	O
of	O
hypoxia-mediated	O
erythrocytosis	O
.	O

The	O
typical	O
blood	O
parameters	O
(	O
Hb	O
17.3	O
g/dL	O
;	O
PCV	O
0.525	O
L/L	O
;	O
RBC	O
5.82	O
x	O
10(12)/L	O
)	O
could	O
not	O
be	O
explained	O
by	O
any	O
of	O
the	O
pathological	O
or	O
physiological	O
conditions	O
causing	O
erythrocytosis	O
.	O

The	O
patient	O
was	O
preventively	O
phlebotomized	O
because	O
of	O
intermittent	O
claudication	O
and	O
erythrocytosis	O
.	O

At	O
the	O
hematological	O
and	O
biochemical	O
levels	O
,	O
no	O
anemia	O
or	O
hemolysis	O
were	O
present	O
and	O
no	O
abnormal	O
Hb	O
fractions	O
were	O
detectable	O
on	O
alkaline	O
electrophoresis	O
or	O
high	O
performance	O
liquid	O
chromatography	O
(HPLC)	O
.	O

Molecular	O
analysis	O
revealed	O
intact	O
alpha-globin	O
genes	O
and	O
a	O
heterozygosity	O
for	O
a	O
(	B-DNAMutation
G	I-DNAMutation
-->	I-DNAMutation
C	I-DNAMutation
)	I-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
1201	I-DNAMutation
of	O
the	O
beta-globin	O
gene	O
,	O
causing	O
a	O
Glu	B-ProteinMutation
272	I-ProteinMutation
to	I-ProteinMutation
stop	I-ProteinMutation
amino	O
acid	O
substitution	O
.	O

The	O
P50	O
measured	O
in	O
full	O
blood	O
indicated	O
that	O
this	O
mutant	O
has	O
an	O
elevated	O
oxygen	O
affinity	O
.	O

This	O
is	O
the	O
fourth	O
single	O
nucleotide	O
substitution	O
at	O
codon	O
23	O
of	O
the	O
beta	O
gene	O
and	O
the	O
second	O
associated	O
with	O
erythrocytosis	O
.	O

Because	O
the	O
family	O
was	O
not	O
available	O
for	O
investigation	O
no	O
information	O
was	O
obtained	O
as	O
to	O
whether	O
the	O
mutation	O
represents	O
a	O
de	O
novo	O
event	O
or	O
was	O
inherited	O
,	O
and	O
might	O
be	O
a	O
more	O
common	O
cause	O
of	O
erythrocytosis	O
in	O
Dutch	O
patients	O
.	O

Considering	O
the	O
relatively	O
high	O
frequency	O
of	O
beta-thalassemia	O
(thal)	O
in	O
the	O
large	O
allochthonous	O
population	O
in	O
The	O
Netherlands	O
,	O
combinations	O
of	O
Hb	O
Zoeterwoude	O
and	O
beta-thal	O
traits	O
may	O
lead	O
to	O
hemizygosity	O
,	O
with	O
severe	O
hypoxia	O
and	O
erythrocytosis	O
from	O
a	O
few	O
months	O
after	O
birth	O
.	O

Bikunin	O
and	O
a1-microglobulin/bikunin	O
precursor	O
(AMBP)	O
gene	O
mutational	O
screening	O
in	O
patients	O
with	O
kidney	O
stones	O
:	O
a	O
case-control	O
study	O
.	O

OBJECTIVE	O
:	O
Bikunin	O
is	O
an	O
inhibitor	O
of	O
kidney	O
stone	O
formation	O
synthesized	O
in	O
the	O
liver	O
together	O
with	O
a(1)-microglobulin	O
from	O
the	O
a(1)-microglobulin/bikunin	O
precursor	O
(AMBP)	O
gene	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
possible	O
association	O
between	O
bikunin/AMBP	O
gene	O
polymorphisms	O
and	O
urinary	O
stone	O
formation	O
.	O

MATERIAL	O
AND	O
METHODS	O
:	O
To	O
analyse	O
the	O
DNA	O
,	O
blood	O
samples	O
were	O
taken	O
from	O
75	O
kidney	O
stone	O
formers	O
who	O
had	O
a	O
familial	O
stone	O
history	O
,	O
35	O
sporadic	O
stone	O
formers	O
and	O
101	O
healthy	O
individuals	O
.	O

Four	O
exons	O
of	O
bikunin	O
gene	O
and	O
five	O
parts	O
of	O
the	O
promoter	O
region	O
of	O
the	O
AMBP	O
gene	O
were	O
screened	O
using	O
single-strand	O
conformation	O
polymorphism	O
and	O
nucleotide	O
sequence	O
analysis	O
.	O

RESULTS	O
:	O
The	O
Init-2	O
region	O
of	O
the	O
promoter	O
of	O
AMBP	O
gene	O
had	O
polymorphisms	O
at	O
positions	O
-218	O
and	O
-189	O
nt	O
giving	O
three	O
different	O
genotypes	O
having	O
1,3	O
,	O
2,4	O
and	O
1,2,3,4	O
alleles	O
with	O
frequencies	O
of	O
17.06%	O
,	O
60.19%	O
and	O
22.75%	O
,	O
respectively	O
,	O
in	O
all	O
groups	O
.	O

Therefore	O
,	O
the	O
Init-2	O
region	O
appears	O
to	O
be	O
polymorphic	O
.	O

As	O
a	O
result	O
,	O
the	O
1,3	O
allele	O
has	O
-218G	O
and	O
-189T	O
complying	O
with	O
the	O
reference	O
database	O
sequence	O
,	O
the	O
2,4	O
allele	O
has	O
-218G	O
and	O
(	B-DNAMutation
T	I-DNAMutation
-->	I-DNAMutation
C	I-DNAMutation
)	I-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
2209	I-DNAMutation
substitution	O
and	O
the	O
allele	O
1,2,3,4	O
genotype	O
has	O
substitutions	O
at	O
positions	O
G>T	B-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
c.898	I-DNAMutation
and	O
C-->T	B-DNAMutation
transversion	I-DNAMutation
at	I-DNAMutation
cDNA	I-DNAMutation
base	I-DNAMutation
463	I-DNAMutation
.	O

CONCLUSIONS	O
:	O
There	O
were	O
no	O
significant	O
differences	O
in	O
allele	O
distribution	O
between	O
patients	O
and	O
controls	O
.	O

These	O
common	O
alleles	O
exist	O
in	O
the	O
Turkish	O
population	O
independent	O
of	O
stone	O
formation	O
.	O

These	O
results	O
are	O
the	O
first	O
to	O
demonstrate	O
the	O
existence	O
of	O
bikunin	O
and	O
AMBP	O
promoter	O
polymorphism	O
.	O

Although	O
the	O
Init-2	O
region	O
of	O
the	O
AMBP	O
gene	O
is	O
the	O
binding	O
site	O
for	O
various	O
transcription	O
factors	O
,	O
the	O
results	O
showed	O
no	O
association	O
between	O
these	O
observed	O
genotypes	O
and	O
stone-forming	O
phenotypes	O
.	O

Identification	O
of	O
a	O
novel	O
FBN1	O
gene	O
mutation	O
in	O
a	O
Chinese	O
family	O
with	O
Marfan	O
syndrome	O
.	O

PURPOSE	O
:	O
To	O
identify	O
the	O
mutation	O
in	O
the	O
fibrillin-1	O
gene	O
(FBN1)	O
in	O
a	O
Chinese	O
family	O
with	O
Marfan	O
syndrome	O
(MFS)	O
.	O

METHODS	O
:	O
Patients	O
and	O
family	O
members	O
were	O
given	O
complete	O
physical	O
,	O
ophthalmic	O
,	O
and	O
cardiovascular	O
examinations	O
.	O

Genomic	O
DNA	O
was	O
extracted	O
from	O
leukocytes	O
of	O
venous	O
blood	O
of	O
six	O
individuals	O
in	O
the	O
family	O
and	O
170	O
healthy	O
Chinese	O
individuals	O
.	O

All	O
of	O
the	O
65	O
coding	O
exons	O
and	O
their	O
flanking	O
intronic	O
boundaries	O
of	O
FBN1	O
were	O
amplified	O
in	O
the	O
proband	O
by	O
polymerase	O
chain	O
reaction	O
and	O
followed	O
by	O
direct	O
sequencing	O
.	O

The	O
mutation	O
identified	O
in	O
the	O
proband	O
was	O
screened	O
in	O
the	O
other	O
family	O
members	O
and	O
the	O
170	O
healthy	O
Chinese	O
individuals	O
by	O
direct	O
sequencing	O
.	O

Protein	O
conservation	O
analysis	O
was	O
performed	O
in	O
six	O
species	O
using	O
an	O
online	O
ClustalW	O
tool	O
.	O

Protein	O
structure	O
was	O
modeled	O
based	O
on	O
the	O
Protein	O
data	O
bank	O
and	O
mutated	O
in	O
DeepView	O
v4.0.1	O
to	O
predict	O
the	O
functional	O
consequences	O
of	O
the	O
mutation	O
.	O

RESULTS	O
:	O
A	O
novel	O
heterozygous	O
G-->C	B-DNAMutation
transversion	I-DNAMutation
at	I-DNAMutation
1245	I-DNAMutation
position	I-DNAMutation
change	O
in	O
exon	O
29	O
of	O
FBN1	O
was	O
detected	O
in	O
the	O
proband	O
,	O
which	O
resulted	O
in	O
the	O
substitution	O
of	O
serine	O
by	O
proline	O
at	O
codon	O
1235	O
(	O
methionine-->valine	B-ProteinMutation
substitution	I-ProteinMutation
at	I-ProteinMutation
codon	I-ProteinMutation
404	I-ProteinMutation
)	O
.	O

This	O
mutation	O
was	O
also	O
present	O
in	O
two	O
family	O
members	O
but	O
absent	O
in	O
the	O
other	O
,	O
unaffected	O
family	O
members	O
and	O
the	O
170	O
healthy	O
Chinese	O
individuals	O
.	O

The	O
mutant	O
residue	O
located	O
in	O
the	O
calcium	O
binding	O
epidermal	O
growth	O
factor-like#15	O
domain	O
is	O
highly	O
conserved	O
among	O
mammalian	O
species	O
and	O
could	O
probably	O
induce	O
conformation	O
change	O
of	O
the	O
domain	O
.	O

CONCLUSIONS	O
:	O
We	O
indentified	O
a	O
novel	O
Ser-->Cys	B-ProteinMutation
substitution	I-ProteinMutation
at	I-ProteinMutation
the	I-ProteinMutation
codon	I-ProteinMutation
326	I-ProteinMutation
mutation	O
in	O
FBN1	O
,	O
which	O
is	O
the	O
causative	O
mutation	O
for	O
MFS	O
in	O
this	O
family	O
.	O

Our	O
result	O
expands	O
the	O
mutation	O
spectrum	O
of	O
FBN1	O
and	O
contributes	O
to	O
the	O
study	O
of	O
the	O
molecular	O
pathogenesis	O
of	O
Marfan	O
syndrome	O
.	O

A	O
human	O
phospholamban	O
promoter	O
polymorphism	O
in	O
dilated	O
cardiomyopathy	O
alters	O
transcriptional	O
regulation	O
by	O
glucocorticoids	O
.	O

Depressed	O
calcium	O
handling	O
by	O
the	O
sarcoplasmic	O
reticulum	O
(SR)	O
Ca-ATPase	O
and	O
its	O
regulator	O
phospholamban	O
(PLN)	O
is	O
a	O
key	O
characteristic	O
of	O
human	O
and	O
experimental	O
heart	O
failure	O
.	O

Accumulating	O
evidence	O
indicates	O
that	O
increases	O
in	O
the	O
relative	O
levels	O
of	O
PLN	O
to	O
Ca-ATPase	O
in	O
failing	O
hearts	O
and	O
resulting	O
inhibition	O
of	O
Ca	O
sequestration	O
during	O
diastole	O
,	O
impairs	O
contractility	O
.	O

Here	O
,	O
we	O
identified	O
a	O
genetic	O
variant	O
in	O
the	O
PLN	O
promoter	O
region	O
,	O
which	O
increases	O
its	O
expression	O
and	O
may	O
serve	O
as	O
a	O
genetic	O
modifier	O
in	O
dilated	O
cardiomyopathy	O
(DCM)	O
.	O

The	O
variant	O
AF177763.1:G-->C	B-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
135	I-DNAMutation
(	O
at	O
position	O
-36	O
bp	O
relative	O
to	O
the	O
PLN	O
transcriptional	O
start	O
site	O
)	O
was	O
found	O
only	O
in	O
the	O
heterozygous	O
form	O
in	O
1	O
out	O
of	O
296	O
normal	O
subjects	O
and	O
in	O
22	O
out	O
of	O
381	O
cardiomyopathy	O
patients	O
(	O
heart	O
failure	O
at	O
age	O
of	O
18-44	O
years	O
,	O
ejection	O
fraction=22+/-9%	O
)	O
.	O

In	O
vitro	O
analysis	O
,	O
using	O
luciferase	O
as	O
a	O
reporter	O
gene	O
in	O
rat	O
neonatal	O
cardiomyocytes	O
,	O
indicated	O
that	O
the	O
PLN-variant	O
increased	O
activity	O
by	O
24%	O
compared	O
to	O
the	O
wild	O
type	O
.	O

Furthermore	O
,	O
the	O
C-->T	B-DNAMutation
transition	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
677	I-DNAMutation
substitution	O
altered	O
the	O
specific	O
sequence	O
of	O
the	O
steroid	O
receptor	O
for	O
the	O
glucocorticoid	O
nuclear	O
receptor	O
(GR)/transcription	O
factor	O
in	O
the	O
PLN	O
promoter	O
,	O
resulting	O
in	O
enhanced	O
binding	O
to	O
the	O
mutated	O
DNA	O
site	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
GTT-->GCT	B-DNAMutation
transition	I-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
23	I-DNAMutation
genetic	O
variant	O
in	O
the	O
human	O
PLN	O
promoter	O
may	O
contribute	O
to	O
depressed	O
contractility	O
and	O
accelerate	O
functional	O
deterioration	O
in	O
heart	O
failure	O
.	O

Phenotype	O
of	O
the	O
202	O
adenine	O
deletion	O
in	O
the	O
parkin	O
gene	O
:	O
40	O
years	O
of	O
follow-up	O
.	O

BACKGROUND	O
:	O
We	O
describe	O
the	O
four	O
decades	O
follow-up	O
of	O
14	O
parkin	O
patients	O
belonging	O
to	O
two	O
large	O
eight-generation-long	O
in-bred	O
Muslim-Arab	O
kindreds	O
.	O

RESULTS	O
:	O
All	O
patients	O
had	O
a	O
single	O
base-pair	O
of	O
adenine	O
deletion	O
at	O
nucleotide	O
202	O
of	O
exon	O
2	O
(202A)	O
of	O
the	O
parkin	O
gene	O
(	O
all	O
homozygous	O
,	O
one	O
heterozygous	O
)	O
.	O

Parkinson's	O
disease	O
onset	O
age	O
was	O
17-68	O
years	O
.	O

Special	O
features	O
were	O
intractable	O
axial	O
symptoms	O
(	O
low	O
back	O
pain	O
,	O
scoliosis	O
,	O
camptocormia	O
,	O
antecollis	O
)	O
,	O
postural	O
tremor	O
,	O
and	O
preserved	O
cognition	O
.	O

CONCLUSIONS	O
:	O
The	O
202A	O
deletion	O
of	O
the	O
parkin	O
gene	O
causes	O
early-onset	O
Parkinson's	O
disease	O
with	O
marked	O
levodopa/STN-DBS-resistant	O
axial	O
features	O
.	O

Postural	O
tremor	O
and	O
preserved	O
cognition	O
,	O
even	O
after	O
40	O
years	O
of	O
disease	O
,	O
were	O
also	O
evident	O
.	O

The	O
promoter	O
of	O
inducible	O
nitric	O
oxide	O
synthase	O
implicated	O
in	O
glaucoma	O
based	O
on	O
genetic	O
analysis	O
and	O
nuclear	O
factor	O
binding	O
.	O

PURPOSE	O
:	O
Nitric	O
oxide	O
has	O
many	O
beneficial	O
functions	O
in	O
the	O
human	O
body	O
at	O
the	O
right	O
amounts	O
,	O
but	O
it	O
can	O
also	O
be	O
hazardous	O
if	O
it	O
is	O
produced	O
in	O
amounts	O
more	O
than	O
needed	O
and	O
has	O
therefore	O
been	O
studied	O
in	O
relation	O
to	O
several	O
neurological	O
and	O
non-neurological	O
disorders	O
.	O

In	O
vitro	O
and	O
in	O
vivo	O
studies	O
demonstrate	O
a	O
connection	O
between	O
the	O
inducible	O
form	O
of	O
Nitric	O
Oxide	O
Synthase	O
,	O
iNOS	O
,	O
and	O
the	O
neuropathological	O
disorder	O
glaucoma	O
,	O
one	O
of	O
the	O
major	O
causes	O
of	O
blindness	O
in	O
the	O
world	O
.	O

In	O
this	O
study	O
,	O
we	O
sought	O
to	O
establish	O
the	O
genetic	O
association	O
between	O
iNOS	O
and	O
primary	O
open	O
angle	O
glaucoma	O
,	O
POAG	O
,	O
and	O
to	O
find	O
the	O
functional	O
element(s)	O
connected	O
with	O
the	O
pathogenesis	O
of	O
the	O
disease	O
.	O

METHODS	O
:	O
Two	O
microsatellites	O
,	O
1	O
insertion/deletion	O
,	O
and	O
8	O
single	O
nucleotide	O
polymorphisms	O
(SNPs)	O
in	O
the	O
regulatory	O
region	O
of	O
iNOS	O
were	O
genotyped	O
in	O
200	O
POAG	O
patients	O
and	O
200	O
age-matched	O
controls	O
.	O

Also	O
,	O
the	O
CCTTT-microsatellite	O
was	O
examined	O
for	O
its	O
protein-binding	O
capability	O
in	O
an	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
EMSA	O
.	O

RESULTS	O
:	O
There	O
was	O
a	O
significant	O
difference	O
in	O
allele	O
distribution	O
of	O
the	O
CCTTT-microsatellite	O
,	O
between	O
patients	O
and	O
controls	O
.	O

(CCTTT)14	O
,	O
which	O
has	O
been	O
reported	O
to	O
have	O
a	O
higher	O
activity	O
in	O
a	O
reporter-construct	O
,	O
was	O
significantly	O
more	O
abundant	O
in	O
POAG	O
patients	O
,	O
while	O
(CCTTT)10	O
and	O
(CCTTT)13	O
were	O
less	O
common	O
.	O

In	O
EMSA	O
,	O
the	O
(CCTTT)14	O
allele	O
exhibited	O
specific	O
binding	O
of	O
nuclear	O
proteins	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
,	O
together	O
with	O
other	O
studies	O
on	O
this	O
gene	O
and	O
the	O
CCTTT-microsatellite	O
,	O
establish	O
,	O
for	O
the	O
first	O
time	O
,	O
a	O
genetic	O
association	O
of	O
iNOS	O
with	O
POAG	O
and	O
suggest	O
a	O
regulatory	O
function	O
for	O
the	O
microsatellite	O
.	O

Adult	O
onset	O
metachromatic	O
leukodystrophy	O
without	O
electroclinical	O
peripheral	O
nervous	O
system	O
involvement	O
:	O
a	O
new	O
mutation	O
in	O
the	O
ARSA	O
gene	O
.	O

BACKGROUND	O
:	O
Metachromatic	O
leukodystrophy	O
(MLD)	O
is	O
a	O
lysosomal	O
storage	O
disease	O
caused	O
by	O
the	O
deficiency	O
of	O
arylsulfatase	O
A	O
(ARSA)	O
.	O

Clinically	O
,	O
the	O
disease	O
is	O
heterogeneous	O
with	O
respect	O
to	O
the	O
age	O
of	O
onset	O
,	O
affection	O
of	O
peripheral	O
and	O
central	O
nervous	O
systems	O
,	O
and	O
progression	O
.	O

OBJECTIVES	O
:	O
To	O
analyze	O
mutations	O
in	O
the	O
ARSA	O
gene	O
of	O
a	O
patient	O
with	O
adult-onset	O
MLD	O
with	O
no	O
signs	O
of	O
peripheral	O
polyneuropathy	O
and	O
to	O
emphasize	O
the	O
clinical	O
,	O
neuroradiologic	O
,	O
neuropathologic	O
,	O
and	O
genetic	O
features	O
of	O
the	O
disease	O
.	O

DESIGN	O
:	O
Case	O
study	O
of	O
a	O
patient	O
clinically	O
presenting	O
with	O
rapidly	O
progressive	O
dementia	O
and	O
behavioral	O
abnormalities	O
.	O

We	O
report	O
the	O
findings	O
of	O
clinical	O
evaluation	O
and	O
neurophysiologic	O
and	O
neuropathologic	O
studies	O
of	O
peripheral	O
nerves	O
;	O
we	O
also	O
performed	O
DNA	O
sequence	O
analysis	O
,	O
transfections	O
,	O
metabolic	O
labeling	O
,	O
and	O
immunoprecipitation	O
of	O
mutant	O
ARSA	O
polypeptides	O
.	O

SETTING	O
:	O
Genetic	O
research	O
and	O
clinical	O
unit	O
,	O
university	O
hospital	O
.	O

RESULTS	O
:	O
Genetic	O
analysis	O
revealed	O
homozygosity	O
for	O
a	O
novel	O
mutation	O
in	O
exon	O
3	O
of	O
ARSA	O
(	O
leucine	B-ProteinMutation
269	I-ProteinMutation
to	I-ProteinMutation
phenylalanine	I-ProteinMutation
)	O
.	O

This	O
substitution	O
leads	O
to	O
a	O
misfolded	O
unstable	O
enzyme	O
with	O
a	O
specific	O
activity	O
less	O
than	O
1%	O
of	O
normal	O
.	O

There	O
were	O
no	O
clinical	O
or	O
neurophysiologic	O
signs	O
of	O
peripheral	O
nervous	O
system	O
dysfunction	O
.	O

Typical	O
neuropathologic	O
signs	O
for	O
MLD	O
were	O
absent	O
from	O
nerve	O
biopsy	O
specimens	O
.	O

CONCLUSIONS	O
:	O
This	O
novel	O
mutation	O
is	O
associated	O
with	O
progressive	O
psychocognitive	O
impairment	O
without	O
clinical	O
or	O
electrophysiologic	O
signs	O
and	O
only	O
minor	O
morphologic	O
signs	O
of	O
peripheral	O
nerve	O
affection	O
.	O

The	O
arginine	B-ProteinMutation
555-to-tryptophan	I-ProteinMutation
substitution	O
causes	O
reduction	O
in	O
enzyme	O
activity	O
to	O
an	O
extent	O
unexpected	O
for	O
an	O
adult	O
patient	O
with	O
MLD	O
.	O

Lack	O
of	O
p16	O
gene	O
mutations	O
in	O
gastric	O
cancers	O
in	O
Kashmir	O
.	O

BACKGROUND	O
AND	O
AIM	O
:	O
The	O
focus	O
of	O
the	O
study	O
was	O
to	O
investigate	O
the	O
frequencies	O
of	O
homozygous	O
deletions	O
and	O
mutations	O
of	O
p16	O
gene	O
in	O
gastric	O
carcinomas	O
in	O
the	O
Kashmiri	O
population	O
.	O

METHODS	O
:	O
A	O
total	O
of	O
84	O
gastric	O
carcinoma	O
patients	O
were	O
screened	O
by	O
the	O
single	O
strand	O
conformation	O
polymorphism	O
(SSCP)	O
technique	O
and	O
later	O
by	O
DNA	O
sequencing	O
to	O
detect	O
mutations	O
of	O
the	O
p16	O
gene	O
.	O

Also	O
PCR	O
was	O
applied	O
further	O
to	O
further	O
detect	O
any	O
homozygous	O
deletions	O
.	O

RESULTS	O
:	O
SSCP	O
and	O
DNA	O
sequencing	O
performed	O
encompassing	O
all	O
the	O
three	O
exons	O
of	O
p16	O
gene	O
could	O
not	O
detect	O
any	O
mutations	O
in	O
any	O
ofl	O
84	O
cases	O
.	O

Though	O
we	O
could	O
observe	O
mobility	O
shifts	O
in	O
SSCP	O
of	O
two	O
samples	O
,	O
subsequent	O
DNA	O
sequencing	O
did	O
not	O
show	O
any	O
mutation	O
.	O

Further	O
PCR	O
could	O
not	O
detect	O
any	O
homozygous	O
deletion	O
in	O
P16	O
in	O
any	O
case	O
.	O

CONCLUSION	O
:	O
Though	O
Kashmir	O
is	O
a	O
high	O
incidence	O
area	O
of	O
gastric	O
carcinomas	O
,	O
p16gene	O
mutations	O
/or	O
deletions	O
do	O
not	O
appear	O
to	O
be	O
involved	O
.	O

Skewed	O
X	O
inactivation	O
in	O
an	O
X	O
linked	O
nystagmus	O
family	O
resulted	O
from	O
a	O
novel	O
,	O
histidine	B-ProteinMutation
626-to-arginine	I-ProteinMutation
,	O
missense	O
mutation	O
in	O
the	O
FRMD7	O
gene	O
.	O

AIMS	O
:	O
This	O
study	O
aimed	O
to	O
identify	O
the	O
underlying	O
genetic	O
defect	O
of	O
a	O
large	O
Turkish	O
X	O
linked	O
nystagmus	O
(NYS)	O
family	O
.	O

METHODS	O
:	O
Both	O
Xp11	O
and	O
Xq26	O
loci	O
were	O
tested	O
by	O
linkage	O
analysis	O
.	O

The	O
12	O
exons	O
and	O
intron-exon	O
junctions	O
of	O
the	O
FRMD7	O
gene	O
were	O
screened	O
by	O
direct	O
sequencing	O
.	O

X	O
chromosome	O
inactivation	O
analysis	O
was	O
performed	O
by	O
enzymatic	O
predigestion	O
of	O
DNA	O
with	O
a	O
methylation-sensitive	O
enzyme	O
,	O
followed	O
by	O
PCR	O
of	O
the	O
polymorphic	O
CAG	O
repeat	O
of	O
the	O
androgen	O
receptor	O
gene	O
.	O

RESULTS	O
:	O
The	O
family	O
contained	O
162	O
individuals	O
,	O
among	O
whom	O
28	O
had	O
NYS	O
.	O

Linkage	O
analysis	O
confirmed	O
the	O
Xq26	O
locus	O
.	O

A	O
novel	O
missense	O
A	B-DNAMutation
>	I-DNAMutation
G	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
313	I-DNAMutation
mutation	O
,	O
which	O
causes	O
the	O
substitution	O
of	O
a	O
conserved	O
arginine	O
at	O
amino	O
acid	O
position	O
229	O
by	O
glycine	O
(	O
arginine	B-ProteinMutation
124-to-cysteine	I-ProteinMutation
)	O
in	O
exon	O
8	O
of	O
the	O
FRMD7	O
gene	O
,	O
was	O
observed	O
.	O

This	O
change	O
was	O
not	O
documented	O
in	O
120	O
control	O
individuals	O
.	O

The	O
clinical	O
findings	O
in	O
a	O
female	O
who	O
was	O
homozygous	O
for	O
the	O
mutation	O
were	O
not	O
different	O
from	O
those	O
of	O
affected	O
heterozygous	O
females	O
.	O

Skewed	O
X	O
inactivation	O
was	O
remarkable	O
in	O
the	O
affected	O
females	O
of	O
the	O
family	O
.	O

CONCLUSIONS	O
:	O
A	O
novel	O
Phe-->Ser	B-ProteinMutation
at	I-ProteinMutation
codon	I-ProteinMutation
15	I-ProteinMutation
mutation	O
in	O
the	O
FRMD7	O
gene	O
causes	O
the	O
NYS	O
phenotype	O
,	O
and	O
skewed	O
X	O
inactivation	O
influences	O
the	O
manifestation	O
of	O
the	O
disease	O
in	O
X	O
linked	O
NYS	O
females	O
.	O

A	O
novel	O
IRF6	O
nonsense	O
mutation	O
(	O
Glu	B-ProteinMutation
272	I-ProteinMutation
to	I-ProteinMutation
stop	I-ProteinMutation
)	O
in	O
a	O
German	O
family	O
with	O
Van	O
der	O
Woude	O
syndrome	O
.	O

Van	O
der	O
Woude	O
syndrome	O
(VWS)	O
is	O
the	O
most	O
common	O
type	O
of	O
syndromic	O
orofacial	O
cleft	O
,	O
which	O
accounts	O
for	O
approximately	O
2%	O
of	O
all	O
cleft	O
lip	O
and	O
palate	O
cases	O
.	O

It	O
is	O
characterised	O
by	O
variable	O
association	O
of	O
lower	O
lip	O
pits	O
,	O
cleft	O
lip	O
and	O
cleft	O
palate	O
,	O
and	O
hypodontia	O
.	O

VWS	O
arises	O
as	O
the	O
result	O
of	O
mutations	O
in	O
the	O
gene	O
encoding	O
interferon	O
regulatory	O
factor	O
6	O
(IRF6)	O
.	O

The	O
disorder	O
is	O
transmitted	O
in	O
an	O
autosomal	O
dominant	O
manner	O
,	O
with	O
high	O
penetrance	O
and	O
variable	O
expressivity	O
.	O

Very	O
recently	O
,	O
mutations	O
of	O
the	O
IRF6	O
gene	O
in	O
exons	O
2-9	O
have	O
been	O
found	O
in	O
VWS	O
patients	O
,	O
suggesting	O
that	O
this	O
gene	O
plays	O
an	O
important	O
role	O
in	O
orofacial	O
development	O
.	O

We	O
report	O
a	O
novel	O
mutation	O
of	O
the	O
IRF6	O
gene	O
in	O
a	O
German	O
family	O
.	O

Five	O
out	O
of	O
the	O
12	O
persons	O
affected	O
were	O
able	O
to	O
be	O
investigated	O
.	O

The	O
mutation	O
produced	O
a	O
stop	O
codon	O
within	O
exon	O
4	O
of	O
the	O
IRF6	O
gene	O
.	O

All	O
5	O
patients	O
were	O
heterozygous	O
for	O
a	O
base	O
substitution	O
-AAGC	B-DNAMutation
at	I-DNAMutation
-222	I-DNAMutation
to	I-DNAMutation
-225	I-DNAMutation
changing	O
the	O
tyrosine	O
codon	O
at	O
amino	O
acid	O
position	O
67	O
into	O
a	O
stop	O
codon	O
(	O
methionine-->valine	B-ProteinMutation
substitution	I-ProteinMutation
at	I-ProteinMutation
codon	I-ProteinMutation
404	I-ProteinMutation
)	O
in	O
exon	O
4	O
.	O

The	O
premature	O
stop	O
codon	O
was	O
responsible	O
for	O
a	O
truncated	O
protein	O
lacking	O
parts	O
of	O
the	O
DNA-	O
binding	O
domain	O
and	O
the	O
complete	O
Smad-interferon	O
regulatory	O
factor-binding	O
domain	O
probably	O
essential	O
for	O
interactions	O
with	O
the	O
Smad	O
transcription	O
factors	O
.	O

Deletion	O
of	O
mouse	O
rad9	O
causes	O
abnormal	O
cellular	O
responses	O
to	O
DNA	O
damage	O
,	O
genomic	O
instability	O
,	O
and	O
embryonic	O
lethality	O
.	O

The	O
fission	O
yeast	O
Schizosaccharomyces	O
pombe	O
rad9	O
gene	O
promotes	O
cell	O
survival	O
through	O
activation	O
of	O
cell	O
cycle	O
checkpoints	O
induced	O
by	O
DNA	O
damage	O
.	O

Mouse	O
embryonic	O
stem	O
cells	O
with	O
a	O
targeted	O
deletion	O
of	O
Mrad9	O
,	O
the	O
mouse	O
ortholog	O
of	O
this	O
gene	O
,	O
were	O
created	O
to	O
evaluate	O
its	O
function	O
in	O
mammals	O
.	O

Mrad9(-/-)	O
cells	O
demonstrated	O
a	O
marked	O
increase	O
in	O
spontaneous	O
chromosome	O
aberrations	O
and	O
HPRT	O
mutations	O
,	O
indicating	O
a	O
role	O
in	O
the	O
maintenance	O
of	O
genomic	O
integrity	O
.	O

These	O
cells	O
were	O
also	O
extremely	O
sensitive	O
to	O
UV	O
light	O
,	O
gamma	O
rays	O
,	O
and	O
hydroxyurea	O
,	O
and	O
heterozygotes	O
were	O
somewhat	O
sensitive	O
to	O
the	O
last	O
two	O
agents	O
relative	O
to	O
Mrad9(+/+)	O
controls	O
.	O

Mrad9(-/-)	O
cells	O
could	O
initiate	O
but	O
not	O
maintain	O
gamma-ray-induced	O
G(2)	O
delay	O
and	O
retained	O
the	O
ability	O
to	O
delay	O
DNA	O
synthesis	O
rapidly	O
after	O
UV	O
irradiation	O
,	O
suggesting	O
that	O
checkpoint	O
abnormalities	O
contribute	O
little	O
to	O
the	O
radiosensitivity	O
observed	O
.	O

Ectopic	O
expression	O
of	O
Mrad9	O
or	O
human	O
HRAD9	O
complemented	O
Mrad9(-/-)	O
cell	O
defects	O
,	O
indicating	O
that	O
the	O
gene	O
has	O
radioresponse	O
and	O
genomic	O
maintenance	O
functions	O
that	O
are	O
evolutionarily	O
conserved	O
.	O

Mrad9(+/-)	O
mice	O
were	O
generated	O
,	O
but	O
heterozygous	O
intercrosses	O
failed	O
to	O
yield	O
Mrad9(-/-)	O
pups	O
,	O
since	O
embryos	O
died	O
at	O
midgestation	O
.	O

Furthermore	O
,	O
Mrad9(-/-)	O
mouse	O
embryo	O
fibroblasts	O
were	O
not	O
viable	O
.	O

These	O
investigations	O
establish	O
Mrad9	O
as	O
a	O
key	O
mammalian	O
genetic	O
element	O
of	O
pathways	O
that	O
regulate	O
the	O
cellular	O
response	O
to	O
DNA	O
damage	O
,	O
maintenance	O
of	O
genomic	O
integrity	O
,	O
and	O
proper	O
embryonic	O
development	O
.	O

Pacemaker	O
channel	O
dysfunction	O
in	O
a	O
patient	O
with	O
sinus	O
node	O
disease	O
.	O

The	O
cardiac	O
pacemaker	O
current	O
I(f)	O
is	O
a	O
major	O
determinant	O
of	O
diastolic	O
depolarization	O
in	O
sinus	O
nodal	O
cells	O
and	O
has	O
a	O
key	O
role	O
in	O
heartbeat	O
generation	O
.	O

Therefore	O
,	O
we	O
hypothesized	O
that	O
some	O
forms	O
of	O
"idiopathic"	O
sinus	O
node	O
dysfunction	O
(SND)	O
are	O
related	O
to	O
inherited	O
dysfunctions	O
of	O
cardiac	O
pacemaker	O
ion	O
channels	O
.	O

In	O
a	O
candidate	O
gene	O
approach	O
,	O
a	O
heterozygous	O
1-bp	O
deletion	O
(	O
-491	B-DNAMutation
A	I-DNAMutation
to	I-DNAMutation
T	I-DNAMutation
)	O
in	O
exon	O
5	O
of	O
the	O
human	O
HCN4	O
gene	O
was	O
detected	O
in	O
a	O
patient	O
with	O
idiopathic	O
SND	O
.	O

The	O
mutant	O
HCN4	O
protein	O
(HCN4-573X)	O
had	O
a	O
truncated	O
C-terminus	O
and	O
lacked	O
the	O
cyclic	O
nucleotide-binding	O
domain	O
.	O

COS-7	O
cells	O
transiently	O
transfected	O
with	O
HCN4-573X	O
cDNA	O
indicated	O
normal	O
intracellular	O
trafficking	O
and	O
membrane	O
integration	O
of	O
HCN4-573X	O
subunits	O
.	O

Patch-clamp	O
experiments	O
showed	O
that	O
HCN4-573X	O
channels	O
mediated	O
I(f)-like	O
currents	O
that	O
were	O
insensitive	O
to	O
increased	O
cellular	O
cAMP	O
levels	O
.	O

Coexpression	O
experiments	O
showed	O
a	O
dominant-negative	O
effect	O
of	O
HCN4-573X	O
subunits	O
on	O
wild-type	O
subunits	O
.	O

These	O
data	O
indicate	O
that	O
the	O
cardiac	O
I(f)	O
channels	O
are	O
functionally	O
expressed	O
but	O
with	O
altered	O
biophysical	O
properties	O
.	O

Taken	O
together	O
,	O
the	O
clinical	O
,	O
genetic	O
,	O
and	O
in	O
vitro	O
data	O
provide	O
a	O
likely	O
explanation	O
for	O
the	O
patient's	O
sinus	O
bradycardia	O
and	O
the	O
chronotropic	O
incompetence	O
.	O

A	O
large	O
heterozygous	O
deletion	O
including	O
the	O
entire	O
C1	O
inhibitor	O
gene	O
in	O
a	O
sporadic	O
case	O
of	O
hereditary	O
angio-oedema	O
.	O

C1	O
inhibitor	O
(C1-INH)	O
deficiency	O
[	O
hereditary	O
or	O
acquired	O
angio-oedema	O
(	O
HAE	O
or	O
AAE)	O
]	O
is	O
characterized	O
by	O
recurring	O
episodes	O
of	O
subcutaneous	O
or	O
submucosal	O
oedema	O
.	O

Many	O
different	O
mutations	O
in	O
the	O
C1-INH	O
gene	O
have	O
been	O
identified	O
as	O
a	O
cause	O
of	O
HAE	O
.	O

We	O
investigated	O
the	O
molecular	O
basis	O
of	O
the	O
disease	O
in	O
a	O
Japanese	O
woman	O
with	O
sporadic	O
HAE	O
.	O

Direct	O
sequencing	O
of	O
genomic	O
DNA	O
revealed	O
no	O
point	O
mutation	O
in	O
the	O
C1-INH	O
gene	O
.	O

Quantitative	O
real-time	O
PCR	O
showed	O
that	O
the	O
copy	O
number	O
of	O
the	O
C1-INH	O
gene	O
in	O
the	O
patient	O
was	O
half	O
that	O
of	O
a	O
healthy	O
control	O
.	O

Furthermore	O
,	O
we	O
identified	O
a	O
650-kbp	O
deletion	O
on	O
the	O
chromosome	O
,	O
which	O
included	O
the	O
C1-INH	O
gene	O
.	O

We	O
evaluated	O
the	O
correlation	O
between	O
the	O
patient's	O
attacks	O
and	O
her	O
coagulation	O
activity	O
.	O

The	O
levels	O
of	O
D-dimer	O
were	O
high	O
during	O
the	O
angio-oedema	O
attacks	O
,	O
and	O
often	O
exceeded	O
the	O
normal	O
range	O
even	O
during	O
remission	O
,	O
thus	O
the	O
level	O
of	O
D-dimer	O
reflected	O
the	O
activity	O
of	O
HAE	O
in	O
this	O
patient	O
.	O

Carrier	O
frequency	O
of	O
mutation	O
G>A	B-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
+1	I-DNAMutation
of	I-DNAMutation
intron	I-DNAMutation
2	I-DNAMutation
in	O
the	O
NBS1	O
gene	O
in	O
a	O
population	O
of	O
Polish	O
pediatric	O
patients	O
with	O
sporadic	O
lymphoid	O
malignancies	O
.	O

Nijmegen	O
breakage	O
syndrome	O
(NBS)	O
is	O
a	O
human	O
autosomal	O
recessive	O
disease	O
characterized	O
by	O
genomic	O
instability	O
and	O
enhanced	O
cancer	O
predisposition	O
,	O
in	O
particular	O
to	O
lymphoma	O
and	O
leukemia	O
.	O

Recently	O
,	O
significantly	O
higher	O
frequencies	O
of	O
heterozygous	O
carriers	O
of	O
the	O
Slavic	O
founder	O
NBS1	O
mutation	O
,	O
(	B-DNAMutation
T	I-DNAMutation
-->	I-DNAMutation
C	I-DNAMutation
)	I-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
2209	I-DNAMutation
,	O
were	O
found	O
in	O
Russian	O
children	O
with	O
sporadic	O
lymphoid	O
malignancies	O
,	O
and	O
in	O
Polish	O
adults	O
with	O
non-Hodgkin	O
lymphoma	O
(NHL)	O
.	O

In	O
addition	O
,	O
the	O
substitution	O
(	B-DNAMutation
G	I-DNAMutation
-->	I-DNAMutation
C	I-DNAMutation
)	I-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
1201	I-DNAMutation
(	O
Ser-->Cys	B-ProteinMutation
substitution	I-ProteinMutation
at	I-ProteinMutation
the	I-ProteinMutation
codon	I-ProteinMutation
326	I-ProteinMutation
)	O
has	O
also	O
been	O
found	O
in	O
excess	O
among	O
children	O
with	O
acute	O
lymphoblastic	O
leukemia	O
(ALL)	O
.	O

In	O
an	O
attempt	O
to	O
asses	O
the	O
contribution	O
of	O
both	O
mutations	O
to	O
the	O
development	O
of	O
sporadic	O
lymphoid	O
malignancies	O
,	O
we	O
analyzed	O
DNA	O
samples	O
from	O
a	O
large	O
group	O
of	O
Polish	O
pediatric	O
patients	O
.	O

The	O
NBS1	O
mutation	O
G>T	B-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
c.898	I-DNAMutation
on	O
one	O
allele	O
was	O
found	O
in	O
3	O
of	O
270	O
patients	O
with	O
ALL	O
and	O
2	O
of	O
212	O
children	O
and	O
adolescents	O
with	O
NHL	O
;	O
no	O
carrier	O
was	O
found	O
among	O
63	O
patients	O
with	O
Hodgkin	O
lymphoma	O
(HL)	O
.	O

No	O
carriers	O
of	O
the	O
variant	O
leucine	B-ProteinMutation
269	I-ProteinMutation
to	I-ProteinMutation
phenylalanine	I-ProteinMutation
were	O
detected	O
in	O
any	O
studied	O
group	O
.	O

The	O
relative	O
frequency	O
of	O
the	O
C-->T	B-DNAMutation
transversion	I-DNAMutation
at	I-DNAMutation
cDNA	I-DNAMutation
base	I-DNAMutation
463	I-DNAMutation
mutation	O
was	O
calculated	O
from	O
a	O
total	O
of	O
6,984	O
controls	O
matched	O
by	O
place	O
of	O
patient	O
residence	O
,	O
of	O
whom	O
42	O
were	O
found	O
to	O
be	O
carriers	O
(	O
frequency	O
=	O
0.006	O
)	O
.	O

In	O
the	O
analyzed	O
population	O
with	O
malignancies	O
,	O
an	O
increased	O
odds	O
ratio	O
for	O
the	O
occurrence	O
of	O
mutation	O
G-->C	B-DNAMutation
transversion	I-DNAMutation
at	I-DNAMutation
1245	I-DNAMutation
position	I-DNAMutation
was	O
found	O
in	O
comparison	O
with	O
the	O
control	O
Polish	O
population	O
(	O
OR	O
range	O
1.48-1.85	O
,	O
95%	O
confidence	O
interval	O
1.18-2.65	O
)	O
.	O

This	O
finding	O
indicates	O
that	O
the	O
frequency	O
of	O
the	O
mutation	O
carriers	O
was	O
indeed	O
increased	O
in	O
patients	O
with	O
ALL	O
and	O
NHL	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Nonetheless	O
,	O
NBS1	O
gene	O
heterozygosity	O
is	O
not	O
a	O
major	O
risk	O
factor	O
for	O
lymphoid	O
malignancies	O
in	O
childhood	O
and	O
adolescence	O
.	O

A	O
novel	O
homozygous	O
splice	O
site	O
mutation	O
in	O
COL7A1	O
in	O
a	O
Chinese	O
patient	O
with	O
severe	O
recessive	O
dystrophic	O
epidermolysis	O
bullosa	O
and	O
squamous	O
cell	O
carcinoma	O
.	O

BACKGROUND	O
:	O
Recessive	O
dystrophic	O
epidermolysis	O
bullosa	O
(RDEB)	O
is	O
an	O
inherited	O
blistering	O
skin	O
disorder	O
caused	O
by	O
mutations	O
in	O
COL7A1	O
gene	O
encoding	O
type	O
VII	O
collagen	O
,	O
the	O
major	O
component	O
of	O
anchoring	O
fibrils	O
in	O
the	O
dermo-epidermal	O
junction	O
.	O

The	O
development	O
of	O
cutaneous	O
squamous	O
cell	O
carcinoma	O
(SCC)	O
is	O
one	O
of	O
the	O
most	O
serious	O
complications	O
of	O
this	O
disease	O
.	O

We	O
report	O
herein	O
a	O
Chinese	O
patient	O
with	O
the	O
severe	O
generalized	O
subtype	O
of	O
RDEB	O
(	O
RDEB-sev	O
gen	O
)	O
complicated	O
by	O
SCC	O
.	O

METHODS	O
:	O
Skin	O
biopsies	O
were	O
examined	O
for	O
histology	O
,	O
basement	O
membrane	O
ultrastructure	O
,	O
and	O
type	O
VII	O
collagen	O
expression	O
.	O

Genomic	O
DNA	O
was	O
extracted	O
from	O
the	O
peripheral	O
blood	O
samples	O
and	O
subjected	O
to	O
polymerase	O
chain	O
reaction	O
amplification	O
and	O
direct	O
automated	O
DNA	O
sequencing	O
.	O

RESULTS	O
:	O
Histopathological	O
examination	O
of	O
the	O
patient's	O
skin	O
revealed	O
an	O
undetectable	O
expression	O
of	O
type	O
VII	O
collagen	O
polypeptides	O
in	O
the	O
basement	O
membrane	O
zone	O
.	O

Mutation	O
analysis	O
identified	O
a	O
novel	O
splice	O
site	O
mutation	O
in	O
intron	O
64	O
(	O
G-->C	B-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
135	I-DNAMutation
)	O
of	O
COL7A1	O
gene	O
,	O
which	O
resulted	O
in	O
an	O
in-frame	O
deletion	O
of	O
exon	O
64	O
in	O
both	O
alleles	O
.	O

CONCLUSIONS	O
:	O
This	O
report	O
contributes	O
to	O
the	O
expanding	O
database	O
of	O
COL7A1	O
mutations	O
and	O
emphasizes	O
the	O
need	O
to	O
elucidate	O
the	O
underlying	O
genetic	O
mechanisms	O
associated	O
with	O
the	O
increased	O
incidence	O
of	O
SCC	O
in	O
RDEB	O
patients	O
.	O

A	O
"null	O
allele"	O
mutation	O
is	O
responsible	O
for	O
erythropoietic	O
protoporphyria	O
in	O
an	O
Israeli	O
patient	O
who	O
underwent	O
liver	O
transplantation	O
:	O
relationships	O
among	O
biochemical	O
,	O
clinical	O
,	O
and	O
genetic	O
parameters	O
.	O

Mutations	O
in	O
the	O
human	O
ferrochelatase	O
gene	O
(FECH)	O
are	O
the	O
primary	O
cause	O
of	O
the	O
inborn	O
disorder	O
erythropoietic	O
protoporphyria	O
(EPP)	O
.	O

While	O
the	O
majority	O
of	O
the	O
EPP	O
patients	O
exhibit	O
only	O
photosensitivity	O
,	O
a	O
small	O
percentage	O
of	O
patients	O
(	O
approximately	O
2%	O
)	O
develop	O
liver	O
complications	O
in	O
addition	O
to	O
the	O
cutaneous	O
symptoms	O
.	O

In	O
this	O
study	O
,	O
the	O
FECH	O
gene	O
of	O
an	O
Israeli	O
EPP	O
patient	O
who	O
suffered	O
from	O
EPP-related	O
liver	O
complications	O
was	O
sequenced	O
.	O

A	O
splicing	O
defect	O
C-->T	B-DNAMutation
transition	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
677	I-DNAMutation
,	O
which	O
is	O
known	O
to	O
cause	O
the	O
deletion	O
of	O
exon	O
10	O
,	O
was	O
identified	O
in	O
the	O
index	O
patient	O
as	O
well	O
as	O
in	O
his	O
symptomatic	O
older	O
sister	O
and	O
his	O
asymptomatic	O
mother	O
.	O

Like	O
the	O
other	O
12	O
known	O
FECH	O
mutations	O
associated	O
with	O
liver	O
complications	O
,	O
GTT-->GCT	B-DNAMutation
transition	I-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
23	I-DNAMutation
is	O
a	O
"null-allele"	O
mutation	O
.	O

Although	O
the	O
two	O
siblings	O
with	O
overt	O
EPP	O
share	O
an	O
identical	O
genotype	O
with	O
respect	O
to	O
both	O
the	O
mutation	O
on	O
one	O
FECH	O
allele	O
and	O
three	O
intragenic	O
single	O
nucleotide	O
polymorphisms	O
,	O
TAC-->AA	B-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
329	I-DNAMutation
,	O
A	B-DNAMutation
>	I-DNAMutation
G	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
313	I-DNAMutation
,	O
and	O
-AAGC	B-DNAMutation
at	I-DNAMutation
-222	I-DNAMutation
to	I-DNAMutation
-225	I-DNAMutation
on	O
the	O
other	O
allele	O
,	O
the	O
sister	O
of	O
the	O
index	O
patient	O
has	O
so	O
far	O
shown	O
no	O
signs	O
of	O
liver	O
involvement	O
,	O
suggesting	O
that	O
additional	O
factors	O
might	O
account	O
for	O
the	O
liver	O
disease	O
in	O
EPP	O
.	O

Successful	O
therapy	O
with	O
argatroban	O
for	O
superior	O
mesenteric	O
vein	O
thrombosis	O
in	O
a	O
patient	O
with	O
congenital	O
antithrombin	O
deficiency	O
.	O

A	O
38-year-old	O
woman	O
was	O
admitted	O
with	O
superior	O
mesenteric	O
vein	O
(SMV)	O
thrombosis	O
,	O
which	O
was	O
refractory	O
to	O
anticoagulation	O
therapy	O
.	O

The	O
plasma	O
antithrombin	O
activity	O
was	O
decreased	O
and	O
hardly	O
compensated	O
by	O
concentrated	O
antithrombin	O
preparation	O
due	O
to	O
high	O
consumption	O
rate	O
.	O

However	O
,	O
successful	O
anticoagulation	O
was	O
achieved	O
by	O
administration	O
of	O
direct	O
thrombin	O
inhibitor	O
,	O
argatroban	O
.	O

Family	O
studies	O
of	O
antithrombin	O
activity	O
revealed	O
that	O
she	O
had	O
type	O
I	O
congenital	O
antithrombin	O
deficiency	O
.	O

A	O
novel	O
heterozygous	O
mutation	O
in	O
the	O
gene	O
for	O
antithrombin	O
(	O
single	O
nucleotide	O
T	O
insertion	O
at	O
7916	O
and	O
7917	O
,	O
arginine	B-ProteinMutation
555-to-tryptophan	I-ProteinMutation
in	O
exon	O
4	O
)	O
was	O
identified	O
.	O

Argatroban	O
administration	O
would	O
be	O
effective	O
in	O
the	O
treatment	O
of	O
congenital	O
antithrombin	O
deficiency	O
with	O
SMV	O
thrombosis	O
.	O

Functional	O
inactivation	O
of	O
the	O
WTX	O
gene	O
is	O
not	O
a	O
frequent	O
event	O
in	O
Wilms'	O
tumors	O
.	O

For	O
many	O
years	O
the	O
precise	O
genetic	O
etiology	O
of	O
the	O
majority	O
of	O
Wilms'	O
tumors	O
has	O
remained	O
unexplained	O
.	O

Recently	O
,	O
the	O
WTX	O
gene	O
,	O
mapped	O
to	O
chromosome	O
Xq11.1	O
,	O
has	O
been	O
reported	O
to	O
be	O
lost	O
or	O
mutated	O
in	O
approximately	O
one-third	O
of	O
Wilms'	O
tumors	O
.	O

Moreover	O
,	O
in	O
female	O
cases	O
,	O
the	O
somatically	O
inactivated	O
alleles	O
were	O
found	O
to	O
invariantly	O
derive	O
from	O
the	O
active	O
chromosome	O
X	O
.	O

Consequently	O
,	O
WTX	O
has	O
been	O
proposed	O
as	O
a	O
'one-hit'	O
tumor	O
suppressor	O
gene	O
.	O

To	O
provide	O
further	O
insights	O
on	O
the	O
contribution	O
of	O
WTX	O
to	O
the	O
development	O
of	O
the	O
disease	O
,	O
we	O
have	O
examined	O
102	O
Wilms'	O
tumors	O
,	O
obtained	O
from	O
43	O
male	O
and	O
57	O
female	O
patients	O
.	O

Quantitative	O
PCR	O
analyses	O
detected	O
WTX	O
deletions	O
in	O
5	O
of	O
45	O
(11%)	O
tumors	O
from	O
males	O
,	O
whereas	O
loss	O
of	O
heterozygosity	O
at	O
WTX-linked	O
microsatellites	O
was	O
observed	O
in	O
9	O
tumors	O
from	O
50	O
informative	O
females	O
(19%)	O
.	O

However	O
,	O
in	O
the	O
latter	O
group	O
,	O
using	O
a	O
combination	O
of	O
HUMARA	O
assay	O
and	O
bisulfite-modified	O
DNA	O
sequencing	O
,	O
we	O
found	O
that	O
the	O
deletion	O
affected	O
the	O
active	O
chromosome	O
X	O
only	O
in	O
two	O
cases	O
(4%)	O
.	O

Sequence	O
analyses	O
detected	O
an	O
inactivating	O
somatic	O
mutation	O
of	O
WTX	O
in	O
a	O
single	O
tumor	O
,	O
in	O
which	O
a	O
strongly	O
reduced	O
expression	O
of	O
the	O
mutant	O
allele	O
respect	O
to	O
the	O
wild-type	O
allele	O
was	O
observed	O
,	O
a	O
finding	O
not	O
consistent	O
with	O
its	O
localization	O
on	O
the	O
active	O
chromosome	O
X	O
.	O

Overall	O
,	O
a	O
functional	O
somatic	O
nullizygosity	O
of	O
the	O
WTX	O
gene	O
was	O
ascertained	O
only	O
in	O
seven	O
of	O
the	O
Wilms'	O
tumors	O
included	O
in	O
the	O
study	O
(	O
approximately	O
7%	O
)	O
.	O

Our	O
findings	O
indicate	O
that	O
previously	O
reported	O
estimates	O
on	O
the	O
proportion	O
of	O
Wilms'	O
tumors	O
due	O
to	O
WTX	O
alterations	O
should	O
be	O
reconsidered	O
.	O

A	O
possible	O
bichromatid	O
mutation	O
in	O
a	O
male	O
gamete	O
giving	O
rise	O
to	O
a	O
female	O
mosaic	O
for	O
two	O
different	O
mutations	O
in	O
the	O
X-linked	O
gene	O
WAS	O
.	O

In	O
genetic	O
disorders	O
caused	O
by	O
point	O
mutations	O
or	O
small	O
frameshift	O
mutations	O
,	O
affected	O
members	O
of	O
the	O
same	O
family	O
are	O
expected	O
to	O
have	O
the	O
same	O
mutation	O
in	O
the	O
causative	O
gene	O
.	O

We	O
have	O
recently	O
evaluated	O
a	O
family	O
in	O
which	O
this	O
was	O
not	O
the	O
case	O
.	O

Maternal	O
cousins	O
with	O
Wiskott-Aldrich	O
syndrome	O
(	O
WAS	O
;	O
MIM	O
301000	O
)	O
had	O
two	O
different	O
but	O
contiguous	O
single	O
base	O
pair	O
deletions	O
in	O
WAS	O
.	O

The	O
proband	O
had	O
an	O
A	O
deletion	O
in	O
codon	O
242	O
in	O
exon	O
7	O
of	O
WAS	O
;	O
his	O
two	O
cousins	O
had	O
a	O
C	O
deletion	O
in	O
codon	O
241	O
.	O

The	O
mother	O
of	O
the	O
proband	O
was	O
heterozygous	O
for	O
the	O
A	O
deletion	O
allele	O
,	O
but	O
her	O
three	O
sisters	O
,	O
including	O
the	O
mother	O
of	O
the	O
affected	O
cousins	O
,	O
were	O
heterozygous	O
for	O
the	O
C	O
deletion	O
.	O

Both	O
deletions	O
occurred	O
on	O
the	O
haplotype	O
from	O
the	O
unaffected	O
maternal	O
great-grandfather	O
.	O

The	O
maternal	O
grandmother	O
,	O
who	O
was	O
a	O
carrier	O
of	O
WAS	O
,	O
based	O
on	O
a	O
non-random	O
pattern	O
of	O
X	O
chromosome	O
inactivation	O
in	O
T	O
cells	O
,	O
was	O
mosaic	O
for	O
both	O
deletions	O
.	O

These	O
findings	O
are	O
most	O
consistent	O
with	O
the	O
mutations	O
originating	O
in	O
a	O
male	O
gamete	O
with	O
different	O
mutations	O
on	O
the	O
two	O
strands	O
of	O
DNA	O
,	O
a	O
bichromatid	O
mutation	O
.	O

Single	O
nucleotide	O
polymorphisms	O
of	O
the	O
HNF4alpha	O
gene	O
are	O
associated	O
with	O
the	O
conversion	O
to	O
type	O
2	O
diabetes	O
mellitus	O
:	O
the	O
STOP-NIDDM	O
trial	O
.	O

Hepatocyte	O
nuclear	O
factor	O
4alpha	O
(HNF4alpha)	O
is	O
a	O
transcription	O
factor	O
,	O
which	O
is	O
necessary	O
for	O
normal	O
function	O
of	O
human	O
liver	O
and	O
pancreatic	O
islets	O
.	O

We	O
investigated	O
whether	O
single	O
nucleotide	O
polymorphisms	O
(SNPs)	O
of	O
HNF4A	O
,	O
encoding	O
HNF4alpha	O
,	O
influenced	O
the	O
conversion	O
from	O
impaired	O
glucose	O
tolerance	O
(IGT)	O
to	O
type	O
2	O
diabetes	O
mellitus	O
in	O
subjects	O
of	O
the	O
STOP-NIDDM	O
trial	O
.	O

This	O
trial	O
aimed	O
at	O
evaluating	O
the	O
effect	O
of	O
acarbose	O
compared	O
to	O
placebo	O
in	O
the	O
prevention	O
of	O
type	O
2	O
diabetes	O
mellitus	O
.	O

Eight	O
SNPs	O
covering	O
the	O
intragenic	O
and	O
alternate	O
P2	O
promoter	O
regions	O
of	O
HNF4A	O
were	O
genotyped	O
in	O
study	O
samples	O
using	O
the	O
TaqMan	O
Allelic	O
Discrimination	O
Assays	O
.	O

Three	O
SNPs	O
in	O
the	O
P2	O
promoter	O
region	O
(	O
rs4810424	O
,	O
rs1884614	O
,	O
and	O
rs2144908	O
)	O
were	O
in	O
almost	O
complete	O
association	O
(	O
D'>0.97	O
,	O
r	O
(	O
2)>0.95	O
)	O
and	O
,	O
therefore	O
,	O
only	O
rs4810424	O
was	O
included	O
in	O
further	O
analyses	O
.	O

Female	O
carriers	O
of	O
the	O
less	O
frequent	O
C	O
allele	O
of	O
rs4810424	O
had	O
a	O
1.7-fold	O
elevated	O
risk	O
[	O
95%	O
confidence	O
interval	O
(CI)	O
1.09-2.66	O
;	O
P=0.020	O
]	O
for	O
the	O
conversion	O
to	O
diabetes	O
compared	O
to	O
women	O
with	O
the	O
common	O
genotype	O
after	O
the	O
adjustment	O
for	O
age	O
,	O
treatment	O
group	O
(	O
placebo	O
or	O
acarbose	O
)	O
,	O
smoking	O
,	O
weight	O
at	O
baseline	O
,	O
and	O
weight	O
change	O
.	O

No	O
association	O
was	O
found	O
in	O
men	O
.	O

Haplotype	O
analysis	O
based	O
on	O
three	O
SNPs	O
(	O
rs4810424	O
,	O
rs2071197	O
,	O
and	O
rs3818247	O
)	O
representing	O
the	O
linkage	O
disequilibrium	O
blocks	O
in	O
our	O
study	O
population	O
indicated	O
that	O
the	O
conversion	O
to	O
type	O
2	O
diabetes	O
mellitus	O
was	O
dependent	O
on	O
the	O
number	O
of	O
risk	O
alleles	O
in	O
different	O
haplotypes	O
in	O
women	O
.	O

Our	O
results	O
suggest	O
that	O
SNPs	O
of	O
HNF4A	O
and	O
their	O
haplotypes	O
predispose	O
to	O
type	O
2	O
diabetes	O
mellitus	O
in	O
female	O
subjects	O
of	O
the	O
STOP-NIDDM	O
study	O
population	O
.	O

Monocyte	O
chemotactic	O
protein-1	O
single	O
nucleotide	O
polymorphisms	O
do	O
not	O
confer	O
susceptibility	O
for	O
the	O
development	O
of	O
adult	O
onset	O
polymyositis/dermatomyositis	O
in	O
UK	O
Caucasians	O
.	O

OBJECTIVES	O
:	O
Polymyositis	O
(PM)	O
and	O
dermatomyositis	O
(DM)	O
form	O
part	O
of	O
the	O
idiopathic	O
inflammatory	O
myopathies	O
(IIMs)	O
.	O

The	O
chemokine	O
monocyte	O
chemotactic	O
protein-1	O
(MCP-1)	O
is	O
expressed	O
at	O
sites	O
of	O
the	O
T	O
cell	O
inflammatory	O
response	O
in	O
the	O
IIMs	O
.	O

We	O
thus	O
investigate	O
whether	O
genetic	O
markers	O
in	O
the	O
MCP-1	O
gene	O
confer	O
disease	O
susceptibility	O
for	O
the	O
development	O
of	O
PM	O
and	O
DM	O
.	O

METHODS	O
:	O
DNA	O
samples	O
were	O
analysed	O
from	O
a	O
group	O
of	O
195	O
UK	O
Caucasian	O
IIM	O
patients	O
,	O
comprising	O
103	O
PM	O
and	O
92	O
DM	O
.	O

Their	O
results	O
were	O
compared	O
with	O
those	O
of	O
162	O
ethnically	O
matched	O
controls	O
.	O

The	O
polymorphic	O
positions	O
of	O
three	O
single	O
nucleotide	O
polymorphisms	O
(SNPs)	O
and	O
one	O
insertion-deletion	O
sequence	O
within	O
regions	O
coding	O
for	O
MCP-1	O
were	O
tested	O
.	O

The	O
SNPs	O
examined	O
were	O
located	O
in	O
intron	O
1	O
(	O
rs2857657	O
,	O
-491	B-DNAMutation
A	I-DNAMutation
to	I-DNAMutation
T	I-DNAMutation
)	O
,	O
exon	O
2	O
(	O
rs4586	O
,	O
G>A	B-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
+1	I-DNAMutation
of	I-DNAMutation
intron	I-DNAMutation
2	I-DNAMutation
)	O
and	O
the	O
3	O
'	O
untranslated	O
region	O
(	O
rs13900	O
,	O
(	O
T	B-DNAMutation
-->	I-DNAMutation
C	I-DNAMutation
)	I-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
2209	I-DNAMutation
)	O
.	O

The	O
insertion-deletion	O
sequence	O
was	O
located	O
in	O
intron	O
1	O
(	O
rs3917887	O
,	O
(	O
G	B-DNAMutation
-->	I-DNAMutation
C	I-DNAMutation
)	I-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
1201	I-DNAMutation
)	O
.	O

Each	O
SNP	O
was	O
tested	O
for	O
Hardy-Weinberg	O
equilibrium	O
and	O
allelic/genotypic	O
associations	O
.	O

Haplotype	O
frequencies	O
were	O
estimated	O
using	O
the	O
Expectation/Maximization	O
algorithm	O
.	O

RESULTS	O
:	O
There	O
was	O
strong	O
linkage	O
disequilibrium	O
present	O
between	O
three	O
out	O
of	O
these	O
four	O
markers	O
.	O

The	O
majority	O
of	O
controls	O
were	O
in	O
Hardy	O
Weinberg	O
equilibrium	O
.	O

No	O
allelic	O
,	O
genotypic	O
or	O
haplotypic	O
associations	O
were	O
detected	O
when	O
comparing	O
PM	O
or	O
DM	O
cases	O
to	O
controls	O
,	O
or	O
when	O
PM	O
and	O
DM	O
were	O
compared	O
with	O
each	O
other	O
.	O

CONCLUSIONS	O
:	O
Genetic	O
markers	O
in	O
the	O
MCP-1	O
gene	O
do	O
not	O
demonstrate	O
significant	O
genetic	O
associations	O
with	O
the	O
IIMs	O
,	O
and	O
do	O
not	O
discriminate	O
PM	O
from	O
DM	O
in	O
a	O
UK	O
Caucasian	O
population	O
.	O

A	O
novel	O
mutation	O
(	O
histidine	B-ProteinMutation
626-to-arginine	I-ProteinMutation
)	O
in	O
the	O
thyroid	O
hormone	O
beta	O
receptor	O
causing	O
resistance	O
to	O
thyroid	O
hormone	O
syndrome	O
.	O

Resistance	O
to	O
thyroid	O
hormone	O
(RTH)	O
is	O
an	O
inherited	O
syndrome	O
characterized	O
by	O
elevated	O
serum	O
thyroid	O
hormones	O
(TH)	O
,	O
failure	O
to	O
suppress	O
pituitary	O
thyroid	O
stimulating	O
hormone	O
(TSH)	O
secretion	O
,	O
and	O
variable	O
peripheral	O
tissue	O
responsiveness	O
to	O
TH	O
.	O

The	O
disorder	O
is	O
associated	O
with	O
diverse	O
mutations	O
in	O
the	O
thyroid	O
hormone	O
beta	O
receptor	O
(TRbeta)	O
.	O

Here	O
,	O
we	O
report	O
a	O
novel	O
natural	O
RTH	O
mutation	O
(	O
arginine	B-ProteinMutation
124-to-cysteine	I-ProteinMutation
)	O
located	O
in	O
the	O
large	O
carboxy-terminal	O
ligand	O
binding	O
domain	O
of	O
TRbeta	O
.	O

The	O
mutation	O
was	O
identified	O
in	O
a	O
22-year-old	O
French	O
woman	O
coming	O
to	O
medical	O
attention	O
because	O
of	O
an	O
increasing	O
overweight	O
.	O

Biochemical	O
tests	O
showed	O
elevated	O
free	O
thyroxine	O
(	O
T4	O
:	O
20.8	O
pg/ml	O
(	O
normal	O
,	O
8.5-18)	O
)	O
and	O
triiodothyronine	O
(	O
T3	O
:	O
5.7	O
pg/ml	O
(	O
normal	O
,	O
1.4-4)	O
)	O
in	O
the	O
serum	O
,	O
together	O
with	O
an	O
inappropriately	O
nonsuppressed	O
TSH	O
level	O
of	O
4.7	O
mU/ml	O
(	O
normal	O
,	O
0.4-4	O
)	O
.	O

Her	O
father	O
and	O
her	O
brother's	O
serum	O
tests	O
also	O
showed	O
biochemical	O
abnormalities	O
consistent	O
with	O
RTH	O
.	O

Direct	O
sequencing	O
of	O
the	O
TRbeta	O
gene	O
revealed	O
a	O
heterozygous	O
transition	O
G>T	B-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
c.898	I-DNAMutation
in	O
exon	O
9	O
resulting	O
in	O
substitution	O
of	O
glutamic	O
acid	O
333	O
by	O
aspartic	O
acid	O
residue	O
(	O
Phe-->Ser	B-ProteinMutation
at	I-ProteinMutation
codon	I-ProteinMutation
15	I-ProteinMutation
)	O
.	O

Further	O
functional	O
analyses	O
of	O
the	O
novel	O
TRbeta	O
mutant	O
were	O
conducted	O
.	O

We	O
found	O
that	O
the	O
Glu	B-ProteinMutation
272	I-ProteinMutation
to	I-ProteinMutation
stop	I-ProteinMutation
mutation	O
neither	O
significantly	O
affected	O
the	O
affinity	O
of	O
the	O
receptor	O
for	O
T3	O
nor	O
modified	O
heterodimer	O
formation	O
with	O
retinoid	O
X	O
receptor	O
(RXR)	O
when	O
bound	O
to	O
DNA	O
.	O

However	O
,	O
in	O
transient	O
transfection	O
assays	O
,	O
the	O
methionine-->valine	B-ProteinMutation
substitution	I-ProteinMutation
at	I-ProteinMutation
codon	I-ProteinMutation
404	I-ProteinMutation
TRbeta	O
mutant	O
exhibited	O
impaired	O
transcriptional	O
regulation	O
on	O
two	O
distinct	O
positively	O
regulated	O
thyroid	O
response	O
elements	O
(	O
F2-	O
and	O
DR4-TREs	O
)	O
as	O
well	O
as	O
on	O
the	O
negatively	O
regulated	O
human	O
TSHalpha	O
promoter	O
.	O

Moreover	O
,	O
a	O
dominant	O
inhibition	O
of	O
the	O
wild-type	O
TRbeta	O
counterpart	O
transactivation	O
function	O
was	O
observed	O
on	O
both	O
a	O
positive	O
(F2-TRE)	O
and	O
a	O
negative	O
(TSHalpha)	O
promoter	O
.	O

These	O
results	O
strongly	O
suggest	O
that	O
the	O
Ser-->Cys	B-ProteinMutation
substitution	I-ProteinMutation
at	I-ProteinMutation
the	I-ProteinMutation
codon	I-ProteinMutation
326	I-ProteinMutation
TRbeta	O
mutation	O
is	O
responsible	O
for	O
the	O
RTH	O
phenotype	O
in	O
the	O
proposita's	O
family	O
.	O

Genetic	O
polymorphism	O
of	O
the	O
binding	O
domain	O
of	O
surfactant	O
protein-A2	O
increases	O
susceptibility	O
to	O
meningococcal	O
disease	O
.	O

BACKGROUND	O
:	O
Meningococcal	O
disease	O
occurs	O
after	O
colonization	O
of	O
the	O
nasopharynx	O
with	O
Neisseria	O
meningitidis	O
.	O

Surfactant	O
protein	O
(SP)-A	O
and	O
SP-D	O
are	O
pattern-recognition	O
molecules	O
of	O
the	O
respiratory	O
tract	O
that	O
activate	O
inflammatory	O
and	O
phagocytic	O
defences	O
after	O
binding	O
to	O
microbial	O
sugars	O
.	O

Variation	O
in	O
the	O
genes	O
of	O
the	O
surfactant	O
proteins	O
affects	O
the	O
expression	O
and	O
function	O
of	O
these	O
molecules	O
.	O

METHODS	O
:	O
Allele	O
frequencies	O
of	O
SP-A1	O
,	O
SP-A2	O
,	O
and	O
SP-D	O
were	O
determined	O
by	O
polymerase	O
chain	O
reaction	O
in	O
303	O
patients	O
with	O
microbiologically	O
proven	O
meningococcal	O
disease	O
,	O
including	O
18	O
patients	O
who	O
died	O
,	O
and	O
222	O
healthy	O
control	O
subjects	O
.	O

RESULTS	O
:	O
Homozygosity	O
of	O
allele	O
1A1	O
of	O
SP-A2	O
increased	O
the	O
risk	O
of	O
meningococcal	O
disease	O
(	O
odds	O
ratio	O
[OR]	O
,	O
7.4	O
;	O
95%	O
confidence	O
interval	O
[CI]	O
,	O
1.3-42.4	O
)	O
;	O
carriage	O
of	O
1A5	O
reduced	O
the	O
risk	O
(	O
OR	O
,	O
0.3	O
;	O
95%	O
CI	O
,	O
0.1-0.97	O
)	O
.	O

An	O
analysis	O
of	O
the	O
multiple	O
single-nucleotide	O
polymorphisms	O
in	O
SP-A	O
demonstrated	O
that	O
homozygosity	O
for	O
alleles	O
encoding	O
lysine	O
(	O
in	O
1A1	O
)	O
rather	O
than	O
glutamine	O
(	O
in	O
1A5	O
)	O
at	O
amino	O
acid	O
223	O
in	O
the	O
carbohydrate	O
recognition	O
domain	O
was	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
meningococcal	O
disease	O
(	O
OR	O
,	O
6.7	O
;	O
95%	O
CI	O
,	O
1.4-31.5	O
)	O
.	O

Carriage	O
of	O
alleles	O
encoding	O
lysine	O
at	O
residue	O
223	O
was	O
found	O
in	O
61%	O
of	O
patients	O
who	O
died	O
,	O
compared	O
with	O
35%	O
of	O
those	O
who	O
survived	O
(	O
OR	O
adjusted	O
for	O
age	O
,	O
2.9	O
;	O
95%	O
CI	O
,	O
1.1-7.7	O
)	O
.	O

Genetic	O
variation	O
of	O
SP-A1	O
and	O
SP-D	O
was	O
not	O
associated	O
with	O
meningococcal	O
disease	O
.	O

CONCLUSIONS	O
:	O
Gene	O
polymorphism	O
resulting	O
in	O
the	O
substitution	O
of	O
glutamine	O
with	O
lysine	O
at	O
residue	O
223	O
in	O
the	O
carbohydrate	O
recognition	O
domain	O
of	O
SP-A2	O
increases	O
susceptibility	O
to	O
meningococcal	O
disease	O
,	O
as	O
well	O
as	O
the	O
risk	O
of	O
death	O
.	O

Four	O
novel	O
mutations	O
in	O
the	O
thiazide-sensitive	O
Na-Cl	O
co-transporter	O
gene	O
in	O
Japanese	O
patients	O
with	O
Gitelman's	O
syndrome	O
.	O

BACKGROUND	O
:	O
Gitelman's	O
syndrome	O
(GS)	O
is	O
an	O
autosomal	O
recessive	O
disorder	O
resulting	O
from	O
inactivating	O
mutations	O
in	O
the	O
thiazide-sensitive	O
Na-Cl	O
co-transporter	O
(NCCT)	O
gene	O
.	O

To	O
date	O
,	O
almost	O
90	O
mutations	O
have	O
been	O
identified	O
.	O

It	O
is	O
possible	O
that	O
there	O
is	O
a	O
population-specific	O
distribution	O
of	O
mutations	O
.	O

In	O
this	O
study	O
,	O
we	O
analysed	O
mutations	O
in	O
the	O
NCCT	O
gene	O
of	O
seven	O
Japanese	O
patients	O
with	O
GS	O
.	O

METHODS	O
:	O
Peripheral	O
blood	O
mononuclear	O
cells	O
were	O
isolated	O
from	O
patients	O
with	O
GS	O
,	O
their	O
family	O
members	O
and	O
healthy	O
control	O
subjects	O
.	O

A	O
mutation	O
analysis	O
of	O
the	O
NCCT	O
gene	O
was	O
performed	O
completely	O
by	O
direct	O
automated	O
sequencing	O
of	O
polymerase	O
chain	O
reaction-amplified	O
DNA	O
products	O
.	O

In	O
patients	O
with	O
a	O
deletion	O
or	O
splice	O
site	O
mutation	O
,	O
we	O
undertook	O
cDNA	O
sequence	O
analysis	O
.	O

RESULTS	O
:	O
We	O
identified	O
nine	O
mutations	O
.	O

Five	O
of	O
them	O
[	O
C-->T	B-DNAMutation
transversion	I-DNAMutation
at	I-DNAMutation
cDNA	I-DNAMutation
base	I-DNAMutation
463	I-DNAMutation
(	O
leucine	B-ProteinMutation
269	I-ProteinMutation
to	I-ProteinMutation
phenylalanine	I-ProteinMutation
)	O
,	O
G-->C	B-DNAMutation
transversion	I-DNAMutation
at	I-DNAMutation
1245	I-DNAMutation
position	I-DNAMutation
(	O
arginine	B-ProteinMutation
555-to-tryptophan	I-ProteinMutation
)	O
,	O
C-->T	B-DNAMutation
transition	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
677	I-DNAMutation
(	O
histidine	B-ProteinMutation
626-to-arginine	I-ProteinMutation
)	O
,	O
G-->C	B-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
135	I-DNAMutation
(	O
arginine	B-ProteinMutation
124-to-cysteine	I-ProteinMutation
)	O
and	O
GTT-->GCT	B-DNAMutation
transition	I-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
23	I-DNAMutation
]	O
have	O
been	O
reported	O
in	O
Japanese	O
patients	O
,	O
but	O
not	O
in	O
GS	O
patients	O
from	O
other	O
ethnic	O
groups	O
.	O

The	O
remaining	O
four	O
mutations	O
[	O
(	B-DNAMutation
TAC-->AA	I-DNAMutation
)	I-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
329	I-DNAMutation
(	O
Phe-->Ser	B-ProteinMutation
at	I-ProteinMutation
codon	I-ProteinMutation
15	I-ProteinMutation
)	O
,	O
A	B-DNAMutation
>	I-DNAMutation
G	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
313	I-DNAMutation
,	O
-AAGC	B-DNAMutation
at	I-DNAMutation
-222	I-DNAMutation
to	I-DNAMutation
-225	I-DNAMutation
and	O
-491	B-DNAMutation
A	I-DNAMutation
to	I-DNAMutation
T	I-DNAMutation
]	O
were	O
novel	O
.	O

In	O
cDNA	O
derived	O
from	O
a	O
patient	O
with	O
G>A	B-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
+1	I-DNAMutation
of	I-DNAMutation
intron	I-DNAMutation
2	I-DNAMutation
,	O
a	O
deletion	O
of	O
exon	O
9	O
and	O
a	O
frameshift	O
at	O
the	O
start	O
of	O
exon	O
10	O
were	O
observed	O
.	O

In	O
cDNA	O
derived	O
from	O
patients	O
with	O
(	B-DNAMutation
G	I-DNAMutation
-->	I-DNAMutation
C	I-DNAMutation
)	I-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
1201	I-DNAMutation
,	O
an	O
additional	O
96	O
bp	O
insertion	O
between	O
exons	O
16	O
and	O
17	O
was	O
observed	O
.	O

Six	O
out	O
of	O
seven	O
patients	O
were	O
compound	O
heterozygotes	O
,	O
and	O
the	O
remaining	O
one	O
carried	O
a	O
single	O
heterozygous	O
mutation	O
.	O

CONCLUSIONS	O
:	O
We	O
found	O
four	O
novel	O
mutations	O
in	O
the	O
NCCT	O
gene	O
in	O
seven	O
Japanese	O
patients	O
with	O
GS	O
.	O

Moreover	O
,	O
our	O
study	O
suggests	O
that	O
the	O
distribution	O
of	O
mutations	O
in	O
the	O
NCCT	O
gene	O
in	O
Japanese	O
GS	O
patients	O
potentially	O
differs	O
from	O
that	O
in	O
other	O
populations	O
.	O

Cdx-2	O
polymorphism	O
in	O
the	O
promoter	O
region	O
of	O
the	O
human	O
vitamin	O
D	O
receptor	O
gene	O
determines	O
susceptibility	O
to	O
fracture	O
in	O
the	O
elderly	O
.	O

A	O
Cdx-2	O
binding	O
site	O
polymorphism	O
(	O
G	O
to	O
A	O
)	O
in	O
the	O
promoter	O
region	O
of	O
the	O
human	O
vitamin	O
D	O
receptor	O
gene	O
was	O
reported	O
.	O

In	O
an	O
ecological	O
study	O
in	O
eight	O
ethnic	O
groups	O
and	O
an	O
association	O
study	O
in	O
2848	O
elderly	O
whites	O
,	O
we	O
found	O
the	O
A-allele	O
to	O
be	O
associated	O
with	O
decreased	O
fracture	O
risk	O
.	O

Our	O
findings	O
expand	O
previous	O
similar	O
findings	O
in	O
a	O
Japanese	O
study	O
to	O
whites	O
and	O
show	O
a	O
relationship	O
with	O
fracture	O
risk	O
of	O
this	O
functional	O
polymorphism	O
.	O

INTRODUCTION	O
:	O
A	O
single	O
nucleotide	O
polymorphism	O
(SNP)	O
within	O
a	O
binding	O
site	O
of	O
the	O
intestinal-specific	O
transcription	O
factor	O
Cdx-2	O
in	O
the	O
promoter	O
region	O
of	O
the	O
human	O
vitamin	O
D	O
receptor	O
(VDR)	O
gene	O
was	O
previously	O
reported	O
.	O

It	O
was	O
found	O
to	O
modulate	O
the	O
transcription	O
of	O
the	O
hVDR	O
gene	O
and	O
to	O
be	O
associated	O
with	O
decreased	O
bone	O
mineral	O
density	O
in	O
a	O
small	O
group	O
of	O
postmenopausal	O
Japanese	O
women	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
relationship	O
between	O
the	O
VDR	O
Cdx-2	O
genotype	O
and	O
risk	O
of	O
fracture	O
.	O

METHODS	O
:	O
We	O
first	O
determined	O
the	O
location	O
of	O
this	O
SNP	O
in	O
the	O
VDR	O
gene	O
by	O
sequencing	O
analysis	O
,	O
and	O
we	O
developed	O
an	O
allele-specific	O
multiplex	O
polymerase	O
chain	O
reaction	O
test	O
to	O
determine	O
the	O
Cdx-2	O
genotype	O
.	O

We	O
then	O
performed	O
an	O
ecological	O
study	O
in	O
eight	O
ethnic	O
groups	O
and	O
an	O
association	O
analysis	O
in	O
a	O
large	O
epidemiological	O
cohort	O
of	O
2848	O
Dutch	O
white	O
men	O
and	O
women	O
,	O
>	O
or	O
=	O
55	O
years	O
old	O
.	O

RESULTS	O
AND	O
CONCLUSIONS	O
:	O
The	O
location	O
of	O
the	O
G	O
to	O
A	O
substitution	O
was	O
found	O
in	O
the	O
promoter	O
region	O
of	O
exon	O
le	O
(le-G-1739A)	O
of	O
the	O
VDR	O
gene	O
.	O

By	O
comparing	O
the	O
frequency	O
of	O
the	O
A-allele	O
in	O
eight	O
different	O
ethnic	O
groups	O
,	O
we	O
observed	O
a	O
negative	O
correlation	O
between	O
prevalence	O
of	O
the	O
A-allele	O
and	O
published	O
hip	O
fracture	O
incidence	O
rates	O
in	O
these	O
ethnic	O
groups	O
(	O
p	O
=	O
0.006	O
for	O
men	O
and	O
p	O
=	O
0.02	O
for	O
women	O
)	O
,	O
suggesting	O
a	O
protective	O
effect	O
of	O
this	O
allele	O
on	O
fracture	O
risk	O
.	O

Subsequently	O
,	O
in	O
the	O
association	O
study	O
,	O
the	O
A-allele	O
(	O
population	O
frequency	O
19%	O
)	O
was	O
observed	O
to	O
have	O
a	O
protective	O
effect	O
on	O
occurrence	O
of	O
osteoporotic	O
fractures	O
,	O
especially	O
for	O
nonvertebral	O
fracture	O
in	O
women	O
(	O
relative	O
risk	O
of	O
AA	O
versus	O
GG	O
genotype	O
is	O
0.2	O
;	O
95%	O
CI	O
,	O
0.05-0.8	O
)	O
.	O

This	O
effect	O
remained	O
after	O
adjustment	O
for	O
age	O
,	O
weight	O
,	O
and	O
bone	O
mineral	O
density	O
.	O

We	O
conclude	O
that	O
the	O
A-allele	O
of	O
the	O
VDR	O
Cdx-2	O
polymorphism	O
is	O
present	O
in	O
whites	O
,	O
albeit	O
at	O
low	O
frequency	O
,	O
and	O
show	O
a	O
protective	O
effect	O
of	O
this	O
allele	O
on	O
risk	O
of	O
fracture	O
.	O

A	O
single	O
nucleotide	O
polymorphism	O
in	O
the	O
IRF5	O
promoter	O
region	O
is	O
associated	O
with	O
susceptibility	O
to	O
rheumatoid	O
arthritis	O
in	O
the	O
Japanese	O
population	O
.	O

OBJECTIVES	O
:	O
Interferon	O
regulatory	O
factor	O
5	O
(IRF5)	O
is	O
a	O
member	O
of	O
the	O
IRF	O
family	O
of	O
transcription	O
factors	O
,	O
which	O
regulate	O
the	O
production	O
of	O
proinflammatory	O
cytokines	O
.	O

Polymorphisms	O
in	O
the	O
IRF5	O
gene	O
have	O
been	O
associated	O
with	O
susceptibility	O
to	O
systemic	O
lupus	O
erythaematosus	O
(SLE)	O
in	O
Caucasian	O
and	O
Asian	O
populations	O
,	O
but	O
their	O
involvement	O
in	O
other	O
autoimmune	O
diseases	O
is	O
still	O
uncertain	O
.	O

Here	O
,	O
we	O
assessed	O
the	O
genetic	O
role	O
of	O
IRF5	O
in	O
susceptibility	O
to	O
rheumatoid	O
arthritis	O
(RA)	O
in	O
Japanese	O
subjects	O
.	O

METHODS	O
:	O
We	O
selected	O
13	O
single	O
nucleotide	O
polymorphisms	O
(SNPs)	O
and	O
a	O
CGGGG	O
insertion-deletion	O
polymorphism	O
in	O
the	O
IRF5	O
gene	O
.	O

We	O
performed	O
2	O
sets	O
of	O
case-control	O
comparisons	O
using	O
Japanese	O
subjects	O
(	O
first	O
set	O
:	O
830	O
patients	O
with	O
RA	O
and	O
658	O
controls	O
;	O
second	O
set	O
:	O
1112	O
patients	O
with	O
RA	O
and	O
940	O
controls	O
)	O
,	O
and	O
then	O
performed	O
a	O
stratified	O
analysis	O
using	O
human	O
leukocyte	O
antigen	O
(HLA)-DRB1	O
shared	O
epitope	O
(SE)	O
status	O
.	O

We	O
genotyped	O
the	O
SNPs	O
using	O
TaqMan	O
assays	O
.	O

RESULTS	O
:	O
A	O
significant	O
association	O
of	O
the	O
rs729302	O
A	O
allele	O
with	O
RA	O
susceptibility	O
was	O
found	O
in	O
both	O
sets	O
(	O
odds	O
ratio	O
(OR)	O
1.22	O
,	O
95%	O
CI	O
1.09	O
to	O
1.35	O
,	O
p<0.001	O
in	O
the	O
combined	O
analysis	O
)	O
.	O

When	O
the	O
patients	O
were	O
stratified	O
by	O
the	O
SE	O
,	O
the	O
rs729302	O
A	O
allele	O
was	O
found	O
to	O
confer	O
increased	O
risk	O
to	O
RA	O
in	O
patients	O
that	O
were	O
SE	O
negative	O
(	O
OR	O
1.50	O
,	O
95%	O
CI	O
1.17	O
to	O
1.92	O
,	O
p	O
=	O
0.001	O
)	O
as	O
compared	O
with	O
patients	O
carrying	O
the	O
SE	O
(	O
OR	O
1.11	O
,	O
95%	O
CI	O
0.93	O
to	O
1.33	O
,	O
p	O
=	O
0.24	O
)	O
.	O

In	O
both	O
sets	O
,	O
no	O
genotyped	O
polymorphisms	O
were	O
significantly	O
associated	O
with	O
RA	O
susceptibility	O
,	O
but	O
rs729302	O
was	O
significantly	O
associated	O
.	O

CONCLUSIONS	O
:	O
These	O
findings	O
indicate	O
that	O
the	O
promoter	O
polymorphism	O
of	O
IRF5	O
is	O
a	O
genetic	O
factor	O
conferring	O
predisposition	O
to	O
RA	O
,	O
and	O
that	O
it	O
contributes	O
considerably	O
to	O
disease	O
pathogenesis	O
in	O
patients	O
that	O
were	O
SE	O
negative	O
.	O

A	O
novel	O
mutation	O
screening	O
system	O
for	O
Ehlers-Danlos	O
Syndrome	O
,	O
vascular	O
type	O
by	O
high-resolution	O
melting	O
curve	O
analysis	O
in	O
combination	O
with	O
small	O
amplicon	O
genotyping	O
using	O
genomic	O
DNA	O
.	O

Ehlers-Danlos	O
syndrome	O
,	O
vascular	O
type	O
(vEDS)	O
(	O
MIM	O
#130050	O
)	O
is	O
an	O
autosomal	O
dominant	O
disorder	O
caused	O
by	O
type	O
III	O
procollagen	O
gene	O
(COL3A1)	O
mutations	O
.	O

Most	O
COL3A1	O
mutations	O
are	O
detected	O
by	O
using	O
total	O
RNA	O
from	O
patient-derived	O
fibroblasts	O
,	O
which	O
requires	O
an	O
invasive	O
skin	O
biopsy	O
.	O

High-resolution	O
melting	O
curve	O
analysis	O
(hrMCA)	O
has	O
recently	O
been	O
developed	O
as	O
a	O
post-PCR	O
mutation	O
scanning	O
method	O
which	O
enables	O
simple	O
,	O
rapid	O
,	O
cost-effective	O
,	O
and	O
highly	O
sensitive	O
mutation	O
screening	O
of	O
large	O
genes	O
.	O

We	O
established	O
a	O
hrMCA	O
method	O
to	O
screen	O
for	O
COL3A1	O
mutations	O
using	O
genomic	O
DNA	O
.	O

PCR	O
primers	O
pairs	O
for	O
COL3A1	O
(	O
52	O
amplicons	O
)	O
were	O
designed	O
to	O
cover	O
all	O
coding	O
regions	O
of	O
the	O
52	O
exons	O
,	O
including	O
the	O
splicing	O
sites	O
.	O

We	O
used	O
15	O
DNA	O
samples	O
(	O
8	O
validation	O
samples	O
and	O
7	O
samples	O
of	O
clinically	O
suspected	O
vEDS	O
patients	O
)	O
in	O
this	O
study	O
.	O

The	O
eight	O
known	O
COL3A1	O
mutations	O
in	O
validation	O
samples	O
were	O
all	O
successfully	O
detected	O
by	O
the	O
hrMCA	O
.	O

In	O
addition	O
,	O
we	O
identified	O
five	O
novel	O
COL3A1	O
mutations	O
,	O
including	O
one	O
deletion	O
(	O
(	B-DNAMutation
T	I-DNAMutation
-->	I-DNAMutation
C	I-DNAMutation
)	I-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
2209	I-DNAMutation
)	O
and	O
one	O
nonsense	O
mutation	O
(	O
G>T	B-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
c.898	I-DNAMutation
)	O
that	O
could	O
not	O
be	O
determined	O
by	O
the	O
conventional	O
total	O
RNA	O
method	O
.	O

Furthermore	O
,	O
we	O
established	O
a	O
small	O
amplicon	O
genotyping	O
(SAG)	O
method	O
for	O
detecting	O
three	O
high	O
frequency	O
coding-region	O
SNPs	O
(	O
rs1800255:G-->C	B-DNAMutation
transversion	I-DNAMutation
at	I-DNAMutation
1245	I-DNAMutation
position	I-DNAMutation
,	O
rs1801184:C-->T	B-DNAMutation
transversion	I-DNAMutation
at	I-DNAMutation
cDNA	I-DNAMutation
base	I-DNAMutation
463	I-DNAMutation
,	O
and	O
rs2271683:C-->T	B-DNAMutation
transition	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
677	I-DNAMutation
)	O
in	O
COL3A1	O
to	O
differentiate	O
mutations	O
before	O
sequencing	O
.	O

The	O
use	O
of	O
hrMCA	O
in	O
combination	O
with	O
SAG	O
from	O
genomic	O
DNA	O
enables	O
rapid	O
detection	O
of	O
COL3A1	O
mutations	O
with	O
high	O
efficiency	O
and	O
specificity	O
.	O

A	O
better	O
understanding	O
of	O
the	O
genotype-phenotype	O
correlation	O
in	O
COL3A1	O
using	O
this	O
method	O
will	O
lead	O
to	O
improve	O
in	O
diagnosis	O
and	O
treatment	O
.	O

Loss-of-function	O
mutations	O
in	O
PTPN11	O
cause	O
metachondromatosis	O
,	O
but	O
not	O
Ollier	O
disease	O
or	O
Maffucci	O
syndrome	O
.	O

Metachondromatosis	O
(MC)	O
is	O
a	O
rare	O
,	O
autosomal	O
dominant	O
,	O
incompletely	O
penetrant	O
combined	O
exostosis	O
and	O
enchondromatosis	O
tumor	O
syndrome	O
.	O

MC	O
is	O
clinically	O
distinct	O
from	O
other	O
multiple	O
exostosis	O
or	O
multiple	O
enchondromatosis	O
syndromes	O
and	O
is	O
unlinked	O
to	O
EXT1	O
and	O
EXT2	O
,	O
the	O
genes	O
responsible	O
for	O
autosomal	O
dominant	O
multiple	O
osteochondromas	O
(MO)	O
.	O

To	O
identify	O
a	O
gene	O
for	O
MC	O
,	O
we	O
performed	O
linkage	O
analysis	O
with	O
high-density	O
SNP	O
arrays	O
in	O
a	O
single	O
family	O
,	O
used	O
a	O
targeted	O
array	O
to	O
capture	O
exons	O
and	O
promoter	O
sequences	O
from	O
the	O
linked	O
interval	O
in	O
16	O
participants	O
from	O
11	O
MC	O
families	O
,	O
and	O
sequenced	O
the	O
captured	O
DNA	O
using	O
high-throughput	O
parallel	O
sequencing	O
technologies	O
.	O

DNA	O
capture	O
and	O
parallel	O
sequencing	O
identified	O
heterozygous	O
putative	O
loss-of-function	O
mutations	O
in	O
PTPN11	O
in	O
4	O
of	O
the	O
11	O
families	O
.	O

Sanger	O
sequence	O
analysis	O
of	O
PTPN11	O
coding	O
regions	O
in	O
a	O
total	O
of	O
17	O
MC	O
families	O
identified	O
mutations	O
in	O
10	O
of	O
them	O
(	O
5	O
frameshift	O
,	O
2	O
nonsense	O
,	O
and	O
3	O
splice-site	O
mutations	O
)	O
.	O

Copy	O
number	O
analysis	O
of	O
sequencing	O
reads	O
from	O
a	O
second	O
targeted	O
capture	O
that	O
included	O
the	O
entire	O
PTPN11	O
gene	O
identified	O
an	O
additional	O
family	O
with	O
a	O
15	O
kb	O
deletion	O
spanning	O
exon	O
7	O
of	O
PTPN11	O
.	O

Microdissected	O
MC	O
lesions	O
from	O
two	O
patients	O
with	O
PTPN11	O
mutations	O
demonstrated	O
loss-of-heterozygosity	O
for	O
the	O
wild-type	O
allele	O
.	O

We	O
next	O
sequenced	O
PTPN11	O
in	O
DNA	O
samples	O
from	O
54	O
patients	O
with	O
the	O
multiple	O
enchondromatosis	O
disorders	O
Ollier	O
disease	O
or	O
Maffucci	O
syndrome	O
,	O
but	O
found	O
no	O
coding	O
sequence	O
PTPN11	O
mutations	O
.	O

We	O
conclude	O
that	O
heterozygous	O
loss-of-function	O
mutations	O
in	O
PTPN11	O
are	O
a	O
frequent	O
cause	O
of	O
MC	O
,	O
that	O
lesions	O
in	O
patients	O
with	O
MC	O
appear	O
to	O
arise	O
following	O
a	O
"second	O
hit,"	O
that	O
MC	O
may	O
be	O
locus	O
heterogeneous	O
since	O
1	O
familial	O
and	O
5	O
sporadically	O
occurring	O
cases	O
lacked	O
obvious	O
disease-causing	O
PTPN11	O
mutations	O
,	O
and	O
that	O
PTPN11	O
mutations	O
are	O
not	O
a	O
common	O
cause	O
of	O
Ollier	O
disease	O
or	O
Maffucci	O
syndrome	O
.	O

Development	O
and	O
validation	O
of	O
a	O
SYBR	O
Green	O
I-based	O
real-time	O
polymerase	O
chain	O
reaction	O
method	O
for	O
detection	O
of	O
haptoglobin	O
gene	O
deletion	O
in	O
clinical	O
materials	O
.	O

BACKGROUND	O
:	O
Anhaptoglobinemic	O
patients	O
run	O
the	O
risk	O
of	O
severe	O
anaphylactic	O
transfusion	O
reaction	O
because	O
they	O
produce	O
serum	O
haptoglobin	O
(Hp)	O
antibodies	O
.	O

Being	O
homozygous	O
for	O
the	O
Hp	O
gene	O
deletion	O
(HP(del))	O
is	O
the	O
only	O
known	O
cause	O
of	O
congenital	O
anhaptoglobinemia	O
,	O
and	O
clinical	O
diagnosis	O
of	O
HP(del)	O
before	O
transfusion	O
is	O
important	O
to	O
prevent	O
anaphylactic	O
shock	O
.	O

We	O
recently	O
developed	O
a	O
5'-nuclease	O
(TaqMan)	O
real-time	O
polymerase	O
chain	O
reaction	O
(PCR)	O
method	O
.	O

STUDY	O
DESIGN	O
AND	O
METHODS	O
:	O
A	O
SYBR	O
Green	O
I-based	O
duplex	O
real-time	O
PCR	O
assay	O
using	O
two	O
forward	O
primers	O
and	O
a	O
common	O
reverse	O
primer	O
followed	O
by	O
melting	O
curve	O
analysis	O
was	O
developed	O
to	O
determine	O
HP(del)	O
zygosity	O
in	O
a	O
single	O
tube	O
.	O

In	O
addition	O
,	O
to	O
obviate	O
initial	O
DNA	O
extraction	O
,	O
we	O
examined	O
serially	O
diluted	O
blood	O
samples	O
as	O
PCR	O
templates	O
.	O

RESULTS	O
:	O
Allelic	O
discrimination	O
of	O
HP(del)	O
yielded	O
optimal	O
results	O
at	O
blood	O
sample	O
dilutions	O
of	O
1:64	O
to	O
1:1024	O
.	O

The	O
results	O
from	O
2231	O
blood	O
samples	O
were	O
fully	O
concordant	O
with	O
those	O
obtained	O
by	O
the	O
TaqMan-based	O
real-time	O
PCR	O
method	O
.	O

CONCLUSION	O
:	O
The	O
detection	O
rate	O
of	O
the	O
HP(del)	O
allele	O
by	O
the	O
SYBR	O
Green	O
I-based	O
method	O
is	O
comparable	O
with	O
that	O
using	O
the	O
TaqMan-based	O
method	O
.	O

This	O
method	O
is	O
readily	O
applicable	O
due	O
to	O
its	O
low	O
initial	O
cost	O
and	O
analyzability	O
using	O
economical	O
real-time	O
PCR	O
machines	O
and	O
is	O
suitable	O
for	O
high-throughput	O
analysis	O
as	O
an	O
alternative	O
method	O
for	O
allelic	O
discrimination	O
of	O
HP(del)	O
.	O

HPRTSardinia	O
:	O
a	O
new	O
point	O
mutation	O
causing	O
HPRT	O
deficiency	O
without	O
Lesch-Nyhan	O
disease	O
.	O

Hypoxanthine-guanine	O
phosphoribosyltransferase	O
(HPRT)	O
deficiency	O
always	O
causing	O
hyperuricemia	O
presents	O
various	O
degrees	O
of	O
neurological	O
manifestations	O
,	O
the	O
most	O
severe	O
which	O
is	O
Lesch-Nyhan	O
syndrome	O
.	O

The	O
HPRT	O
gene	O
is	O
situated	O
in	O
the	O
region	O
Xq26-q27.2	O
and	O
consists	O
of	O
9	O
exons	O
.	O

At	O
least	O
300	O
different	O
mutations	O
at	O
different	O
sites	O
in	O
the	O
HPRT	O
coding	O
region	O
from	O
exon	O
1	O
to	O
exon	O
9	O
have	O
been	O
identified	O
.	O

A	O
new	O
mutation	O
in	O
the	O
HPRT	O
gene	O
has	O
been	O
determined	O
in	O
one	O
patient	O
with	O
complete	O
deficiency	O
of	O
erythrocyte	O
activity	O
,	O
with	O
hyperuricemia	O
and	O
gout	O
but	O
without	O
Lesch-Nyhan	O
disease	O
.	O

Analysis	O
of	O
cultured	O
fibroblasts	O
revealed	O
minimal	O
residual	O
HPRT	O
activity	O
mainly	O
when	O
guanine	O
was	O
the	O
substrate	O
.	O

Genomic	O
DNA	O
sequencing	O
demonstrated	O
patient's	O
mother	O
heterozygosity	O
for	O
the	O
mutation	O
and	O
no	O
mutation	O
in	O
her	O
brother	O
.	O

The	O
mutation	O
consists	O
in	O
a	O
G-->C	B-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
135	I-DNAMutation
(	O
GTT-->GCT	B-DNAMutation
transition	I-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
23	I-DNAMutation
)	O
in	O
exon	O
6	O
,	O
resulting	O
in	O
proline	O
to	O
serine	O
substitution	O
at	O
codon	O
155	O
(	O
Glu	B-ProteinMutation
272	I-ProteinMutation
to	I-ProteinMutation
stop	I-ProteinMutation
)	O
.	O

This	O
mutation	O
had	O
not	O
been	O
reported	O
previously	O
and	O
has	O
been	O
designated	O
HPRT(Sardinia)	O
.	O

The	O
mutation	O
identified	O
in	O
this	O
patient	O
allows	O
some	O
expression	O
of	O
functional	O
enzyme	O
in	O
nucleated	O
cells	O
such	O
as	O
fibroblasts	O
,	O
indicating	O
that	O
such	O
cell	O
type	O
may	O
add	O
further	O
information	O
to	O
conventional	O
blood	O
analysis	O
.	O

A	O
multicentre	O
survey	O
gathering	O
patients	O
with	O
variant	O
neurological	O
forms	O
could	O
contribute	O
to	O
understand	O
the	O
pathophysiology	O
of	O
the	O
neurobehavioral	O
symptoms	O
of	O
HPRT	O
deficiency	O
.	O

Beta-thalassemia	O
in	O
association	O
with	O
a	O
new	O
delta-chain	O
hemoglobin	O
variant	O
[	O
delta116(g18)methionine-->valine	B-ProteinMutation
substitution	I-ProteinMutation
at	I-ProteinMutation
codon	I-ProteinMutation
404	I-ProteinMutation
]	O
:	O
implications	O
for	O
carrier	O
screening	O
and	O
prenatal	O
diagnosis	O
.	O

We	O
describe	O
a	O
complicated	O
genetic	O
counseling	O
and	O
prenatal	O
diagnostic	O
case	O
involving	O
an	O
East	O
Indian	O
couple	O
that	O
had	O
lost	O
two	O
consecutive	O
pregnancies	O
.	O

Hemoglobinopathy	O
screening	O
was	O
conducted	O
to	O
investigate	O
the	O
possibility	O
of	O
Hb	O
Bart's	O
hydrops	O
fetalis	O
or	O
Hb	O
H	O
hydrops	O
fetalis	O
.	O

The	O
initial	O
work-up	O
indicated	O
that	O
alpha-thalassemia	O
was	O
not	O
a	O
contributing	O
factor	O
,	O
with	O
both	O
parents	O
being	O
carriers	O
of	O
single	O
gene	O
deletions	O
(-alpha(3.7)/alphaalpha)	O
.	O

However	O
,	O
the	O
Hb	O
electrophoresis	O
results	O
indicated	O
that	O
the	O
couple	O
might	O
be	O
at	O
risk	O
for	O
having	O
children	O
with	O
Hb	O
E/Hb	O
Lepore	O
disease	O
.	O

Subsequent	O
DNA	O
testing	O
demonstrated	O
that	O
the	O
father	O
carried	O
the	O
Hb	O
E	O
mutation	O
,	O
but	O
failed	O
to	O
confirm	O
that	O
the	O
mother	O
carries	O
the	O
Hb	O
Lepore	O
deletion	O
.	O

Sequence	O
analysis	O
revealed	O
that	O
the	O
mother	O
was	O
heterozygous	O
for	O
a	O
common	O
East	O
Indian	O
beta(0)-thalassemia	O
mutation	O
,	O
yet	O
had	O
a	O
normal	O
level	O
of	O
Hb	O
A(2)	O
.	O

The	O
mother	O
also	O
carried	O
a	O
previously	O
unreported	O
missense	O
mutation	O
of	O
the	O
delta-globin	O
gene	O
,	O
in	O
cis	O
with	O
the	O
beta(0)-thalassemia	O
mutation	O
,	O
which	O
gave	O
rise	O
to	O
the	O
minor	O
Hb	O
variant	O
originally	O
misidentified	O
as	O
Hb	O
Lepore	O
.	O

This	O
case	O
illustrates	O
the	O
importance	O
of	O
comprehensive	O
molecular	O
analyses	O
for	O
accurate	O
assessment	O
of	O
genetic	O
risks	O
for	O
hemoglobinopathy	O
syndromes	O
.	O

TNFA	O
A	B-DNAMutation
>	I-DNAMutation
G	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
313	I-DNAMutation
in	O
two	O
international	O
population-based	O
cohorts	O
and	O
risk	O
of	O
asthma	O
.	O

Genetic	O
association	O
studies	O
have	O
related	O
the	O
tumour	O
necrosis	O
factor-alpha	O
gene	O
(TNFA)	O
guanine	O
to	O
adenine	O
substitution	O
of	O
nucleotide	O
-308	O
(	O
(	B-DNAMutation
TAC-->AA	I-DNAMutation
)	I-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
329	I-DNAMutation
)	O
polymorphism	O
to	O
increased	O
risk	O
of	O
asthma	O
,	O
but	O
results	O
are	O
inconsistent	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
test	O
whether	O
two	O
single-nucleotide	O
polymorphisms	O
,	O
of	O
TNFA	O
and	O
of	O
the	O
lymphotoxin-alpha	O
gene	O
(LTA)	O
,	O
are	O
associated	O
with	O
asthma	O
,	O
bronchial	O
hyperresponsiveness	O
and	O
atopy	O
in	O
adults	O
,	O
by	O
combining	O
the	O
results	O
of	O
two	O
large	O
population-based	O
multicentric	O
studies	O
and	O
conducting	O
a	O
meta-analysis	O
of	O
previously	O
published	O
studies	O
.	O

The	O
European	O
Community	O
Respiratory	O
Health	O
Survey	O
(ECRHS)	O
and	O
Swiss	O
Cohort	O
Study	O
on	O
Air	O
Pollution	O
and	O
Lung	O
and	O
Heart	O
Diseases	O
in	O
Adults	O
(SAPALDIA)	O
used	O
comparable	O
protocols	O
,	O
including	O
questionnaires	O
for	O
respiratory	O
symptoms	O
and	O
measures	O
of	O
lung	O
function	O
and	O
atopy	O
.	O

DNA	O
samples	O
from	O
11,136	O
participants	O
were	O
genotyped	O
at	O
TNFA	O
-308	O
and	O
LTA	O
252	O
.	O

Logistic	O
regression	O
employing	O
fixed	O
and	O
random	O
effects	O
models	O
and	O
nonparametric	O
techniques	O
were	O
used	O
.	O

The	O
prevalence	O
of	O
asthma	O
was	O
6%	O
.	O

The	O
TNFA	O
-AAGC	B-DNAMutation
at	I-DNAMutation
-222	I-DNAMutation
to	I-DNAMutation
-225	I-DNAMutation
polymorphism	O
was	O
associated	O
with	O
increased	O
asthma	O
prevalence	O
and	O
with	O
bronchial	O
hyperresponsiveness	O
.	O

No	O
consistent	O
association	O
was	O
found	O
for	O
atopy	O
.	O

The	O
LTA	O
-491	B-DNAMutation
A	I-DNAMutation
to	I-DNAMutation
T	I-DNAMutation
polymorphism	O
was	O
not	O
associated	O
with	O
any	O
of	O
the	O
outcomes	O
.	O

A	O
meta-analysis	O
of	O
17	O
studies	O
showed	O
an	O
increased	O
asthma	O
risk	O
for	O
the	O
TNFA	O
-308	O
adenine	O
allele	O
.	O

The	O
tumour	O
necrosis	O
factor-alpha	O
gene	O
nucleotide	O
-308	O
polymorphism	O
is	O
associated	O
with	O
a	O
moderately	O
increased	O
risk	O
of	O
asthma	O
and	O
bronchial	O
hyperresponsiveness	O
,	O
but	O
not	O
with	O
atopy	O
.	O

These	O
results	O
are	O
supported	O
by	O
a	O
meta-analysis	O
of	O
previously	O
published	O
studies	O
.	O

Association	O
of	O
atopy	O
and	O
eczema	O
with	O
polymorphisms	O
in	O
T-cell	O
immunoglobulin	O
domain	O
and	O
mucin	O
domain-IL-2-inducible	O
T-cell	O
kinase	O
gene	O
cluster	O
in	O
chromosome	O
5	O
q	O
33	O
.	O

BACKGROUND	O
:	O
The	O
T-cell	O
immunoglobulin	O
domain	O
and	O
mucin	O
domain	O
(TIM)	O
gene	O
family	O
and	O
the	O
gene	O
for	O
IL-2-inducible	O
T-cell	O
kinase	O
(ITK)	O
,	O
located	O
in	O
chromosome	O
5	O
q	O
33	O
and	O
potentially	O
involved	O
in	O
the	O
T-cell	O
proliferation	O
and	O
differentiation	O
,	O
are	O
good	O
candidate	O
genes	O
for	O
allergic	O
diseases	O
.	O

OBJECTIVE	O
:	O
We	O
assessed	O
the	O
role	O
of	O
polymorphisms	O
in	O
the	O
TIM	O
family	O
genes	O
and	O
ITK	O
in	O
atopy	O
,	O
eczema	O
,	O
and	O
asthma	O
.	O

METHODS	O
:	O
Twenty-one	O
polymorphisms	O
in	O
the	O
TIM-ITK	O
gene	O
cluster	O
were	O
genotyped	O
in	O
564	O
children	O
enrolled	O
in	O
the	O
Tucson	O
Children's	O
Respiratory	O
Study	O
.	O

Skin	O
prick	O
tests	O
to	O
common	O
allergens	O
were	O
performed	O
at	O
age	O
6.1	O
years	O
(n=508)	O
,	O
age	O
10.8	O
years	O
(n=539)	O
,	O
and	O
age	O
16.6	O
years	O
(n=424)	O
.	O

Asthma	O
and	O
eczema	O
were	O
assessed	O
by	O
questionnaire	O
at	O
these	O
3	O
points	O
.	O

Averaged	O
relative	O
risks	O
were	O
estimated	O
.	O

RESULTS	O
:	O
One	O
15-bp	O
insertion/deletion	O
in	O
exon	O
4	O
of	O
TIM	O
1	O
was	O
significantly	O
related	O
to	O
atopy	O
and	O
eczema	O
(	O
relative	O
risk	O
associated	O
with	O
carrying	O
at	O
least	O
1	O
rare	O
allele=1.24	O
[1.07--1.45]	O
,	O
P=.005	O
;	O
and	O
1.43	O
[1.01--2.01]	O
,	O
P=.004	O
,	O
respectively	O
)	O
.	O

The	O
3	O
tested	O
single	O
nucleotide	O
polymorphisms	O
(SNPs)	O
in	O
TIM	O
3	O
were	O
significantly	O
related	O
to	O
atopy	O
and	O
eczema	O
.	O

One	O
of	O
them	O
,	O
at	O
position	O
+4259	O
calculated	O
from	O
the	O
translation	O
start	O
site	O
,	O
predicts	O
a	O
putative	O
change	O
in	O
the	O
amino	O
acid	O
sequence	O
of	O
the	O
protein	O
,	O
and	O
was	O
the	O
most	O
strongly	O
related	O
to	O
atopy	O
(	O
relative	O
risk=1.28	O
[1.12--1.47]	O
;	O
P=.0003	O
)	O
.	O

SNPs	O
in	O
the	O
5'	O
genomic	O
region	O
in	O
ITK	O
,	O
which	O
show	O
moderate	O
linkage	O
disequilibrium	O
with	O
those	O
in	O
TIM	O
3	O
,	O
had	O
an	O
independent	O
effect	O
on	O
atopy	O
.	O

None	O
of	O
the	O
polymorphisms	O
studied	O
was	O
related	O
to	O
asthma	O
.	O

CONCLUSION	O
:	O
Our	O
findings	O
support	O
a	O
potential	O
role	O
for	O
SNPs	O
in	O
TIM	O
1	O
,	O
TIM	O
3	O
,	O
and	O
ITK	O
,	O
independent	O
of	O
each	O
other	O
,	O
in	O
allergic	O
diseases	O
.	O

A	O
novel	O
DFNA5	O
mutation	O
,	O
G>A	B-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
+1	I-DNAMutation
of	I-DNAMutation
intron	I-DNAMutation
2	I-DNAMutation
,	O
in	O
the	O
splice	O
donor	O
site	O
of	O
intron	O
8	O
causes	O
late-onset	O
non-syndromic	O
hearing	O
loss	O
in	O
a	O
Chinese	O
family	O
.	O

We	O
report	O
here	O
the	O
clinical	O
,	O
genetic	O
,	O
and	O
molecular	O
characteristics	O
of	O
a	O
large	O
Chinese	O
family	O
exhibiting	O
non-syndromic	O
,	O
late-onset	O
autosomal	O
dominant	O
sensorineural	O
hearing	O
loss	O
.	O

Clinical	O
evaluation	O
revealed	O
variable	O
phenotypes	O
of	O
hearing	O
loss	O
in	O
terms	O
of	O
severity	O
and	O
age-at-onset	O
of	O
disease	O
in	O
these	O
subjects	O
.	O

Genome-wide	O
linkage	O
analysis	O
mapped	O
the	O
disease	O
gene	O
to	O
the	O
DFNA5	O
locus	O
with	O
a	O
maximum	O
two-point	O
log	O
odds	O
score	O
of	O
5.39	O
at	O
[theta]	O
=	O
0	O
for	O
marker	O
D7S2457	O
.	O

DNA	O
sequencing	O
of	O
DFNA5	O
revealed	O
a	O
novel	O
heterozygous	O
(	B-DNAMutation
G	I-DNAMutation
-->	I-DNAMutation
C	I-DNAMutation
)	I-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
1201	I-DNAMutation
substitution	O
in	O
the	O
splice	O
donor	O
site	O
of	O
intron	O
8	O
.	O

Reverse	O
transcriptase-polymerase	O
chain	O
reaction	O
(RT-PCR)	O
showed	O
skipping	O
of	O
exon	O
8	O
in	O
the	O
mutant	O
transcript	O
.	O

This	O
mutation	O
faithfully	O
cosegregated	O
with	O
hearing	O
loss	O
in	O
the	O
family	O
.	O

In	O
addition	O
,	O
the	O
mutation	O
was	O
absent	O
in	O
100	O
unrelated	O
control	O
DNA	O
samples	O
of	O
Chinese	O
origin	O
.	O

The	O
(	B-DNAMutation
T	I-DNAMutation
-->	I-DNAMutation
C	I-DNAMutation
)	I-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
2209	I-DNAMutation
mutation	O
is	O
predicted	O
to	O
create	O
a	O
shift	O
in	O
the	O
reading	O
frame	O
and	O
introduce	O
a	O
stop	O
codon	O
at	O
position	O
372	O
,	O
thereby	O
resulting	O
in	O
a	O
prematurely	O
truncated	O
DFNA5	O
protein	O
.	O

Up	O
to	O
date	O
,	O
a	O
total	O
of	O
four	O
mutations	O
in	O
DFNA5	O
have	O
been	O
reported	O
to	O
lead	O
to	O
hearing	O
impairment	O
,	O
all	O
of	O
them	O
result	O
in	O
skipping	O
of	O
exon	O
8	O
at	O
the	O
mRNA	O
level	O
.	O

Our	O
findings	O
provide	O
further	O
support	O
for	O
the	O
hypothesis	O
that	O
DFNA5-associated	O
hearing	O
loss	O
is	O
caused	O
by	O
a	O
very	O
specific	O
gain-of-function	O
mutation	O
.	O

Restricted	O
genetic	O
defects	O
underlie	O
human	O
complement	O
C6	O
deficiency	O
.	O

Complement	O
C6	O
homozygous	O
deficiency	O
(C6D)	O
has	O
been	O
rarely	O
observed	O
in	O
Caucasians	O
but	O
was	O
reported	O
at	O
higher	O
prevalence	O
among	O
African-Americans	O
.	O

We	O
report	O
on	O
the	O
molecular	O
basis	O
of	O
C6D	O
in	O
seven	O
unrelated	O
black	O
individuals	O
of	O
North	O
or	O
Central	O
Africa	O
descent	O
who	O
live	O
in	O
France	O
.	O

These	O
patients	O
have	O
presented	O
Neisseria	O
meningitidis	O
infection	O
(	O
four	O
cases	O
)	O
,	O
focal	O
and	O
segmental	O
glomerulosclerosis	O
with	O
hyalinosis	O
(	O
one	O
case	O
)	O
,	O
systemic	O
lupus	O
erythematosus	O
(	O
one	O
case	O
)	O
or	O
Still's	O
disease	O
(	O
one	O
case	O
)	O
.	O

All	O
patients	O
exhibited	O
undetectable	O
antigenic	O
C6	O
by	O
using	O
a	O
sensitive	O
ELISA	O
assay	O
.	O

An	O
additional	O
four	O
cases	O
of	O
complete	O
C6	O
deficiency	O
with	O
no	O
associated	O
disease	O
have	O
been	O
characterized	O
after	O
family	O
studies	O
.	O

Exons	O
6	O
,	O
7	O
and	O
12	O
have	O
been	O
described	O
recently	O
as	O
the	O
location	O
of	O
molecular	O
defects	O
on	O
the	O
C6	O
gene	O
in	O
randomly	O
chosen	O
black	O
Americans	O
.	O

Genomic	O
DNA	O
from	O
the	O
seven	O
patients	O
were	O
subjected	O
to	O
direct	O
polymerase	O
chain	O
reaction	O
amplification	O
of	O
these	O
three	O
exons	O
.	O

Nucleotide	O
sequencing	O
analysis	O
of	O
the	O
amplified	O
DNA	O
fragments	O
revealed	O
a	O
homozygous	O
single-base	O
deletion	O
(	O
G>T	B-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
c.898	I-DNAMutation
)	O
in	O
exon	O
12	O
in	O
three	O
cases	O
and	O
four	O
compound	O
heterozygous	O
deletions	O
for	O
a	O
single	O
base	O
in	O
exon	O
7	O
(	O
C-->T	B-DNAMutation
transversion	I-DNAMutation
at	I-DNAMutation
cDNA	I-DNAMutation
base	I-DNAMutation
463	I-DNAMutation
)	O
or	O
in	O
exon	O
6	O
(	O
G-->C	B-DNAMutation
transversion	I-DNAMutation
at	I-DNAMutation
1245	I-DNAMutation
position	I-DNAMutation
)	O
associated	O
with	O
the	O
same	O
deletion	O
in	O
exon	O
12	O
(	O
C-->T	B-DNAMutation
transition	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
677	I-DNAMutation
)	O
.	O

Our	O
observations	O
further	O
establish	O
the	O
restricted	O
pattern	O
of	O
genetic	O
defects	O
associated	O
with	O
homozygous	O
C6	O
complement	O
deficiency	O
in	O
individuals	O
of	O
African	O
descent	O
.	O

The	O
number	O
of	O
lymph	O
node	O
metastases	O
in	O
gastric	O
cancer	O
correlates	O
with	O
the	O
angiotensin	O
I-converting	O
enzyme	O
gene	O
insertion/deletion	O
polymorphism	O
.	O

PURPOSE	O
:	O
In	O
the	O
present	O
study	O
,	O
we	O
aimed	O
to	O
substantiate	O
the	O
putative	O
significance	O
of	O
angiotensin	O
I-converting	O
enzyme	O
(ACE)	O
on	O
gastric	O
cancer	O
biology	O
by	O
investigating	O
the	O
influence	O
of	O
its	O
gene	O
polymorphism	O
on	O
gastric	O
cancer	O
progression	O
.	O

EXPERIMENTAL	O
DESIGN	O
:	O
Genomic	O
DNA	O
was	O
purified	O
from	O
peripheral	O
blood	O
mononuclear	O
cells	O
or	O
tissue	O
specimens	O
.	O

Amplified	O
ACE	O
gene	O
fragments	O
were	O
separated	O
on	O
agarose	O
gels	O
.	O

D	O
or	O
I	O
alleles	O
were	O
identified	O
by	O
the	O
presence	O
of	O
190-	O
or	O
490-bp	O
fragments	O
,	O
respectively	O
.	O

Local	O
expression	O
of	O
ACE	O
was	O
investigated	O
by	O
immunohistochemistry	O
.	O

RESULTS	O
:	O
Twenty-four	O
of	O
113	O
(21%)	O
gastric	O
cancer	O
patients	O
had	O
the	O
II	O
,	O
57	O
(51%)	O
the	O
ID	O
,	O
and	O
32	O
(28%)	O
the	O
DD	O
genotype	O
.	O

The	O
distribution	O
of	O
the	O
ACE	O
genotypes	O
did	O
not	O
differ	O
significantly	O
from	O
the	O
control	O
group	O
of	O
189	O
patients	O
without	O
gastric	O
cancer	O
.	O

However	O
,	O
the	O
ACE	O
genotypes	O
correlated	O
with	O
the	O
number	O
of	O
lymph	O
node	O
metastases	O
and	O
the	O
Unio	O
Internationale	O
Contra	O
Cancrum	O
(UICC)	O
tumor	O
stage	O
.	O

Patients	O
with	O
the	O
II	O
genotype	O
had	O
a	O
highly	O
significantly	O
smaller	O
number	O
of	O
lymph	O
node	O
metastases	O
(	O
P	O
<	O
0.001	O
)	O
and	O
a	O
significantly	O
lower	O
UICC	O
tumor	O
stage	O
(	O
P	O
=	O
0.01	O
)	O
than	O
patients	O
with	O
the	O
DD	O
genotype	O
.	O

No	O
correlation	O
was	O
found	O
between	O
tumor	O
type	O
,	O
tumor	O
location	O
,	O
local	O
tumor	O
growth	O
,	O
distant	O
metastases	O
,	O
and	O
the	O
ACE	O
genotype	O
.	O

The	O
expression	O
of	O
ACE	O
in	O
gastric	O
cancer	O
was	O
investigated	O
by	O
immunohistochemistry	O
in	O
100	O
of	O
113	O
patients	O
.	O

ACE	O
was	O
expressed	O
by	O
endothelial	O
cells	O
in	O
all	O
(100%)	O
specimens	O
and	O
by	O
tumor	O
cells	O
in	O
56	O
(56%)	O
specimens	O
.	O

CONCLUSIONS	O
:	O
Our	O
study	O
shows	O
that	O
ACE	O
is	O
expressed	O
locally	O
in	O
gastric	O
cancer	O
and	O
that	O
the	O
gene	O
polymorphism	O
influences	O
metastatic	O
behavior	O
.	O

Co-inheritance	O
of	O
a	O
PKD1	O
mutation	O
and	O
homozygous	O
PKD2	O
variant	O
:	O
a	O
potential	O
modifier	O
in	O
autosomal	O
dominant	O
polycystic	O
kidney	O
disease	O
.	O

BACKGROUND	O
:	O
Autosomal	O
dominant	O
polycystic	O
kidney	O
disease	O
(ADPKD)	O
,	O
which	O
is	O
caused	O
by	O
mutations	O
in	O
polycystins	O
1	O
(PC1)	O
and	O
2	O
(PC2)	O
,	O
is	O
one	O
of	O
the	O
most	O
commonly	O
inherited	O
renal	O
diseases	O
,	O
affecting	O
~1	O
:	O
1000	O
Caucasians	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
We	O
screened	O
Greek	O
ADPKD	O
patients	O
with	O
the	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
(DGGE)	O
assay	O
and	O
direct	O
sequencing	O
.	O

RESULTS	O
:	O
We	O
identified	O
a	O
patient	O
homozygous	O
for	O
a	O
nucleotide	O
change	O
G-->C	B-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
135	I-DNAMutation
,	O
resulting	O
in	O
a	O
novel	O
homozygous	O
substitution	O
of	O
the	O
non-polar	O
hydrophobic	O
phenylalanine	O
to	O
the	O
polar	O
hydrophilic	O
cysteine	O
in	O
exon	O
6	O
at	O
codon	O
482	O
(	O
Ser-->Cys	B-ProteinMutation
substitution	I-ProteinMutation
at	I-ProteinMutation
the	I-ProteinMutation
codon	I-ProteinMutation
326	I-ProteinMutation
)	O
of	O
the	O
PKD2	O
gene	O
and	O
a	O
de-novo	O
PKD1	O
splice-site	O
variant	O
GTT-->GCT	B-DNAMutation
transition	I-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
23	I-DNAMutation
.	O

We	O
did	O
not	O
find	O
this	O
PKD2	O
variant	O
in	O
a	O
screen	O
of	O
280	O
chromosomes	O
of	O
healthy	O
subjects	O
,	O
supporting	O
its	O
pathogenicity	O
.	O

The	O
proband's	O
parents	O
did	O
not	O
have	O
the	O
PKD1	O
mutation	O
.	O

Real-time	O
PCR	O
of	O
the	O
PKD2	O
transcript	O
from	O
a	O
skin	O
biopsy	O
revealed	O
20-fold	O
higher	O
expression	O
in	O
the	O
patient	O
than	O
in	O
a	O
healthy	O
subject	O
and	O
was	O
higher	O
in	O
the	O
patient's	O
peripheral	O
blood	O
mononuclear	O
cells	O
(PBMCs)	O
than	O
in	O
those	O
of	O
her	O
heterozygote	O
daughter	O
and	O
a	O
healthy	O
subject	O
.	O

The	O
greater	O
gene	O
expression	O
was	O
also	O
supported	O
by	O
Western	O
blotting	O
.	O

Inner	O
medullar	O
collecting	O
duct	O
(IMCD)	O
cells	O
transfected	O
with	O
the	O
mutant	O
PKD2	O
mouse	O
gene	O
presented	O
a	O
perinuclear	O
and	O
diffuse	O
cytoplasmic	O
localization	O
compared	O
with	O
the	O
wild	O
type	O
ER	O
localization	O
.	O

Patch-clamping	O
of	O
PBMCs	O
from	O
the	O
leucine	B-ProteinMutation
269	I-ProteinMutation
to	I-ProteinMutation
phenylalanine	I-ProteinMutation
homozygous	O
and	O
heterozygous	O
subjects	O
revealed	O
lower	O
polycystin-2	O
channel	O
function	O
than	O
in	O
controls	O
.	O

CONCLUSIONS	O
:	O
We	O
report	O
for	O
the	O
first	O
time	O
a	O
patient	O
with	O
ADPKD	O
who	O
is	O
heterozygous	O
for	O
a	O
de	O
novo	O
PKD1	O
variant	O
and	O
homozygous	O
for	O
a	O
novel	O
PKD2	O
mutation	O
.	O

Clinical	O
characterization	O
and	O
evaluation	O
of	O
DYT1	O
gene	O
in	O
Indian	O
primary	O
dystonia	O
patients	O
.	O

OBJECTIVES	O
:	O
Dystonia	O
is	O
a	O
common	O
movement	O
disorder	O
.	O

The	O
purpose	O
of	O
this	O
study	O
is	O
to	O
examine	O
the	O
relative	O
distribution	O
of	O
the	O
primary	O
dystonia	O
subtypes	O
and	O
identify	O
mutation	O
(s)	O
in	O
the	O
DYT1	O
gene	O
in	O
Indian	O
patients	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Primary	O
dystonia	O
patients	O
(	O
n	O
=	O
178	O
)	O
and	O
controls	O
(	O
n	O
=	O
63	O
)	O
,	O
lacking	O
any	O
symptoms	O
of	O
the	O
disease	O
,	O
were	O
recruited	O
for	O
the	O
study	O
from	O
eastern	O
India	O
.	O

The	O
nucleotide	O
variants	O
in	O
the	O
DYT1	O
gene	O
were	O
identified	O
by	O
carrying	O
out	O
polymerase	O
chain	O
reaction	O
,	O
single	O
stranded	O
conformation	O
polymorphism	O
,	O
and	O
DNA	O
sequencing	O
.	O

RESULTS	O
:	O
Unlike	O
other	O
reports	O
,	O
pain	O
and/or	O
tremor	O
was	O
more	O
common	O
in	O
our	O
sporadic	O
patients	O
than	O
in	O
familial	O
cases	O
.	O

Three	O
reported	O
and	O
two	O
novel	O
changes	O
were	O
identified	O
in	O
this	O
gene	O
.	O

The	O
homozygous	O
genotype	O
(G,G)	O
for	O
a	O
missense	O
variant	O
(	O
A	B-DNAMutation
>	I-DNAMutation
G	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
313	I-DNAMutation
;	O
arginine	B-ProteinMutation
555-to-tryptophan	I-ProteinMutation
)	O
was	O
significantly	O
over-represented	O
in	O
the	O
patients	O
compared	O
with	O
controls	O
(	O
P	O
<	O
0.05	O
)	O
.	O

However	O
,	O
the	O
commonly	O
reported	O
3	O
bp	O
deletion	O
(	O
(	B-DNAMutation
TAC-->AA	I-DNAMutation
)	I-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
329	I-DNAMutation
)	O
was	O
not	O
detected	O
.	O

CONCLUSION	O
:	O
Our	O
results	O
suggest	O
that	O
the	O
DYT1	O
gene	O
might	O
have	O
a	O
limited	O
role	O
in	O
causation	O
of	O
dystonia	O
in	O
the	O
Indian	O
population	O
.	O

Chasing	O
the	O
ubiquitous	O
RET	O
proto-oncogene	O
in	O
South	O
African	O
MEN2	O
families--implications	O
for	O
the	O
surgeon	O
.	O

The	O
RET	O
proto-oncogene	O
(	O
REarranged	O
during	O
Transfection	O
;	O
RET	O
)	O
plays	O
an	O
important	O
role	O
in	O
the	O
causation	O
of	O
many	O
thyroid	O
tumours	O
.	O

Germline	O
RET	O
proto-oncogene	O
missense	O
mutations	O
have	O
been	O
clearly	O
linked	O
to	O
medullary	O
thyroid	O
carcinoma	O
(MTC)	O
and	O
the	O
inherited	O
cancer	O
syndrome	O
multiple	O
endocrine	O
neoplasia	O
type	O
2	O
(	O
MEN2A	O
,	O
MEN2B	O
)	O
.	O

METHODS	O
:	O
We	O
investigated	O
a	O
cohort	O
of	O
MEN2-related	O
patients	O
referred	O
to	O
Tygerberg	O
Hospital	O
,	O
W	O
Cape	O
(2003-2009)	O
.	O

The	O
study	O
cohort	O
was	O
divided	O
into	O
three	O
groups	O
based	O
on	O
pathology	O
(	O
viz	O
.	O

MEN/MTC	O
,	O
phaeochromocytoma	O
,	O
and	O
a	O
miscellaneous	O
group	O
of	O
MEN	O
pathologies	O
)	O
.	O

Families	O
with	O
identified	O
high-risk	O
factors	O
were	O
recalled	O
.	O

Serum	O
calcitonin	O
levels	O
were	O
monitored	O
where	O
indicated	O
.	O

DNA	O
was	O
extracted	O
from	O
whole	O
blood	O
by	O
standard	O
techniques	O
and	O
polymerase	O
chain	O
reaction	O
(PCR)	O
products	O
screened	O
for	O
RET	O
gene	O
variations	O
by	O
heteroduplex	O
single-strand	O
duplication	O
techniques	O
(	O
heteroduplex	O
single-strand	O
conformation	O
polymorphism	O
analysis	O
)	O
being	O
validated	O
with	O
automated	O
sequencing	O
techniques	O
showing	O
conformational	O
variants	O
in	O
acrylamide	O
gel	O
.	O

RESULTS	O
:	O
We	O
screened	O
40	O
persons	O
,	O
male/female	O
ratio	O
1:1.5	O
.	O

Three	O
ethnic	O
groups	O
were	O
represented	O
(	O
white	O
(12)	O
,	O
black	O
(11)	O
and	O
mixed	O
race	O
(	O
17	O
)	O
)	O
.	O

Nine	O
were	O
index	O
MTC	O
cases	O
,	O
5	O
phaeochromocytoma	O
,	O
3	O
Hirschsprung's	O
disease-MEN	O
associations	O
and	O
2	O
miscellaneous	O
(	O
1	O
neuroblastoma	O
,	O
1	O
intestinal	O
neuronal	O
dysplasia	O
)	O
,	O
while	O
1	O
fell	O
into	O
the	O
MEN2B	O
category	O
.	O

The	O
remaining	O
19	O
were	O
unaffected	O
relatives	O
screened	O
for	O
carrier	O
status	O
,	O
among	O
whom	O
afamilial	O
recurrence	O
was	O
observed	O
in	O
7	O
.	O

On	O
genetic	O
testing	O
,	O
an	O
RET	O
point	O
mutation	O
at	O
the	O
high-risk	O
634	O
cysteine	O
allele	O
was	O
identified	O
in	O
11	O
cases	O
.	O

A	O
further	O
cysteine	O
radical	O
mutation	O
at	O
the	O
620	O
position	O
was	O
related	O
to	O
MEN2	O
in	O
3	O
families	O
plus	O
1	O
other	O
family	O
referred	O
from	O
elsewhere	O
.	O

Other	O
less-recognised	O
gene	O
variations	O
were	O
detected	O
throughout	O
the	O
RET	O
gene	O
in	O
70%	O
of	O
cases	O
and	O
included	O
the	O
691	O
position	O
on	O
codon	O
11	O
(	O
11	O
cases	O
)	O
;	O
the	O
432	O
position	O
(	O
4	O
cases	O
,	O
1	O
homozygous	O
)	O
intronic	O
mutations	O
on	O
exon	O
4	O
(	O
1	O
case	O
)	O
;	O
and	O
an	O
-AAGC	B-DNAMutation
at	I-DNAMutation
-222	I-DNAMutation
to	I-DNAMutation
-225	I-DNAMutation
and	O
a	O
histidine	B-ProteinMutation
626-to-arginine	I-ProteinMutation
variation	O
in	O
exon	O
19	O
in	O
2	O
MEN	O
families	O
.	O

Fifteen	O
MTC	O
patients	O
have	O
had	O
thyroidectomies	O
,	O
of	O
which	O
2	O
were	O
prophylactic	O
(	O
C-cell	O
hyperplasia	O
;	O
early	O
occult	O
MTC	O
)	O
.	O

A	O
further	O
3	O
are	O
awaiting	O
prophylactic	O
surgery	O
.	O

CONCLUSION	O
:	O
RET	O
gene	O
mutation	O
carries	O
a	O
risk	O
of	O
MEN2	O
and	O
MTC	O
in	O
all	O
ethnic	O
groups	O
in	O
South	O
Africa	O
.	O

Prophylactic	O
surgery	O
may	O
prevent	O
MTC	O
,	O
so	O
genetic	O
screening	O
is	O
important	O
to	O
identify	O
and	O
treat	O
high-risk	O
patients	O
.	O

Monitoring	O
the	O
isochromosome	O
i(7)(q10)	O
in	O
the	O
bone	O
marrow	O
of	O
patients	O
with	O
Shwachman	O
syndrome	O
by	O
real-time	O
quantitative	O
PCR	O
.	O

Clonal	O
chromosome	O
anomalies	O
may	O
be	O
found	O
in	O
the	O
bone	O
marrow	O
(BM)	O
of	O
patients	O
with	O
Shwachman	O
syndrome	O
,	O
who	O
are	O
at	O
risk	O
to	O
develop	O
myelodysplastic	O
syndromes	O
and/or	O
acute	O
myeloid	O
leukemias	O
.	O

In	O
particular	O
,	O
an	O
isochromosome	O
i(7)(q10)	O
is	O
frequent	O
,	O
and	O
is	O
usually	O
monitored	O
by	O
chromosome	O
analyses	O
.	O

We	O
tested	O
an	O
approach	O
by	O
real-time	O
quantitative	O
polymerase	O
chain	O
reaction	O
(RQ-PCR)	O
on	O
a	O
chromosome	O
7	O
polymorphism	O
.	O

Five	O
DNA	O
samples	O
of	O
2	O
Shwachman	O
syndrome	O
patients	O
with	O
clonal	O
i(7)(q10)	O
in	O
the	O
BM	O
were	O
used	O
.	O

Both	O
were	O
heterozygous	O
for	O
the	O
diallelic	O
indel	O
polymorphism	O
MID1064	O
,	O
which	O
maps	O
in	O
7q35	O
.	O

The	O
percentage	O
of	O
i(7)(q10)-positive	O
cells	O
was	O
extrapolated	O
from	O
the	O
ratio	O
of	O
the	O
2	O
alleles	O
measured	O
by	O
means	O
of	O
an	O
allele-specific	O
RQ-PCR	O
assay	O
.	O

The	O
results	O
were	O
compared	O
with	O
cytogenetic	O
analyses	O
on	O
the	O
same	O
material	O
used	O
for	O
RQ-PCR	O
.	O

In	O
1	O
patient	O
,	O
the	O
RQ-PCR	O
results	O
matched	O
well	O
with	O
those	O
of	O
chromosome	O
analyses	O
,	O
whereas	O
in	O
the	O
other	O
one	O
RQ-PCR	O
showed	O
that	O
around	O
40%	O
of	O
the	O
BM	O
cells	O
were	O
abnormal	O
,	O
while	O
they	O
resulted	O
to	O
be	O
nearly	O
80%	O
with	O
conventional	O
monitoring	O
assays	O
.	O

As	O
the	O
results	O
obtained	O
by	O
RQ-PCR	O
refer	O
to	O
the	O
DNA	O
of	O
around	O
128,000	O
BM	O
cells	O
,	O
our	O
method	O
proved	O
to	O
be	O
feasible	O
and	O
more	O
efficient	O
in	O
the	O
quantitative	O
evaluation	O
of	O
the	O
i(7)(q10)-positive	O
clone	O
than	O
conventional	O
ones	O
.	O

Evidence	O
for	O
alternative	O
candidate	O
genes	O
near	O
RB1	O
involved	O
in	O
clonal	O
expansion	O
of	O
in	O
situ	O
urothelial	O
neoplasia	O
.	O

In	O
this	O
paper	O
,	O
we	O
present	O
whole-organ	O
histologic	O
and	O
genetic	O
mapping	O
studies	O
using	O
hypervariable	O
DNA	O
markers	O
on	O
chromosome	O
13	O
and	O
then	O
integrate	O
the	O
recombination-	O
and	O
single-nucleotide	O
polymorphic	O
sites	O
(SNPs)-based	O
deletion	O
maps	O
with	O
the	O
annotated	O
genome	O
sequence	O
.	O

Using	O
bladders	O
resected	O
from	O
patients	O
with	O
invasive	O
urothelial	O
carcinoma	O
,	O
we	O
studied	O
allelic	O
patterns	O
of	O
40	O
microsatellite	O
markers	O
mapping	O
to	O
all	O
regions	O
of	O
chromosome	O
13	O
and	O
79	O
SNPs	O
located	O
within	O
the	O
13q14	O
region	O
containing	O
the	O
RB1	O
gene	O
.	O

A	O
whole-organ	O
histologic	O
and	O
genetic	O
mapping	O
strategy	O
was	O
used	O
to	O
identify	O
the	O
evolution	O
of	O
allelic	O
losses	O
on	O
chromosome	O
13	O
during	O
the	O
progression	O
of	O
bladder	O
neoplasia	O
.	O

Markers	O
mapping	O
to	O
chromosomal	O
regions	O
involved	O
in	O
clonal	O
expansion	O
of	O
preneoplastic	O
intraurothelial	O
lesions	O
were	O
subsequently	O
tested	O
in	O
25	O
tumors	O
and	O
21	O
voided	O
urine	O
samples	O
of	O
patients	O
with	O
bladder	O
cancer	O
.	O

Four	O
clusters	O
of	O
allelic	O
losses	O
mapping	O
to	O
distinct	O
regions	O
of	O
chromosome	O
13	O
were	O
identified	O
.	O

Markers	O
mapping	O
to	O
the	O
13q14	O
region	O
that	O
is	O
flanked	O
by	O
D13S263	O
and	O
D13S276	O
,	O
which	O
contains	O
the	O
RB1	O
gene	O
,	O
showed	O
allelic	O
losses	O
associated	O
with	O
early	O
clonal	O
expansion	O
of	O
intraurothelial	O
neoplasia	O
.	O

Such	O
losses	O
could	O
be	O
identified	O
in	O
approximately	O
32%	O
bladder	O
tumor	O
tissue	O
samples	O
and	O
38%	O
of	O
voided	O
urines	O
from	O
patients	O
with	O
bladder	O
cancer	O
.	O

The	O
integration	O
of	O
distribution	O
patterns	O
of	O
clonal	O
allelic	O
losses	O
revealed	O
by	O
the	O
microsatellite	O
markers	O
with	O
those	O
obtained	O
by	O
genotyping	O
of	O
SNPs	O
disclosed	O
that	O
the	O
loss	O
within	O
an	O
approximately	O
4-Mb	O
segment	O
centered	O
around	O
RB1	O
may	O
represent	O
an	O
incipient	O
event	O
in	O
bladder	O
neoplasia	O
.	O

However	O
,	O
the	O
inactivation	O
of	O
RB1	O
occurred	O
later	O
and	O
was	O
associated	O
with	O
the	O
onset	O
of	O
severe	O
dysplasia/carcinoma	O
in	O
situ	O
.	O

Our	O
studies	O
provide	O
evidence	O
for	O
the	O
presence	O
of	O
critical	O
alternative	O
candidate	O
genes	O
mapping	O
to	O
the	O
13q14	O
region	O
that	O
are	O
involved	O
in	O
clonal	O
expansion	O
of	O
neoplasia	O
within	O
the	O
bladder	O
antecedent	O
to	O
the	O
inactivation	O
of	O
the	O
RB1	O
gene	O
.	O

Is	O
the	O
European	O
spatial	O
distribution	O
of	O
the	O
HIV-1-resistant	O
CCR5--491	B-DNAMutation
A	I-DNAMutation
to	I-DNAMutation
T	I-DNAMutation
allele	O
formed	O
by	O
a	O
breakdown	O
of	O
the	O
pathocenosis	O
due	O
to	O
the	O
historical	O
Roman	O
expansion	O
.	O

We	O
studied	O
the	O
possible	O
effects	O
of	O
the	O
expansion	O
of	O
ancient	O
Mediterranean	O
civilizations	O
during	O
the	O
five	O
centuries	O
before	O
and	O
after	O
Christ	O
on	O
the	O
European	O
distribution	O
of	O
the	O
mutant	O
allele	O
for	O
the	O
chemokine	O
receptor	O
gene	O
CCR5	O
which	O
has	O
a	O
32-bp	O
deletion	O
(	O
CCR5-G>A	B-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
+1	I-DNAMutation
of	I-DNAMutation
intron	I-DNAMutation
2	I-DNAMutation
)	O
.	O

There	O
is	O
a	O
strong	O
evidence	O
for	O
the	O
unitary	O
origin	O
of	O
the	O
CCR5-(G	B-DNAMutation
-->	I-DNAMutation
C	I-DNAMutation
)	I-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
1201	I-DNAMutation
mutation	O
,	O
this	O
it	O
is	O
found	O
principally	O
in	O
Europe	O
and	O
Western	O
Asia	O
,	O
with	O
generally	O
a	O
north-south	O
downhill	O
cline	O
frequency	O
.	O

Homozygous	O
carriers	O
of	O
this	O
mutation	O
show	O
a	O
resistance	O
to	O
HIV-1	O
infection	O
and	O
a	O
slower	O
progression	O
towards	O
AIDS	O
.	O

However	O
,	O
HIV	O
has	O
clearly	O
emerged	O
too	O
recently	O
to	O
have	O
been	O
the	O
selective	O
force	O
on	O
CCR5	O
.	O

Our	O
analyses	O
showed	O
strong	O
negative	O
correlations	O
in	O
Europe	O
between	O
the	O
allele	O
frequency	O
and	O
two	O
historical	O
parameters	O
,	O
i.e	O
.	O

the	O
first	O
colonization	O
dates	O
by	O
the	O
great	O
ancient	O
Mediterranean	O
civilizations	O
,	O
and	O
the	O
distances	O
from	O
the	O
Northern	O
frontiers	O
of	O
the	O
Roman	O
Empire	O
in	O
its	O
greatest	O
expansion	O
.	O

Moreover	O
,	O
other	O
studies	O
have	O
shown	O
that	O
the	O
deletion	O
frequencies	O
in	O
both	O
German	O
Bronze	O
Age	O
and	O
Swedish	O
Neolithic	O
populations	O
were	O
similar	O
to	O
those	O
found	O
in	O
the	O
corresponding	O
modern	O
populations	O
,	O
and	O
this	O
deletion	O
has	O
been	O
found	O
in	O
ancient	O
DNA	O
of	O
around	O
7000	O
years	O
ago	O
,	O
suggesting	O
that	O
in	O
the	O
past	O
,	O
the	O
deletion	O
frequency	O
could	O
have	O
been	O
relatively	O
high	O
in	O
European	O
populations	O
.	O

In	O
addition	O
,	O
in	O
West	O
Nile	O
virus	O
pathogenesis	O
,	O
CCR5	O
plays	O
an	O
antimicrobial	O
role	O
showing	O
that	O
host	O
genetic	O
factors	O
are	O
highly	O
pathogen-specific	O
.	O

Our	O
results	O
added	O
to	O
all	O
these	O
previous	O
data	O
suggest	O
that	O
the	O
actual	O
European	O
allele	O
frequency	O
distribution	O
might	O
not	O
be	O
due	O
to	O
genes	O
spreading	O
,	O
but	O
to	O
a	O
negative	O
selection	O
resulting	O
in	O
the	O
spread	O
of	O
pathogens	O
principally	O
during	O
Roman	O
expansion	O
.	O

Indeed	O
,	O
as	O
gene	O
flows	O
from	O
colonizers	O
to	O
European	O
native	O
populations	O
were	O
extremely	O
low	O
,	O
the	O
mutational	O
changes	O
might	O
be	O
associated	O
with	O
vulnerability	O
to	O
imported	O
infections	O
.	O

To	O
date	O
,	O
the	O
nature	O
of	O
the	O
parasites	O
remains	O
unknown	O
;	O
however	O
,	O
zoonoses	O
could	O
be	O
incriminated	O
.	O

Gene	O
polymorphisms	O
implicated	O
in	O
influencing	O
susceptibility	O
to	O
venous	O
and	O
arterial	O
thromboembolism	O
:	O
frequency	O
distribution	O
in	O
a	O
healthy	O
German	O
population	O
.	O

Evolvement	O
and	O
progression	O
of	O
cardiovascular	O
diseases	O
affecting	O
the	O
venous	O
and	O
arterial	O
system	O
are	O
influenced	O
by	O
a	O
multitude	O
of	O
environmental	O
and	O
hereditary	O
factors	O
.	O

Many	O
of	O
these	O
hereditary	O
factors	O
consist	O
of	O
defined	O
gene	O
polymorphisms	O
,	O
such	O
as	O
single	O
nucleotide	O
polymorphisms	O
(SNPs)	O
or	O
insertion-deletion	O
polymorphisms	O
,	O
which	O
directly	O
or	O
indirectly	O
affect	O
the	O
hemostatic	O
system	O
.	O

The	O
frequencies	O
of	O
individual	O
hemostatic	O
gene	O
polymorphisms	O
in	O
different	O
normal	O
populations	O
are	O
well	O
defined	O
.	O

However	O
,	O
descriptions	O
of	O
patterns	O
of	O
genetic	O
variability	O
of	O
a	O
larger	O
extent	O
of	O
different	O
factors	O
of	O
hereditary	O
hypercoagulability	O
in	O
single	O
populations	O
are	O
scarce	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
i	O
)	O
to	O
give	O
a	O
detailed	O
description	O
of	O
the	O
frequencies	O
of	O
factors	O
of	O
hereditary	O
thrombophilia	O
and	O
their	O
combinations	O
in	O
a	O
German	O
population	O
(	O
n	O
=	O
282	O
)	O
and	O
ii	O
)	O
to	O
compare	O
their	O
distributions	O
with	O
those	O
reported	O
for	O
other	O
regions	O
.	O

Variants	O
of	O
coagulation	O
factors	O
[	O
factor	O
V	O
(	B-DNAMutation
T	I-DNAMutation
-->	I-DNAMutation
C	I-DNAMutation
)	I-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
2209	I-DNAMutation
(	O
factor	O
V	O
Leiden	O
)	O
,	O
factor	O
V	O
G>T	B-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
c.898	I-DNAMutation
(	O
factor	O
V	O
HR2	O
haplotype	O
)	O
,	O
factor	O
VII	O
arginine	B-ProteinMutation
124-to-cysteine	I-ProteinMutation
,	O
factor	O
XIII	O
Phe-->Ser	B-ProteinMutation
at	I-ProteinMutation
codon	I-ProteinMutation
15	I-ProteinMutation
,	O
beta-fibrinogen	O
C-->T	B-DNAMutation
transversion	I-DNAMutation
at	I-DNAMutation
cDNA	I-DNAMutation
base	I-DNAMutation
463	I-DNAMutation
,	O
prothrombin	O
G-->C	B-DNAMutation
transversion	I-DNAMutation
at	I-DNAMutation
1245	I-DNAMutation
position	I-DNAMutation
]	O
,	O
coagulation	O
inhibitors	O
[	O
tissue	O
factor	O
pathway	O
inhibitor	O
G-->C	B-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
135	I-DNAMutation
,	O
thrombomodulin	O
C-->T	B-DNAMutation
transition	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
677	I-DNAMutation
]	O
,	O
fibrinolytic	O
factors	O
[	O
angiotensin	O
converting	O
enzyme	O
intron	O
16	O
insertion/deletion	O
,	O
factor	O
VII-activating	O
protease	O
GTT-->GCT	B-DNAMutation
transition	I-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
23	I-DNAMutation
(	O
FSAP	O
Marburg	O
I	O
)	O
,	O
plasminogen	O
activator	O
inhibitor	O
1-675	O
insertion/deletion	O
(5G/4G)	O
,	O
tissue	O
plasminogen	O
activator	O
intron	O
h	O
deletion/insertion	O
]	O
,	O
and	O
other	O
factors	O
implicated	O
in	O
influencing	O
susceptibility	O
to	O
thromboembolic	O
diseases	O
[	O
apolipoprotein	O
E2/E3/E4	O
,	O
glycoprotein	O
Ia	O
A	B-DNAMutation
>	I-DNAMutation
G	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
313	I-DNAMutation
,	O
methylenetetrahydrofolate	O
reductase	O
TAC-->AA	B-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
329	I-DNAMutation
]	O
were	O
included	O
.	O

The	O
distribution	O
of	O
glycoprotein	O
Ia	O
-AAGC	B-DNAMutation
at	I-DNAMutation
-222	I-DNAMutation
to	I-DNAMutation
-225	I-DNAMutation
deviated	O
significantly	O
from	O
the	O
Hardy-Weinberg	O
equilibrium	O
,	O
and	O
a	O
comparison	O
with	O
previously	O
published	O
data	O
indicates	O
marked	O
region	O
and	O
ethnicity	O
dependent	O
differences	O
in	O
the	O
genotype	O
distributions	O
of	O
some	O
other	O
factors	O
.	O

Structural	O
and	O
biochemical	O
basis	O
for	O
novel	O
mutations	O
in	O
homozygous	O
Israeli	O
maple	O
syrup	O
urine	O
disease	O
patients	O
:	O
a	O
proposed	O
mechanism	O
for	O
the	O
thiamin-responsive	O
phenotype	O
.	O

Maple	O
syrup	O
urine	O
disease	O
(MSUD)	O
results	O
from	O
mutations	O
affecting	O
different	O
subunits	O
of	O
the	O
mitochondrial	O
branched-chain	O
alpha-ketoacid	O
dehydrogenase	O
complex	O
.	O

In	O
this	O
study	O
,	O
we	O
identified	O
seven	O
novel	O
mutations	O
in	O
MSUD	O
patients	O
from	O
Israel	O
.	O

These	O
include	O
Glu	B-ProteinMutation
272	I-ProteinMutation
to	I-ProteinMutation
stop-alpha	I-ProteinMutation
(	O
TGC	O
to	O
TGG	O
)	O
in	O
the	O
E1alpha	O
subunit	O
;	O
methionine-->valine	B-ProteinMutation
substitution	I-ProteinMutation
at	I-ProteinMutation
codon	I-ProteinMutation
404-beta	I-ProteinMutation
(	O
CAT	O
to	O
TAT	O
)	O
,	O
Ser-->Cys	B-ProteinMutation
substitution	I-ProteinMutation
at	I-ProteinMutation
the	I-ProteinMutation
codon	I-ProteinMutation
326-beta	I-ProteinMutation
(	O
GTT	O
to	O
GGT	O
)	O
,	O
-491	B-DNAMutation
A	I-DNAMutation
to	I-DNAMutation
T	I-DNAMutation
,	O
and	O
G>A	B-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
+1	I-DNAMutation
of	I-DNAMutation
intron	I-DNAMutation
2	I-DNAMutation
(	O
exon	O
10	O
)	O
in	O
the	O
E1beta	O
subunit	O
;	O
and	O
leucine	B-ProteinMutation
269	I-ProteinMutation
to	I-ProteinMutation
phenylalanine	I-ProteinMutation
(	O
CAC	O
to	O
CGC	O
)	O
and	O
arginine	B-ProteinMutation
555-to-tryptophan	I-ProteinMutation
(	O
TCA	O
to	O
TGA	O
)	O
affecting	O
the	O
E2	O
subunit	O
of	O
the	O
branched-chain	O
alpha-ketoacid	O
dehydrogenase	O
complex	O
.	O

Recombinant	O
E1	O
proteins	O
carrying	O
the	O
histidine	B-ProteinMutation
626-to-arginine-alpha	I-ProteinMutation
or	O
arginine	B-ProteinMutation
124-to-cysteine-beta	I-ProteinMutation
mutation	O
show	O
no	O
catalytic	O
activity	O
with	O
defective	O
subunit	O
assembly	O
and	O
reduced	O
binding	O
affinity	O
for	O
cofactor	O
thiamin	O
diphosphate	O
.	O

The	O
mutant	O
E1	O
harboring	O
the	O
Phe-->Ser	B-ProteinMutation
at	I-ProteinMutation
codon	I-ProteinMutation
15-beta	I-ProteinMutation
substitution	O
cannot	O
be	O
expressed	O
,	O
suggesting	O
aberrant	O
folding	O
caused	O
by	O
this	O
mutation	O
.	O

These	O
E1	O
mutations	O
are	O
ubiquitously	O
associated	O
with	O
the	O
classic	O
phenotype	O
in	O
homozygous-affected	O
patients	O
.	O

The	O
Glu	B-ProteinMutation
272	I-ProteinMutation
to	I-ProteinMutation
stop	I-ProteinMutation
substitution	O
in	O
the	O
E2	O
subunit	O
abolishes	O
the	O
key	O
catalytic	O
residue	O
that	O
functions	O
as	O
a	O
general	O
base	O
in	O
the	O
acyltransfer	O
reaction	O
,	O
resulting	O
in	O
a	O
completely	O
inactive	O
E2	O
component	O
.	O

However	O
,	O
wild-type	O
E1	O
activity	O
is	O
enhanced	O
by	O
E1	O
binding	O
to	O
this	O
full-length	O
mutant	O
E2	O
in	O
vitro	O
.	O

We	O
propose	O
that	O
the	O
augmented	O
E1	O
activity	O
is	O
responsible	O
for	O
robust	O
thiamin	O
responsiveness	O
in	O
homozygous	O
patients	O
carrying	O
the	O
methionine-->valine	B-ProteinMutation
substitution	I-ProteinMutation
at	I-ProteinMutation
codon	I-ProteinMutation
404	I-ProteinMutation
E2	O
mutation	O
and	O
that	O
the	O
presence	O
of	O
a	O
full-length	O
mutant	O
E2	O
is	O
diagnostic	O
of	O
this	O
MSUD	O
phenotype	O
.	O

The	O
present	O
results	O
offer	O
a	O
structural	O
and	O
biochemical	O
basis	O
for	O
these	O
novel	O
mutations	O
and	O
will	O
facilitate	O
DNA-based	O
diagnosis	O
for	O
MSUD	O
in	O
the	O
Israeli	O
population	O
.	O

Analysis	O
of	O
the	O
(	B-DNAMutation
G	I-DNAMutation
-->	I-DNAMutation
C	I-DNAMutation
)	I-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
1201	I-DNAMutation
polymorphism	O
in	O
the	O
5'-untranslated	O
region	O
of	O
the	O
RAD51	O
gene	O
in	O
breast	O
cancer	O
.	O

The	O
breast	O
cancer	O
suppressor	O
proteins	O
BRCA1	O
and	O
BRCA2	O
interact	O
with	O
RAD51	O
,	O
a	O
protein	O
essential	O
for	O
maintaining	O
genomic	O
stability	O
by	O
playing	O
a	O
central	O
role	O
in	O
homology-dependent	O
recombinational	O
repair	O
of	O
the	O
DNA	O
double-strand	O
breaks	O
.	O

Therefore	O
,	O
genetic	O
variability	O
in	O
the	O
RAD51	O
gene	O
may	O
contribute	O
to	O
the	O
appearance	O
and/or	O
progression	O
of	O
breast	O
cancer	O
.	O

A	O
single	O
nucleotide	O
polymorphism	O
in	O
the	O
5'-	O
untranslated	O
region	O
of	O
RAD51	O
(	O
a	O
G	O
to	O
C	O
substitution	O
at	O
position	O
135	O
,	O
the	O
(	B-DNAMutation
T	I-DNAMutation
-->	I-DNAMutation
C	I-DNAMutation
)	I-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
2209	I-DNAMutation
polymorphism	O
)	O
is	O
reported	O
to	O
modulate	O
breast	O
cancer	O
risk	O
.	O

We	O
investigated	O
the	O
distribution	O
of	O
genotypes	O
and	O
frequency	O
of	O
alleles	O
of	O
the	O
G>T	B-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
c.898	I-DNAMutation
polymorphism	O
in	O
breast	O
cancer	O
.	O

Tumor	O
tissues	O
were	O
obtained	O
from	O
postmenopausal	O
women	O
with	O
node-negative	O
and	O
node-positive	O
breast	O
carcinoma	O
with	O
uniform	O
tumor	O
size	O
.	O

Blood	O
samples	O
from	O
age	O
matched	O
healthy	O
women	O
served	O
as	O
control	O
.	O

The	O
C-->T	B-DNAMutation
transversion	I-DNAMutation
at	I-DNAMutation
cDNA	I-DNAMutation
base	I-DNAMutation
463	I-DNAMutation
polymorphism	O
was	O
determined	O
by	O
PCR-based	O
MvaI	O
restriction	O
fragment	O
length	O
polymorphism	O
.	O

The	O
distribution	O
of	O
the	O
genotypes	O
of	O
the	O
G-->C	B-DNAMutation
transversion	I-DNAMutation
at	I-DNAMutation
1245	I-DNAMutation
position	I-DNAMutation
polymorphism	O
did	O
not	O
differ	O
significantly	O
(	O
P	O
>	O
0.05	O
)	O
from	O
those	O
predicted	O
by	O
the	O
Hardy-Weinberg	O
distribution	O
.	O

There	O
were	O
no	O
differences	O
in	O
the	O
genotype	O
distribution	O
and	O
allele	O
frequencies	O
between	O
node-positive	O
and	O
node-negative	O
patients	O
.	O

There	O
were	O
no	O
significant	O
differences	O
between	O
distributions	O
of	O
the	O
genotypes	O
in	O
subgroups	O
assigned	O
to	O
histological	O
grades	O
according	O
to	O
Scarf-Bloom-Richardson	O
criteria	O
and	O
the	O
distribution	O
predicted	O
by	O
Hardy-Weinberg	O
equilibrium	O
(	O
P	O
>	O
0.05	O
)	O
.	O

Our	O
study	O
implies	O
that	O
the	O
C-->T	B-DNAMutation
transition	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
677	I-DNAMutation
polymorphism	O
of	O
the	O
RAD51	O
gene	O
may	O
not	O
be	O
directly	O
involved	O
in	O
the	O
development	O
and/or	O
progression	O
of	O
breast	O
cancer	O
and	O
so	O
it	O
may	O
not	O
be	O
useful	O
as	O
an	O
independent	O
marker	O
in	O
this	O
disease	O
.	O

Fabry	O
disease	O
female	O
proband	O
with	O
clinical	O
manifestations	O
similar	O
to	O
hypertrophic	O
cardiomyopathy	O
.	O

Fabry's	O
disease	O
is	O
an	O
X-linked	O
inborn	O
error	O
of	O
glycosphingolipid	O
catabolism	O
,	O
resulting	O
from	O
a	O
deficiency	O
in	O
alpha-galactosidase	O
A	O
(	O
alpha-Gal	O
A	O
)	O
.	O

A	O
56-year-old	O
Japanese	O
woman	O
was	O
at	O
first	O
suspected	O
of	O
having	O
hypertrophic	O
cardiomyopathy	O
.	O

The	O
patient	O
and	O
her	O
son	O
had	O
alpha-Gal	O
A	O
activity	O
in	O
leukocytes	O
that	O
was	O
remarkably	O
below	O
the	O
limit	O
of	O
controls	O
.	O

DNA	O
analysis	O
of	O
the	O
alpha-Gal	O
A	O
gene	O
revealed	O
a	O
novel	O
missense	O
mutation	O
at	O
codon	O
19	O
in	O
exon	O
1	O
,	O
resulting	O
in	O
leucine-to-proline	O
substitution	O
.	O

As	O
a	O
result	O
she	O
was	O
confirmed	O
as	O
a	O
classic	O
Fabry	O
heterozygote	O
.	O

Recent	O
advances	O
in	O
enzyme	O
replacement	O
therapy	O
can	O
reverse	O
the	O
storage	O
of	O
glycosphingolipids	O
in	O
Fabry's	O
disease	O
.	O

Thus	O
,	O
in	O
patients	O
with	O
cardiac	O
hypertrophy	O
,	O
it	O
is	O
important	O
to	O
differentiate	O
Fabry's	O
disease	O
from	O
other	O
causes	O
of	O
hypertrophy	O
.	O

Therefore	O
,	O
it	O
is	O
necessary	O
to	O
measure	O
alpha-Gal	O
A	O
activity	O
in	O
all	O
suspected	O
cases	O
and	O
to	O
analyze	O
genetic	O
abnormalities	O
in	O
heterozygotes	O
.	O

Mutation	O
analysis	O
of	O
SLC7A9	O
in	O
cystinuria	O
patients	O
in	O
Sweden	O
.	O

Cystinuria	O
is	O
an	O
autosomal	O
recessive	O
disorder	O
characterized	O
by	O
increased	O
urinary	O
excretion	O
of	O
cystine	O
and	O
dibasic	O
amino	O
acids	O
,	O
which	O
cause	O
recurrent	O
stone	O
formation	O
in	O
affected	O
individuals	O
.	O

Three	O
subtypes	O
of	O
cystinuria	O
have	O
been	O
described	O
(	O
type	O
I	O
,	O
II	O
,	O
and	O
III	O
)	O
:	O
type	O
I	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
SLC3A1	O
gene	O
,	O
whereas	O
nontype	O
I	O
(	O
II	O
and	O
III	O
)	O
has	O
been	O
associated	O
with	O
SLC7A9	O
mutations	O
.	O

Of	O
the	O
53	O
patients	O
reported	O
in	O
our	O
previous	O
work	O
,	O
patients	O
that	O
showed	O
SLC7A9	O
mutations	O
in	O
single-strand	O
conformation	O
polymorphism	O
(SSCP)	O
screening	O
and/or	O
either	O
lacked	O
or	O
showed	O
heterozygosity	O
for	O
SLC3A1	O
mutations	O
were	O
included	O
in	O
the	O
present	O
study	O
.	O

The	O
entire	O
coding	O
region	O
and	O
the	O
exon/intron	O
boundaries	O
of	O
the	O
SLC7A9	O
gene	O
were	O
analyzed	O
by	O
means	O
of	O
both	O
SSCP	O
and	O
DNA	O
sequencing	O
in	O
16	O
patients	O
,	O
all	O
but	O
one	O
of	O
which	O
were	O
clinically	O
diagnosed	O
as	O
homozygous	O
cystinurics	O
.	O

Three	O
novel	O
SLC7A9	O
mutations	O
were	O
identified	O
in	O
the	O
patient	O
group	O
:	O
two	O
missense	O
mutations	O
(	O
Ser-->Cys	B-ProteinMutation
substitution	I-ProteinMutation
at	I-ProteinMutation
the	I-ProteinMutation
codon	I-ProteinMutation
326	I-ProteinMutation
and	O
leucine	B-ProteinMutation
269	I-ProteinMutation
to	I-ProteinMutation
phenylalanine	I-ProteinMutation
)	O
,	O
and	O
one	O
single	O
base-pair	O
deletion	O
(	O
G-->C	B-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
135	I-DNAMutation
)	O
.	O

We	O
also	O
detected	O
the	O
previously	O
reported	O
arginine	B-ProteinMutation
555-to-tryptophan	I-ProteinMutation
and	O
nine	O
novel	O
polymorphisms	O
in	O
the	O
patients	O
.	O

Mutations	O
histidine	B-ProteinMutation
626-to-arginine	I-ProteinMutation
and	O
GTT-->GCT	B-DNAMutation
transition	I-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
23	I-DNAMutation
occurred	O
on	O
different	O
alleles	O
in	O
one	O
individual	O
,	O
and	O
we	O
suggest	O
that	O
these	O
mutations	O
cause	O
cystinuria	O
in	O
this	O
patient	O
.	O

One	O
patient	O
that	O
was	O
homozygously	O
mutated	O
in	O
the	O
SLC3A1	O
gene	O
carried	O
the	O
third	O
novel	O
mutation	O
(	O
arginine	B-ProteinMutation
124-to-cysteine	I-ProteinMutation
)	O
.	O

We	O
conclude	O
that	O
SLC3A1	O
is	O
still	O
the	O
major	O
disease	O
gene	O
among	O
Swedish	O
cystinuria	O
patients	O
,	O
with	O
only	O
a	O
minor	O
contribution	O
of	O
SLC7A9	O
mutations	O
as	O
the	O
genetic	O
basis	O
of	O
cystinuria	O
.	O

The	O
absence	O
of	O
SLC3A1	O
and	O
SLC7A9	O
mutations	O
in	O
a	O
substantial	O
proportion	O
of	O
the	O
patients	O
implies	O
that	O
mutations	O
in	O
parts	O
of	O
the	O
genes	O
that	O
were	O
not	O
analyzed	O
may	O
be	O
present	O
,	O
as	O
well	O
as	O
large	O
deletions	O
that	O
escape	O
detection	O
by	O
the	O
methods	O
used	O
.	O

However	O
,	O
our	O
results	O
raise	O
the	O
question	O
of	O
whether	O
other	O
,	O
as	O
yet	O
unknown	O
genes	O
,	O
may	O
also	O
be	O
involved	O
in	O
cystinuria	O
.	O

The	O
first	O
founder	O
DGUOK	O
mutation	O
associated	O
with	O
hepatocerebral	O
mitochondrial	O
DNA	O
depletion	O
syndrome	O
.	O

Deoxyguanosine	O
kinase	O
(dGK)	O
deficiency	O
is	O
a	O
frequent	O
cause	O
of	O
mitochondrial	O
DNA	O
depletion	O
associated	O
with	O
a	O
hepatocerebral	O
phenotype	O
.	O

In	O
this	O
study	O
,	O
we	O
describe	O
a	O
new	O
splice	O
site	O
mutation	O
in	O
the	O
DGUOK	O
gene	O
and	O
the	O
clinical	O
,	O
radiologic	O
,	O
and	O
genetic	O
features	O
of	O
these	O
DGUOK	O
patients	O
.	O

This	O
new	O
DGUOK	O
homozygous	O
mutation	O
(	O
A	B-DNAMutation
>	I-DNAMutation
G	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
313	I-DNAMutation
)	O
was	O
identified	O
in	O
three	O
patients	O
from	O
two	O
North-African	O
consanguineous	O
families	O
with	O
combined	O
respiratory	O
chain	O
deficiencies	O
and	O
mitochondrial	O
DNA	O
depletion	O
in	O
the	O
liver	O
.	O

Brain	O
MRIs	O
are	O
normal	O
in	O
DGUOK	O
patients	O
in	O
the	O
literature	O
.	O

Interestingly	O
,	O
we	O
found	O
subtentorial	O
abnormal	O
myelination	O
and	O
moderate	O
hyperintensity	O
in	O
the	O
bilateral	O
pallidi	O
in	O
our	O
patients	O
.	O

This	O
new	O
mutation	O
creates	O
a	O
cryptic	O
splice	O
site	O
in	O
intron	O
3	O
(	O
in	O
position	O
-62	O
)	O
and	O
is	O
predicted	O
to	O
result	O
in	O
a	O
larger	O
protein	O
with	O
an	O
in-frame	O
insertion	O
of	O
20	O
amino	O
acids	O
.	O

In	O
silico	O
analysis	O
of	O
the	O
putative	O
impact	O
of	O
the	O
insertion	O
shows	O
serious	O
clashes	O
in	O
protein	O
conformation	O
:	O
this	O
insertion	O
disrupts	O
the	O
alpha5	O
helix	O
of	O
the	O
dGK	O
kinase	O
domain	O
,	O
rendering	O
the	O
protein	O
unable	O
to	O
bind	O
purine	O
deoxyribonucleosides	O
.	O

In	O
addition	O
,	O
a	O
common	O
haplotype	O
that	O
segregated	O
with	O
the	O
disease	O
in	O
both	O
families	O
was	O
detected	O
by	O
haplotype	O
reconstruction	O
with	O
10	O
markers	O
(	O
microsatellites	O
and	O
SNPs	O
)	O
,	O
which	O
span	O
4.6	O
Mb	O
of	O
DNA	O
covering	O
the	O
DGUOK	O
locus	O
.	O

In	O
conclusion	O
,	O
we	O
report	O
a	O
new	O
DGUOK	O
splice	O
site	O
mutation	O
that	O
provide	O
insight	O
into	O
a	O
critical	O
protein	O
domain	O
(	O
dGK	O
kinase	O
domain	O
)	O
and	O
the	O
first	O
founder	O
mutation	O
in	O
a	O
North-African	O
population	O
.	O

Microevolution	O
between	O
paired	O
antral	O
and	O
paired	O
antrum	O
and	O
corpus	O
Helicobacter	O
pylori	O
isolates	O
recovered	O
from	O
individual	O
patients	O
.	O

Sequence	O
variations	O
located	O
at	O
the	O
signal	O
sequence	O
and	O
mid-region	O
within	O
the	O
vacA	O
gene	O
,	O
the	O
3'-end	O
of	O
the	O
cagA	O
gene	O
,	O
the	O
indel	O
motifs	O
at	O
the	O
3'-end	O
of	O
the	O
cag	O
pathogenicity	O
island	O
and	O
the	O
regions	O
upstream	O
of	O
the	O
vacA	O
and	O
ribA	O
genes	O
were	O
determined	O
by	O
PCR	O
in	O
19	O
paired	O
antral	O
or	O
antrum	O
and	O
corpus	O
Helicobacter	O
pylori	O
isolates	O
obtained	O
at	O
the	O
same	O
endoscopic	O
session	O
,	O
and	O
three	O
antral	O
pairs	O
taken	O
sequentially	O
.	O

Random	O
amplification	O
of	O
polymorphic	O
DNA	O
(RAPD)-PCR	O
and	O
fluorescent	O
amplified	O
fragment	O
length	O
polymorphism	O
(FAFLP)-PCR	O
fingerprinting	O
were	O
applied	O
to	O
these	O
paired	O
clinical	O
isolates	O
.	O

The	O
FAFLP-PCR	O
profiles	O
generated	O
were	O
phylogenetically	O
analysed	O
.	O

For	O
the	O
22	O
paired	O
isolates	O
there	O
were	O
no	O
differences	O
within	O
pairs	O
at	O
five	O
of	O
the	O
genetic	O
loci	O
studied	O
.	O

However	O
,	O
six	O
pairs	O
of	O
isolates	O
(27%)	O
,	O
of	O
which	O
four	O
were	O
antrum	O
and	O
corpus	O
pairs	O
,	O
showed	O
differences	O
in	O
the	O
numbers	O
of	O
repeats	O
located	O
at	O
the	O
3'-end	O
of	O
the	O
cagA	O
gene	O
.	O

RAPD-PCR	O
fingerprinting	O
showed	O
that	O
16	O
(73%)	O
pairs	O
,	O
nine	O
of	O
which	O
were	O
antrum	O
and	O
corpus	O
pairs	O
,	O
possessed	O
identical	O
profiles	O
,	O
while	O
six	O
(27%)	O
displayed	O
distinctly	O
different	O
profiles	O
,	O
indicating	O
mixed	O
infections	O
.	O

Three	O
of	O
the	O
six	O
pairs	O
showing	O
differences	O
at	O
the	O
3'-end	O
of	O
the	O
cagA	O
gene	O
yielded	O
identical	O
RAPD-PCR	O
fingerprints	O
.	O

FAFLP-PCR	O
fingerprinting	O
and	O
phylogenetic	O
analysis	O
revealed	O
that	O
all	O
16	O
pairs	O
that	O
displayed	O
identical	O
RAPD-PCR	O
profiles	O
had	O
highly	O
similar	O
,	O
but	O
not	O
identical	O
,	O
fingerprints	O
,	O
demonstrating	O
that	O
these	O
pairs	O
were	O
ancestrally	O
related	O
but	O
had	O
undergone	O
minor	O
genomic	O
alterations	O
.	O

Two	O
antrum	O
and	O
corpus	O
pairs	O
of	O
isolates	O
,	O
within	O
the	O
latter	O
group	O
,	O
were	O
isolates	O
obtained	O
from	O
two	O
siblings	O
from	O
the	O
same	O
family	O
.	O

This	O
analysis	O
demonstrated	O
that	O
each	O
sibling	O
was	O
colonized	O
by	O
ancestrally	O
related	O
strains	O
that	O
exhibited	O
differences	O
in	O
vacA	O
genotype	O
characteristics	O
.	O

Homozygous	O
deletion	O
related	O
to	O
Alu	O
repeats	O
in	O
RLBP1	O
causes	O
retinitis	O
punctata	O
albescens	O
.	O

PURPOSE	O
:	O
Retinitis	O
punctata	O
albescens	O
(RPA)	O
is	O
an	O
infrequently	O
occurring	O
form	O
of	O
autosomal	O
recessive	O
(	O
and	O
rarely	O
dominant	O
)	O
retinal	O
dystrophy	O
featuring	O
early-onset	O
severe	O
night	O
blindness	O
and	O
tiny	O
,	O
dotlike	O
,	O
white	O
deposits	O
in	O
the	O
fundus	O
.	O

RPA	O
is	O
associated	O
mostly	O
with	O
mutations	O
in	O
RLBP1	O
and	O
occasionally	O
in	O
RHO	O
,	O
RDS	O
,	O
and	O
RDH5	O
.	O

In	O
this	O
study	O
,	O
mutations	O
were	O
sought	O
in	O
RLBP1	O
,	O
which	O
encodes	O
the	O
retinol	O
binding	O
protein	O
CRALBP	O
in	O
patients	O
with	O
typical	O
RPA	O
.	O

METHODS	O
:	O
Clinical	O
investigation	O
included	O
funduscopy	O
,	O
visual	O
field	O
testing	O
,	O
electroretinogram	O
recording	O
,	O
and	O
adaptometry	O
.	O

The	O
7	O
coding	O
exons	O
(3-9)	O
of	O
RLBP1	O
and	O
the	O
15th	O
(last)	O
exon	O
of	O
ABDH2	O
were	O
PCR	O
amplified	O
and	O
sequenced	O
.	O

Long-distance	O
PCR	O
and	O
cloning	O
of	O
genomic	O
DNA	O
were	O
performed	O
to	O
characterize	O
the	O
deletion	O
.	O

RESULTS	O
:	O
The	O
study	O
involved	O
a	O
24-year-old	O
Moroccan	O
patient	O
with	O
typical	O
RPA	O
,	O
born	O
of	O
first-cousin	O
parents	O
.	O

He	O
carried	O
a	O
7.36-kb	O
homozygous	O
deletion	O
encompassing	O
the	O
last	O
3	O
exons	O
of	O
RLBP1	O
(	O
7	O
,	O
8	O
,	O
and	O
9	O
)	O
and	O
part	O
of	O
the	O
intergenic	O
region	O
between	O
RLBP1	O
and	O
ABHD2	O
,	O
which	O
lies	O
downstream	O
of	O
RLBP1	O
.	O

This	O
deletion	O
abolishes	O
the	O
retinal	O
binding	O
site	O
of	O
CRALBP	O
.	O

The	O
telomeric	O
breakpoint	O
of	O
the	O
deletion	O
(	O
in	O
RLBP1	O
intron	O
6	O
)	O
is	O
embedded	O
in	O
an	O
Alu	O
element	O
,	O
whereas	O
the	O
centromeric	O
breakpoint	O
(	O
in	O
the	O
intergenic	O
region	O
)	O
lies	O
between	O
two	O
Alu	O
elements	O
placed	O
in	O
the	O
opposite	O
orientation	O
.	O

CONCLUSIONS	O
:	O
Because	O
of	O
the	O
high	O
density	O
of	O
Alu	O
elements	O
in	O
RLBP1	O
,	O
a	O
systematic	O
search	O
should	O
be	O
made	O
for	O
deletions	O
in	O
this	O
gene	O
when	O
one	O
or	O
both	O
alleles	O
lack	O
point	O
mutations	O
,	O
in	O
the	O
case	O
of	O
RPA	O
or	O
flecked	O
retinal	O
dystrophy	O
.	O

A	O
cluster	O
of	O
autosomal	O
recessive	O
spondylocostal	O
dysostosis	O
caused	O
by	O
three	O
newly	O
identified	O
DLL3	O
mutations	O
segregating	O
in	O
a	O
small	O
village	O
.	O

In	O
1982	O
,	O
one	O
of	O
us	O
reported	O
a	O
cluster	O
of	O
eight	O
individuals	O
affected	O
by	O
spondylocostal	O
dysostosis	O
(	O
SD	O
,	O
MIM	O
277300	O
)	O
in	O
four	O
nuclear	O
families	O
indigenous	O
to	O
a	O
village	O
from	O
eastern	O
Switzerland	O
.	O

We	O
tested	O
the	O
hypothesis	O
that	O
the	O
molecular	O
basis	O
for	O
this	O
cluster	O
was	O
segregation	O
of	O
a	O
single	O
mutation	O
in	O
the	O
DLL3	O
gene	O
,	O
recently	O
linked	O
to	O
SD	O
.	O

Marker	O
haplotypes	O
around	O
the	O
DLL3	O
locus	O
contradicted	O
this	O
hypothesis	O
as	O
three	O
different	O
haplotypes	O
were	O
seen	O
in	O
affected	O
individuals	O
,	O
but	O
sequence	O
analysis	O
showed	O
that	O
three	O
unreported	O
DLL3	O
mutations	O
were	O
segregating	O
:	O
a	O
duplication	O
of	O
17	O
bp	O
in	O
exon	O
8	O
(	O
(	B-DNAMutation
TAC-->AA	I-DNAMutation
)	I-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
329	I-DNAMutation
)	O
,	O
a	O
single-nucleotide	O
deletion	O
in	O
exon	O
5	O
(	O
-AAGC	B-DNAMutation
at	I-DNAMutation
-222	I-DNAMutation
to	I-DNAMutation
-225	I-DNAMutation
)	O
,	O
and	O
a	O
Phe-->Ser	B-ProteinMutation
at	I-ProteinMutation
codon	I-ProteinMutation
15	I-ProteinMutation
nonsense	O
mutation	O
in	O
exon	O
6	O
.	O

Contrary	O
to	O
our	O
initial	O
assumption	O
of	O
a	O
single	O
allele	O
segregating	O
in	O
this	O
small	O
community	O
,	O
three	O
different	O
pathogenic	O
alleles	O
were	O
observed	O
,	O
with	O
a	O
putative	O
founder	O
mutation	O
occurring	O
at	O
the	O
homozygous	O
state	O
but	O
also	O
compounding	O
with	O
,	O
and	O
thus	O
revealing	O
,	O
two	O
other	O
independent	O
mutations	O
.	O

As	O
all	O
three	O
mutations	O
predict	O
truncation	O
of	O
the	O
DLL3	O
protein	O
and	O
loss	O
of	O
the	O
membrane-attaching	O
domain	O
,	O
the	O
results	O
confirm	O
that	O
autosomal	O
recessive	O
spondylocostal	O
dysostosis	O
represents	O
the	O
null	O
phenotype	O
of	O
DLL3	O
,	O
with	O
remarkable	O
phenotypic	O
consistency	O
across	O
families	O
.	O

Severe	O
prothrombin	O
deficiency	O
caused	O
by	O
prothrombin-Edmonton	O
(	O
Glu	B-ProteinMutation
272	I-ProteinMutation
to	I-ProteinMutation
stop	I-ProteinMutation
)	O
combined	O
with	O
a	O
previously	O
undetected	O
deletion	O
.	O

BACKGROUND	O
:	O
During	O
infancy	O
,	O
a	O
male	O
patient	O
experienced	O
several	O
life-threatening	O
bleeding	O
episodes	O
.	O

Standard	O
coagulation	O
tests	O
revealed	O
that	O
the	O
patient's	O
plasma	O
prothrombin	O
activity	O
was	O
8%	O
,	O
while	O
his	O
father's	O
and	O
mother's	O
levels	O
were	O
74%	O
and	O
62%	O
,	O
respectively	O
.	O

OBJECTIVES	O
:	O
A	O
molecular	O
genetic	O
approach	O
was	O
used	O
to	O
determine	O
the	O
molecular	O
basis	O
of	O
prothrombin	O
deficiency	O
within	O
the	O
family	O
.	O

PATIENT/METHODS	O
:	O
Prothrombin	O
genomic	O
DNA	O
fragments	O
were	O
amplified	O
by	O
using	O
the	O
polymerase	O
chain	O
reaction	O
(PCR)	O
.	O

In	O
addition	O
,	O
liver	O
cDNA	O
fragments	O
were	O
amplified	O
from	O
the	O
patient	O
by	O
using	O
reverse	O
transcription	O
(RT)	O
and	O
PCR	O
.	O

The	O
nucleotide	O
sequences	O
of	O
the	O
DNA	O
fragments	O
were	O
determined	O
.	O

RESULTS	O
:	O
A	O
novel	O
,	O
heterozygous	O
point	O
mutation	O
(	O
-491	B-DNAMutation
A	I-DNAMutation
to	I-DNAMutation
T	I-DNAMutation
,	O
named	O
prothrombin-Edmonton	O
)	O
was	O
detected	O
in	O
the	O
patient	O
and	O
his	O
mother	O
,	O
resulting	O
in	O
the	O
mutation	O
of	O
Arg-4	O
in	O
the	O
prothrombin	O
propeptide	O
to	O
Gln	O
(	O
methionine-->valine	B-ProteinMutation
substitution	I-ProteinMutation
at	I-ProteinMutation
codon	I-ProteinMutation
404	I-ProteinMutation
)	O
.	O

RT-PCR	O
analysis	O
of	O
the	O
patient's	O
liver	O
sample	O
demonstrated	O
the	O
presence	O
of	O
two	O
mRNA	O
transcripts	O
that	O
differed	O
by	O
the	O
presence	O
or	O
absence	O
of	O
exon	O
11	O
.	O

Real-time	O
PCR	O
analysis	O
on	O
genomic	O
DNA	O
and	O
cDNA	O
confirmed	O
a	O
deletion	O
(	O
G>A	B-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
+1	I-DNAMutation
of	I-DNAMutation
intron	I-DNAMutation
2	I-DNAMutation
)	O
in	O
the	O
paternal	O
allele	O
.	O

CONCLUSIONS	O
:	O
The	O
patient	O
has	O
a	O
maternally-inherited	O
point	O
mutation	O
(	O
Ser-->Cys	B-ProteinMutation
substitution	I-ProteinMutation
at	I-ProteinMutation
the	I-ProteinMutation
codon	I-ProteinMutation
326	I-ProteinMutation
)	O
and	O
a	O
paternally-inherited	O
deletion	O
.	O

By	O
analogy	O
with	O
the	O
previously	O
reported	O
factor	O
IX	O
San	O
Dimas	O
,	O
the	O
leucine	B-ProteinMutation
269	I-ProteinMutation
to	I-ProteinMutation
phenylalanine	I-ProteinMutation
mutation	O
probably	O
causes	O
under-carboxylation	O
of	O
prothrombin	O
and	O
poor	O
cleavage	O
of	O
the	O
propeptide	O
in	O
the	O
hepatocyte	O
.	O

The	O
deletion	O
probably	O
results	O
in	O
a	O
polypeptide	O
that	O
lacks	O
50	O
amino	O
acids	O
from	O
the	O
protease	O
domain	O
;	O
this	O
is	O
likely	O
to	O
impair	O
folding	O
,	O
secretion	O
,	O
stability	O
and/or	O
activity	O
of	O
the	O
truncated	O
prothrombin	O
.	O

The	O
two	O
mutations	O
combine	O
to	O
give	O
the	O
prothrombin	O
deficiency	O
observed	O
in	O
the	O
patient	O
.	O

Interstitial	O
deletion	O
of	O
13q14.13-q32.3	O
presenting	O
with	O
Arima	O
syndrome	O
and	O
bilateral	O
retinoblastoma	O
.	O

A	O
patient	O
with	O
a	O
large	O
deletion	O
of	O
the	O
distal	O
part	O
of	O
the	O
long	O
arm	O
of	O
chromosome	O
13	O
showed	O
severe	O
psychomotor	O
retardation	O
,	O
a	O
characteristic	O
face	O
,	O
nystagmus	O
,	O
retinopathy	O
,	O
cystic	O
kidney	O
disease	O
,	O
and	O
brain	O
malformation	O
with	O
molar	O
tooth	O
sign	O
and	O
cerebellar	O
vermis	O
hypoplasia	O
,	O
a	O
phenotype	O
typical	O
of	O
Arima	O
syndrome	O
.	O

This	O
patient	O
also	O
had	O
bilateral	O
retinoblastoma	O
.	O

Fluorescent	O
in	O
situ	O
hybridization	O
and	O
single-nucleotide-polymorphism	O
genotyping	O
microarray	O
demonstrated	O
an	O
interstitial	O
deletion	O
of	O
54	O
Mbp	O
,	O
ranging	O
from	O
13q14.13	O
to	O
13q32.3	O
and	O
involving	O
the	O
RB1	O
gene	O
.	O

This	O
patient	O
is	O
the	O
first	O
case	O
of	O
Arima	O
syndrome	O
,	O
or	O
a	O
Joubert	O
syndrome-related	O
disorder	O
,	O
that	O
showed	O
linkage	O
to	O
chromosome	O
13q	O
.	O

Alpha2B-adrenergic	O
receptor	O
insertion/deletion	O
polymorphism	O
in	O
women	O
with	O
spontaneous	O
recurrent	O
abortions	O
.	O

AIM	O
:	O
The	O
aim	O
of	O
our	O
study	O
was	O
to	O
investigate	O
the	O
relationship	O
between	O
the	O
alpha2B-adrenoreceptor	O
insertion/deletion	O
(I/D)	O
polymorphism	O
and	O
recurrent	O
spontaneous	O
abortions	O
(RSA)	O
.	O

METHODS	O
:	O
Genotyping	O
was	O
performed	O
in	O
48	O
women	O
with	O
a	O
history	O
of	O
at	O
least	O
three	O
consecutive	O
spontaneous	O
abortions	O
and	O
96	O
women	O
with	O
at	O
least	O
two	O
live	O
births	O
and	O
no	O
history	O
of	O
pregnancy	O
loss	O
.	O

Peripheral	O
venous	O
puncture	O
,	O
DNA	O
extraction	O
and	O
PCR	O
were	O
used	O
for	O
the	O
research	O
of	O
DD	O
,	O
ID	O
and	O
II	O
genotype	O
characters	O
.	O

RESULTS	O
:	O
The	O
distribution	O
of	O
DD	O
,	O
ID	O
and	O
II	O
genotypes	O
of	O
the	O
alpha2B-adrenoreceptor	O
gene	O
was	O
2	O
(4.2%)	O
,	O
19	O
(39.6%)	O
and	O
27	O
(56.2%)	O
in	O
the	O
study	O
group	O
and	O
6	O
(6.5%)	O
,	O
28	O
(30.4%)	O
and	O
58	O
(63%)	O
in	O
the	O
control	O
group	O
,	O
respectively	O
.	O

There	O
was	O
no	O
significant	O
difference	O
between	O
the	O
groups	O
.	O

The	O
presence	O
of	O
the	O
D	O
allele	O
was	O
not	O
associated	O
with	O
RSA	O
(	O
P	O
=	O
0.78	O
,	O
odds	O
ratio	O
=	O
0.88	O
,	O
95%	O
CI	O
=	O
0.47-1.65	O
)	O
.	O

CONCLUSION	O
:	O
Our	O
data	O
fall	O
short	O
of	O
showing	O
any	O
association	O
between	O
the	O
presence	O
of	O
the	O
alpha2B	O
D	O
allele	O
and	O
the	O
occurrence	O
of	O
spontaneous	O
abortions	O
in	O
the	O
examined	O
population	O
.	O

Mutation	O
analysis	O
of	O
DMBT1	O
in	O
glioblastoma	O
,	O
medulloblastoma	O
and	O
oligodendroglial	O
tumors	O
.	O

DMBT1	O
has	O
been	O
implicated	O
as	O
a	O
candidate	O
tumor	O
suppressor	O
gene	O
on	O
chromosome	O
10q	O
for	O
brain	O
,	O
gastrointestinal	O
and	O
lung	O
cancer	O
.	O

Homozygous	O
deletion	O
and	O
lack	O
of	O
expression	O
are	O
2	O
known	O
mechanisms	O
for	O
inactivating	O
DMBT1	O
.	O

We	O
evaluated	O
whether	O
somatic	O
mutation	O
,	O
which	O
represents	O
a	O
major	O
inactivation	O
mechanism	O
for	O
most	O
tumor	O
suppressor	O
genes	O
,	O
occurs	O
in	O
the	O
DMBT1	O
gene	O
.	O

A	O
total	O
of	O
102	O
primary	O
brain	O
tumors	O
,	O
consisting	O
of	O
25	O
glioblastoma	O
multiforme	O
,	O
24	O
medulloblastoma	O
and	O
53	O
oligodendroglial	O
tumors	O
,	O
were	O
analyzed	O
by	O
conformation-sensitive	O
gel	O
electrophoresis	O
in	O
all	O
54	O
coding	O
exons	O
of	O
DMBT1	O
.	O

Twelve	O
different	O
base	O
substitutions	O
were	O
detected	O
in	O
26	O
(25%)	O
tumors	O
.	O

Eight	O
base	O
substitutions	O
resulted	O
in	O
amino	O
acid	O
changes	O
and	O
4	O
were	O
silent	O
.	O

These	O
base	O
changes	O
were	O
also	O
detected	O
in	O
tumor-matched	O
blood	O
samples	O
,	O
however	O
,	O
indicating	O
that	O
the	O
base	O
variations	O
represent	O
genetic	O
polymorphisms	O
.	O

We	O
also	O
assessed	O
homozygous	O
deletions	O
of	O
the	O
DMBT1	O
gene	O
in	O
the	O
series	O
and	O
found	O
that	O
16	O
of	O
95	O
(	O
5	O
glioblastomas	O
,	O
5	O
medulloblastomas	O
,	O
6	O
oligodendroglial	O
tumors	O
;	O
total	O
17%	O
)	O
tumors	O
harbor	O
such	O
alteration	O
.	O

High-quality	O
blood	O
DNA	O
samples	O
were	O
available	O
in	O
5	O
tumors	O
carrying	O
homozygous	O
deletion	O
and	O
,	O
using	O
long-range	O
PCR	O
,	O
3	O
of	O
these	O
blood	O
samples	O
showed	O
germline	O
hemizygous	O
deletions	O
in	O
a	O
region	O
between	O
introns	O
10	O
and	O
26	O
of	O
DMBT1	O
.	O

Our	O
results	O
showed	O
that	O
mutation	O
does	O
not	O
play	O
a	O
role	O
in	O
inactivation	O
of	O
DMBT1	O
in	O
brain	O
tumors	O
.	O

Intragenic	O
homozygous	O
deletion	O
of	O
DMBT1	O
is	O
common	O
in	O
brain	O
tumors	O
and	O
is	O
likely	O
a	O
result	O
of	O
a	O
germline	O
deletion	O
of	O
1	O
allele	O
followed	O
by	O
loss	O
of	O
the	O
second	O
allele	O
during	O
tumor	O
development	O
.	O

Mutations	O
in	O
the	O
NDP	O
gene	O
:	O
contribution	O
to	O
Norrie	O
disease	O
,	O
familial	O
exudative	O
vitreoretinopathy	O
and	O
retinopathy	O
of	O
prematurity	O
.	O

BACKGROUND	O
:	O
To	O
examine	O
the	O
contribution	O
of	O
mutations	O
within	O
the	O
Norrie	O
disease	O
(NDP)	O
gene	O
to	O
the	O
clinically	O
similar	O
retinal	O
diseases	O
Norrie	O
disease	O
,	O
X-linked	O
familial	O
exudative	O
vitreoretinopathy	O
(FEVR)	O
,	O
Coat's	O
disease	O
and	O
retinopathy	O
of	O
prematurity	O
(ROP)	O
.	O

METHODS	O
:	O
A	O
dataset	O
comprising	O
13	O
Norrie-FEVR	O
,	O
one	O
Coat's	O
disease	O
,	O
31	O
ROP	O
patients	O
and	O
90	O
ex-premature	O
babies	O
of	O
<32	O
weeks'	O
gestation	O
underwent	O
an	O
ophthalmologic	O
examination	O
and	O
were	O
screened	O
for	O
mutations	O
within	O
the	O
NDP	O
gene	O
by	O
direct	O
DNA	O
sequencing	O
,	O
denaturing	O
high-performance	O
liquid	O
chromatography	O
or	O
gel	O
electrophoresis	O
.	O

Controls	O
were	O
only	O
screened	O
using	O
denaturing	O
high-performance	O
liquid	O
chromatography	O
and	O
gel	O
electrophoresis	O
.	O

Confirmation	O
of	O
mutations	O
identified	O
was	O
obtained	O
by	O
DNA	O
sequencing	O
.	O

RESULTS	O
:	O
Evidence	O
for	O
two	O
novel	O
mutations	O
in	O
the	O
NDP	O
gene	O
was	O
presented	O
:	O
arginine	B-ProteinMutation
555-to-tryptophan	I-ProteinMutation
in	O
one	O
FEVR	O
patient	O
and	O
histidine	B-ProteinMutation
626-to-arginine	I-ProteinMutation
in	O
monozygotic	O
twin	O
Norrie	O
disease	O
patients	O
.	O

Furthermore	O
,	O
a	O
previously	O
described	O
14-bp	O
deletion	O
located	O
in	O
the	O
5'	O
unstranslated	O
region	O
of	O
the	O
NDP	O
gene	O
was	O
detected	O
in	O
three	O
cases	O
of	O
regressed	O
ROP	O
.	O

A	O
second	O
heterozygotic	O
14-bp	O
deletion	O
was	O
detected	O
in	O
an	O
unaffected	O
ex-premature	O
girl	O
.	O

Only	O
two	O
of	O
the	O
13	O
Norrie-FEVR	O
index	O
cases	O
had	O
the	O
full	O
features	O
of	O
Norrie	O
disease	O
with	O
deafness	O
and	O
mental	O
retardation	O
.	O

CONCLUSION	O
:	O
Two	O
novel	O
mutations	O
within	O
the	O
coding	O
region	O
of	O
the	O
NDP	O
gene	O
were	O
found	O
,	O
one	O
associated	O
with	O
a	O
severe	O
disease	O
phenotypes	O
of	O
Norrie	O
disease	O
and	O
the	O
other	O
with	O
FEVR	O
.	O

A	O
deletion	O
within	O
the	O
non-coding	O
region	O
was	O
associated	O
with	O
only	O
mild-regressed	O
ROP	O
,	O
despite	O
the	O
presence	O
of	O
low	O
birthweight	O
,	O
prematurity	O
and	O
exposure	O
to	O
oxygen	O
.	O

In	O
full-term	O
children	O
with	O
retinal	O
detachment	O
only	O
15%	O
appear	O
to	O
have	O
the	O
full	O
features	O
of	O
Norrie	O
disease	O
and	O
this	O
is	O
important	O
for	O
counselling	O
parents	O
on	O
the	O
possible	O
long-term	O
outcome	O
.	O

Combination	O
of	O
polymorphisms	O
within	O
5'	O
and	O
3'	O
untranslated	O
regions	O
of	O
thymidylate	O
synthase	O
gene	O
modulates	O
survival	O
in	O
5	O
fluorouracil-treated	O
colorectal	O
cancer	O
patients	O
.	O

In	O
the	O
present	O
study	O
we	O
explored	O
the	O
effect	O
of	O
three	O
polymorphisms	O
of	O
the	O
TS	O
gene	O
on	O
overall	O
and	O
progression-	O
free	O
survival	O
of	O
colorectal	O
cancer	O
(CRC)	O
patients	O
subjected	O
to	O
5FU	O
chemotherapy	O
.	O

A	O
28	O
bp	O
variable	O
number	O
of	O
tandem	O
repeats	O
(VNTR)	O
,	O
a	O
(	B-DNAMutation
G	I-DNAMutation
-->	I-DNAMutation
C	I-DNAMutation
)	I-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
1201	I-DNAMutation
single	O
nucleotide	O
polymorphism	O
(SNP)	O
,	O
and	O
a	O
deletion	O
of	O
6	O
bp	O
at	O
position	O
1494	O
were	O
studied	O
.	O

The	O
possible	O
combined	O
effect	O
of	O
these	O
DNA	O
polymorphisms	O
on	O
the	O
clinical	O
outcome	O
of	O
patients	O
was	O
also	O
evaluated	O
.	O

A	O
retrospective	O
study	O
was	O
carried	O
out	O
on	O
paraffin-embedded	O
sections	O
from	O
113	O
patients	O
diagnosed	O
of	O
advanced	O
CRC	O
.	O

TS	O
genotyping	O
methods	O
were	O
polymerase	O
chain	O
reaction	O
(PCR)	O
for	O
VNTR	O
and	O
PCR	O
,	O
followed	O
by	O
restriction	O
length	O
fragment	O
polymorphism	O
(PCR-RFLP)	O
for	O
SNP	O
and	O
(	B-DNAMutation
T	I-DNAMutation
-->	I-DNAMutation
C	I-DNAMutation
)	I-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
2209	I-DNAMutation
.	O

To	O
study	O
the	O
combined	O
effect	O
of	O
TS	O
polymorphisms	O
,	O
four	O
categories	O
were	O
defined	O
accordingly	O
to	O
the	O
level	O
of	O
expression	O
attributed	O
to	O
SNP	O
and	O
G>T	B-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
c.898	I-DNAMutation
genotypes	O
:	O
C_allele	O
6-	O
,	O
C_6+/6+	O
,	O
G_allele6-	O
and	O
G_6+/6+	O
.	O

VNTR	O
and	O
C-->T	B-DNAMutation
transversion	I-DNAMutation
at	I-DNAMutation
cDNA	I-DNAMutation
base	I-DNAMutation
463	I-DNAMutation
genotypes	O
varied	O
with	O
tumour	O
anatomical	O
site	O
:	O
2R/2R	O
genotype	O
was	O
rare	O
in	O
left-sided	O
tumours	O
(	O
7.0%	O
vs	O
.	O

26.3%	O
of	O
right-sided	O
and	O
24.1%	O
of	O
rectal	O
cancers	O
;	O
P<0.01	O
)	O
,	O
where	O
the	O
variant	O
allele	O
6-	O
was	O
very	O
frequent	O
(69.0%)	O
.	O

Instead	O
,	O
most	O
patients	O
with	O
right-sided	O
tumours	O
were	O
wild-type	O
homozygous	O
6+/6+	O
(63.9%)	O
(P<0.01)	O
.	O

Heterozygous	O
6+/6-	O
genotype	O
was	O
more	O
frequent	O
among	O
tumours	O
classified	O
as	O
C	O
(50.0%)	O
and	O
D	O
(76.5%)	O
Dukes	O
stages	O
(P=0.05)	O
.	O

None	O
of	O
the	O
studied	O
polymorphisms	O
alone	O
affected	O
overall	O
or	O
progression-free	O
survival	O
(PFS)	O
.	O

C_6+/6+	O
and	O
G_6+/6+	O
combined	O
genotypes	O
were	O
respectively	O
associated	O
to	O
the	O
best	O
and	O
worst	O
PFS	O
(	O
P=0.03	O
when	O
compared	O
with	O
each	O
other	O
)	O
,	O
while	O
combinations	O
carrying	O
the	O
allele	O
6-	O
determined	O
an	O
intermediate	O
evolution	O
that	O
might	O
be	O
indicative	O
of	O
a	O
variable	O
response	O
to	O
chemotherapy	O
.	O

The	O
rate	O
of	O
Dukes	O
B	O
stage	O
tumours	O
was	O
unexpectedly	O
high	O
(59.1%)	O
among	O
patients	O
with	O
the	O
unfavourable	O
G_6+/6+	O
combination	O
.	O

In	O
our	O
study	O
the	O
combination	O
of	O
high	O
TS	O
expression	O
genotypes	O
G_6+/6+	O
identifies	O
a	O
group	O
of	O
high	O
risk	O
within	O
CRC	O
patients	O
treated	O
with	O
5FU	O
.	O

Identified	O
hidden	O
genomic	O
changes	O
in	O
mantle	O
cell	O
lymphoma	O
using	O
high-resolution	O
single	O
nucleotide	O
polymorphism	O
genomic	O
array	O
.	O

OBJECTIVE	O
:	O
Mantle	O
cell	O
lymphoma	O
(MCL)	O
is	O
a	O
lymphoma	O
characterized	O
by	O
aberrant	O
activation	O
of	O
CCND1/cyclin	O
D1	O
followed	O
by	O
sequential	O
genetic	O
abnormalities	O
.	O

Genomic	O
abnormalities	O
in	O
MCL	O
have	O
been	O
extensively	O
examined	O
by	O
classical	O
cytogenetics	O
and	O
microarray-based	O
comparative	O
genomic	O
hybridization	O
techniques	O
,	O
pointing	O
out	O
a	O
number	O
of	O
alterations	O
in	O
genomic	O
regions	O
that	O
correlate	O
with	O
the	O
neoplastic	O
phenotype	O
and	O
survival	O
.	O

Recently	O
,	O
single	O
nucleotide	O
polymorphism	O
genomic	O
microarrays	O
(SNP-chip)	O
have	O
been	O
developed	O
and	O
used	O
for	O
analysis	O
of	O
cancer	O
genomics	O
.	O

This	O
technique	O
allows	O
detection	O
of	O
genomic	O
changes	O
with	O
higher	O
resolution	O
,	O
including	O
loss	O
of	O
heterozygosity	O
without	O
changes	O
of	O
gene	O
dosage	O
,	O
so-called	O
acquired	O
uniparental	O
disomy	O
(aUPD)	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
We	O
have	O
examined	O
33	O
samples	O
of	O
MCL	O
(	O
28	O
primary	O
MCL	O
and	O
5	O
cell	O
lines	O
)	O
using	O
the	O
250,000	O
SNP-chip	O
from	O
Affymetrix	O
.	O

RESULTS	O
:	O
Known	O
alterations	O
were	O
confirmed	O
by	O
SNP	O
arrays	O
,	O
including	O
deletion	O
of	O
INK4A/ARF	O
,	O
duplication/amplification	O
of	O
MYC	O
,	O
deletion	O
of	O
ATM	O
,	O
and	O
deletion	O
of	O
TP53	O
.	O

We	O
also	O
identified	O
a	O
duplication/amplification	O
that	O
occurred	O
at	O
13q	O
involving	O
oncogenic	O
microRNA	O
,	O
miR17-92	O
.	O

We	O
found	O
other	O
genomic	O
abnormalities	O
,	O
including	O
duplication/amplification	O
of	O
cyclin	O
D1	O
,	O
del(1p)	O
,	O
del(6q)	O
,	O
dup(3q)	O
and	O
dup(18q)	O
.	O

Our	O
SNP-chip	O
analysis	O
detected	O
these	O
abnormalities	O
at	O
high	O
resolution	O
,	O
allowing	O
us	O
to	O
narrow	O
the	O
size	O
of	O
the	O
commonly	O
deleted	O
regions	O
,	O
including	O
1p	O
and	O
6q	O
.	O

Our	O
SNP-chip	O
analysis	O
detected	O
a	O
number	O
of	O
aUPD	O
sites	O
,	O
including	O
whole	O
chromosome	O
9	O
aUPD	O
and	O
9p	O
aUPD	O
.	O

We	O
also	O
found	O
an	O
MCL	O
case	O
with	O
19p	O
,	O
leading	O
to	O
homozygous	O
deletion	O
of	O
TNFSF	O
genes	O
.	O

CONCLUSION	O
:	O
SNP-chip	O
analysis	O
detected	O
in	O
MCL	O
very	O
small	O
genomic	O
gains/losses	O
,	O
as	O
well	O
as	O
aUPDs	O
,	O
which	O
could	O
not	O
be	O
detected	O
by	O
more	O
conventional	O
methods	O
.	O

A	O
novel	O
single-nucleotide	O
substitution	O
,	O
arginine	B-ProteinMutation
124-to-cysteine	I-ProteinMutation
,	O
in	O
the	O
leukotriene	O
C4	O
synthase	O
gene	O
associated	O
with	O
allergic	O
diseases	O
.	O

Cysteinyl	O
leukotrienes	O
(cysLTs)	O
play	O
important	O
roles	O
in	O
bronchial	O
asthma	O
,	O
and	O
can	O
mediate	O
bronchial	O
smooth	O
muscle	O
constriction	O
and	O
increase	O
mucous	O
secretion	O
,	O
vascular	O
permeability	O
and	O
cellular	O
infiltration	O
.	O

We	O
identified	O
a	O
novel	O
heterozygous	O
single-nucleotide	O
substitution	O
G-->C	B-DNAMutation
transversion	I-DNAMutation
at	I-DNAMutation
1245	I-DNAMutation
position	I-DNAMutation
(	O
Phe-->Ser	B-ProteinMutation
at	I-ProteinMutation
codon	I-ProteinMutation
15	I-ProteinMutation
)	O
in	O
the	O
first	O
exon	O
of	O
the	O
leukotriene	O
C4	O
synthase	O
gene	O
(LTC4S)	O
.	O

This	O
substitution	O
was	O
detected	O
in	O
5	O
of	O
141	O
allergic	O
patients	O
,	O
but	O
not	O
in	O
110	O
nonallergic	O
subjects	O
.	O

There	O
was	O
a	O
difference	O
in	O
the	O
Glu	B-ProteinMutation
272	I-ProteinMutation
to	I-ProteinMutation
stop	I-ProteinMutation
frequency	O
between	O
the	O
allergic	O
patients	O
and	O
nonallergic	O
subjects	O
(	O
Fisher's	O
exact	O
test	O
,	O
p=0.0460	O
)	O
.	O

The	O
five	O
patients	O
with	O
methionine-->valine	B-ProteinMutation
substitution	I-ProteinMutation
at	I-ProteinMutation
codon	I-ProteinMutation
404	I-ProteinMutation
had	O
allergic	O
diseases	O
such	O
as	O
bronchial	O
asthma	O
and/or	O
allergic	O
dermatitis	O
.	O

Furthermore	O
,	O
a	O
familial	O
analysis	O
of	O
Ser-->Cys	B-ProteinMutation
substitution	I-ProteinMutation
at	I-ProteinMutation
the	I-ProteinMutation
codon	I-ProteinMutation
326	I-ProteinMutation
revealed	O
a	O
link	O
with	O
allergic	O
diseases	O
.	O

Thus	O
,	O
our	O
results	O
suggest	O
that	O
leucine	B-ProteinMutation
269	I-ProteinMutation
to	I-ProteinMutation
phenylalanine	I-ProteinMutation
in	O
the	O
LTC4S	O
might	O
be	O
associated	O
with	O
allergic	O
diseases	O
.	O

Roles	O
of	O
G1359A	O
polymorphism	O
of	O
the	O
cannabinoid	O
receptor	O
gene	O
(CNR1)	O
on	O
weight	O
loss	O
and	O
adipocytokines	O
after	O
a	O
hypocaloric	O
diet	O
.	O

BACKGROUND	O
:	O
A	O
intragenic	O
biallelic	O
polymorphism	O
(	O
G-->C	B-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
135	I-DNAMutation
)	O
of	O
the	O
CB1	O
gene	O
resulting	O
in	O
the	O
substitution	O
of	O
the	O
G	O
to	O
A	O
at	O
nucleotide	O
position	O
1359	O
in	O
codon	O
435	O
(Thr)	O
,	O
was	O
reported	O
as	O
a	O
common	O
polymorphism	O
in	O
Caucasian	O
populations	O
.	O

Intervention	O
studies	O
with	O
this	O
polymorphism	O
have	O
not	O
been	O
realized	O
.	O

OBJECTIVE	O
:	O
We	O
decided	O
to	O
investigate	O
the	O
role	O
of	O
the	O
polymorphism	O
(G1359A)	O
of	O
CB1	O
receptor	O
gene	O
on	O
adipocytokines	O
response	O
and	O
weight	O
loss	O
secondary	O
to	O
a	O
lifestyle	O
modification	O
(	O
Mediterranean	O
hypocaloric	O
diet	O
and	O
exercise	O
)	O
in	O
obese	O
patients	O
.	O

DESIGN	O
:	O
A	O
population	O
of	O
94	O
patients	O
with	O
obesity	O
was	O
analyzed	O
.	O

Before	O
and	O
after	O
3	O
months	O
on	O
a	O
hypocaloric	O
diet	O
,	O
an	O
anthropometric	O
evaluation	O
,	O
an	O
assessment	O
of	O
nutritional	O
intake	O
and	O
a	O
biochemical	O
analysis	O
were	O
performed	O
.	O

The	O
statistical	O
analysis	O
was	O
performed	O
for	O
the	O
combined	O
G1359A	O
and	O
A1359A	O
as	O
a	O
group	O
and	O
wild	O
type	O
G1359G	O
as	O
second	O
group	O
,	O
with	O
a	O
dominant	O
model	O
.	O

Results	O
:	O
Forty	O
seven	O
patients	O
(50%)	O
had	O
the	O
genotype	O
G1359G	O
(	O
wild	O
type	O
group	O
)	O
and	O
47	O
(50%)	O
patients	O
G1359A	O
(	O
41	O
patients	O
,	O
43.6%	O
)	O
or	O
A1359A	O
(	O
6	O
patients	O
,	O
6.4%	O
)	O
(	O
mutant	O
type	O
group	O
)	O
had	O
the	O
genotype	O
.	O

In	O
wild	O
and	O
mutant	O
type	O
groups	O
,	O
weight	O
,	O
body	O
mass	O
index	O
,	O
fat	O
mass	O
,	O
waist	O
circumference	O
and	O
systolic	O
blood	O
pressure	O
decreased	O
.	O

In	O
mutant	O
type	O
group	O
,	O
resistin	O
(	O
4.15	O
	O
	O
	O
1.7	O
ng/ml	O
vs	O
.	O

3.90	O
	O
	O
	O
2.1	O
ng/ml	O
:	O
P	O
<	O
0.05	O
)	O
,	O
leptin	O
(	O
78.4	O
	O
	O
	O
69	O
ng/ml	O
vs	O
66.2	O
	O
	O
	O
32	O
ng/ml	O
:	O
P	O
<	O
0.05	O
)	O
and	O
IL-6	O
(	O
1.40	O
	O
	O
	O
1.9	O
pg/ml	O
vs	O
0.81	O
	O
	O
	O
1.5	O
pg/ml	O
:	O
P	O
<	O
0.05	O
)	O
levels	O
decreased	O
after	O
dietary	O
treatment	O
.	O

CONCLUSION	O
:	O
The	O
novel	O
finding	O
of	O
this	O
study	O
is	O
the	O
association	O
of	O
the	O
mutant	O
allele	O
(A1359)	O
with	O
a	O
decrease	O
of	O
resistin	O
,	O
leptin	O
and	O
interleukin-6	O
secondary	O
to	O
weight	O
loss	O
.	O

Genetic	O
polymorphism	O
in	O
chemokine	O
CCL22	O
and	O
susceptibility	O
to	O
Helicobacter	O
pylori	O
infection-related	O
gastric	O
carcinoma	O
.	O

BACKGROUND	O
:	O
Gastric	O
carcinoma	O
is	O
widely	O
considered	O
to	O
be	O
related	O
to	O
Helicobacter	O
pylori	O
infection	O
,	O
and	O
the	O
chemokine	O
(	O
C-C	O
motif	O
)	O
ligand	O
22	O
(CCL22)	O
plays	O
an	O
important	O
role	O
in	O
suppressing	O
immune	O
responses	O
against	O
H	O
.	O

pylori	O
and	O
tumor	O
cells	O
.	O

In	O
this	O
study	O
,	O
the	O
authors	O
examined	O
the	O
association	O
between	O
single	O
nucleotide	O
polymorphisms	O
(SNPs)	O
in	O
the	O
CCL22	O
gene	O
and	O
the	O
risk	O
of	O
gastric	O
carcinoma	O
.	O

METHODS	O
:	O
Information	O
on	O
SNPs	O
in	O
the	O
CCL22	O
coding	O
region	O
was	O
obtained	O
from	O
the	O
HapMap	O
Project	O
database	O
.	O

Genotypes	O
were	O
determined	O
in	O
a	O
case-control	O
cohort	O
that	O
consisted	O
of	O
1001	O
patients	O
with	O
gastric	O
carcinoma	O
and	O
1066	O
controls	O
,	O
and	O
odds	O
ratios	O
(ORs)	O
and	O
95%	O
confidence	O
intervals	O
(	O
95%	O
CIs	O
)	O
were	O
computed	O
by	O
using	O
a	O
logistic	O
regression	O
model	O
.	O

Serum	O
H	O
.	O

pylori	O
antibody	O
levels	O
were	O
measured	O
by	O
using	O
an	O
enzyme-linked	O
immunosorbent	O
assay	O
.	O

RESULTS	O
:	O
The	O
C-->T	B-DNAMutation
transition	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
677	I-DNAMutation
SNP	O
(	O
reference	O
SNP	O
no	O
.	O

4359426	O
)	O
in	O
exon	O
1	O
of	O
the	O
CCL22	O
gene	O
,	O
which	O
causes	O
a	O
2	O
aspartate	O
(2Asp)	O
to	O
2	O
alanine	O
(2Ala)	O
substitution	O
in	O
the	O
CCL22	O
protein	O
,	O
was	O
associated	O
with	O
a	O
significantly	O
increased	O
risk	O
of	O
gastric	O
carcinoma	O
.	O

Individuals	O
who	O
were	O
homozygous	O
for	O
the	O
Ala/Ala	O
genotype	O
had	O
an	O
OR	O
of	O
2.27	O
(	O
95%	O
CI	O
,	O
1.28-4.02	O
)	O
compared	O
with	O
individuals	O
who	O
had	O
the	O
Asp/Asp	O
genotype	O
.	O

Stratification	O
analysis	O
indicated	O
that	O
the	O
association	O
was	O
more	O
pronounced	O
among	O
men	O
(	O
OR	O
,	O
2.64	O
;	O
95%	O
CI	O
,	O
1.29-5.41	O
)	O
and	O
among	O
younger	O
individuals	O
(	O
OR	O
,	O
2.85	O
;	O
95%	O
CI	O
,	O
1.36-5.96	O
)	O
compared	O
with	O
women	O
and	O
older	O
individuals	O
.	O

Moreover	O
,	O
a	O
multiplicative	O
joint	O
effect	O
between	O
the	O
CCL22	O
SNP	O
and	O
H	O
.	O

pylori	O
infection	O
that	O
intensified	O
the	O
risk	O
was	O
observed	O
(	O
OR	O
for	O
the	O
presence	O
of	O
both	O
Ala/Ala	O
genotype	O
and	O
H	O
.	O

pylori	O
infection	O
,	O
18.37	O
;	O
95%	O
CI	O
,	O
2.30-146.67	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
results	O
from	O
this	O
study	O
suggested	O
that	O
the	O
CCL22	O
polymorphism	O
is	O
associated	O
with	O
an	O
increase	O
risk	O
of	O
developing	O
H	O
.	O

pylori	O
infection-related	O
gastric	O
carcinoma	O
.	O

Subfertility	O
in	O
mice	O
harboring	O
a	O
mutation	O
in	O
betaB2-crystallin	O
.	O

PURPOSE	O
:	O
betaB2-crystallin	O
is	O
one	O
of	O
the	O
most	O
abundant	O
proteins	O
of	O
the	O
adult	O
ocular	O
lens	O
of	O
mammals	O
although	O
it	O
is	O
expressed	O
at	O
lower	O
levels	O
in	O
several	O
extralenticular	O
locations	O
.	O

While	O
mutations	O
in	O
betaB2-crystallin	O
are	O
known	O
to	O
result	O
in	O
lens	O
opacities	O
,	O
alterations	O
in	O
tissues	O
besides	O
the	O
lens	O
have	O
not	O
been	O
previously	O
investigated	O
in	O
these	O
mutants	O
.	O

Since	O
we	O
found	O
mice	O
harboring	O
the	O
Crybb2Phil	O
mutation	O
bred	O
poorly	O
,	O
here	O
we	O
assess	O
the	O
contribution	O
of	O
betaB2-crystallin	O
to	O
mouse	O
fertility	O
and	O
determine	O
the	O
expression	O
pattern	O
of	O
betaB2-crystallin	O
in	O
the	O
testis	O
.	O

METHODS	O
:	O
The	O
expression	O
pattern	O
of	O
betaB2-crystallin	O
in	O
the	O
testis	O
was	O
analyzed	O
by	O
rt-PCR	O
,	O
western	O
blotting	O
,	O
and	O
immunohistochemistry	O
.	O

The	O
fecundity	O
of	O
wildtype	O
and	O
Crybb2Phil	O
mice	O
was	O
analyzed	O
by	O
quantitative	O
fertility	O
testing	O
.	O

The	O
morphology	O
of	O
testes	O
and	O
ovaries	O
was	O
assessed	O
by	O
hematoxylin	O
and	O
eosin	O
staining	O
.	O

RESULTS	O
:	O
In	O
the	O
mouse	O
testis	O
,	O
betaB2-crystallin	O
mRNA	O
is	O
found	O
at	O
low	O
levels	O
at	O
birth	O
,	O
but	O
its	O
expression	O
upregulates	O
in	O
this	O
tissue	O
as	O
the	O
testis	O
is	O
primed	O
to	O
initiate	O
spermatogenesis	O
.	O

Western	O
blotting	O
detected	O
betaB2-crystallin	O
protein	O
in	O
sperm	O
obtained	O
from	O
mice	O
,	O
cattle	O
,	O
and	O
humans	O
while	O
immunolocalization	O
detected	O
this	O
protein	O
in	O
developing	O
sperm	O
from	O
the	O
spermatocyte	O
stage	O
onward	O
.	O

Male	O
and	O
female	O
mice	O
homozygous	O
for	O
a	O
12	O
nucleotide	O
inframe	O
deletion	O
mutation	O
in	O
betaB2-crystallin	O
are	O
subfertile	O
when	O
analyzed	O
on	O
a	O
Swiss	O
Webster	O
derived	O
background	O
due	O
to	O
defects	O
in	O
egg	O
and	O
sperm	O
production	O
.	O

However	O
,	O
mice	O
harboring	O
the	O
same	O
mutation	O
on	O
the	O
C57Bl/6	O
genetic	O
background	O
did	O
not	O
exhibit	O
any	O
defects	O
in	O
reproductive	O
function	O
.	O

CONCLUSIONS	O
:	O
betaB2-crystallin	O
is	O
expressed	O
in	O
developing	O
and	O
mature	O
sperm	O
and	O
mice	O
of	O
both	O
sexes	O
harboring	O
the	O
Philly	O
mutation	O
in	O
the	O
betaB2-crystallin	O
gene	O
are	O
subfertile	O
when	O
analyzed	O
on	O
a	O
Swiss	O
Webster	O
genetic	O
background	O
.	O

While	O
these	O
data	O
are	O
suggestive	O
of	O
a	O
role	O
for	O
betaB2-crystallin	O
in	O
fertility	O
,	O
definitive	O
determination	O
of	O
this	O
will	O
await	O
the	O
creation	O
of	O
a	O
betaB2-crystallin	O
null	O
mouse	O
.	O

Angiotensin-converting	O
enzyme	O
(ACE)	O
serum	O
levels	O
and	O
gene	O
polymorphism	O
in	O
Egyptian	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
.	O

OBJECTIVES	O
:	O
To	O
investigate	O
the	O
association	O
of	O
angiotensin-converting	O
enzyme	O
(ACE)	O
gene	O
polymorphism	O
and	O
serum	O
ACE	O
level	O
among	O
Egyptian	O
SLE	O
patients	O
and	O
its	O
relation	O
to	O
disease	O
activity	O
parameters	O
.	O

SUBJECTS	O
AND	O
METHODS	O
:	O
We	O
enrolled	O
50	O
Egyptian	O
female	O
systemic	O
lupus	O
erythematosus	O
(SLE)	O
patients	O
and	O
29	O
healthy	O
controls	O
.	O

Measurement	O
of	O
serum	O
ACE	O
level	O
was	O
done	O
using	O
ELISA	O
,	O
and	O
the	O
ACE	O
genotype	O
was	O
determined	O
by	O
polymerase	O
chain	O
reaction	O
using	O
genomic	O
DNA	O
from	O
peripheral	O
blood	O
.	O

RESULTS	O
:	O
A	O
significant	O
difference	O
was	O
found	O
in	O
ACE	O
genotypes	O
between	O
SLE	O
patients	O
and	O
controls	O
(	O
	O
(	O
2	O
	O
	O
)=	O
	O
	O
7.84	O
,	O
p	O
	O
	O
=	O
	O
	O
0.02	O
)	O
.	O

The	O
frequency	O
of	O
ACE	O
DD	O
versus	O
(	O
DI	O
and	O
II	O
)	O
genotypes	O
was	O
significantly	O
higher	O
in	O
SLE	O
patients	O
compared	O
with	O
controls	O
(	O
	O
(	O
2	O
	O
	O
)=	O
	O
	O
5.57	O
,	O
p	O
=	O
0.018	O
and	O
OR	O
for	O
risk	O
of	O
SLE	O
was	O
3.1	O
with	O
95%	O
confidence	O
interval	O
:	O
1.198.06	O
)	O
.	O

Mean	O
serum	O
ACE	O
level	O
was	O
significantly	O
higher	O
in	O
the	O
SLE	O
group	O
compared	O
with	O
controls	O
(	O
p	O
	O
	O
=	O
	O
	O
0.006	O
)	O
.	O

Subjects	O
with	O
DD	O
genotype	O
had	O
a	O
significantly	O
higher	O
mean	O
level	O
than	O
those	O
with	O
DI	O
(	O
p	O
	O
	O
=	O
	O
	O
0.015	O
)	O
and	O
II	O
genotypes	O
(	O
p	O
	O
	O
=	O
	O
	O
0.02	O
)	O
.	O

Lupus	O
nephritis	O
patients	O
had	O
a	O
significantly	O
higher	O
frequency	O
of	O
DD	O
versus	O
DI	O
and	O
II	O
genotypes	O
compared	O
with	O
lupus	O
patients	O
without	O
nephritis	O
(	O
Fisher's	O
exact	O
test	O
,	O
p	O
	O
	O
=	O
	O
	O
0.025	O
)	O
and	O
controls	O
(	O
	O
	O
(2)	O
=8.74	O
,	O
p	O
	O
	O
=	O
	O
	O
0.003	O
)	O
.	O

SLE	O
patients	O
with	O
vasculopathy	O
had	O
a	O
significantly	O
higher	O
frequency	O
of	O
DD	O
versus	O
DI/II	O
genotypes	O
compared	O
with	O
SLE	O
patients	O
without	O
vasculopathy	O
(	O
Fisher's	O
exact	O
test	O
,	O
p	O
	O
	O
=	O
	O
	O
0.04	O
)	O
and	O
controls	O
(	O
	O
(	O
2	O
	O
	O
)=	O
	O
	O
9.84	O
and	O
p	O
	O
	O
=	O
	O
	O
0.002	O
)	O
.	O

Mean	O
serum	O
ACE	O
level	O
was	O
significantly	O
higher	O
in	O
the	O
lupus	O
nephritis	O
and	O
SLE	O
patients	O
with	O
vasculopathy	O
compared	O
with	O
controls	O
(	O
p	O
	O
	O
=	O
	O
	O
0.008	O
,	O
p	O
	O
	O
=	O
	O
	O
0.001	O
,	O
respectively	O
)	O
.	O

Significant	O
positive	O
correlations	O
were	O
found	O
between	O
serum	O
ACE	O
level	O
and	O
serum	O
creatinine	O
and	O
24	O
	O
	O
h	O
proteinuria	O
(	O
p	O
	O
	O
=	O
	O
	O
0.03	O
,	O
0.009	O
,	O
respectively	O
)	O
.	O

SLE	O
patients	O
with	O
DD	O
genotype	O
had	O
a	O
statistically	O
significant	O
higher	O
mean	O
SLEDAI	O
score	O
than	O
those	O
with	O
(DI/II)	O
genotypes	O
(	O
p	O
	O
	O
=	O
	O
	O
0.02	O
)	O
.	O

Significant	O
positive	O
correlation	O
was	O
found	O
between	O
serum	O
ACE	O
levels	O
and	O
SLEDAI	O
scores	O
(	O
p	O
	O
	O
=	O
	O
	O
0.04	O
)	O
.	O

CONCLUSION	O
:	O
ACE	O
genotype	O
and	O
subsequently	O
serum	O
ACE	O
level	O
could	O
be	O
associated	O
with	O
the	O
disease	O
activity	O
of	O
Egyptian	O
SLE	O
patients	O
;	O
in	O
addition	O
,	O
ACE	O
deletion	O
polymorphism	O
might	O
be	O
used	O
as	O
one	O
of	O
the	O
predictive	O
factors	O
for	O
the	O
activity	O
of	O
SLE	O
.	O

Further	O
studies	O
on	O
a	O
larger	O
number	O
of	O
patients	O
should	O
be	O
done	O
to	O
determine	O
the	O
exact	O
prevalence	O
of	O
ACE	O
gene	O
polymorphism	O
among	O
Egyptian	O
SLE	O
patients	O
.	O

Spectrum	O
of	O
mutations	O
in	O
the	O
arylsulfatase	O
A	O
gene	O
in	O
a	O
Canadian	O
DNA	O
collection	O
including	O
two	O
novel	O
frameshift	O
mutations	O
,	O
a	O
new	O
missense	O
mutation	O
(	O
arginine	B-ProteinMutation
555-to-tryptophan	I-ProteinMutation
)	O
and	O
an	O
MLD	O
mutation	O
(	O
histidine	B-ProteinMutation
626-to-arginine	I-ProteinMutation
)	O
in	O
cis	O
with	O
a	O
pseudodeficiency	O
allele	O
.	O

We	O
describe	O
three	O
novel	O
mutations	O
in	O
the	O
human	O
arylsulfatase	O
A	O
gene	O
in	O
three	O
patients	O
with	O
MLD	O
,	O
an	O
autosomal	O
recessive	O
lysosomal	O
storage	O
disorder	O
.	O

An	O
insertion	O
,	O
GTT-->GCT	B-DNAMutation
transition	I-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
23	I-DNAMutation
in	O
exon	O
8	O
and	O
a	O
deletion	O
,	O
A	B-DNAMutation
>	I-DNAMutation
G	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
313	I-DNAMutation
,	O
in	O
exon	O
3	O
will	O
both	O
result	O
in	O
frameshifts	O
.	O

A	O
mutation	O
in	O
exon	O
8	O
,	O
TAC-->AA	B-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
329	I-DNAMutation
,	O
results	O
in	O
a	O
missense	O
mutation	O
arginine	B-ProteinMutation
124-to-cysteine	I-ProteinMutation
,	O
disrupting	O
an	O
unusual	O
cysteine-knot	O
at	O
the	O
C-terminal	O
end	O
of	O
the	O
protein	O
.	O

All	O
three	O
mutations	O
are	O
heterozygous	O
with	O
previously	O
documented	O
mutations	O
.	O

A	O
previously	O
reported	O
mutation	O
,	O
Phe-->Ser	B-ProteinMutation
at	I-ProteinMutation
codon	I-ProteinMutation
15	I-ProteinMutation
was	O
identified	O
on	O
a	O
pseudodeficiency	O
allele	O
.	O

These	O
mutations	O
are	O
part	O
of	O
a	O
heterogeneous	O
spectrum	O
of	O
mutations	O
found	O
in	O
a	O
collection	O
of	O
DNA	O
samples	O
from	O
MLD	O
patients	O
from	O
across	O
Canada	O
and	O
the	O
USA	O
.	O

Role	O
of	O
homozygous	O
DC-SIGNR	O
5/5	O
tandem	O
repeat	O
polymorphism	O
in	O
HIV-1	O
exposed	O
seronegative	O
North	O
Indian	O
individuals	O
.	O

Despite	O
multiple	O
sexual	O
exposures	O
to	O
HIV-1	O
virus	O
,	O
some	O
individuals	O
remain	O
HIV-1	O
seronegative	O
.	O

Although	O
several	O
genetic	O
factors	O
have	O
been	O
related	O
to	O
HIV-1	O
resistance	O
,	O
the	O
homozygosity	O
for	O
a	O
mutation	O
in	O
CCR5	O
gene	O
(	O
the	O
32-bp	O
deletion	O
,	O
i.e.	O
,	O
CCR5--AAGC	B-DNAMutation
at	I-DNAMutation
-222	I-DNAMutation
to	I-DNAMutation
-225	I-DNAMutation
allele	O
)	O
is	O
presently	O
considered	O
the	O
most	O
relevant	O
one	O
.	O

The	O
C-type	O
lectins	O
,	O
DC-SIGN	O
(	O
present	O
on	O
dendritic	O
cells	O
and	O
macrophages	O
)	O
and	O
DC-SIGNR	O
(	O
present	O
on	O
endothelial	O
cells	O
in	O
liver	O
and	O
lymph	O
nodes	O
)	O
efficiently	O
bind	O
and	O
transmit	O
HIV-1	O
to	O
susceptible	O
cell	O
in	O
trans	O
,	O
thereby	O
augmenting	O
the	O
infection	O
.	O

A	O
potential	O
association	O
of	O
the	O
DC-SIGN	O
and	O
DC-SIGNR	O
neck	O
domain	O
repeat	O
polymorphism	O
and	O
risk	O
of	O
HIV-1	O
infection	O
is	O
currently	O
under	O
debate	O
.	O

To	O
determine	O
the	O
influence	O
of	O
host	O
genetic	O
factors	O
on	O
HIV-1	O
resistance	O
,	O
we	O
conducted	O
genetic	O
risk	O
association	O
study	O
in	O
HIV-1-exposed	O
seronegative	O
(	O
n	O
=	O
47	O
)	O
individuals	O
,	O
HIV-1	O
seronegative	O
(	O
n	O
=	O
262	O
)	O
healthy	O
control	O
,	O
and	O
HIV-1-infected	O
seropositive	O
patients	O
(	O
n	O
=	O
168	O
)	O
for	O
polymorphism	O
in	O
neck	O
domain	O
of	O
DC-SIGN	O
and	O
DC-SIGNR	O
genes	O
.	O

The	O
DC-SIGN	O
and	O
DC-SIGNR	O
genotypes	O
were	O
identified	O
by	O
polymerase	O
chain	O
reaction	O
method	O
in	O
DNA	O
extracted	O
from	O
peripheral	O
blood	O
and	O
confirmed	O
by	O
sequencing	O
.	O

Fisher	O
exact	O
or	O
chi	O
(2)	O
test	O
was	O
used	O
for	O
static	O
analysis	O
.	O

DC-SIGN	O
genotype	O
and	O
allele	O
distribution	O
was	O
fairly	O
similar	O
in	O
HIV-1-exposed	O
seronegative	O
,	O
HIV-1	O
seropositive	O
,	O
and	O
HIV-1	O
seronegative	O
control	O
.	O

There	O
was	O
no	O
statistical	O
significance	O
in	O
the	O
differences	O
in	O
the	O
distribution	O
of	O
DC-SIGN	O
genotypes	O
.	O

A	O
total	O
of	O
13	O
genotypes	O
were	O
found	O
in	O
DC-SIGNR	O
neck	O
repeat	O
region	O
polymorphism	O
.	O

Among	O
all	O
the	O
genotypes	O
,	O
only	O
5/5	O
homozygous	O
showed	O
significant	O
reduced	O
risk	O
of	O
HIV-1	O
infection	O
in	O
HIV-1-exposed	O
seronegative	O
individuals	O
(	O
p	O
=	O
0.009	O
)	O
.	O

A	O
unique	O
genotype	O
8/5	O
heterozygous	O
was	O
also	O
found	O
in	O
HIV-1	O
seropositive	O
individual	O
,	O
which	O
is	O
not	O
reported	O
elsewhere	O
.	O

Identification	O
of	O
a	O
frameshift	O
mutation	O
in	O
Osterix	O
in	O
a	O
patient	O
with	O
recessive	O
osteogenesis	O
imperfecta	O
.	O

Osteogenesis	O
imperfecta	O
,	O
or	O
"brittle	O
bone	O
disease,"	O
is	O
a	O
type	O
I	O
collagen-related	O
condition	O
associated	O
with	O
osteoporosis	O
and	O
increased	O
risk	O
of	O
bone	O
fractures	O
.	O

Using	O
a	O
combination	O
of	O
homozygosity	O
mapping	O
and	O
candidate	O
gene	O
approach	O
,	O
we	O
have	O
identified	O
a	O
homozygous	O
single	O
base	O
pair	O
deletion	O
(	O
-491	B-DNAMutation
A	I-DNAMutation
to	I-DNAMutation
T	I-DNAMutation
)	O
in	O
SP7/Osterix	O
(OSX)	O
in	O
an	O
Egyptian	O
child	O
with	O
recessive	O
osteogenesis	O
imperfecta	O
.	O

The	O
clinical	O
findings	O
from	O
this	O
patient	O
include	O
recurrent	O
fractures	O
,	O
mild	O
bone	O
deformities	O
,	O
delayed	O
tooth	O
eruption	O
,	O
normal	O
hearing	O
,	O
and	O
white	O
sclera	O
.	O

OSX	O
encodes	O
a	O
transcription	O
factor	O
containing	O
three	O
Cys2-His2	O
zinc-finger	O
DNA-binding	O
domains	O
at	O
its	O
C	O
terminus	O
,	O
which	O
,	O
in	O
mice	O
,	O
has	O
been	O
shown	O
to	O
be	O
essential	O
for	O
bone	O
formation	O
.	O

The	O
frameshift	O
caused	O
by	O
the	O
G>A	B-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
+1	I-DNAMutation
of	I-DNAMutation
intron	I-DNAMutation
2	I-DNAMutation
deletion	O
removes	O
the	O
last	O
81	O
amino	O
acids	O
of	O
the	O
protein	O
,	O
including	O
the	O
third	O
zinc-finger	O
motif	O
.	O

This	O
finding	O
adds	O
another	O
locus	O
to	O
the	O
spectrum	O
of	O
genes	O
associated	O
with	O
osteogenesis	O
imperfecta	O
and	O
reveals	O
that	O
SP7/OSX	O
also	O
plays	O
a	O
key	O
role	O
in	O
human	O
bone	O
development	O
.	O

Resequencing	O
of	O
IRS2	O
reveals	O
rare	O
variants	O
for	O
obesity	O
but	O
not	O
fasting	O
glucose	O
homeostasis	O
in	O
Hispanic	O
children	O
.	O

Our	O
objective	O
was	O
to	O
resequence	O
insulin	O
receptor	O
substrate	O
2	O
(IRS2)	O
to	O
identify	O
variants	O
associated	O
with	O
obesity-	O
and	O
diabetes-related	O
traits	O
in	O
Hispanic	O
children	O
.	O

Exonic	O
and	O
intronic	O
segments	O
,	O
5'	O
and	O
3'	O
flanking	O
regions	O
of	O
IRS2	O
(	O
	O
	O
14.5	O
kb	O
)	O
,	O
were	O
bidirectionally	O
sequenced	O
for	O
single	O
nucleotide	O
polymorphism	O
(SNP)	O
discovery	O
in	O
934	O
Hispanic	O
children	O
using	O
3730XL	O
DNA	O
Sequencers	O
.	O

Additionally	O
,	O
15	O
SNPs	O
derived	O
from	O
Illumina	O
HumanOmni1-Quad	O
BeadChips	O
were	O
analyzed	O
.	O

Measured	O
genotype	O
analysis	O
tested	O
associations	O
between	O
SNPs	O
and	O
obesity	O
and	O
diabetes-related	O
traits	O
.	O

Bayesian	O
quantitative	O
trait	O
nucleotide	O
analysis	O
was	O
used	O
to	O
statistically	O
infer	O
the	O
most	O
likely	O
functional	O
polymorphisms	O
.	O

A	O
total	O
of	O
140	O
SNPs	O
were	O
identified	O
with	O
minor	O
allele	O
frequencies	O
(MAF)	O
ranging	O
from	O
0.001	O
to	O
0.47	O
.	O

Forty-two	O
of	O
the	O
70	O
coding	O
SNPs	O
result	O
in	O
nonsynonymous	O
amino	O
acid	O
substitutions	O
relative	O
to	O
the	O
consensus	O
sequence	O
;	O
28	O
SNPs	O
were	O
detected	O
in	O
the	O
promoter	O
,	O
12	O
in	O
introns	O
,	O
28	O
in	O
the	O
3'-UTR	O
,	O
and	O
2	O
in	O
the	O
5'-UTR	O
.	O

Two	O
insertion/deletions	O
(indels)	O
were	O
detected	O
.	O

Ten	O
independent	O
rare	O
SNPs	O
(	O
MAF	O
=	O
0.001-0.009	O
)	O
were	O
associated	O
with	O
obesity-related	O
traits	O
(	O
P	O
=	O
0.01-0.00002	O
)	O
.	O

SNP	O
10510452_139	O
in	O
the	O
promoter	O
region	O
was	O
shown	O
to	O
have	O
a	O
high	O
posterior	O
probability	O
(	O
P	O
=	O
0.77-0.86	O
)	O
of	O
influencing	O
BMI	O
,	O
fat	O
mass	O
,	O
and	O
waist	O
circumference	O
in	O
Hispanic	O
children	O
.	O

SNP	O
10510452_139	O
contributed	O
between	O
2	O
and	O
4%	O
of	O
the	O
population	O
variance	O
in	O
body	O
weight	O
and	O
composition	O
.	O

None	O
of	O
the	O
SNPs	O
or	O
indels	O
were	O
associated	O
with	O
diabetes-related	O
traits	O
or	O
accounted	O
for	O
a	O
previously	O
identified	O
quantitative	O
trait	O
locus	O
on	O
chromosome	O
13	O
for	O
fasting	O
serum	O
glucose	O
.	O

Rare	O
but	O
not	O
common	O
IRS2	O
variants	O
may	O
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
body	O
weight	O
but	O
not	O
an	O
essential	O
role	O
in	O
fasting	O
glucose	O
homeostasis	O
in	O
Hispanic	O
children	O
.	O

Loss	O
of	O
heterozygosity	O
and	O
transcriptome	O
analyses	O
of	O
a	O
1.2	O
Mb	O
candidate	O
ovarian	O
cancer	O
tumor	O
suppressor	O
locus	O
region	O
at	O
17q25.1-q25.2	O
.	O

Loss	O
of	O
heterozygosity	O
(LOH)	O
analysis	O
was	O
performed	O
in	O
epithelial	O
ovarian	O
cancers	O
(EOC)	O
to	O
further	O
characterize	O
a	O
previously	O
identified	O
candidate	O
tumor	O
suppressor	O
gene	O
(TSG)	O
region	O
encompassing	O
D17S801	O
at	O
chromosomal	O
region	O
17q25.1	O
.	O

LOH	O
of	O
at	O
least	O
one	O
informative	O
marker	O
was	O
observed	O
for	O
100	O
(71%)	O
of	O
140	O
malignant	O
EOC	O
samples	O
in	O
an	O
analysis	O
of	O
6	O
polymorphic	O
markers	O
(cen-D17S1839-D17S785-D17S1817-D17S801-D17S751-D17S722-tel)	O
.	O

The	O
combined	O
LOH	O
analysis	O
revealed	O
a	O
453	O
kilobase	O
(Kb)	O
minimal	O
region	O
of	O
deletion	O
(MRD)	O
bounded	O
by	O
D17S1817	O
and	O
D17S751	O
.	O

Human	O
and	O
mouse	O
genome	O
assemblies	O
were	O
used	O
to	O
resolve	O
marker	O
inconsistencies	O
in	O
the	O
D17S1839-D17S722	O
interval	O
and	O
identify	O
candidates	O
.	O

The	O
region	O
contains	O
32	O
known	O
and	O
strongly	O
predicted	O
genes	O
,	O
9	O
of	O
which	O
overlap	O
the	O
MRD	O
.	O

The	O
reference	O
genomic	O
sequences	O
share	O
nearly	O
identical	O
gene	O
structures	O
and	O
the	O
organization	O
of	O
the	O
region	O
is	O
highly	O
collinear	O
.	O

Although	O
,	O
the	O
region	O
does	O
not	O
show	O
any	O
large	O
internal	O
duplications	O
,	O
a	O
1.5	O
Kb	O
inverted	O
duplicated	O
sequence	O
of	O
87%	O
nucleotide	O
identity	O
was	O
observed	O
in	O
a	O
13	O
Kb	O
region	O
surrounding	O
D17S801	O
.	O

Transcriptome	O
analysis	O
by	O
Affymetrix	O
GeneChip	O
and	O
reverse	O
transcription	O
(RT)-polymerase	O
chain	O
reaction	O
(PCR)	O
methods	O
of	O
3	O
well	O
characterized	O
EOC	O
cell	O
lines	O
and	O
primary	O
cultures	O
of	O
normal	O
ovarian	O
surface	O
epithelial	O
(NOSE)	O
cells	O
was	O
performed	O
with	O
32	O
candidates	O
spanning	O
D17S1839-D17S722	O
interval	O
.	O

RT-PCR	O
analysis	O
of	O
8	O
known	O
or	O
strongly	O
predicted	O
genes	O
residing	O
in	O
the	O
MRD	O
in	O
10	O
EOC	O
samples	O
,	O
that	O
exhibited	O
LOH	O
of	O
the	O
MRD	O
,	O
identified	O
FLJ22341	O
as	O
a	O
strong	O
candidate	O
TSG	O
.	O

The	O
proximal	O
repeat	O
sequence	O
of	O
D17S801	O
occurs	O
8	O
Kb	O
upstream	O
of	O
the	O
putative	O
promoter	O
region	O
of	O
FLJ22341	O
.	O

RT-PCR	O
analysis	O
of	O
the	O
EOC	O
samples	O
and	O
cell	O
lines	O
identified	O
DKFZP434P0316	O
that	O
maps	O
proximal	O
to	O
the	O
MRD	O
,	O
as	O
a	O
candidate	O
.	O

While	O
Affymetrix	O
technology	O
was	O
useful	O
for	O
initially	O
eliminating	O
less	O
promising	O
candidates	O
,	O
subsequent	O
RT-PCR	O
analysis	O
of	O
well-characterized	O
EOC	O
samples	O
was	O
essential	O
to	O
prioritize	O
TSG	O
candidates	O
for	O
further	O
study	O
.	O

An	O
improved	O
tetra-primer	O
PCR	O
approach	O
for	O
the	O
detection	O
of	O
the	O
FGFR3	O
Glu	B-ProteinMutation
272	I-ProteinMutation
to	I-ProteinMutation
stop	I-ProteinMutation
mutation	O
responsible	O
for	O
achondroplasia	O
.	O

Achondroplasia	O
is	O
the	O
most	O
common	O
form	O
of	O
dwarfism	O
and	O
has	O
an	O
incidence	O
of	O
approximately	O
1/7500	O
.	O

In	O
more	O
than	O
98%	O
of	O
cases	O
,	O
the	O
disease	O
is	O
associated	O
with	O
a	O
G	O
to	O
A	O
or	O
G	O
to	O
C	O
substitution	O
at	O
nucleotide	O
position	O
1138	O
(	O
methionine-->valine	B-ProteinMutation
substitution	I-ProteinMutation
at	I-ProteinMutation
codon	I-ProteinMutation
404	I-ProteinMutation
)	O
of	O
the	O
fibroblast	O
growth	O
factor	O
receptor	O
3	O
(FGFR3)	O
gene	O
.	O

We	O
have	O
developed	O
a	O
sensitive	O
single	O
tube	O
tetra-primer	O
PCR	O
assay	O
to	O
detect	O
both	O
the	O
(	B-DNAMutation
G	I-DNAMutation
-->	I-DNAMutation
C	I-DNAMutation
)	I-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
1201	I-DNAMutation
and	O
(	B-DNAMutation
T	I-DNAMutation
-->	I-DNAMutation
C	I-DNAMutation
)	I-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
2209	I-DNAMutation
mutations	O
and	O
can	O
successfully	O
distinguish	O
DNA	O
samples	O
that	O
are	O
homozygous	O
and	O
heterozygous	O
for	O
the	O
G>T	B-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
c.898	I-DNAMutation
mutation	O
.	O

Titration	O
studies	O
showed	O
that	O
the	O
assay	O
could	O
reliably	O
detect	O
one	O
copy	O
of	O
the	O
mutant	O
allele	O
in	O
a	O
mix	O
of	O
100	O
wild-type	O
alleles	O
.	O

The	O
assay	O
has	O
been	O
tested	O
in	O
50	O
healthy	O
controls	O
,	O
3	O
known	O
patients	O
with	O
achondroplasia	O
,	O
and	O
5	O
amniotic	O
fluids	O
suspected	O
of	O
having	O
achondroplasia	O
and	O
for	O
whom	O
we	O
had	O
previously	O
determined	O
the	O
genotypes	O
for	O
the	O
C-->T	B-DNAMutation
transversion	I-DNAMutation
at	I-DNAMutation
cDNA	I-DNAMutation
base	I-DNAMutation
463	I-DNAMutation
mutation	O
by	O
PCR-RFLP	O
.	O

We	O
have	O
observed	O
complete	O
concordance	O
between	O
methods	O
.	O

Our	O
tetra-primer	O
PCR	O
assay	O
is	O
sensitive	O
,	O
low-cost	O
,	O
and	O
easy	O
to	O
use	O
method	O
for	O
FGFR3	O
Ser-->Cys	B-ProteinMutation
substitution	I-ProteinMutation
at	I-ProteinMutation
the	I-ProteinMutation
codon	I-ProteinMutation
326	I-ProteinMutation
genotyping	O
,	O
which	O
could	O
be	O
used	O
even	O
in	O
"low-tech"	O
laboratories	O
.	O

Roles	O
of	O
G1359A	O
polymorphism	O
of	O
the	O
cannabinoid	O
receptor	O
gene	O
(CNR1)	O
on	O
weight	O
loss	O
and	O
adipocytokines	O
after	O
a	O
hypocaloric	O
diet	O
.	O

BACKGROUND	O
:	O
A	O
intragenic	O
biallelic	O
polymorphism	O
(	O
G>A	B-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
+1	I-DNAMutation
of	I-DNAMutation
intron	I-DNAMutation
2	I-DNAMutation
)	O
of	O
the	O
CB1	O
gene	O
resulting	O
in	O
the	O
substitution	O
of	O
the	O
G	O
to	O
A	O
at	O
nucleotide	O
position	O
1359	O
in	O
codon	O
435	O
(Thr)	O
,	O
was	O
reported	O
as	O
a	O
common	O
polymorphism	O
in	O
Caucasian	O
populations	O
.	O

Intervention	O
studies	O
with	O
this	O
polymorphism	O
have	O
not	O
been	O
realized	O
.	O

OBJECTIVE	O
:	O
We	O
decided	O
to	O
investigate	O
the	O
role	O
of	O
the	O
polymorphism	O
(G1359A)	O
of	O
CB1	O
receptor	O
gene	O
on	O
adipocytokines	O
response	O
and	O
weight	O
loss	O
secondary	O
to	O
a	O
lifestyle	O
modification	O
(	O
Mediterranean	O
hypocaloric	O
diet	O
and	O
exercise	O
)	O
in	O
obese	O
patients	O
.	O

DESIGN	O
:	O
A	O
population	O
of	O
94	O
patients	O
with	O
obesity	O
was	O
analyzed	O
.	O

Before	O
and	O
after	O
3	O
months	O
on	O
a	O
hypocaloric	O
diet	O
,	O
an	O
anthropometric	O
evaluation	O
,	O
an	O
assessment	O
of	O
nutritional	O
intake	O
and	O
a	O
biochemical	O
analysis	O
were	O
performed	O
.	O

The	O
statistical	O
analysis	O
was	O
performed	O
for	O
the	O
combined	O
G1359A	O
and	O
A1359A	O
as	O
a	O
group	O
and	O
wild	O
type	O
G1359G	O
as	O
second	O
group	O
,	O
with	O
a	O
dominant	O
model	O
.	O

Results	O
:	O
Forty	O
seven	O
patients	O
(50%)	O
had	O
the	O
genotype	O
G1359G	O
(	O
wild	O
type	O
group	O
)	O
and	O
47	O
(50%)	O
patients	O
G1359A	O
(	O
41	O
patients	O
,	O
43.6%	O
)	O
or	O
A1359A	O
(	O
6	O
patients	O
,	O
6.4%	O
)	O
(	O
mutant	O
type	O
group	O
)	O
had	O
the	O
genotype	O
.	O

In	O
wild	O
and	O
mutant	O
type	O
groups	O
,	O
weight	O
,	O
body	O
mass	O
index	O
,	O
fat	O
mass	O
,	O
waist	O
circumference	O
and	O
systolic	O
blood	O
pressure	O
decreased	O
.	O

In	O
mutant	O
type	O
group	O
,	O
resistin	O
(	O
4.15	O
	O
	O
	O
1.7	O
ng/ml	O
vs	O
.	O

3.90	O
	O
	O
	O
2.1	O
ng/ml	O
:	O
P	O
<	O
0.05	O
)	O
,	O
leptin	O
(	O
78.4	O
	O
	O
	O
69	O
ng/ml	O
vs	O
66.2	O
	O
	O
	O
32	O
ng/ml	O
:	O
P	O
<	O
0.05	O
)	O
and	O
IL-6	O
(	O
1.40	O
	O
	O
	O
1.9	O
pg/ml	O
vs	O
0.81	O
	O
	O
	O
1.5	O
pg/ml	O
:	O
P	O
<	O
0.05	O
)	O
levels	O
decreased	O
after	O
dietary	O
treatment	O
.	O

CONCLUSION	O
:	O
The	O
novel	O
finding	O
of	O
this	O
study	O
is	O
the	O
association	O
of	O
the	O
mutant	O
allele	O
(A1359)	O
with	O
a	O
decrease	O
of	O
resistin	O
,	O
leptin	O
and	O
interleukin-6	O
secondary	O
to	O
weight	O
loss	O
.	O

A	O
single-nucleotide	O
polymorphism	O
in	O
the	O
5'-untranslated	O
region	O
of	O
the	O
hPER2	O
gene	O
is	O
associated	O
with	O
diurnal	O
preference	O
.	O

The	O
PERIOD2	O
(PER2)	O
gene	O
is	O
a	O
key	O
component	O
of	O
the	O
molecular	O
mechanism	O
that	O
generates	O
circadian	O
rhythms	O
in	O
mammals	O
.	O

A	O
missense	O
mutation	O
in	O
the	O
human	O
PER2	O
gene	O
has	O
previously	O
been	O
linked	O
to	O
advanced	O
sleep	O
phase	O
syndrome	O
(ASPS)	O
.	O

We	O
have	O
investigated	O
three	O
other	O
single-nucleotide	O
polymorphisms	O
in	O
the	O
hPER2	O
gene	O
,	O
one	O
downstream	O
of	O
the	O
transcription	O
start	O
site	O
(	O
(	B-DNAMutation
G	I-DNAMutation
-->	I-DNAMutation
C	I-DNAMutation
)	I-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
1201	I-DNAMutation
)	O
,	O
one	O
in	O
exon	O
2	O
in	O
the	O
5'-untranslated	O
region	O
(5'-UTR)	O
(	O
(	B-DNAMutation
T	I-DNAMutation
-->	I-DNAMutation
C	I-DNAMutation
)	I-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
2209	I-DNAMutation
)	O
,	O
and	O
one	O
missense	O
mutation	O
(	O
G>T	B-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
c.898	I-DNAMutation
)	O
causing	O
a	O
glycine	O
to	O
glutamine	O
substitution	O
in	O
the	O
predicted	O
protein	O
.	O

Subjects	O
selected	O
from	O
a	O
group	O
of	O
484	O
volunteers	O
for	O
extreme	O
morning	O
or	O
evening	O
preference	O
,	O
or	O
intermediate	O
diurnal	O
preference	O
were	O
genotyped	O
with	O
regard	O
to	O
the	O
three	O
polymorphisms	O
(	O
n=35	O
for	O
each	O
group	O
)	O
.	O

Whereas	O
allele	O
frequencies	O
for	O
the	O
other	O
two	O
polymorphisms	O
did	O
not	O
differ	O
significantly	O
between	O
any	O
of	O
the	O
groups	O
,	O
the	O
111G	O
allele	O
frequency	O
was	O
significantly	O
higher	O
in	O
subjects	O
with	O
extreme	O
morning	O
preference	O
(0.14)	O
than	O
in	O
subjects	O
with	O
extreme	O
evening	O
preference	O
(0.03)	O
(	O
Fisher's	O
exact	O
test	O
,	O
two-sided	O
P	O
value=0.031	O
,	O
odds	O
ratio=5.67	O
)	O
.	O

No	O
significant	O
difference	O
in	O
111G	O
allele	O
frequency	O
was	O
observed	O
between	O
either	O
of	O
these	O
groups	O
and	O
subjects	O
with	O
intermediate	O
diurnal	O
preference	O
.	O

Computer	O
prediction	O
indicated	O
that	O
the	O
C-->T	B-DNAMutation
transversion	I-DNAMutation
at	I-DNAMutation
cDNA	I-DNAMutation
base	I-DNAMutation
463	I-DNAMutation
polymorphism	O
,	O
which	O
occurs	O
12	O
bases	O
upstream	O
from	O
the	O
translation	O
start	O
codon	O
,	O
might	O
alter	O
the	O
secondary	O
structure	O
of	O
the	O
transcript	O
.	O

The	O
PER2	O
111G	O
allele	O
associates	O
with	O
morning	O
preference	O
and	O
is	O
a	O
potential	O
candidate	O
allele	O
for	O
ASPS	O
.	O

A	O
novel	O
single-nucleotide	O
substitution	O
,	O
arginine	B-ProteinMutation
555-to-tryptophan	I-ProteinMutation
,	O
in	O
the	O
leukotriene	O
C4	O
synthase	O
gene	O
associated	O
with	O
allergic	O
diseases	O
.	O

Cysteinyl	O
leukotrienes	O
(cysLTs)	O
play	O
important	O
roles	O
in	O
bronchial	O
asthma	O
,	O
and	O
can	O
mediate	O
bronchial	O
smooth	O
muscle	O
constriction	O
and	O
increase	O
mucous	O
secretion	O
,	O
vascular	O
permeability	O
and	O
cellular	O
infiltration	O
.	O

We	O
identified	O
a	O
novel	O
heterozygous	O
single-nucleotide	O
substitution	O
G-->C	B-DNAMutation
transversion	I-DNAMutation
at	I-DNAMutation
1245	I-DNAMutation
position	I-DNAMutation
(	O
histidine	B-ProteinMutation
626-to-arginine	I-ProteinMutation
)	O
in	O
the	O
first	O
exon	O
of	O
the	O
leukotriene	O
C4	O
synthase	O
gene	O
(LTC4S)	O
.	O

This	O
substitution	O
was	O
detected	O
in	O
5	O
of	O
141	O
allergic	O
patients	O
,	O
but	O
not	O
in	O
110	O
nonallergic	O
subjects	O
.	O

There	O
was	O
a	O
difference	O
in	O
the	O
arginine	B-ProteinMutation
124-to-cysteine	I-ProteinMutation
frequency	O
between	O
the	O
allergic	O
patients	O
and	O
nonallergic	O
subjects	O
(	O
Fisher's	O
exact	O
test	O
,	O
p=0.0460	O
)	O
.	O

The	O
five	O
patients	O
with	O
arginine	B-ProteinMutation
555-to-tryptophan	I-ProteinMutation
had	O
allergic	O
diseases	O
such	O
as	O
bronchial	O
asthma	O
and/or	O
allergic	O
dermatitis	O
.	O

Furthermore	O
,	O
a	O
familial	O
analysis	O
of	O
histidine	B-ProteinMutation
626-to-arginine	I-ProteinMutation
revealed	O
a	O
link	O
with	O
allergic	O
diseases	O
.	O

Thus	O
,	O
our	O
results	O
suggest	O
that	O
arginine	B-ProteinMutation
124-to-cysteine	I-ProteinMutation
in	O
the	O
LTC4S	O
might	O
be	O
associated	O
with	O
allergic	O
diseases	O
.	O

Tenomodulin	O
is	O
associated	O
with	O
obesity	O
and	O
diabetes	O
risk	O
:	O
the	O
Finnish	O
diabetes	O
prevention	O
study	O
.	O

We	O
recently	O
showed	O
that	O
long-term	O
weight	O
reduction	O
changes	O
the	O
gene	O
expression	O
profile	O
of	O
adipose	O
tissue	O
in	O
overweight	O
individuals	O
with	O
impaired	O
glucose	O
tolerance	O
(IGT)	O
.	O

One	O
of	O
the	O
responding	O
genes	O
was	O
X-chromosomal	O
tenomodulin	O
(TNMD)	O
,	O
a	O
putative	O
angiogenesis	O
inhibitor	O
.	O

Our	O
aim	O
was	O
to	O
study	O
the	O
associations	O
of	O
individual	O
single	O
nucleotide	O
polymorphisms	O
and	O
haplotypes	O
with	O
adiposity	O
,	O
glucose	O
metabolism	O
,	O
and	O
the	O
risk	O
of	O
type	O
2	O
diabetes	O
(T2D)	O
.	O

Seven	O
single	O
nucleotide	O
polymorphisms	O
from	O
two	O
different	O
haploblocks	O
were	O
genotyped	O
from	O
507	O
participants	O
of	O
the	O
Finnish	O
Diabetes	O
Prevention	O
Study	O
(DPS)	O
.	O

Sex-specific	O
genotype	O
effects	O
were	O
observed	O
.	O

Three	O
markers	O
of	O
haploblock	O
1	O
were	O
associated	O
with	O
features	O
of	O
adiposity	O
in	O
women	O
(	O
rs5966709	O
,	O
rs4828037	O
)	O
and	O
men	O
(rs11798018)	O
.	O

Markers	O
rs2073163	O
and	O
rs1155794	O
from	O
haploblock	O
2	O
were	O
associated	O
with	O
2-hour	O
plasma	O
glucose	O
levels	O
in	O
men	O
during	O
the	O
3-year	O
follow-up	O
.	O

The	O
same	O
two	O
markers	O
together	O
with	O
rs2073162	O
associated	O
with	O
the	O
conversion	O
of	O
IGT	O
to	O
T2D	O
in	O
men	O
.	O

The	O
risk	O
of	O
developing	O
T2D	O
was	O
approximately	O
2-fold	O
in	O
individuals	O
with	O
genotypes	O
associated	O
with	O
higher	O
2-hour	O
plasma	O
glucose	O
levels	O
;	O
the	O
hazard	O
ratios	O
were	O
2.192	O
(	O
p	O
=	O
0.025	O
)	O
for	O
rs2073162-A	O
,	O
2.191	O
(	O
p	O
=	O
0.027	O
)	O
for	O
rs2073163-C	O
,	O
and	O
1.998	O
(	O
p	O
=	O
0.054	O
)	O
for	O
rs1155974-T	O
.	O

These	O
results	O
suggest	O
that	O
TNMD	O
polymorphisms	O
are	O
associated	O
with	O
adiposity	O
and	O
also	O
with	O
glucose	O
metabolism	O
and	O
conversion	O
from	O
IGT	O
to	O
T2D	O
in	O
men	O
.	O

cAMP	O
sensitivity	O
of	O
HCN	O
pacemaker	O
channels	O
determines	O
basal	O
heart	O
rate	O
but	O
is	O
not	O
critical	O
for	O
autonomic	O
rate	O
control	O
.	O

BACKGROUND	O
:	O
HCN	O
channels	O
activate	O
the	O
pacemaker	O
current	O
I(f)	O
,	O
which	O
is	O
thought	O
to	O
contribute	O
significantly	O
to	O
generation	O
and	O
regulation	O
of	O
heart	O
rhythm	O
.	O

HCN4	O
represents	O
the	O
dominant	O
isotype	O
in	O
the	O
sinoatrial	O
node	O
and	O
binding	O
of	O
cAMP	O
was	O
suggested	O
to	O
be	O
necessary	O
for	O
autonomic	O
heart	O
rate	O
regulation	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
In	O
a	O
candidate	O
gene	O
approach	O
,	O
a	O
heterozygous	O
insertion	O
of	O
13	O
nucleotides	O
in	O
exon	O
6	O
of	O
the	O
HCN4	O
gene	O
leading	O
to	O
a	O
truncated	O
cyclic	O
nucleotide-binding	O
domain	O
was	O
identified	O
in	O
a	O
45-year-old	O
woman	O
with	O
sinus	O
bradycardia	O
.	O

Biophysical	O
properties	O
determined	O
by	O
whole-cell	O
patch-clamp	O
recording	O
of	O
HEK293	O
cells	O
demonstrated	O
that	O
mutant	O
subunits	O
(HCN4-695X)	O
were	O
insensitive	O
to	O
cAMP	O
.	O

Heteromeric	O
channels	O
composed	O
of	O
wild-type	O
and	O
mutant	O
subunits	O
failed	O
to	O
respond	O
to	O
cAMP-like	O
homomeric	O
mutant	O
channels	O
,	O
indicating	O
a	O
dominant-negative	O
suppression	O
of	O
cAMP-induced	O
channel	O
activation	O
by	O
mutant	O
subunits	O
.	O

Pedigree	O
analysis	O
identified	O
7	O
additional	O
living	O
carriers	O
showing	O
similar	O
clinical	O
phenotypes	O
,	O
that	O
is	O
,	O
sinus	O
node	O
dysfunction	O
with	O
mean	O
resting	O
heart	O
rate	O
of	O
45.9	O
	O
4.6	O
bpm	O
(n=8)	O
compared	O
with	O
66.5	O
	O
9.1	O
bpm	O
of	O
unaffected	O
relatives	O
(	O
n=6	O
;	O
P<0.01	O
)	O
.	O

Clinical	O
evaluation	O
revealed	O
no	O
ischemic	O
or	O
structural	O
heart	O
disease	O
in	O
any	O
family	O
member	O
.	O

Importantly	O
,	O
mutant	O
carriers	O
exhibited	O
normal	O
heart	O
rate	O
variance	O
and	O
full	O
ability	O
to	O
accelerate	O
heart	O
rate	O
under	O
physical	O
activity	O
or	O
pharmacological	O
stimulation	O
.	O

Moreover	O
,	O
mutant	O
carriers	O
displayed	O
distinctive	O
sinus	O
arrhythmias	O
and	O
premature	O
beats	O
linked	O
to	O
adrenergic	O
stress	O
.	O

CONCLUSIONS	O
:	O
In	O
humans	O
,	O
cAMP	O
responsiveness	O
of	O
I(f)	O
determines	O
basal	O
heart	O
rate	O
but	O
is	O
not	O
critical	O
for	O
maximum	O
heart	O
rate	O
,	O
heart	O
rate	O
variability	O
,	O
or	O
chronotropic	O
competence	O
.	O

Furthermore	O
,	O
cAMP-activated	O
I(f)	O
may	O
stabilize	O
heart	O
rhythm	O
during	O
chronotropic	O
response	O
.	O

A	O
single	O
nucleotide	O
polymorphism	O
in	O
the	O
IRF5	O
promoter	O
region	O
is	O
associated	O
with	O
susceptibility	O
to	O
rheumatoid	O
arthritis	O
in	O
the	O
Japanese	O
population	O
.	O

OBJECTIVES	O
:	O
Interferon	O
regulatory	O
factor	O
5	O
(IRF5)	O
is	O
a	O
member	O
of	O
the	O
IRF	O
family	O
of	O
transcription	O
factors	O
,	O
which	O
regulate	O
the	O
production	O
of	O
proinflammatory	O
cytokines	O
.	O

Polymorphisms	O
in	O
the	O
IRF5	O
gene	O
have	O
been	O
associated	O
with	O
susceptibility	O
to	O
systemic	O
lupus	O
erythaematosus	O
(SLE)	O
in	O
Caucasian	O
and	O
Asian	O
populations	O
,	O
but	O
their	O
involvement	O
in	O
other	O
autoimmune	O
diseases	O
is	O
still	O
uncertain	O
.	O

Here	O
,	O
we	O
assessed	O
the	O
genetic	O
role	O
of	O
IRF5	O
in	O
susceptibility	O
to	O
rheumatoid	O
arthritis	O
(RA)	O
in	O
Japanese	O
subjects	O
.	O

METHODS	O
:	O
We	O
selected	O
13	O
single	O
nucleotide	O
polymorphisms	O
(SNPs)	O
and	O
a	O
CGGGG	O
insertion-deletion	O
polymorphism	O
in	O
the	O
IRF5	O
gene	O
.	O

We	O
performed	O
2	O
sets	O
of	O
case-control	O
comparisons	O
using	O
Japanese	O
subjects	O
(	O
first	O
set	O
:	O
830	O
patients	O
with	O
RA	O
and	O
658	O
controls	O
;	O
second	O
set	O
:	O
1112	O
patients	O
with	O
RA	O
and	O
940	O
controls	O
)	O
,	O
and	O
then	O
performed	O
a	O
stratified	O
analysis	O
using	O
human	O
leukocyte	O
antigen	O
(HLA)-DRB1	O
shared	O
epitope	O
(SE)	O
status	O
.	O

We	O
genotyped	O
the	O
SNPs	O
using	O
TaqMan	O
assays	O
.	O

RESULTS	O
:	O
A	O
significant	O
association	O
of	O
the	O
rs729302	O
A	O
allele	O
with	O
RA	O
susceptibility	O
was	O
found	O
in	O
both	O
sets	O
(	O
odds	O
ratio	O
(OR)	O
1.22	O
,	O
95%	O
CI	O
1.09	O
to	O
1.35	O
,	O
p<0.001	O
in	O
the	O
combined	O
analysis	O
)	O
.	O

When	O
the	O
patients	O
were	O
stratified	O
by	O
the	O
SE	O
,	O
the	O
rs729302	O
A	O
allele	O
was	O
found	O
to	O
confer	O
increased	O
risk	O
to	O
RA	O
in	O
patients	O
that	O
were	O
SE	O
negative	O
(	O
OR	O
1.50	O
,	O
95%	O
CI	O
1.17	O
to	O
1.92	O
,	O
p	O
=	O
0.001	O
)	O
as	O
compared	O
with	O
patients	O
carrying	O
the	O
SE	O
(	O
OR	O
1.11	O
,	O
95%	O
CI	O
0.93	O
to	O
1.33	O
,	O
p	O
=	O
0.24	O
)	O
.	O

In	O
both	O
sets	O
,	O
no	O
genotyped	O
polymorphisms	O
were	O
significantly	O
associated	O
with	O
RA	O
susceptibility	O
,	O
but	O
rs729302	O
was	O
significantly	O
associated	O
.	O

CONCLUSIONS	O
:	O
These	O
findings	O
indicate	O
that	O
the	O
promoter	O
polymorphism	O
of	O
IRF5	O
is	O
a	O
genetic	O
factor	O
conferring	O
predisposition	O
to	O
RA	O
,	O
and	O
that	O
it	O
contributes	O
considerably	O
to	O
disease	O
pathogenesis	O
in	O
patients	O
that	O
were	O
SE	O
negative	O
.	O

Identification	O
of	O
a	O
novel	O
FBN1	O
gene	O
mutation	O
in	O
a	O
Chinese	O
family	O
with	O
Marfan	O
syndrome	O
.	O

PURPOSE	O
:	O
To	O
identify	O
the	O
mutation	O
in	O
the	O
fibrillin-1	O
gene	O
(FBN1)	O
in	O
a	O
Chinese	O
family	O
with	O
Marfan	O
syndrome	O
(MFS)	O
.	O

METHODS	O
:	O
Patients	O
and	O
family	O
members	O
were	O
given	O
complete	O
physical	O
,	O
ophthalmic	O
,	O
and	O
cardiovascular	O
examinations	O
.	O

Genomic	O
DNA	O
was	O
extracted	O
from	O
leukocytes	O
of	O
venous	O
blood	O
of	O
six	O
individuals	O
in	O
the	O
family	O
and	O
170	O
healthy	O
Chinese	O
individuals	O
.	O

All	O
of	O
the	O
65	O
coding	O
exons	O
and	O
their	O
flanking	O
intronic	O
boundaries	O
of	O
FBN1	O
were	O
amplified	O
in	O
the	O
proband	O
by	O
polymerase	O
chain	O
reaction	O
and	O
followed	O
by	O
direct	O
sequencing	O
.	O

The	O
mutation	O
identified	O
in	O
the	O
proband	O
was	O
screened	O
in	O
the	O
other	O
family	O
members	O
and	O
the	O
170	O
healthy	O
Chinese	O
individuals	O
by	O
direct	O
sequencing	O
.	O

Protein	O
conservation	O
analysis	O
was	O
performed	O
in	O
six	O
species	O
using	O
an	O
online	O
ClustalW	O
tool	O
.	O

Protein	O
structure	O
was	O
modeled	O
based	O
on	O
the	O
Protein	O
data	O
bank	O
and	O
mutated	O
in	O
DeepView	O
v4.0.1	O
to	O
predict	O
the	O
functional	O
consequences	O
of	O
the	O
mutation	O
.	O

RESULTS	O
:	O
A	O
novel	O
heterozygous	O
C-->T	B-DNAMutation
transition	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
677	I-DNAMutation
change	O
in	O
exon	O
29	O
of	O
FBN1	O
was	O
detected	O
in	O
the	O
proband	O
,	O
which	O
resulted	O
in	O
the	O
substitution	O
of	O
serine	O
by	O
proline	O
at	O
codon	O
1235	O
(	O
methionine-->valine	B-ProteinMutation
substitution	I-ProteinMutation
at	I-ProteinMutation
codon	I-ProteinMutation
404	I-ProteinMutation
)	O
.	O

This	O
mutation	O
was	O
also	O
present	O
in	O
two	O
family	O
members	O
but	O
absent	O
in	O
the	O
other	O
,	O
unaffected	O
family	O
members	O
and	O
the	O
170	O
healthy	O
Chinese	O
individuals	O
.	O

The	O
mutant	O
residue	O
located	O
in	O
the	O
calcium	O
binding	O
epidermal	O
growth	O
factor-like#15	O
domain	O
is	O
highly	O
conserved	O
among	O
mammalian	O
species	O
and	O
could	O
probably	O
induce	O
conformation	O
change	O
of	O
the	O
domain	O
.	O

CONCLUSIONS	O
:	O
We	O
indentified	O
a	O
novel	O
Ser-->Cys	B-ProteinMutation
substitution	I-ProteinMutation
at	I-ProteinMutation
the	I-ProteinMutation
codon	I-ProteinMutation
326	I-ProteinMutation
mutation	O
in	O
FBN1	O
,	O
which	O
is	O
the	O
causative	O
mutation	O
for	O
MFS	O
in	O
this	O
family	O
.	O

Our	O
result	O
expands	O
the	O
mutation	O
spectrum	O
of	O
FBN1	O
and	O
contributes	O
to	O
the	O
study	O
of	O
the	O
molecular	O
pathogenesis	O
of	O
Marfan	O
syndrome	O
.	O

A	O
novel	O
ATP7A	O
gross	O
deletion	O
mutation	O
in	O
a	O
Korean	O
patient	O
with	O
Menkes	O
disease	O
.	O

Menkes	O
disease	O
(	O
MD	O
,	O
MIM	O
309400	O
)	O
is	O
a	O
fatal	O
X-linked	O
recessive	O
disorder	O
that	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
gene	O
encoding	O
ATP7A	O
,	O
a	O
copper-transporting	O
,	O
P-type	O
ATPase	O
.	O

Patients	O
with	O
MD	O
are	O
characterized	O
by	O
progressive	O
hypotonia	O
,	O
seizures	O
,	O
failure	O
to	O
thrive	O
,	O
and	O
death	O
in	O
early	O
childhood	O
.	O

Two	O
Korean	O
patients	O
were	O
diagnosed	O
with	O
Menkes	O
disease	O
by	O
clinical	O
and	O
biochemical	O
findings	O
.	O

We	O
found	O
one	O
missense	O
mutation	O
and	O
one	O
gross	O
deletion	O
in	O
the	O
ATP7A	O
gene	O
in	O
the	O
patients	O
.	O

The	O
missense	O
mutation	O
in	O
Patient	O
1	O
,	O
G-->C	B-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
135	I-DNAMutation
(	O
leucine	B-ProteinMutation
269	I-ProteinMutation
to	I-ProteinMutation
phenylalanine	I-ProteinMutation
)	O
in	O
exon	O
20	O
,	O
was	O
identified	O
in	O
a	O
previous	O
report	O
.	O

Patient	O
2	O
had	O
a	O
gross	O
deletion	O
of	O
GTT-->GCT	B-DNAMutation
transition	I-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
23	I-DNAMutation
,	O
which	O
was	O
a	O
novel	O
mutation	O
.	O

The	O
patients'	O
mothers	O
were	O
shown	O
to	O
be	O
carriers	O
of	O
the	O
respective	O
mutations	O
.	O

Prenatal	O
DNA	O
diagnosis	O
in	O
the	O
family	O
of	O
Patient	O
2	O
was	O
successfully	O
performed	O
,	O
showing	O
a	O
male	O
fetus	O
with	O
the	O
wild-type	O
genotype	O
.	O

The	O
gross	O
deletion	O
is	O
the	O
first	O
mutation	O
to	O
be	O
identified	O
in	O
the	O
ATP7A	O
gene	O
in	O
Korean	O
MD	O
patients	O
.	O

We	O
expect	O
that	O
our	O
findings	O
will	O
be	O
helpful	O
in	O
understanding	O
the	O
wide	O
range	O
of	O
genetic	O
variation	O
in	O
ATP7A	O
in	O
Korean	O
MD	O
patients	O
.	O

Molecular	O
diagnosis	O
of	O
46,XY	O
DSD	O
and	O
identification	O
of	O
a	O
novel	O
8	O
nucleotide	O
deletion	O
in	O
exon	O
1	O
of	O
the	O
SRD5A2	O
gene	O
.	O

Phenotypic	O
presentation	O
of	O
46,XY	O
DSD	O
depends	O
on	O
the	O
underlying	O
defects	O
.	O

Defect	O
in	O
androgen	O
action	O
on	O
the	O
target	O
tissues	O
or	O
production	O
of	O
active	O
metabolite	O
share	O
common	O
morphological	O
features	O
.	O

Molecular	O
study	O
may	O
help	O
differentiating	O
these	O
abnormalities	O
with	O
precision	O
.	O

Mutational	O
analysis	O
of	O
androgen	O
receptor	O
(AR)	O
and	O
SRD5A2	O
genes	O
was	O
performed	O
in	O
29	O
patients	O
with	O
46,XY	O
DSD	O
,	O
by	O
PCR-SSCP	O
.	O

The	O
amplicons	O
that	O
showed	O
an	O
aberrant	O
migration	O
in	O
SSCP	O
were	O
subjected	O
to	O
sequencing	O
.	O

Interestingly	O
,	O
six	O
patients	O
from	O
4	O
unrelated	O
families	O
(	O
a	O
pair	O
of	O
sibs	O
,	O
uncle/nephew	O
and	O
other	O
two	O
isolated	O
)	O
were	O
identified	O
with	O
mutations	O
in	O
SRD5A2	O
gene	O
.	O

In	O
five	O
patients	O
arginine	B-ProteinMutation
555-to-tryptophan	I-ProteinMutation
missense	O
mutation	O
was	O
detected	O
,	O
of	O
which	O
four	O
were	O
homozygous	O
and	O
one	O
was	O
compound	O
heterozygous	O
:	O
A	B-DNAMutation
>	I-DNAMutation
G	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
313	I-DNAMutation
(	O
histidine	B-ProteinMutation
626-to-arginine	I-ProteinMutation
)	O
and	O
arginine	B-ProteinMutation
124-to-cysteine	I-ProteinMutation
.	O

Another	O
patient	O
with	O
isolated	O
micropenis	O
harbored	O
a	O
heterozygous	O
Phe-->Ser	B-ProteinMutation
at	I-ProteinMutation
codon	I-ProteinMutation
15	I-ProteinMutation
missense	O
mutation	O
.	O

No	O
AR	O
gene	O
mutation	O
was	O
detected	O
.	O

In	O
conclusion	O
,	O
our	O
study	O
suggests	O
that	O
Glu	B-ProteinMutation
272	I-ProteinMutation
to	I-ProteinMutation
stop	I-ProteinMutation
mutation	O
is	O
common	O
amongst	O
patients	O
with	O
SRD5A2	O
gene	O
defect	O
from	O
the	O
Northern	O
states	O
of	O
India	O
.	O

Also	O
,	O
it	O
records	O
a	O
novel	O
deletion	O
in	O
exon	O
1	O
of	O
SRD5A2	O
gene	O
in	O
a	O
patient	O
with	O
severe	O
hypospadias	O
.	O

Resequencing	O
of	O
IRS2	O
reveals	O
rare	O
variants	O
for	O
obesity	O
but	O
not	O
fasting	O
glucose	O
homeostasis	O
in	O
Hispanic	O
children	O
.	O

Our	O
objective	O
was	O
to	O
resequence	O
insulin	O
receptor	O
substrate	O
2	O
(IRS2)	O
to	O
identify	O
variants	O
associated	O
with	O
obesity-	O
and	O
diabetes-related	O
traits	O
in	O
Hispanic	O
children	O
.	O

Exonic	O
and	O
intronic	O
segments	O
,	O
5'	O
and	O
3'	O
flanking	O
regions	O
of	O
IRS2	O
(	O
	O
	O
14.5	O
kb	O
)	O
,	O
were	O
bidirectionally	O
sequenced	O
for	O
single	O
nucleotide	O
polymorphism	O
(SNP)	O
discovery	O
in	O
934	O
Hispanic	O
children	O
using	O
3730XL	O
DNA	O
Sequencers	O
.	O

Additionally	O
,	O
15	O
SNPs	O
derived	O
from	O
Illumina	O
HumanOmni1-Quad	O
BeadChips	O
were	O
analyzed	O
.	O

Measured	O
genotype	O
analysis	O
tested	O
associations	O
between	O
SNPs	O
and	O
obesity	O
and	O
diabetes-related	O
traits	O
.	O

Bayesian	O
quantitative	O
trait	O
nucleotide	O
analysis	O
was	O
used	O
to	O
statistically	O
infer	O
the	O
most	O
likely	O
functional	O
polymorphisms	O
.	O

A	O
total	O
of	O
140	O
SNPs	O
were	O
identified	O
with	O
minor	O
allele	O
frequencies	O
(MAF)	O
ranging	O
from	O
0.001	O
to	O
0.47	O
.	O

Forty-two	O
of	O
the	O
70	O
coding	O
SNPs	O
result	O
in	O
nonsynonymous	O
amino	O
acid	O
substitutions	O
relative	O
to	O
the	O
consensus	O
sequence	O
;	O
28	O
SNPs	O
were	O
detected	O
in	O
the	O
promoter	O
,	O
12	O
in	O
introns	O
,	O
28	O
in	O
the	O
3'-UTR	O
,	O
and	O
2	O
in	O
the	O
5'-UTR	O
.	O

Two	O
insertion/deletions	O
(indels)	O
were	O
detected	O
.	O

Ten	O
independent	O
rare	O
SNPs	O
(	O
MAF	O
=	O
0.001-0.009	O
)	O
were	O
associated	O
with	O
obesity-related	O
traits	O
(	O
P	O
=	O
0.01-0.00002	O
)	O
.	O

SNP	O
10510452_139	O
in	O
the	O
promoter	O
region	O
was	O
shown	O
to	O
have	O
a	O
high	O
posterior	O
probability	O
(	O
P	O
=	O
0.77-0.86	O
)	O
of	O
influencing	O
BMI	O
,	O
fat	O
mass	O
,	O
and	O
waist	O
circumference	O
in	O
Hispanic	O
children	O
.	O

SNP	O
10510452_139	O
contributed	O
between	O
2	O
and	O
4%	O
of	O
the	O
population	O
variance	O
in	O
body	O
weight	O
and	O
composition	O
.	O

None	O
of	O
the	O
SNPs	O
or	O
indels	O
were	O
associated	O
with	O
diabetes-related	O
traits	O
or	O
accounted	O
for	O
a	O
previously	O
identified	O
quantitative	O
trait	O
locus	O
on	O
chromosome	O
13	O
for	O
fasting	O
serum	O
glucose	O
.	O

Rare	O
but	O
not	O
common	O
IRS2	O
variants	O
may	O
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
body	O
weight	O
but	O
not	O
an	O
essential	O
role	O
in	O
fasting	O
glucose	O
homeostasis	O
in	O
Hispanic	O
children	O
.	O

Muscle	O
glycogenosis	O
and	O
mitochondrial	O
hepatopathy	O
in	O
an	O
infant	O
with	O
mutations	O
in	O
both	O
the	O
myophosphorylase	O
and	O
deoxyguanosine	O
kinase	O
genes	O
.	O

OBJECTIVES	O
:	O
To	O
document	O
2	O
apparently	O
incongruous	O
clinical	O
disorders	O
occurring	O
in	O
the	O
same	O
infant	O
:	O
congenital	O
myopathy	O
with	O
myophosphorylase	O
deficiency	O
(	O
McArdle	O
disease	O
)	O
and	O
mitochondrial	O
hepatopathy	O
with	O
liver	O
failure	O
and	O
mitochondrial	O
DNA	O
depletion	O
.	O

METHODS	O
:	O
An	O
infant	O
girl	O
born	O
to	O
consanguineous	O
Moroccan	O
parents	O
had	O
severe	O
congenital	O
hypotonia	O
and	O
hepatomegaly	O
,	O
developed	O
liver	O
failure	O
,	O
and	O
died	O
at	O
5	O
months	O
of	O
age	O
.	O

We	O
studied	O
muscle	O
and	O
liver	O
biopsy	O
specimens	O
histochemically	O
and	O
biochemically	O
,	O
and	O
we	O
sequenced	O
the	O
whole	O
coding	O
regions	O
of	O
the	O
deoxyguanosine	O
kinase	O
(dGK)	O
and	O
myophosphorylase	O
(PYGM)	O
genes	O
.	O

RESULTS	O
:	O
Muscle	O
biopsy	O
specimens	O
showed	O
subsarcolemmal	O
glycogen	O
accumulation	O
and	O
negative	O
histochemical	O
reaction	O
for	O
phosphorylase	O
.	O

Liver	O
biopsy	O
specimens	O
showed	O
micronodular	O
cirrhosis	O
and	O
massive	O
mitochondrial	O
proliferation	O
.	O

Biochemical	O
analysis	O
showed	O
phosphorylase	O
deficiency	O
in	O
muscle	O
and	O
cytochrome	O
c	O
oxidase	O
deficiency	O
in	O
liver	O
.	O

We	O
identified	O
a	O
novel	O
homozygous	O
missense	O
G-to-A	O
mutation	O
at	O
codon	O
456	O
in	O
exon	O
11	O
of	O
PYGM	O
,	O
as	O
well	O
as	O
a	O
homozygous	O
4-base	O
pair	O
GATT	O
duplication	O
(	O
nucleotides	O
763-766	O
)	O
in	O
exon	O
6	O
of	O
dGK	O
,	O
which	O
produces	O
a	O
frame	O
shift	O
and	O
a	O
premature	O
TGA	O
stop	O
codon	O
at	O
nucleotides	O
766	O
to	O
768	O
,	O
resulting	O
in	O
a	O
truncated	O
255-amino	O
acid	O
protein	O
.	O

Both	O
mutations	O
were	O
absent	O
in	O
100	O
healthy	O
individuals	O
.	O

CONCLUSIONS	O
:	O
Our	O
data	O
further	O
expand	O
the	O
genetic	O
heterogeneity	O
in	O
patients	O
with	O
McArdle	O
disease	O
;	O
confirm	O
the	O
strong	O
relationship	O
between	O
mitochondrial	O
DNA	O
depletion	O
syndrome	O
,	O
liver	O
involvement	O
,	O
and	O
dGK	O
mutations	O
;	O
and	O
suggest	O
that	O
genetic	O
"double	O
trouble"	O
should	O
be	O
considered	O
in	O
patients	O
with	O
unusual	O
severe	O
phenotypes	O
.	O

A	O
human	O
phospholamban	O
promoter	O
polymorphism	O
in	O
dilated	O
cardiomyopathy	O
alters	O
transcriptional	O
regulation	O
by	O
glucocorticoids	O
.	O

Depressed	O
calcium	O
handling	O
by	O
the	O
sarcoplasmic	O
reticulum	O
(SR)	O
Ca-ATPase	O
and	O
its	O
regulator	O
phospholamban	O
(PLN)	O
is	O
a	O
key	O
characteristic	O
of	O
human	O
and	O
experimental	O
heart	O
failure	O
.	O

Accumulating	O
evidence	O
indicates	O
that	O
increases	O
in	O
the	O
relative	O
levels	O
of	O
PLN	O
to	O
Ca-ATPase	O
in	O
failing	O
hearts	O
and	O
resulting	O
inhibition	O
of	O
Ca	O
sequestration	O
during	O
diastole	O
,	O
impairs	O
contractility	O
.	O

Here	O
,	O
we	O
identified	O
a	O
genetic	O
variant	O
in	O
the	O
PLN	O
promoter	O
region	O
,	O
which	O
increases	O
its	O
expression	O
and	O
may	O
serve	O
as	O
a	O
genetic	O
modifier	O
in	O
dilated	O
cardiomyopathy	O
(DCM)	O
.	O

The	O
variant	O
AF177763.1:-AAGC	B-DNAMutation
at	I-DNAMutation
-222	I-DNAMutation
to	I-DNAMutation
-225	I-DNAMutation
(	O
at	O
position	O
-36	O
bp	O
relative	O
to	O
the	O
PLN	O
transcriptional	O
start	O
site	O
)	O
was	O
found	O
only	O
in	O
the	O
heterozygous	O
form	O
in	O
1	O
out	O
of	O
296	O
normal	O
subjects	O
and	O
in	O
22	O
out	O
of	O
381	O
cardiomyopathy	O
patients	O
(	O
heart	O
failure	O
at	O
age	O
of	O
18-44	O
years	O
,	O
ejection	O
fraction=22+/-9%	O
)	O
.	O

In	O
vitro	O
analysis	O
,	O
using	O
luciferase	O
as	O
a	O
reporter	O
gene	O
in	O
rat	O
neonatal	O
cardiomyocytes	O
,	O
indicated	O
that	O
the	O
PLN-variant	O
increased	O
activity	O
by	O
24%	O
compared	O
to	O
the	O
wild	O
type	O
.	O

Furthermore	O
,	O
the	O
-491	B-DNAMutation
A	I-DNAMutation
to	I-DNAMutation
T	I-DNAMutation
substitution	O
altered	O
the	O
specific	O
sequence	O
of	O
the	O
steroid	O
receptor	O
for	O
the	O
glucocorticoid	O
nuclear	O
receptor	O
(GR)/transcription	O
factor	O
in	O
the	O
PLN	O
promoter	O
,	O
resulting	O
in	O
enhanced	O
binding	O
to	O
the	O
mutated	O
DNA	O
site	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
G>A	B-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
+1	I-DNAMutation
of	I-DNAMutation
intron	I-DNAMutation
2	I-DNAMutation
genetic	O
variant	O
in	O
the	O
human	O
PLN	O
promoter	O
may	O
contribute	O
to	O
depressed	O
contractility	O
and	O
accelerate	O
functional	O
deterioration	O
in	O
heart	O
failure	O
.	O

Bikunin	O
and	O
a1-microglobulin/bikunin	O
precursor	O
(AMBP)	O
gene	O
mutational	O
screening	O
in	O
patients	O
with	O
kidney	O
stones	O
:	O
a	O
case-control	O
study	O
.	O

OBJECTIVE	O
:	O
Bikunin	O
is	O
an	O
inhibitor	O
of	O
kidney	O
stone	O
formation	O
synthesized	O
in	O
the	O
liver	O
together	O
with	O
a(1)-microglobulin	O
from	O
the	O
a(1)-microglobulin/bikunin	O
precursor	O
(AMBP)	O
gene	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
possible	O
association	O
between	O
bikunin/AMBP	O
gene	O
polymorphisms	O
and	O
urinary	O
stone	O
formation	O
.	O

MATERIAL	O
AND	O
METHODS	O
:	O
To	O
analyse	O
the	O
DNA	O
,	O
blood	O
samples	O
were	O
taken	O
from	O
75	O
kidney	O
stone	O
formers	O
who	O
had	O
a	O
familial	O
stone	O
history	O
,	O
35	O
sporadic	O
stone	O
formers	O
and	O
101	O
healthy	O
individuals	O
.	O

Four	O
exons	O
of	O
bikunin	O
gene	O
and	O
five	O
parts	O
of	O
the	O
promoter	O
region	O
of	O
the	O
AMBP	O
gene	O
were	O
screened	O
using	O
single-strand	O
conformation	O
polymorphism	O
and	O
nucleotide	O
sequence	O
analysis	O
.	O

RESULTS	O
:	O
The	O
Init-2	O
region	O
of	O
the	O
promoter	O
of	O
AMBP	O
gene	O
had	O
polymorphisms	O
at	O
positions	O
-218	O
and	O
-189	O
nt	O
giving	O
three	O
different	O
genotypes	O
having	O
1,3	O
,	O
2,4	O
and	O
1,2,3,4	O
alleles	O
with	O
frequencies	O
of	O
17.06%	O
,	O
60.19%	O
and	O
22.75%	O
,	O
respectively	O
,	O
in	O
all	O
groups	O
.	O

Therefore	O
,	O
the	O
Init-2	O
region	O
appears	O
to	O
be	O
polymorphic	O
.	O

As	O
a	O
result	O
,	O
the	O
1,3	O
allele	O
has	O
-218G	O
and	O
-189T	O
complying	O
with	O
the	O
reference	O
database	O
sequence	O
,	O
the	O
2,4	O
allele	O
has	O
-218G	O
and	O
(	B-DNAMutation
T	I-DNAMutation
-->	I-DNAMutation
C	I-DNAMutation
)	I-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
2209	I-DNAMutation
substitution	O
and	O
the	O
allele	O
1,2,3,4	O
genotype	O
has	O
substitutions	O
at	O
positions	O
(	B-DNAMutation
G	I-DNAMutation
-->	I-DNAMutation
C	I-DNAMutation
)	I-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
1201	I-DNAMutation
and	O
G>T	B-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
c.898	I-DNAMutation
.	O

CONCLUSIONS	O
:	O
There	O
were	O
no	O
significant	O
differences	O
in	O
allele	O
distribution	O
between	O
patients	O
and	O
controls	O
.	O

These	O
common	O
alleles	O
exist	O
in	O
the	O
Turkish	O
population	O
independent	O
of	O
stone	O
formation	O
.	O

These	O
results	O
are	O
the	O
first	O
to	O
demonstrate	O
the	O
existence	O
of	O
bikunin	O
and	O
AMBP	O
promoter	O
polymorphism	O
.	O

Although	O
the	O
Init-2	O
region	O
of	O
the	O
AMBP	O
gene	O
is	O
the	O
binding	O
site	O
for	O
various	O
transcription	O
factors	O
,	O
the	O
results	O
showed	O
no	O
association	O
between	O
these	O
observed	O
genotypes	O
and	O
stone-forming	O
phenotypes	O
.	O

Two	O
new	O
beta-chain	O
variants	O
:	O
Hb	O
Tripoli	O
[	O
beta26(B8)methionine-->valine	B-ProteinMutation
substitution	I-ProteinMutation
at	I-ProteinMutation
codon	I-ProteinMutation
404	I-ProteinMutation
]	O
and	O
Hb	O
Tizi-Ouzou	O
[	O
beta29(B11)Ser-->Cys	B-ProteinMutation
substitution	I-ProteinMutation
at	I-ProteinMutation
the	I-ProteinMutation
codon	I-ProteinMutation
326	I-ProteinMutation
]	O
.	O

Two	O
new	O
beta-globin	O
chain	O
variants	O
:	O
Hb	O
Tripoli	O
:	O
G-->C	B-DNAMutation
transversion	I-DNAMutation
at	I-DNAMutation
1245	I-DNAMutation
position	I-DNAMutation
[	O
beta26(B8)leucine	B-ProteinMutation
269	I-ProteinMutation
to	I-ProteinMutation
phenylalanine	I-ProteinMutation
]	O
and	O
Hb	O
Tizi-Ouzou	O
:	O
C-->T	B-DNAMutation
transversion	I-DNAMutation
at	I-DNAMutation
cDNA	I-DNAMutation
base	I-DNAMutation
463	I-DNAMutation
[	O
beta29(B11)arginine	B-ProteinMutation
555-to-tryptophan	I-ProteinMutation
]	O
are	O
described	O
on	O
the	O
first	O
exon	O
of	O
the	O
beta-globin	O
gene	O
.	O

The	O
two	O
variants	O
are	O
characterized	O
by	O
DNA	O
sequencing	O
and	O
mass	O
spectrometry	O
(MS)	O
.	O

Hematological	O
abnormalities	O
were	O
found	O
in	O
the	O
two	O
carriers	O
.	O

The	O
presence	O
of	O
microcytosis	O
and	O
hypochromia	O
is	O
explained	O
by	O
an	O
additional	O
homozygous	O
3.7	O
kb	O
alpha(+)	O
thalassemic	O
deletion	O
for	O
the	O
carrier	O
of	O
Hb	O
Tizi-Ouzou	O
.	O

Hb	O
Tizi-Ouzou	O
showed	O
a	O
slight	O
instability	O
in	O
vitro	O
.	O

The	O
same	O
hematological	O
abnormalities	O
associated	O
with	O
anemia	O
are	O
difficult	O
to	O
explain	O
for	O
Hb	O
Tripoli's	O
carrier	O
in	O
the	O
absence	O
of	O
an	O
alpha-globin	O
genes	O
abnormality	O
and	O
could	O
suggest	O
a	O
possible	O
abnormal	O
splicing	O
.	O

Screening	O
of	O
the	O
LIX1	O
gene	O
in	O
Japanese	O
and	O
Malaysian	O
patients	O
with	O
SMA	O
and/or	O
SMA-like	O
disorder	O
.	O

BACKGROUND	O
:	O
The	O
majority	O
of	O
spinal	O
muscular	O
atrophy	O
(SMA)	O
patients	O
showed	O
homozygous	O
deletion	O
or	O
other	O
mutations	O
of	O
SMN1	O
.	O

However	O
,	O
the	O
genetic	O
etiology	O
of	O
a	O
significant	O
number	O
of	O
SMA	O
patients	O
has	O
not	O
been	O
clarified	O
.	O

Recently	O
,	O
mutation	O
in	O
the	O
gene	O
underlying	O
cat	O
SMA	O
,	O
limb	O
expression	O
1	O
(LIX1)	O
,	O
has	O
been	O
reported	O
.	O

Similarity	O
in	O
clinical	O
and	O
pathological	O
features	O
of	O
cat	O
and	O
human	O
SMA	O
may	O
give	O
an	O
insight	O
into	O
possible	O
similarity	O
of	O
the	O
genetic	O
etiology	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
In	O
this	O
study	O
,	O
we	O
screened	O
for	O
a	O
mutation	O
in	O
LIX1	O
using	O
direct	O
DNA	O
sequencing	O
in	O
our	O
SMA	O
and/or	O
SMA-like	O
patients	O
who	O
retained	O
SMN1	O
.	O

A	O
total	O
of	O
33	O
patients	O
were	O
enrolled	O
in	O
this	O
study	O
,	O
of	O
which	O
22	O
were	O
Japanese	O
and	O
11	O
were	O
Malaysians	O
.	O

All	O
these	O
patients	O
possessed	O
at	O
least	O
two	O
copies	O
of	O
SMN1	O
.	O

RESULTS	O
:	O
We	O
did	O
not	O
identify	O
any	O
pathogenic	O
mutations	O
in	O
the	O
coding	O
regions	O
or	O
splice	O
sites	O
of	O
LIX1	O
in	O
the	O
patients	O
.	O

In	O
addition	O
,	O
we	O
described	O
a	O
polymorphism	O
within	O
LIX1	O
intron	O
3	O
,	O
G-->C	B-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
135	I-DNAMutation
.	O

We	O
found	O
that	O
A-allele	O
is	O
significantly	O
more	O
frequent	O
in	O
SMA	O
patients	O
compared	O
to	O
normal	O
individuals	O
.	O

CONCLUSION	O
:	O
Molecular	O
genetic	O
analysis	O
of	O
our	O
SMA	O
and/or	O
SMA-like	O
patients	O
suggests	O
that	O
LIX1	O
is	O
not	O
associated	O
with	O
the	O
development	O
of	O
their	O
disorders	O
.	O

However	O
,	O
the	O
number	O
of	O
patients	O
analyzed	O
in	O
this	O
study	O
was	O
very	O
limited	O
,	O
and	O
a	O
larger	O
study	O
with	O
bigger	O
sample	O
size	O
is	O
needed	O
to	O
confirm	O
this	O
result	O
.	O

C10ORF97	O
is	O
a	O
novel	O
tumor-suppressor	O
gene	O
of	O
non-small-cell	O
lung	O
cancer	O
and	O
a	O
functional	O
variant	O
of	O
this	O
gene	O
increases	O
the	O
risk	O
of	O
non-small-cell	O
lung	O
cancer	O
.	O

In	O
an	O
earlier	O
study	O
we	O
showed	O
that	O
C10ORF97	O
(	O
chromosome-10	O
,	O
open	O
reading	O
frame-97	O
)	O
was	O
expressed	O
in	O
almost	O
all	O
of	O
the	O
tissues	O
and	O
cell	O
lines	O
tested	O
,	O
and	O
that	O
it	O
inhibited	O
the	O
growth	O
of	O
seven	O
tumor	O
cell	O
lines	O
,	O
including	O
two	O
lung	O
carcinoma	O
cell	O
lines	O
(	O
A549	O
and	O
PG	O
)	O
.	O

Here	O
,	O
we	O
show	O
that	O
C10ORF97	O
is	O
downregulated	O
in	O
non-small-cell	O
lung	O
cancer	O
(NSCLC)	O
tissue	O
compared	O
with	O
normal	O
lung	O
tissue	O
.	O

Overexpression	O
of	O
C10ORF97	O
significantly	O
suppressed	O
human	O
lung	O
carcinoma	O
A549	O
cell	O
growth	O
(	O
proliferation	O
and	O
anchorage-independent	O
growth	O
in	O
soft	O
agar	O
)	O
and	O
motility	O
(	O
migration	O
and	O
adhesion	O
)	O
.	O

This	O
tumor-suppressive	O
function	O
of	O
C10ORF97	O
was	O
also	O
verified	O
in	O
vivo	O
.	O

We	O
further	O
found	O
that	O
C10ORF97	O
caused	O
G(1)	O
arrest	O
of	O
A549	O
cells	O
and	O
modulated	O
the	O
expression	O
level	O
of	O
several	O
cell-cycle	O
regulators	O
(	O
such	O
as	O
CDK2	O
,	O
cyclin-E	O
and	O
p27	O
)	O
.	O

These	O
effects	O
of	O
C10ORF97	O
were	O
mediated	O
by	O
physical	O
association	O
between	O
C10ORF97	O
and	O
Jun-activating	O
domain-binding	O
protein-1	O
(JAB1)	O
,	O
and	O
blocking	O
of	O
JAB1-mediated	O
translocation	O
of	O
p27	O
from	O
the	O
nucleus	O
to	O
the	O
cytoplasm	O
.	O

Together	O
,	O
these	O
results	O
indicated	O
that	O
C10ORF97	O
functions	O
as	O
a	O
novel	O
tumor	O
suppressor	O
by	O
modulating	O
several	O
key	O
G(1)/S-regulatory	O
proteins	O
by	O
interacting	O
with	O
JAB1	O
.	O

These	O
findings	O
led	O
us	O
to	O
hypothesize	O
that	O
a	O
single-nucleotide	O
polymorphism	O
(SNP)	O
in	O
the	O
C10ORF97	O
gene	O
that	O
affects	O
its	O
expression	O
might	O
be	O
associated	O
with	O
susceptibility	O
to	O
NSCLC	O
.	O

SNP216	O
C-->T	B-DNAMutation
transition	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
677	I-DNAMutation
(rs2297882)	O
in	O
the	O
C10ORF97	O
Kozak	O
sequence	O
was	O
identified	O
,	O
and	O
allele	O
T	O
of	O
SNP216	O
suppressed	O
C10ORF97	O
expression	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Furthermore	O
,	O
the	O
TT	O
genotype	O
of	O
SNP216	O
was	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
NSCLC	O
(	O
adjusted	O
odds	O
ratio=1.73	O
(	O
95%	O
confidence	O
interval	O
:	O
1.33-2.25	O
)	O
,	O
P=4.6	O
	O
	O
10(-5)	O
)	O
.	O

These	O
data	O
indicated	O
that	O
C10ORF97	O
is	O
a	O
tumor	O
suppressor	O
of	O
NSCLC	O
progression	O
and	O
C10ORF97-SNP216	O
may	O
serve	O
as	O
a	O
predictor	O
of	O
NSCLC	O
.	O

Large	O
contiguous	O
gene	O
deletions	O
in	O
Sj	O
	O
gren-Larsson	O
syndrome	O
.	O

Sj	O
	O
gren-Larsson	O
syndrome	O
(SLS)	O
is	O
an	O
autosomal	O
recessive	O
disorder	O
characterized	O
by	O
ichthyosis	O
,	O
mental	O
retardation	O
,	O
spasticity	O
and	O
mutations	O
in	O
the	O
ALDH3A2	O
gene	O
for	O
fatty	O
aldehyde	O
dehydrogenase	O
,	O
an	O
enzyme	O
that	O
catalyzes	O
the	O
oxidation	O
of	O
fatty	O
aldehyde	O
to	O
fatty	O
acid	O
.	O

More	O
than	O
70	O
mutations	O
have	O
been	O
identified	O
in	O
SLS	O
patients	O
,	O
including	O
small	O
deletions	O
or	O
insertions	O
,	O
missense	O
mutations	O
,	O
splicing	O
defects	O
and	O
complex	O
nucleotide	O
changes	O
.	O

We	O
now	O
describe	O
2	O
SLS	O
patients	O
whose	O
disease	O
is	O
caused	O
by	O
large	O
contiguous	O
gene	O
deletions	O
of	O
the	O
ALDH3A2	O
locus	O
on	O
17p11.2	O
.	O

The	O
deletions	O
were	O
defined	O
using	O
long	O
distance	O
inverse	O
PCR	O
and	O
microarray-based	O
comparative	O
genomic	O
hybridization	O
.	O

A	O
24-year-old	O
SLS	O
female	O
was	O
homozygous	O
for	O
a	O
352-kb	O
deletion	O
involving	O
ALDH3A2	O
and	O
4	O
contiguous	O
genes	O
including	O
ALDH3A1	O
,	O
which	O
codes	O
for	O
the	O
major	O
soluble	O
protein	O
in	O
cornea	O
.	O

Although	O
lacking	O
corneal	O
disease	O
,	O
she	O
showed	O
severe	O
symptoms	O
of	O
SLS	O
with	O
uncommon	O
deterioration	O
in	O
oral	O
motor	O
function	O
and	O
loss	O
of	O
ambulation	O
.	O

The	O
other	O
19-month-old	O
female	O
patient	O
was	O
a	O
compound	O
heterozygote	O
for	O
a	O
1.44-Mb	O
contiguous	O
gene	O
deletion	O
and	O
a	O
missense	O
mutation	O
(	O
GTT-->GCT	B-DNAMutation
transition	I-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
23	I-DNAMutation
,	O
histidine	B-ProteinMutation
626-to-arginine	I-ProteinMutation
)	O
in	O
ALDH3A2	O
.	O

These	O
studies	O
suggest	O
that	O
large	O
gene	O
deletions	O
may	O
account	O
for	O
up	O
to	O
5%	O
of	O
the	O
mutant	O
alleles	O
in	O
SLS	O
.	O

Geneticists	O
should	O
consider	O
the	O
possibility	O
of	O
compound	O
heterozygosity	O
for	O
large	O
deletions	O
in	O
patients	O
with	O
SLS	O
and	O
other	O
inborn	O
errors	O
of	O
metabolism	O
,	O
which	O
has	O
implications	O
for	O
carrier	O
testing	O
and	O
prenatal	O
diagnosis	O
.	O

Genome-wide	O
analysis	O
of	O
neuroblastomas	O
using	O
high-density	O
single	O
nucleotide	O
polymorphism	O
arrays	O
.	O

BACKGROUND	O
:	O
Neuroblastomas	O
are	O
characterized	O
by	O
chromosomal	O
alterations	O
with	O
biological	O
and	O
clinical	O
significance	O
.	O

We	O
analyzed	O
paired	O
blood	O
and	O
primary	O
tumor	O
samples	O
from	O
22	O
children	O
with	O
high-risk	O
neuroblastoma	O
for	O
loss	O
of	O
heterozygosity	O
(LOH)	O
and	O
DNA	O
copy	O
number	O
change	O
using	O
the	O
Affymetrix	O
10K	O
single	O
nucleotide	O
polymorphism	O
(SNP)	O
array	O
.	O

FINDINGS	O
:	O
Multiple	O
areas	O
of	O
LOH	O
and	O
copy	O
number	O
gain	O
were	O
seen	O
.	O

The	O
most	O
commonly	O
observed	O
area	O
of	O
LOH	O
was	O
on	O
chromosome	O
arm	O
11q	O
(	O
15/22	O
samples	O
;	O
68%	O
)	O
.	O

Chromosome	O
11q	O
LOH	O
was	O
highly	O
associated	O
with	O
occurrence	O
of	O
chromosome	O
3p	O
LOH	O
:	O
9	O
of	O
the	O
15	O
samples	O
with	O
11q	O
LOH	O
had	O
concomitant	O
3p	O
LOH	O
(	O
P	O
=	O
0.016	O
)	O
.	O

Chromosome	O
1p	O
LOH	O
was	O
seen	O
in	O
one-third	O
of	O
cases	O
.	O

LOH	O
events	O
on	O
chromosomes	O
11q	O
and	O
1p	O
were	O
generally	O
accompanied	O
by	O
copy	O
number	O
loss	O
,	O
indicating	O
hemizygous	O
deletion	O
within	O
these	O
regions	O
.	O

The	O
one	O
exception	O
was	O
on	O
chromosome	O
11p	O
,	O
where	O
LOH	O
in	O
all	O
four	O
cases	O
was	O
accompanied	O
by	O
normal	O
copy	O
number	O
or	O
diploidy	O
,	O
implying	O
uniparental	O
disomy	O
.	O

Gain	O
of	O
copy	O
number	O
was	O
most	O
frequently	O
observed	O
on	O
chromosome	O
arm	O
17q	O
(	O
21/22	O
samples	O
;	O
95%	O
)	O
and	O
was	O
associated	O
with	O
allelic	O
imbalance	O
in	O
six	O
samples	O
.	O

Amplification	O
of	O
MYCN	O
was	O
also	O
noted	O
,	O
and	O
also	O
amplification	O
of	O
a	O
second	O
gene	O
,	O
ALK	O
,	O
in	O
a	O
single	O
case	O
.	O

CONCLUSIONS	O
:	O
This	O
analysis	O
demonstrates	O
the	O
power	O
of	O
SNP	O
arrays	O
for	O
high-resolution	O
determination	O
of	O
LOH	O
and	O
DNA	O
copy	O
number	O
change	O
in	O
neuroblastoma	O
,	O
a	O
tumor	O
in	O
which	O
specific	O
allelic	O
changes	O
drive	O
clinical	O
outcome	O
and	O
selection	O
of	O
therapy	O
.	O

Two	O
sites	O
in	O
the	O
MAPT	O
region	O
confer	O
genetic	O
risk	O
for	O
Guam	O
ALS/PDC	O
and	O
dementia	O
.	O

Unusual	O
forms	O
of	O
amyotrophic	O
lateral	O
sclerosis	O
(ALS-G)	O
,	O
Parkinsonism	O
dementia	O
complex	O
(PDC-G)	O
and	O
Guam	O
dementia	O
(GD)	O
are	O
found	O
in	O
Chamorros	O
,	O
the	O
indigenous	O
people	O
of	O
Guam	O
.	O

Neurofibrillary	O
tangles	O
composed	O
of	O
hyperphosphorylated	O
tau	O
are	O
a	O
neuropathologic	O
feature	O
of	O
these	O
closely	O
related	O
disorders	O
.	O

To	O
determine	O
if	O
variation	O
in	O
the	O
gene	O
that	O
encodes	O
microtubule-associated	O
protein	O
tau	O
gene	O
(MAPT)	O
contributes	O
to	O
risk	O
for	O
these	O
disorders	O
,	O
we	O
genotyped	O
nine	O
single	O
nucleotide	O
polymorphism	O
(SNP)	O
sites	O
and	O
one	O
insertion/deletion	O
in	O
the	O
5'	O
end	O
of	O
MAPT	O
in	O
54	O
ALS-G	O
,	O
135	O
PDC-G	O
,	O
153	O
GD	O
and	O
258	O
control	O
subjects	O
,	O
all	O
of	O
whom	O
are	O
Chamorros	O
.	O

Variation	O
at	O
three	O
SNPs	O
(	O
sites	O
2	O
,	O
6	O
and	O
9	O
)	O
influenced	O
risk	O
for	O
ALS-G	O
,	O
PDC-G	O
and	O
GD	O
.	O

SNP2	O
acts	O
through	O
a	O
dominant	O
mechanism	O
and	O
is	O
independent	O
of	O
the	O
risk	O
conferred	O
by	O
SNPs	O
6	O
and	O
9	O
,	O
the	O
latter	O
two	O
acting	O
by	O
a	O
recessive	O
mechanism	O
.	O

Persons	O
with	O
the	O
high-risk	O
SNP6	O
and	O
SNP9	O
AC/AC	O
diplotype	O
had	O
an	O
increased	O
risk	O
of	O
3-fold	O
[	O
95%	O
confidence	O
interval	O
(	O
CI)=1.10-8.25	O
]	O
for	O
GD	O
,	O
4-fold	O
(	O
95%	O
CI=1.40-11.64	O
)	O
for	O
PDC-G	O
and	O
6-fold	O
(	O
95%	O
CI=1.44-32.14	O
)	O
for	O
ALS-G	O
,	O
compared	O
to	O
persons	O
with	O
other	O
diplotypes	O
after	O
adjusting	O
for	O
SNP2	O
.	O

Carriers	O
of	O
the	O
SNP2	O
G	O
allele	O
had	O
an	O
increased	O
risk	O
of	O
1.6-fold	O
(	O
95%	O
CI=1.00-2.62	O
)	O
for	O
GD	O
,	O
2-fold	O
(	O
95%	O
CI=1.28-3.66	O
)	O
for	O
PDC-G	O
,	O
and	O
1.5-fold	O
(	O
95%	O
CI=0.74-3.00	O
)	O
for	O
ALS-G	O
,	O
compared	O
to	O
non-carriers	O
after	O
adjusting	O
for	O
SNPs	O
6	O
and	O
9	O
.	O

Others	O
have	O
shown	O
that	O
SNP6	O
is	O
also	O
associated	O
with	O
risk	O
for	O
progressive	O
supranuclear	O
palsy	O
.	O

These	O
two	O
independent	O
cis-acting	O
sites	O
presumably	O
influence	O
risk	O
for	O
Guam	O
neuro-degenerative	O
disorders	O
by	O
regulating	O
MAPT	O
expression	O
.	O

Lack	O
of	O
association	O
between	O
ADRA2B-4825	O
gene	O
insertion/deletion	O
polymorphism	O
and	O
migraine	O
in	O
Chinese	O
Han	O
population	O
.	O

OBJECTIVE	O
:	O
The	O
present	O
study	O
aimed	O
to	O
estimate	O
the	O
association	O
between	O
susceptibility	O
to	O
migraine	O
and	O
the	O
12-nucleotide	O
insertion/deletion	O
(indel)	O
polymorphism	O
in	O
promoter	O
region	O
of	O
alpha(2B)-adrenergic	O
receptor	O
gene	O
(ADRA2B)	O
.	O

METHODS	O
:	O
A	O
case-control	O
study	O
was	O
carried	O
out	O
in	O
Chinese	O
Han	O
population	O
,	O
including	O
368	O
cases	O
of	O
migraine	O
and	O
517	O
controls	O
.	O

Genomic	O
DNA	O
was	O
extracted	O
from	O
blood	O
samples	O
,	O
and	O
DNA	O
fragments	O
containing	O
the	O
site	O
of	O
polymorphism	O
were	O
amplified	O
by	O
PCR	O
.	O

Data	O
were	O
adjusted	O
for	O
sex	O
,	O
age	O
,	O
migraine	O
history	O
and	O
family	O
history	O
,	O
and	O
analyzed	O
using	O
a	O
logistic	O
regression	O
model	O
.	O

RESULTS	O
:	O
There	O
was	O
no	O
association	O
between	O
indel	O
polymorphism	O
and	O
migraine	O
,	O
at	O
either	O
the	O
allele	O
or	O
the	O
genotype	O
level	O
.	O

CONCLUSION	O
:	O
These	O
findings	O
do	O
not	O
support	O
a	O
functional	O
significance	O
of	O
ADRA2B	O
indel	O
polymorphism	O
at	O
position	O
-4825	O
relative	O
to	O
the	O
start	O
codon	O
in	O
the	O
far	O
upstream	O
region	O
of	O
the	O
promoter	O
in	O
the	O
present	O
migraine	O
subjects	O
.	O

Phenotype	O
of	O
the	O
202	O
adenine	O
deletion	O
in	O
the	O
parkin	O
gene	O
:	O
40	O
years	O
of	O
follow-up	O
.	O

BACKGROUND	O
:	O
We	O
describe	O
the	O
four	O
decades	O
follow-up	O
of	O
14	O
parkin	O
patients	O
belonging	O
to	O
two	O
large	O
eight-generation-long	O
in-bred	O
Muslim-Arab	O
kindreds	O
.	O

RESULTS	O
:	O
All	O
patients	O
had	O
a	O
single	O
base-pair	O
of	O
adenine	O
deletion	O
at	O
nucleotide	O
202	O
of	O
exon	O
2	O
(202A)	O
of	O
the	O
parkin	O
gene	O
(	O
all	O
homozygous	O
,	O
one	O
heterozygous	O
)	O
.	O

Parkinson's	O
disease	O
onset	O
age	O
was	O
17-68	O
years	O
.	O

Special	O
features	O
were	O
intractable	O
axial	O
symptoms	O
(	O
low	O
back	O
pain	O
,	O
scoliosis	O
,	O
camptocormia	O
,	O
antecollis	O
)	O
,	O
postural	O
tremor	O
,	O
and	O
preserved	O
cognition	O
.	O

CONCLUSIONS	O
:	O
The	O
202A	O
deletion	O
of	O
the	O
parkin	O
gene	O
causes	O
early-onset	O
Parkinson's	O
disease	O
with	O
marked	O
levodopa/STN-DBS-resistant	O
axial	O
features	O
.	O

Postural	O
tremor	O
and	O
preserved	O
cognition	O
,	O
even	O
after	O
40	O
years	O
of	O
disease	O
,	O
were	O
also	O
evident	O
.	O

Single	O
nucleotide	O
polymorphism	O
discovery	O
in	O
TBX1	O
in	O
individuals	O
with	O
and	O
without	O
22q11.2	O
deletion	O
syndrome	O
.	O

BACKGROUND	O
:	O
Children	O
with	O
22q11.2	O
deletion	O
syndrome	O
(22q11.2DS)	O
have	O
a	O
wide	O
range	O
of	O
clinical	O
features	O
.	O

TBX1	O
has	O
been	O
proposed	O
as	O
a	O
candidate	O
gene	O
for	O
some	O
of	O
the	O
features	O
in	O
this	O
condition	O
.	O

Polymorphisms	O
in	O
the	O
nondeleted	O
TBX1	O
,	O
which	O
may	O
affect	O
the	O
function	O
of	O
the	O
sole	O
TBX1	O
gene	O
in	O
individuals	O
with	O
the	O
22q11.2DS	O
,	O
may	O
be	O
a	O
key	O
to	O
understanding	O
the	O
phenotypic	O
variability	O
among	O
individuals	O
with	O
a	O
shared	O
deletion	O
.	O

Comprehensive	O
single	O
nucleotide	O
polymorphism	O
(SNP)	O
discovery	O
by	O
resequencing	O
candidate	O
genes	O
can	O
identify	O
genetic	O
variants	O
that	O
influence	O
a	O
given	O
phenotype	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
further	O
characterize	O
the	O
sequence	O
variability	O
in	O
TBX1	O
by	O
identifying	O
all	O
common	O
SNPs	O
in	O
this	O
gene	O
.	O

METHODS	O
:	O
We	O
resequenced	O
TBX1	O
in	O
29	O
children	O
with	O
a	O
documented	O
22q11.2	O
deletion	O
and	O
95	O
nondeleted	O
,	O
healthy	O
individuals	O
.	O

We	O
estimated	O
allele	O
frequencies	O
,	O
performed	O
tagSNP	O
selection	O
,	O
and	O
inferred	O
haplotypes	O
.	O

We	O
also	O
compared	O
SNP	O
frequencies	O
between	O
22q11.2DS	O
and	O
control	O
samples	O
.	O

RESULTS	O
:	O
We	O
identified	O
355	O
biallelic	O
markers	O
among	O
the	O
190	O
chromosomes	O
resequenced	O
in	O
the	O
control	O
panel	O
.	O

The	O
vast	O
majority	O
of	O
the	O
markers	O
identified	O
were	O
SNPs	O
(	O
n	O
=	O
331	O
)	O
,	O
and	O
the	O
remainder	O
indels	O
(	O
n	O
=	O
24	O
)	O
.	O

We	O
did	O
not	O
identify	O
SNPs	O
or	O
indels	O
in	O
the	O
cis-	O
regulatory	O
element	O
(	O
FOX-binding	O
site	O
)	O
upstream	O
of	O
TBX1	O
.	O

In	O
children	O
with	O
22q11.2DS	O
we	O
detected	O
187	O
biallelic	O
markers	O
,	O
six	O
of	O
which	O
were	O
indels	O
.	O

Four	O
of	O
the	O
seven	O
coding	O
SNPs	O
identified	O
in	O
the	O
controls	O
were	O
identified	O
in	O
children	O
with	O
22q11.2DS	O
.	O

CONCLUSIONS	O
:	O
This	O
comprehensive	O
SNP	O
discovery	O
data	O
can	O
be	O
used	O
to	O
select	O
SNPs	O
to	O
genotype	O
for	O
future	O
association	O
studies	O
assessing	O
the	O
role	O
of	O
TBX1	O
and	O
phenotypic	O
variability	O
in	O
individuals	O
with	O
22q11.2DS	O
.	O

Genetic	O
polymorphisms	O
in	O
the	O
carbonyl	O
reductase	O
3	O
gene	O
CBR3	O
and	O
the	O
NAD(P)H:quinone	O
oxidoreductase	O
1	O
gene	O
NQO1	O
in	O
patients	O
who	O
developed	O
anthracycline-related	O
congestive	O
heart	O
failure	O
after	O
childhood	O
cancer	O
.	O

BACKGROUND	O
:	O
Exposure	O
to	O
anthracyclines	O
as	O
part	O
of	O
cancer	O
therapy	O
has	O
been	O
associated	O
with	O
the	O
development	O
of	O
congestive	O
heart	O
failure	O
(CHF)	O
.	O

The	O
potential	O
role	O
of	O
genetic	O
risk	O
factors	O
in	O
anthracycline-related	O
CHF	O
remains	O
to	O
be	O
defined	O
.	O

Thus	O
,	O
in	O
this	O
study	O
,	O
the	O
authors	O
examined	O
whether	O
common	O
polymorphisms	O
in	O
candidate	O
genes	O
involved	O
in	O
the	O
pharmacodynamics	O
of	O
anthracyclines	O
(	O
in	O
particular	O
,	O
the	O
nicotinamide	O
adenine	O
dinucleotide	O
phosphate:quinone	O
oxidoreductase	O
1	O
gene	O
NQO1	O
and	O
the	O
carbonyl	O
reductase	O
3	O
gene	O
CBR3	O
)	O
had	O
an	O
impact	O
on	O
the	O
risk	O
of	O
anthracycline-related	O
CHF	O
.	O

METHODS	O
:	O
A	O
nested	O
case-control	O
study	O
was	O
conducted	O
within	O
a	O
cohort	O
of	O
1979	O
patients	O
enrolled	O
in	O
the	O
Childhood	O
Cancer	O
Survivor	O
Study	O
who	O
received	O
treatment	O
with	O
anthracyclines	O
and	O
had	O
available	O
DNA	O
.	O

Thirty	O
patients	O
with	O
CHF	O
(cases)	O
and	O
115	O
matched	O
controls	O
were	O
genotyped	O
for	O
polymorphisms	O
in	O
NQO1	O
(NQO1*2)	O
and	O
CBR3	O
(	O
the	O
CBR3	O
valine	O
[V]	O
to	O
methionine	O
[M]	O
substitution	O
at	O
position	O
244	O
[	O
arginine	B-ProteinMutation
124-to-cysteine]	I-ProteinMutation
)	O
.	O

Enzyme	O
activity	O
assays	O
with	O
recombinant	O
CBR3	O
isoforms	O
(	O
CBR3	O
V244	O
and	O
CBR3	O
M244	O
)	O
and	O
the	O
anthracycline	O
substrate	O
doxorubicin	O
were	O
used	O
to	O
investigate	O
the	O
functional	O
impact	O
of	O
the	O
CBR3	O
Phe-->Ser	B-ProteinMutation
at	I-ProteinMutation
codon	I-ProteinMutation
15	I-ProteinMutation
polymorphism	O
.	O

RESULTS	O
:	O
Multivariate	O
analyses	O
adjusted	O
for	O
sex	O
and	O
primary	O
disease	O
recurrence	O
were	O
used	O
to	O
test	O
for	O
associations	O
between	O
the	O
candidate	O
genetic	O
polymorphisms	O
(	O
NQO1*2	O
and	O
CBR3	O
Glu	B-ProteinMutation
272	I-ProteinMutation
to	I-ProteinMutation
stop	I-ProteinMutation
)	O
and	O
the	O
risk	O
of	O
CHF	O
.	O

Analyses	O
indicated	O
no	O
association	O
between	O
the	O
NQO1*2	O
polymorphism	O
and	O
the	O
risk	O
of	O
anthracycline-related	O
CHF	O
(	O
odds	O
ratio	O
[OR]	O
,	O
1.04	O
;	O
P=.97	O
)	O
.	O

There	O
was	O
a	O
trend	O
toward	O
an	O
association	O
between	O
the	O
CBR3	O
methionine-->valine	B-ProteinMutation
substitution	I-ProteinMutation
at	I-ProteinMutation
codon	I-ProteinMutation
404	I-ProteinMutation
polymorphism	O
and	O
the	O
risk	O
of	O
CHF	O
(	O
OR	O
,	O
8.16	O
;	O
P=.056	O
for	O
G/G	O
vs	O
A/A	O
;	O
OR	O
,	O
5.44	O
;	O
P=.092	O
for	O
G/A	O
vs	O
A/A	O
)	O
.	O

In	O
line	O
,	O
recombinant	O
CBR3	O
V244	O
(	O
G	O
allele	O
)	O
synthesized	O
2.6-fold	O
more	O
cardiotoxic	O
doxorubicinol	O
per	O
unit	O
of	O
time	O
than	O
CBR3	O
M244	O
(	O
A	O
allele	O
;	O
CBR3	O
V244	O
[	O
8.26+/-3.57	O
nmol/hour.mg	O
]	O
vs	O
CBR3	O
M244	O
[	O
3.22+/-0.67	O
nmol/hour.mg	O
]	O
;	O
P=.01	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
functional	O
CBR3	O
Ser-->Cys	B-ProteinMutation
substitution	I-ProteinMutation
at	I-ProteinMutation
the	I-ProteinMutation
codon	I-ProteinMutation
326	I-ProteinMutation
polymorphism	O
may	O
have	O
an	O
impact	O
on	O
the	O
risk	O
of	O
anthracycline-related	O
CHF	O
among	O
childhood	O
cancer	O
survivors	O
by	O
modulating	O
the	O
intracardiac	O
formation	O
of	O
cardiotoxic	O
anthracycline	O
alcohol	O
metabolites	O
.	O

Larger	O
confirmatory	O
case-control	O
studies	O
are	O
warranted	O
.	O

Hb	O
zoeterwoude	O
[	O
beta23(B5)leucine	B-ProteinMutation
269	I-ProteinMutation
to	I-ProteinMutation
phenylalanine)	I-ProteinMutation
]	O
:	O
a	O
new	O
beta-globin	O
variant	O
found	O
in	O
association	O
with	O
erythrocytosis	O
.	O

We	O
describe	O
the	O
characterization	O
of	O
a	O
new	O
hemoglobin	O
(Hb)	O
variant	O
found	O
in	O
a	O
77-year-old	O
Dutch	O
woman	O
,	O
suspected	O
of	O
hypoxia-mediated	O
erythrocytosis	O
.	O

The	O
typical	O
blood	O
parameters	O
(	O
Hb	O
17.3	O
g/dL	O
;	O
PCV	O
0.525	O
L/L	O
;	O
RBC	O
5.82	O
x	O
10(12)/L	O
)	O
could	O
not	O
be	O
explained	O
by	O
any	O
of	O
the	O
pathological	O
or	O
physiological	O
conditions	O
causing	O
erythrocytosis	O
.	O

The	O
patient	O
was	O
preventively	O
phlebotomized	O
because	O
of	O
intermittent	O
claudication	O
and	O
erythrocytosis	O
.	O

At	O
the	O
hematological	O
and	O
biochemical	O
levels	O
,	O
no	O
anemia	O
or	O
hemolysis	O
were	O
present	O
and	O
no	O
abnormal	O
Hb	O
fractions	O
were	O
detectable	O
on	O
alkaline	O
electrophoresis	O
or	O
high	O
performance	O
liquid	O
chromatography	O
(HPLC)	O
.	O

Molecular	O
analysis	O
revealed	O
intact	O
alpha-globin	O
genes	O
and	O
a	O
heterozygosity	O
for	O
a	O
A	B-DNAMutation
>	I-DNAMutation
G	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
313	I-DNAMutation
of	O
the	O
beta-globin	O
gene	O
,	O
causing	O
a	O
arginine	B-ProteinMutation
555-to-tryptophan	I-ProteinMutation
amino	O
acid	O
substitution	O
.	O

The	O
P50	O
measured	O
in	O
full	O
blood	O
indicated	O
that	O
this	O
mutant	O
has	O
an	O
elevated	O
oxygen	O
affinity	O
.	O

This	O
is	O
the	O
fourth	O
single	O
nucleotide	O
substitution	O
at	O
codon	O
23	O
of	O
the	O
beta	O
gene	O
and	O
the	O
second	O
associated	O
with	O
erythrocytosis	O
.	O

Because	O
the	O
family	O
was	O
not	O
available	O
for	O
investigation	O
no	O
information	O
was	O
obtained	O
as	O
to	O
whether	O
the	O
mutation	O
represents	O
a	O
de	O
novo	O
event	O
or	O
was	O
inherited	O
,	O
and	O
might	O
be	O
a	O
more	O
common	O
cause	O
of	O
erythrocytosis	O
in	O
Dutch	O
patients	O
.	O

Considering	O
the	O
relatively	O
high	O
frequency	O
of	O
beta-thalassemia	O
(thal)	O
in	O
the	O
large	O
allochthonous	O
population	O
in	O
The	O
Netherlands	O
,	O
combinations	O
of	O
Hb	O
Zoeterwoude	O
and	O
beta-thal	O
traits	O
may	O
lead	O
to	O
hemizygosity	O
,	O
with	O
severe	O
hypoxia	O
and	O
erythrocytosis	O
from	O
a	O
few	O
months	O
after	O
birth	O
.	O

A	O
combination	O
of	O
defective	O
DNA	O
and	O
protective	O
host	O
factors	O
are	O
found	O
in	O
a	O
set	O
of	O
HIV-1	O
ancestral	O
LTNPs	O
.	O

We	O
studied	O
viral	O
evolution	O
in	O
three	O
HIV-1	O
ancestral	O
patients	O
from	O
a	O
group	O
of	O
LTNPs	O
;	O
although	O
some	O
minor	O
sequences	O
showing	O
viral	O
evolution	O
were	O
detected	O
in	O
all	O
patients	O
,	O
the	O
extremely	O
low	O
viral	O
evolution	O
of	O
their	O
viruses	O
was	O
shown	O
by	O
the	O
phylogenetic	O
analysis	O
of	O
the	O
env	O
sequences	O
.	O

Complete	O
nucleotide	O
sequencing	O
of	O
viral	O
DNA	O
showed	O
the	O
major	O
presence	O
of	O
deletions	O
.	O

In	O
two	O
patients	O
,	O
deletions	O
of	O
1088	O
and	O
228	O
nucleotides	O
mapped	O
to	O
5'	O
LTR-gag	O
region	O
;	O
in	O
the	O
other	O
,	O
a	O
247	O
nucleotide	O
deletion	O
was	O
positioned	O
in	O
pol	O
gene	O
up	O
to	O
the	O
vif	O
ORF	O
.	O

These	O
deleted	O
genomes	O
became	O
dominant	O
during	O
follow	O
up	O
.	O

Patient's	O
viruses	O
displayed	O
13	O
common	O
mutations	O
in	O
conserved	O
residues	O
,	O
from	O
the	O
5'	O
LTR	O
to	O
the	O
nef	O
gene	O
.	O

These	O
mutations	O
provided	O
evidence	O
of	O
a	O
common	O
origin	O
.	O

Regarding	O
host	O
characteristics	O
,	O
one	O
patient	O
had	O
HLA	O
B2705/B5801	O
;	O
another	O
B1402/B5701	O
;	O
whereas	O
a	O
third	O
showed	O
B3901/B4402	O
and	O
was	O
-AAGC	B-DNAMutation
at	I-DNAMutation
-222	I-DNAMutation
to	I-DNAMutation
-225-CCR5	I-DNAMutation
heterozygous	O
.	O

These	O
HIV	O
controllers	O
presented	O
a	O
combination	O
of	O
deleted	O
viral	O
genomes	O
and	O
host	O
protective	O
factors	O
.	O

Genetic	O
alterations	O
in	O
primary	O
glioblastomas	O
in	O
Japan	O
.	O

Current	O
knowledge	O
of	O
genetic	O
alterations	O
in	O
glioblastomas	O
is	O
based	O
largely	O
on	O
genetic	O
analyses	O
of	O
tumors	O
from	O
mainly	O
caucasian	O
patients	O
in	O
the	O
United	O
States	O
and	O
Europe	O
.	O

In	O
the	O
present	O
study	O
,	O
screening	O
for	O
several	O
key	O
genetic	O
alterations	O
was	O
performed	O
on	O
77	O
primary	O
(	O
de	O
novo	O
)	O
glioblastomas	O
in	O
Japanese	O
patients	O
.	O

SSCP	O
followed	O
by	O
DNA	O
sequencing	O
revealed	O
TP53	O
mutations	O
in	O
16	O
of	O
73	O
(22%)	O
glioblastomas	O
and	O
PTEN	O
mutations	O
in	O
13	O
of	O
63	O
(21%)	O
cases	O
analyzed	O
.	O

Polymerase	O
chain	O
reaction	O
(PCR)	O
showed	O
EGFR	O
amplification	O
in	O
25	O
of	O
77	O
(32%)	O
cases	O
and	O
p16	O
homozygous	O
deletion	O
in	O
32	O
of	O
77	O
(42%)	O
cases	O
.	O

Quantitative	O
microsatellite	O
analysis	O
revealed	O
LOH	O
10q	O
in	O
41	O
of	O
59	O
(69%)	O
glioblastomas	O
.	O

The	O
frequencies	O
of	O
these	O
genetic	O
alterations	O
were	O
similar	O
to	O
those	O
reported	O
for	O
primary	O
glioblastomas	O
at	O
the	O
population	O
level	O
in	O
Switzerland	O
.	O

As	O
previously	O
observed	O
for	O
glioblastomas	O
in	O
Europe	O
,	O
there	O
was	O
a	O
positive	O
association	O
between	O
EGFR	O
amplification	O
and	O
p16	O
deletion	O
(p=0.009)	O
,	O
whereas	O
there	O
was	O
an	O
inverse	O
association	O
between	O
TP53	O
mutations	O
and	O
p16	O
deletion	O
(p=0.049)	O
in	O
glioblastomas	O
in	O
Japan	O
.	O

Multivariate	O
analyses	O
showed	O
that	O
radiotherapy	O
was	O
significantly	O
predictive	O
for	O
longer	O
survival	O
of	O
glioblastoma	O
patients	O
(p=0.002)	O
.	O

SSCP	O
followed	O
by	O
DNA	O
sequencing	O
of	O
the	O
kinase	O
domain	O
(	O
exons	O
18-21	O
)	O
of	O
the	O
EGFR	O
gene	O
revealed	O
mutations	O
in	O
2	O
ou	O
of	O
69	O
(3%)	O
glioblastomas	O
in	O
Japan	O
and	O
in	O
4	O
of	O
81	O
(5%)	O
glioblastomas	O
in	O
Switzerland	O
.	O

The	O
allele	O
frequencies	O
of	O
polymorphisms	O
at	O
-491	B-DNAMutation
A	I-DNAMutation
to	I-DNAMutation
T	I-DNAMutation
(Gln/Gln)	O
in	O
glioblastomas	O
in	O
Japan	O
were	O
G/G	O
(82.4%)	O
,	O
G/A	O
(10.8%)	O
,	O
A/A	O
(6.8%)	O
,	O
corresponding	O
to	O
G	O
0.878	O
versus	O
A	O
0.122	O
,	O
significantly	O
different	O
from	O
those	O
in	O
glioblastomas	O
in	O
Switzerland	O
:	O
G/G	O
(27.2%)	O
,	O
G/A	O
(28.4%)	O
,	O
A/A	O
(44.4%)	O
,	O
corresponding	O
to	O
G	O
0.414	O
versus	O
A	O
0.586	O
(	O
p	O
<	O
0.0001	O
)	O
.	O

These	O
results	O
suggest	O
that	O
primary	O
glioblastomas	O
in	O
Japan	O
show	O
genetic	O
alterations	O
similar	O
to	O
those	O
in	O
Switzerland	O
,	O
suggesting	O
a	O
similar	O
molecular	O
basis	O
in	O
caucasians	O
and	O
Asians	O
,	O
despite	O
different	O
genetic	O
backgrounds	O
,	O
including	O
different	O
status	O
of	O
a	O
polymorphism	O
in	O
the	O
EGFR	O
gene	O
.	O

A	O
novel	O
IRF6	O
nonsense	O
mutation	O
(	O
histidine	B-ProteinMutation
626-to-arginine	I-ProteinMutation
)	O
in	O
a	O
German	O
family	O
with	O
Van	O
der	O
Woude	O
syndrome	O
.	O

Van	O
der	O
Woude	O
syndrome	O
(VWS)	O
is	O
the	O
most	O
common	O
type	O
of	O
syndromic	O
orofacial	O
cleft	O
,	O
which	O
accounts	O
for	O
approximately	O
2%	O
of	O
all	O
cleft	O
lip	O
and	O
palate	O
cases	O
.	O

It	O
is	O
characterised	O
by	O
variable	O
association	O
of	O
lower	O
lip	O
pits	O
,	O
cleft	O
lip	O
and	O
cleft	O
palate	O
,	O
and	O
hypodontia	O
.	O

VWS	O
arises	O
as	O
the	O
result	O
of	O
mutations	O
in	O
the	O
gene	O
encoding	O
interferon	O
regulatory	O
factor	O
6	O
(IRF6)	O
.	O

The	O
disorder	O
is	O
transmitted	O
in	O
an	O
autosomal	O
dominant	O
manner	O
,	O
with	O
high	O
penetrance	O
and	O
variable	O
expressivity	O
.	O

Very	O
recently	O
,	O
mutations	O
of	O
the	O
IRF6	O
gene	O
in	O
exons	O
2-9	O
have	O
been	O
found	O
in	O
VWS	O
patients	O
,	O
suggesting	O
that	O
this	O
gene	O
plays	O
an	O
important	O
role	O
in	O
orofacial	O
development	O
.	O

We	O
report	O
a	O
novel	O
mutation	O
of	O
the	O
IRF6	O
gene	O
in	O
a	O
German	O
family	O
.	O

Five	O
out	O
of	O
the	O
12	O
persons	O
affected	O
were	O
able	O
to	O
be	O
investigated	O
.	O

The	O
mutation	O
produced	O
a	O
stop	O
codon	O
within	O
exon	O
4	O
of	O
the	O
IRF6	O
gene	O
.	O

All	O
5	O
patients	O
were	O
heterozygous	O
for	O
a	O
base	O
substitution	O
G>A	B-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
+1	I-DNAMutation
of	I-DNAMutation
intron	I-DNAMutation
2	I-DNAMutation
changing	O
the	O
tyrosine	O
codon	O
at	O
amino	O
acid	O
position	O
67	O
into	O
a	O
stop	O
codon	O
(	O
arginine	B-ProteinMutation
124-to-cysteine	I-ProteinMutation
)	O
in	O
exon	O
4	O
.	O

The	O
premature	O
stop	O
codon	O
was	O
responsible	O
for	O
a	O
truncated	O
protein	O
lacking	O
parts	O
of	O
the	O
DNA-	O
binding	O
domain	O
and	O
the	O
complete	O
Smad-interferon	O
regulatory	O
factor-binding	O
domain	O
probably	O
essential	O
for	O
interactions	O
with	O
the	O
Smad	O
transcription	O
factors	O
.	O

Association	O
study	O
of	O
complement	O
factor	O
H	O
,	O
C2	O
,	O
CFB	O
,	O
and	O
C3	O
and	O
age-related	O
macular	O
degeneration	O
in	O
a	O
Han	O
Chinese	O
population	O
.	O

PURPOSE	O
:	O
Genes	O
in	O
the	O
complement	O
pathway	O
,	O
including	O
complement	O
factor	O
H	O
(CFH)	O
,	O
C2/BF	O
,	O
and	O
C3	O
,	O
have	O
been	O
reported	O
to	O
be	O
associated	O
with	O
age-related	O
macular	O
degeneration	O
(AMD)	O
.	O

Genetic	O
variants	O
,	O
single-nucleotide	O
polymorphisms	O
(SNPs)	O
,	O
in	O
these	O
genes	O
were	O
geno-typed	O
for	O
a	O
case-control	O
association	O
study	O
in	O
a	O
mainland	O
Han	O
Chinese	O
population	O
.	O

METHODS	O
:	O
One	O
hundred	O
and	O
fifty-eight	O
patients	O
with	O
wet	O
AMD	O
,	O
80	O
patients	O
with	O
soft	O
drusen	O
,	O
and	O
220	O
matched	O
control	O
subjects	O
were	O
recruited	O
among	O
Han	O
Chinese	O
in	O
mainland	O
China	O
.	O

Seven	O
SNPs	O
in	O
CFH	O
and	O
two	O
SNPs	O
in	O
C2	O
,	O
CFB'	O
,	O
and	O
C3	O
were	O
genotyped	O
using	O
the	O
ABI	O
SNaPshot	O
method	O
.	O

A	O
deletion	O
of	O
84,682	O
base	O
pairs	O
covering	O
the	O
CFHR1	O
and	O
CFHR3	O
genes	O
was	O
detected	O
by	O
direct	O
polymerase	O
chain	O
reaction	O
and	O
gel	O
electrophoresis	O
.	O

RESULTS	O
:	O
Four	O
SNPs	O
,	O
including	O
rs3753394	O
(	O
P	O
=	O
0.0276	O
)	O
,	O
rs800292	O
(	O
P	O
=	O
0.0266	O
)	O
,	O
rs1061170	O
(	O
P	O
=	O
0.00514	O
)	O
,	O
and	O
rs1329428	O
(	O
P	O
=	O
0.0089	O
)	O
,	O
in	O
CFH	O
showed	O
a	O
significant	O
association	O
with	O
wet	O
AMD	O
in	O
the	O
cohort	O
of	O
this	O
study	O
.	O

A	O
haplotype	O
containing	O
these	O
four	O
SNPs	O
(CATA)	O
significantly	O
increased	O
protection	O
of	O
wet	O
AMD	O
with	O
a	O
P	O
value	O
of	O
0.0005	O
and	O
an	O
odds	O
ratio	O
of	O
0.29	O
(	O
95%	O
confidence	O
interval	O
:	O
0.15-0.60	O
)	O
.	O

Unlike	O
in	O
other	O
populations	O
,	O
rs2274700	O
and	O
rs1410996	O
did	O
not	O
show	O
a	O
significant	O
association	O
with	O
AMD	O
in	O
the	O
Chinese	O
population	O
of	O
this	O
study	O
.	O

None	O
of	O
the	O
SNPs	O
in	O
CFH	O
showed	O
a	O
significant	O
association	O
with	O
drusen	O
,	O
and	O
none	O
of	O
the	O
SNPs	O
in	O
CFH	O
,	O
C2	O
,	O
CFB	O
,	O
and	O
C3	O
showed	O
a	O
significant	O
association	O
with	O
either	O
wet	O
AMD	O
or	O
drusen	O
in	O
the	O
cohort	O
of	O
this	O
study	O
.	O

The	O
CFHR1	O
and	O
CFHR3	O
deletion	O
was	O
not	O
polymorphic	O
in	O
the	O
Chinese	O
population	O
and	O
was	O
not	O
associated	O
with	O
wet	O
AMD	O
or	O
drusen	O
.	O

CONCLUSION	O
:	O
This	O
study	O
showed	O
that	O
SNPs	O
rs3753394	O
(	O
P	O
=	O
0.0276	O
)	O
,	O
rs800292	O
(	O
P	O
=	O
0.0266	O
)	O
,	O
rs1061170	O
(	O
P	O
=	O
0.00514	O
)	O
,	O
and	O
rs1329428	O
(	O
P	O
=	O
0.0089	O
)	O
,	O
but	O
not	O
rs7535263	O
,	O
rs1410996	O
,	O
or	O
rs2274700	O
,	O
in	O
CFH	O
were	O
significantly	O
associated	O
with	O
wet	O
AMD	O
in	O
a	O
mainland	O
Han	O
Chinese	O
population	O
.	O

This	O
study	O
showed	O
that	O
CFH	O
was	O
more	O
likely	O
to	O
be	O
AMD	O
susceptibility	O
gene	O
at	O
Chr.1q31	O
based	O
on	O
the	O
finding	O
that	O
the	O
CFHR1	O
and	O
CFHR3	O
deletion	O
was	O
not	O
polymorphic	O
in	O
the	O
cohort	O
of	O
this	O
study	O
,	O
and	O
none	O
of	O
the	O
SNPs	O
that	O
were	O
significantly	O
associated	O
with	O
AMD	O
in	O
a	O
white	O
population	O
in	O
C2	O
,	O
CFB	O
,	O
and	O
C3	O
genes	O
showed	O
a	O
significant	O
association	O
with	O
AMD	O
.	O

Novel	O
mutations	O
in	O
the	O
IRF6	O
gene	O
in	O
Brazilian	O
families	O
with	O
Van	O
der	O
Woude	O
syndrome	O
.	O

Van	O
der	O
Woude	O
Syndrome	O
(VWS)	O
is	O
an	O
autosomal	O
craniofacial	O
disorder	O
characterized	O
by	O
lower	O
lip	O
pits	O
and	O
cleft	O
lip	O
and/or	O
palate	O
.	O

Mutations	O
in	O
the	O
interferon	O
regulatory	O
factor	O
6	O
(IRF6)	O
gene	O
have	O
been	O
identified	O
in	O
patients	O
with	O
VWS	O
.	O

To	O
identify	O
novel	O
IRF6	O
mutations	O
in	O
patients	O
affected	O
by	O
VWS	O
,	O
we	O
screened	O
2	O
Brazilian	O
families	O
,	O
sequencing	O
the	O
entire	O
IRF6-coding	O
region	O
and	O
flanking	O
intronic	O
boundaries	O
.	O

Two	O
novel	O
heterozygous	O
mutations	O
were	O
identified	O
:	O
a	O
frame	O
shift	O
mutation	O
with	O
deletion	O
of	O
G	O
at	O
the	O
nucleotide	O
position	O
520	O
in	O
the	O
exon	O
6	O
(	O
(	B-DNAMutation
G	I-DNAMutation
-->	I-DNAMutation
C	I-DNAMutation
)	I-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
1201	I-DNAMutation
)	O
,	O
and	O
a	O
missense	O
single	O
nucleotide	O
substitution	O
from	O
T	O
to	O
A	O
at	O
nucleotide	O
position	O
1135	O
in	O
exon	O
8	O
(	O
(	B-DNAMutation
T	I-DNAMutation
-->	I-DNAMutation
C	I-DNAMutation
)	I-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
2209	I-DNAMutation
)	O
.	O

By	O
using	O
restriction	O
enzyme	O
analysis	O
,	O
we	O
were	O
able	O
to	O
demonstrate	O
the	O
lack	O
of	O
similar	O
mutations	O
in	O
unrelated	O
healthy	O
individuals	O
and	O
non-syndromic	O
cleft	O
lip	O
and	O
palate	O
patients	O
.	O

Our	O
results	O
further	O
confirmed	O
that	O
haploinsufficiency	O
of	O
the	O
IRF6	O
gene	O
results	O
in	O
VWS	O
.	O

Allele-specific	O
amplification	O
in	O
cancer	O
revealed	O
by	O
SNP	O
array	O
analysis	O
.	O

Amplification	O
,	O
deletion	O
,	O
and	O
loss	O
of	O
heterozygosity	O
of	O
genomic	O
DNA	O
are	O
hallmarks	O
of	O
cancer	O
.	O

In	O
recent	O
years	O
a	O
variety	O
of	O
studies	O
have	O
emerged	O
measuring	O
total	O
chromosomal	O
copy	O
number	O
at	O
increasingly	O
high	O
resolution	O
.	O

Similarly	O
,	O
loss-of-heterozygosity	O
events	O
have	O
been	O
finely	O
mapped	O
using	O
high-throughput	O
genotyping	O
technologies	O
.	O

We	O
have	O
developed	O
a	O
probe-level	O
allele-specific	O
quantitation	O
procedure	O
that	O
extracts	O
both	O
copy	O
number	O
and	O
allelotype	O
information	O
from	O
single	O
nucleotide	O
polymorphism	O
(SNP)	O
array	O
data	O
to	O
arrive	O
at	O
allele-specific	O
copy	O
number	O
across	O
the	O
genome	O
.	O

Our	O
approach	O
applies	O
an	O
expectation-maximization	O
algorithm	O
to	O
a	O
model	O
derived	O
from	O
a	O
novel	O
classification	O
of	O
SNP	O
array	O
probes	O
.	O

This	O
method	O
is	O
the	O
first	O
to	O
our	O
knowledge	O
that	O
is	O
able	O
to	O
(a)	O
determine	O
the	O
generalized	O
genotype	O
of	O
aberrant	O
samples	O
at	O
each	O
SNP	O
site	O
(	O
e.g.	O
,	O
CCCCT	O
at	O
an	O
amplified	O
site	O
)	O
,	O
and	O
(b)	O
infer	O
the	O
copy	O
number	O
of	O
each	O
parental	O
chromosome	O
across	O
the	O
genome	O
.	O

With	O
this	O
method	O
,	O
we	O
are	O
able	O
to	O
determine	O
not	O
just	O
where	O
amplifications	O
and	O
deletions	O
occur	O
,	O
but	O
also	O
the	O
haplotype	O
of	O
the	O
region	O
being	O
amplified	O
or	O
deleted	O
.	O

The	O
merit	O
of	O
our	O
model	O
and	O
general	O
approach	O
is	O
demonstrated	O
by	O
very	O
precise	O
genotyping	O
of	O
normal	O
samples	O
,	O
and	O
our	O
allele-specific	O
copy	O
number	O
inferences	O
are	O
validated	O
using	O
PCR	O
experiments	O
.	O

Applying	O
our	O
method	O
to	O
a	O
collection	O
of	O
lung	O
cancer	O
samples	O
,	O
we	O
are	O
able	O
to	O
conclude	O
that	O
amplification	O
is	O
essentially	O
monoallelic	O
,	O
as	O
would	O
be	O
expected	O
under	O
the	O
mechanisms	O
currently	O
believed	O
responsible	O
for	O
gene	O
amplification	O
.	O

This	O
suggests	O
that	O
a	O
specific	O
parental	O
chromosome	O
may	O
be	O
targeted	O
for	O
amplification	O
,	O
whether	O
because	O
of	O
germ	O
line	O
or	O
somatic	O
variation	O
.	O

An	O
R	O
software	O
package	O
containing	O
the	O
methods	O
described	O
in	O
this	O
paper	O
is	O
freely	O
available	O
at	O
http://genome.dfci.harvard.edu/~tlaframb/PLASQ	O
.	O

